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Abstract 
Background: Women in sub-Saharan Africa carry a disproportionate burden and risk of HIV. In this 
context, women at high HIV risk are not a discrete group, rather on a spectrum of risk caused by a 
multitude of behavioural, economic, structural, cultural and geographic factors. Pre-exposure 
prophylaxis (PrEP) is a promising new HIV prevention method, effective at reducing HIV risk when 
adhered to. However, the results of PrEP trials and implementation studies to date reveal challenges 
in women’s programme retention and drug adherence. There are also concerns that behavioural 
disinhibition (reductions in condom use) following the introduction of PrEP may further limit its 
ability to avert infections. In the context of HIV resource limitations and decreasing donor budgets, 
this thesis seeks to use mathematical modelling to assess strategies for PrEP scale-up for women 
across a spectrum of risk in sub-Saharan Africa, accounting for heterogeneities in HIV risk factors and 
PrEP programme outcomes. Considering the challenges faced by policy makers in using 
mathematical models to guide decision making, often considered to be complex ‘black boxes’, this 
thesis also sets out to assess the contexts in which simple models are sufficient to guide policy 
making around the introduction of a new HIV prevention intervention. 
Methods: This thesis adopts mathematical modelling approaches to inform HIV policy making. First, 
a simple static model of HIV risk to female sex workers is developed and used to assess the impact of 
behavioural disinhibition on PrEP’s ability to avert HIV infections. The static model formulation is 
then evolved to incorporate dynamic effects to account for the downstream effects of population 
interactions. The models account for heterogeneities in women’s HIV risk factors and PrEP 
programme outcomes, and the low levels of PrEP programme retention and adherence reported in 
studies. The outcomes of the static and dynamic model formulation are compared over different 
time horizons and epidemic contexts, to contribute to understanding around the importance of 
modelling complexity to inform HIV policy. Finally, the static model is refined to represent women 
across a more broadly defined spectrum of risk: women 15-24 years, 25-34 years, 35-49 years and 
female sex workers. The models are parameterised to case study countries spanning a range of high 
HIV burden contexts in sub-Saharan Africa: South Africa, Zimbabwe and Kenya, and used to assess 
strategies for PrEP scale-up in each country, considering cost-effectiveness and population-level 
impact. 
Conclusions: PrEP is likely to be of benefit in reducing HIV risk in women across a spectrum of HIV-
risk in sub-Saharan Africa, even if reductions in condom use occur. PrEP will be most cost-effective 
for individuals at great HIV risk, such as female sex workers. However, PrEP has potential to 
significantly reduce the number of new infections at population-level if made widely available 
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beyond those at highest individual risk, including to women in the general population. Strategies for 
PrEP scale-up will need to weigh the potential cost-effectiveness and population-level impact of PrEP 
with the potential for PrEP integration into a wide range of national services and at community level, 
in order to significantly bring down the costs and improve cost-effectiveness in resource-constrained 
environments.  
Static models can be sufficiently robust to inform policy making around the introduction of new HIV 
prevention interventions in high HIV-burden settings over short-medium time horizon of up to 5 
years, where underlying HIV epidemics have reached equilibrium. Over longer timeframes, and in 
contexts where the underlying HIV epidemics are still evolving (other than over short time horizons 
of less than a year), static models may under-emphasize situations of programmatic importance and 
dynamic models will be more appropriate to guide decision making.  
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Preface: Motivation for PhD 
 
Observed challenges in use of modelling to inform policy making in global public health 
For the last 12 years I have worked in policy making at national and international levels in public 
health and development, with a particular focus on HIV. Having come originally from an educational 
background in mathematical modelling, I have always taken a particular interest in how policy 
makers perceive, use and trust mathematical models.  
I have witnessed or been part of processes to adopt mathematical models to inform resource 
allocation at national and international levels, to inform the global advocacy and resource 
mobilization agenda, national and global target setting, to set global-level key performance 
indicators, and to inform normative guidance around the adoption of policy directions and technical 
norms. Throughout these processes, a number of mathematical models have had tremendous 
influence on decision making, the allocation of resources and ultimately public health outcomes 
across the world. It has been my experience that the policy makers who are relying on the outcomes 
of these models are rarely able to fully engage with or interrogate the models to determine the 
extent to which they are appropriate to inform their decision making. I have often heard models 
typified as ‘black box’ processes, with policy makers challenged to assess the appropriateness of the 
model, its inputs, and uncertainty around communicated results or implications. 
In undertaking a PhD, it was therefore a keen interest of mine to explore the use of mathematical 
modelling to inform policy making; in particular, elements of model complexity and their importance 
in informing decision making in HIV. 
 
Motivations for focus on HIV prevention in high-risk women in sub-Saharan Africa  
With the highest burden of HIV in the world, sub-Saharan Africa is central to the global HIV 
response. In this region, women face the highest burden of HIV, driven by a complex combination of 
biological, epidemiological, cultural and structural factors. These cultural, epidemiological and 
structural drivers of HIV differ tremendously by locality and cultural context. It is impossible not to 
be touched by the challenges faced by women across the region, including in many cases, not having 
full agency to control their HIV status. Focusing on ways to prevent HIV for women across a 
spectrum of risk in sub-Saharan Africa was a driving factor in my decision to undertake a PhD.  
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Thesis Structure 
This thesis is divided into six chapters: Background, Methods, Research Papers 1, 2 and 3, and 
Discussion.  
The Background chapter consists of four parts: 1) epidemiological and policy background on HIV in 
women in sub-Saharan Africa; 2) an overview of PrEP, including open policy questions in relation to 
PrEP for high-risk women in sub-Saharan Africa; 3) an overview of the use of mathematical 
modelling to inform HIV policy making, including outstanding challenges; and 4) PhD aim and 
objectives. The aim and objectives of this PhD are: 
Aim: to use mathematical modelling to inform policy making around the scale-up of PrEP for women 
across a spectrum of high HIV risk in sub-Saharan Africa, accounting for heterogeneities in HIV risk 
factors and potential PrEP programme outcomes 
Objectives: 
1. To assess the potential effectiveness of PrEP in reducing HIV infections among high-risk women 
in sub-Saharan Africa 
2. To explore the extent to which behavioural disinhibition may outweigh the potential benefits of 
PrEP  
3. To assess the robustness of conclusions made on the basis of static modelling techniques to 
incorporation of dynamic effects, to contribute to understanding around the importance of 
modelling complexity to inform HIV policy making 
4. To explore strategies for the scale-up of PrEP across high-risk women at population-level, 
weighing considerations around HIV infection reduction and cost-effectiveness  
5. To evaluate strategies for PrEP scale-up in more than one country setting in sub-Saharan Africa, 
to explore how the approach to PrEP scale-up may differ by epidemic and implementation 
context 
The Methods chapter gives an overview of the methodological approaches used in the three 
research chapters, describing how they build upon each other. Each research chapter is proceeded 
by a brief introduction, noting the PhD objectives that the research seeks to address, and followed 
by a short summary of the implications of the research. 
Research Paper 1 explores the extent to which behavioural disinhibition may outweigh the potential 
HIV risk reduction benefits of PrEP for high-risk women, considering a spectrum of baseline condom 
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consistencies and levels of HIV risk reduction achieved on PrEP. It is applied to the high HIV risk 
population of female sex workers, in the high HIV risk setting of inner-city Johannesburg, South 
Africa. The analysis is undertaken using a simple static Bernoulli formulation of HIV risk. 
Research Paper 2 assesses the extent to which the conclusions of Research Paper 1 hold, when the 
dynamics of population interactions are accounted for through the incorporation of dynamic 
modelling effects. The outcomes of the two models are compared over different time horizons of 3 
months to 20 years, and applied to different epidemic contexts. 
Research Paper 3 explores strategies for PrEP scale-up among groups of women at high HIV risk, 
weighing cost-effectiveness on an individual basis with potential population-level impact. The 
analysis is applied to three settings, spanning a range high HIV burden sub-Saharan African contexts: 
Kenya, Zimbabwe and South Africa, and to four broadly-defined female population groups at risk of 
HIV in these settings: female sex workers, adolescent girls and young women aged 15-24 years; 
women aged 25-34 years; and women aged 35-49 years. 
The Discussion chapter is divided into six parts: 1) main findings; 2) contributions of the thesis; 3) 
limitations; 4) key area not addressed through research; 5) areas for further research; and 6) 
conclusions.  
There are five appendices to the thesis. Appendix 1 is a table of ongoing, planned and completed 
PrEP open-label extension, demonstration and implementation projects among women in sub-
Saharan Africa. Appendices 2-4 are the Supplementary Materials to Research Papers 1-3, and 
Appendix 5 is recent commentary on risk compensation, to which I contributed. 
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Chapter 1 
1. Background 
 
This chapter sets out background to the use of mathematical modelling to inform policy making 
around the scale-up of PrEP for HIV prevention in high-risk women in sub-Saharan Africa in four 
sections: 
Section 1.1 gives background on the HIV epidemic in sub-Saharan Africa, the particular HIV 
prevention needs among women, and relevant aspects of the policy and development landscape; 
Section 1.2 sets out an introduction to PrEP as an emerging HIV prevention tool, and the open policy 
questions in relation to its use by women across a spectrum of HIV risk in sub-Saharan Africa; 
Section 1.3 describes the use of mathematical modelling in HIV policy making, key considerations 
around model choice, and the outstanding challenges with the use of models for policy making; 
Section 1.4 gives a summary of the open policy questions around PrEP for high-risk women in sub-
Saharan Africa and around the use of modelling to inform HIV policy making, followed by the aims 
and objectives of the PhD.  
 
1.1  Epidemiologic and Policy background: HIV in women in sub-Saharan Africa 
1.1.1 Overview of the HIV epidemic in sub-Saharan Africa 
Since the introduction of the human immunodeficiency virus (HIV) to humans most likely in 1920s 
Kinshasa, Democratic Republic of Congo1, the virus has spread differentially across regions of the 
world, influenced by dominant modes of transmission, biological, virological, cultural, political and 
structural factors2,3. Sub-Saharan Africa (SSA) has been the region hardest hit, with more 65% new 
infections and almost 70% of all people living with HIV4. Eastern and southern Africa is the sub-
region most affected, with 20.4 million people living with HIV compared to 5.0 million in west and 
central Africa, and 800,000 compared to 280,000 new infections in 20184. In SSA 59% all new adult 
infections (aged 15 years and older) are among women5. The distribution of new HIV infections by 
population group in 2018 in west and central Africa and eastern and southern Africa is set out below 
in Figure 1. 
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Figure 1: Distribution of new HIV infections by population group.  
Reproduced from UNAIDS, 20194. 
1.1.2 Higher HIV risk among women in sub-Saharan Africa 
Women in sub-Saharan Africa are at greater HIV risk than men for a number reasons spanning 
physiological, structural, behavioural, economic and cultural factors5. HIV risk, as estimated through 
mathematical models, depends on a number of factors, including the basic risk of HIV transmission 
(e.g. from a male to a female through penile-vaginal intercourse); the likelihood that sexual partners 
are HIV positive; the infectiousness of HIV positive partners (determined by stage of infection and 
whether they are taking antiretroviral treatment); the presence of sexually transmitted infections in 
partnerships; the number of partners, sex acts and frequency of partner change; and the effective 
use of HIV prevention measures such as condoms or male circumcision6,7. This section focuses on the 
factors that give rise to comparatively higher HIV risk among women in sub-Saharan Africa. 
In regions, such as sub-Saharan Africa, where heterosexual sex is the main route of HIV transmission, 
women are at higher physiological HIV risk than men per sex act, for reasons including differences in 
the mucosal immunology of women’s and men’s genitalia8,9 and that women have a greater mucosal 
surface area at risk of injury during sexual intercourse10. The basic risk of HIV transmission per 
penile-vaginal sex act is estimated to be approximately twice that for women (8 per 10,000 
exposures, 95% confidence interval (CI) 6-11 per 10,000) than men (4 per 10,000 exposures, 95% CI 
1-14 per 10,000)11, although there remains uncertainty in these estimates11,9.
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In sub-Saharan Africa, younger women are more likely than younger men to be in age-disparate 
relationships, with, for example, 17% and 14% of women 15-19 years reporting relationships with 
men at least 10 years older in Zimbabwe12 and Kenya13 respectively, and 36% South African women 
15-19 years reporting relationships with men at least 5 years older.14 Given that HIV prevalence 
peaks later in men than women across the region15, older men are more likely to be HIV positive 
than younger men, increasing the likelihood of HIV transmission to younger women through age-
disparate relationships. Indeed, across sub-Saharan Africa, adolescent girls and young women aged 
15-24 years are at 2.4 times the risk of HIV than males the same age4. Graphs demonstrating the 
earlier adult (15-49 years) HIV prevalence peak in women and later peak in men in two countries in 
sub-Saharan Africa, eSwatini and Malawi, are shown in Figure 2. 
 
Figure 2: HIV prevalence for adults 15-49 years by 5-year age group and sex, for eSwatini 2016-2017 (left) and Malawi 
2015-2016 (right).  
Source: PHIA final reports, eSwatini 201916 and Malawi 201817. Error bars represent 95% confidence intervals.  
 
Whilst sexually transmitted infection (STI) levels are heterogenous across sub-Saharan Africa (and 
much of the available data dated), STI levels remain high among many populations18. For example, 
prevalence of herpes simplex virus type 2 (HSV2) among 15-24 years olds is estimated to be between 
33.7% and 78.6% across southern and eastern Africa clinic and community settings19, and syphilis 
levels of 23% have been reported among sex workers in Zambia20. STIs, especially those that are 
ulcerative, may increase HIV transmission9,21 by a cofactor of up to 6 (depending on the STI)22, 
exacerbating underlying risks. 
Sub-Saharan Africa is vast heterogenous region made up of a multitude of cultural contexts and 
norms23. Nonetheless, patriarchy remains the dominant force in a number of cultures across the 
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region10. This affects women’s ability to choose their sexual partners, and when they have sex, their 
ability to protect themselves during intercourse, as well as acceptability around multiple concurrent 
sexual partners for men10. Where concurrency results in networks of sexual partners, HIV infection, 
especially in early highly viraemic stages, can be readily transmitted throughout the network of 
sexual partners24. 
Cultural norms that negatively affect women’s agency over sex vary by culture and context. These 
range from wife inheritance among certain communities in Zimbabwe, Malawi, Zambia, Namibia and 
Uganda, to widow cleansing (through unprotected sex with a man chosen by community elders) 
among certain communities in Kenya, Malawi, Zambia and Bostwana25. Female economic 
disempowerment is a major structural driver of increased HIV risk for women, arising for reasons 
including lack of ability to complete education and obtain gainful employment26 and land 
disinheritance laws25. Economic disempowerment is associated with earlier sexual debut, having 
multiple sexual partners, forced, violent or transactional sex (intercourse in exchange for money, 
goods or other material benefit),  all of which have been shown to increase HIV transmission10,27–29. 
Gender-based violence (GBV), reported by more than half of women in many sub-Saharan African 
contexts30,31, is both a driver and consequence of HIV32. GBV increases HIV transmission by affecting 
women’s ability to negotiate safe sex, women’s agency in health-seeking behaviours33 and the risk of 
physiological trauma through intercourse32. A recent Ugandan study found an increase in the risk of 
HIV transmission by up to 55% as a result of GBV34.  
1.1.3 Spectrum of HIV risk among women in sub-Saharan Africa 
This section focuses on the changing, heterogenous HIV risk factors that mean that women at ‘high 
HIV risk’ in sub-Saharan Africa are far from a discrete group, rather on a spectrum of risk defined by 
a multitude of factors, spanning behavioural, economic, structural, cultural, age and geography.  
To start, HIV incidence among the ‘general population’ (a heterogenous group in itself) reveals 
significant differences in HIV risk by age group and sex alone. For example, as shown in in Figure 3 
from the recent PHIA studies from eSwatini16 and Malawi17, women 15-24 years and 35-49 years in 
eSwatini and women 15-24 years and 25-34 years in Malawi are at considerably higher HIV risk than 
their male counterparts of the same age group, as well as compared to the adults 15-49 years 
overall. 
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Figure 3: Adult HIV incidence, ART-adjusted, by 10-year age group and sex, for eSwatini 2016-2017 (left) and Malawi 
2015-2016 (right).  
Source: PHIA final reports, eSwatini 201916 and Malawi 201817. Error bars represent 95% confidence intervals.  
 
Since partner HIV prevalence is a predominant driver of HIV, a woman’s HIV risk is likely to be 
greater in regions with higher male HIV prevalence (assuming the majority of sexual intercourse is 
heterosexual)6,7. At sub-national level, male HIV prevalence is incredibly diverse, as evidenced 
through the PHIA studies recently undertaken in the region35. Viral suppression, reducing the 
infectiousness of HIV positive males on anti-retroviral treatment to zero36, also varies significantly at 
sub-national level and by age-group35,37,38. By way of example, the heterogenous adult (15-49 years) 
HIV prevalence at sub-national level for Kenya and South Africa are shown in Figure 4.  
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Figure 4: Sub-national HIV prevalence for adults 15-49 years, 2017 for Kenya (left hand side) by county, and South Africa 
(right hand side) by province.  
Sources: Kenya AIDS Response Progress Report 201839 and Fifth South African National HIV Prevalence, Incidence and 
Behaviour and Communication Survey, 201814. 
 
Migration is widespread across parts of the sub-continent. Higher-prevalence male populations may 
be resident in or often pass through communities with lower levels of HIV prevalence. This is the 
case, for example, on the major highways through sub-Saharan Africa40–42, where truck drivers with 
often higher levels of HIV than the communities through which they pass engage in transactional sex 
or sex worker on their journeys. Truck drivers passing through depots across the southern corridor 
of the Trans-Africa highway were found to have 3 times the national HIV prevalence of men of the 
same age group in the domestic population42. Similarly, the risk of HIV transmission to women is 
often higher in communities hosting male migrant workers. In the South African communities 
hosting Mozambican migrant mine workers, more than 50% miners reported two or more partners 
in the last 12 months, 18.5% used a condom at last sexual intercourse, and nearly three quarters of 
HIV-positive mine workers were unaware of their HIV status43. 
HIV risk is higher among women who engage in transactional sex44,15 (transactional sex describing 
the continuum of sexual relationships where there is an implicit or overt exchange of goods, money 
or benefits in social status45,29). Transactional sex in the region spans women exchanging sex-for-fish 
among fishing communities spanning Namibia to Lake Victoria27, to sex in exchange for school fees 
or transport in Soweto, South Africa28. A recent systematic review found prevalence of transactional 
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sex of up to 14% among adolescent girls and young women, aged 15-24 years (AGYW), in sub-
Saharan Africa, and up to 30% among women across all age groups, with women who practice 
transactional sex between 1.5 and 2 times more likely to be HIV-infected than those who do not29. 
Transactional sex has been shown to be associated with gender-based violence, a risk factor for 
HIV46. 
Female sex workers (FSW) are among women at highest risk of HIV infection in society, at up to 13-
times the risk of women in the general population across lower- and middle-income countries, and 
with vastly elevated levels of STIs47. HIV prevalence among FSW varies by context, ranging from less 
than 1% in Comoros48 to 72% in Hillbrow, inner-city Johannesburg49. FSW face risk of HIV acquisition 
from each of their partner groups: regular partners (e.g. boyfriends or husbands), to regular and 
occasional clients, with often blurred distinctions in between50.  
FSW clients often come from groups who have multiple sexual partners and elevated levels of HIV 
prevalence compared to men in the general population, such as seasonal agricultural workers, truck 
drivers, sailors and men in the military50. FSW may face challenges in negotiating consistent use of 
condoms with clients due to power imbalances50 or threat of reduced income, with FSW in some 
contexts receiving a quarter of the price for sexual intercourse where condoms are insisted upon51. 
FSW may face also pressure from pimps to engage in condomless sex, as documented in Ethiopia52, 
as well as barriers to access to condoms, STI treatment and post-rape care (including post-exposure 
prophylaxis)50. Police are well-document perpetrators of violence against FSW, rape, extortion 
(including demands for sexual intercourse)53,54, especially affecting non-brothel based FSW, without 
intermediaries to negotiate for them50.  
The regular partners of sex workers may themselves have higher than average prevalence of HIV and 
engage in high HIV-risk behaviours50,55,56. Condom use with regular partners, as with regular clients, 
is typically very low, as a sign of trust57,58. In one study of boyfriends of FSW in Benin and Guinea, 
70% of boyfriends reported having been clients of at least one other FSW59. Several studies postulate 
greater likelihood of HIV transmission from regular partners than clients, due to low levels of 
condom use with the former50,55.  
Sex work is thought to account for greater onwards transmission of HIV in contexts where HIV 
epidemics are increasing and the basic reproductive number (number of secondary cases caused by 
a primary case) of HIV is high, but less so in stable generalised epidemics when HIV is endemic in 
high-burden contexts and some risk factors (such as lack of condom use in transactional and age 
discordant relationships) may be higher in the general population60–62. 
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In conclusion, HIV risk is neither constant nor homogenous in any one group at any time. The large 
number of risk factors contributing to an individual’s HIV risk means that the continuum of risk does 
not always place self-identifying sex workers at the highest end and women who consider 
themselves to be in the general population at the other. Rather, HIV risk evolves over time according 
changes in risk behaviours, population movement, vulnerabilities and structural norms50.  
1.1.4 Global health and development landscape for scaling up HIV prevention efforts 
Scaling-up HIV prevention for high-risk women in sub-Saharan Africa is recognised as a global 
priority, with particular attention given to the needs of adolescent girls and young women63–65. 
However, there is limited fiscal space for scaling up resources for HIV prevention among 
programmes in sub-Saharan Africa. In spite of the successful 2020-2022 replenishment of the Global 
Fund to Fight AIDS, TB and Malaria (the second biggest external funder of HIV programmes in sub-
Saharan Africa)66, external resources for HIV have overall been flatlining over the past years, and 
increases in domestic spending on health have not taken place across countries in the region at a 
pace needed to meet the needs63,64,67,68. In 2018, for the first time since the year 2000, the total 
resources available globally for the HIV response have started to decline4, with the $1.9 billion 
available in 2018 less than half the annual amount estimated to be needed to achieve UNAIDS’s 
2020 global Fast Track targets (see below for an explanation of these targets)4,69. 
Increasing domestic resources for HIV prevention is also challenging in the context of the global 
drive for countries to ensure universal health coverage (UHC) - ensuring that all people and 
communities have equal access to health services (promotive, preventive, curative, rehabilitative 
and palliative), of sufficient quality to improve the health of those receiving the services, and with 
the people accessing them protected from financial risk whilst doing so70.  Achieving UHC by 2030 is 
one of the ten targets under the health-focused sustainable development goal (SGD) 371: Ensure 
healthy lives and promote well-being for all at all ages; specifically SDG 3.8: Achieve universal health 
coverage, including financial risk protection, access to quality essential health-care services and 
access to safe, effective, quality and affordable essential medicines and vaccines for all.  
Unlike the under the 2015 Millennium Development Goals (MDGs), where one of eight goals was 
specifically HIV-focused (MDG 6: Combat HIV/AIDS, Malaria and Other Diseases)72, under the SDGs, 
HIV takes comparatively less priority, falling under a different SDG 3 target, SDG 3.3: By 2030, end 
the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, 
water-borne diseases and other communicable diseases. Commitment to the SDGs has been pledged 
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by all UN Member States (including all Sovereign States in Sub-Saharan Africa)71, with support for 
SDG 3 underpinned by commitment of the 12 leading global health and development organizations 
(including those with an HIV-focus: the Global Fund to Fight AIDS, TB and Malaria (Global Fund), 
UNAIDS, Unitaid, as well as the World Health Organization (WHO)) through the Global Action Plan 
for healthy lives and well-being for all (Global Action Plan)73.  
HIV prevention is a constituent component of a comprehensive universal health care system, just as 
a strong health system is critical in the successful delivery and achievement of the HIV 
response4,70,74,75. This interdependence plays out at country level, with an underlying tension 
between the need to continue to support and scale up the HIV response and the need for country 
Treasuries to prioritise investments in health systems and UHC75–78. Among donors, the biggest 
external financers of HIV programmes, PEPFAR (the U.S. President’s Emergency Plan for AIDS Relief) 
and the Global Fund, remain committed to the HIV response68,79. However, this tension between 
prioritizing investments ‘vertically’ in HIV versus ‘horizontally’ UHC is ubiquitous, with the Global 
Fund also focusing investments on building resilient and sustainable systems for health (as well as 
the Malaria and TB responses)74, and other bilateral donors, including those who have been former 
bilateral supporters of the HIV response (such as Germany, Sweden and Japan)80–83 now prioritizing 
the use of their development assistance for health to incentivize health systems strengthening and 
UHC delivery in the SDG landscape83,84.  
Available budget space for HIV programming is also squeezed in the context of the global drive to 
scale up antiretroviral treatment (ART) for all people living with HIV. Since 2016, ART has been 
recommended for all people living with HIV, regardless of their stage of HIV infection85. Having 
previously been prioritised for people with more advanced stages of HIV infection (CD4 count less 
than or equal to 500 cell/mm3 per 2013 guidance), this updated guidance was based on the results of 
randomized control trials and observational studies, which suggested that earlier initiation of 
treatment reduces mortality and the chance of HIV-associated coinfections85. It was also based on 
the results of a randomized control trial, which showed that earlier ART reduced the risk of HIV 
transmission to HIV-negative partners (supported by others since published86), and the results of 
modelling and ecological studies, which suggested that high uptake and retention of ART at 
population level would reduce HIV incidence at population level87–91; termed ‘treatment as 
prevention’85.  
Based on the emerging evidence, in 2014, UNAIDS concurrently published their strategy Fast Track: 
Ending the AIDS Epidemic by 2030 (Fast Track)69. The Fast Track strategy encourages all countries 
globally to achieve “90-90-90” targets by 2020 (90% of people living with HIV (PLHIV) knowing their 
29 
 
status (i.e. receiving an HIV test), 90% of PLHIV who know their status receiving ART, and 90% of 
people on ART having viral suppression so their immune system remains strong and they are no 
longer infectious) and 95-95-95 targets by 203069. These ambitious targets have been spearheaded 
in particular by UNAIDS69,92 and PEPFAR79,93, as well as using Global Fund resources in many eastern 
and southern African countries94.  
Whilst more recent randomized-control trials and observational studies have since highlighted that 
the anticipated benefits of treatment as prevention are unlikely to materialise95–98, treatment for all 
remains a global strategy4, with many national and donor budgets prioritised for treatment, leaving 
more limited space for HIV prevention activities94. The drive for treatment scale-up has also resulted 
in high ‘treatment mortgages’, since once individuals have been started on ART, they should be 
continued on treatment for life, meaning funds for prevention need to be additional and resources 
cannot be reprioritised away from ART budgets. A lesser-recognized paradox of this situation is that 
the modelling underpinning the treatment as prevention aspect of the global 90-90-90 and 95-95-95 
targets assumed full access to prevention activities69,88,95. So whilst this strategy has been immensely 
successful in reducing mortality among people living with HIV4,99, the current budget imbalances in 
many countries may be self-limiting from a prevention point of view95,100. As a consequence, the 
need for innovative and effective HIV prevention approaches, especially to address the drivers of HIV 
risk among high-risk women in sub-Saharan Africa, must be met by cost-efficient interventions to be 
feasible and be prioritizable in a resource constrained environment. 
  
30 
 
1.2  PrEP as a potential tool to reduce HIV incidence 
1.2.1 Overview of combination prevention prior to PrEP introduction 
Prior to PrEP introduction, normative guidance on HIV prevention in high-prevalence settings 
consisted of a ‘combination approach’ based on saturated coverage of condoms, targeted 
prevention interventions for adolescent girls and young women, voluntary medical male 
circumcision (VMMC), behavioural and structural interventions, focused communication and 
demand creation using new and digital media, as well as secondary prevention using post-exposure 
prophylaxis (PEP) after possible HIV exposure69. A comprehensive package of interventions for key 
populations (MSM, transgender people, sex workers, PWID, incarcerated people101) included 
comprehensive condom and lubricant programming, harm reduction programmes for people who 
inject drugs, behavioural and structural interventions, VMMC, PEP, prevention of HIV in healthcare 
settings102. In 2015, HIV prevention guidance was updated to include HIV testing and HIV treatment 
for people living with HIV, regardless of CD4 count, for reasons including the anticipated benefits of 
HIV treatment as prevention103. However, as set out at the beginning of this chapter, the 
implementation of these HIV prevention interventions has been insufficient to address the global 
HIV prevention needs, including for high-risk women in sub-Saharan Africa, and new approaches 
were called for104. 
 
1.2.2 Overview of PrEP  
This section gives an overview of evidence to date on PrEP use-effectiveness and introduces the PrEP 
programme cascade.  
Oral PrEP is the use of tablet-form antiretroviral drugs among HIV negative persons to prevent HIV 
acquisition. The six early oral PrEP randomized controlled trials (RCTs) took place globally between 
2007 and 2011, using oral PrEP formulations of either tenofovir (TDF) or tenofovir and emtricitabine 
(TDF/FTC, known commercially as Truvada). The study population, location, study name, PrEP 
formulation, number of participants, adherence and HIV risk reduction effectiveness corresponding 
to each of the trials is set out in Table 1 below. 
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Population/ 
Location/ Study  
Oral PrEP 
Formulation 
Number of 
Participants Adherence 
HIV Risk 
Reduction 
Effectiveness 
MSM and TGW (multiple geographic regions) 
iPrEx105 TDF/FTC vs 
placebo 
2,499 51% by drug 
detection 
44% (95% CI: 
15%, 63%; 
p=0.005) 
People who inject drugs, Thailand 
Bangkok Tenofovir 
Study106 
TDF vs placebo 2,413 83% based on 
study drug 
diaries 
48·9 (95% CI: 
9·6%, 72·2%; 
p=0.01) 
Women in Africa 
FEM-PrEP107 (women 
18-35 years) 
TDF/FTC vs 
placebo 
2,120 37% by drug 
detection 
6% (95% CI: -
52%, 41%; 
p=0.81) 
VOICE108 (women 18-
45 years, oral arms 
only) 
TDF/FTC and FTC 
vs placebo 
3,019 28–29% by drug 
detection 
TDF: −49% (95% 
CI: −129%, 3%; 
p=0.07); 
TDF/FTC: −4% 
(95% CI: −49%, 
27%; p=0.81) 
Serodiscordant couples in Africa 
Partners PrEP109 TDF/FTC and FTC 
vs placebo 
4,758 82% by drug 
detection 
TDF: 67% (95% 
CI: 44%, 81%; 
p<0.001); 
FTC/TDF: 75% 
(95% CI: 55%, 
87%; p<0.001) 
Heterosexual men and women in Africa 
TDF2110 TDF/FTC vs 
placebo 
1,219 84% by clinic pill 
count 
62% (95% CI: 
22%, 83%; 
p=0.03) 
Table 1: Results of the six early oral PrEP randomized controlled trials.  
The table set out the population, location, study name, oral PrEP drug formulation, number of participants, adherence and 
effectiveness levels for each of the six studies. TDF is short for tenofovir and FTC is short for emtricitabine. The table builds 
on that from Haberer111. 
 
 Of the six RCTs, four found oral PrEP to be effective in reducing HIV incidence, with effectiveness 
directly associated with drug adherence111. The two trials, FEM-PrEP107 and VOICE108, that were 
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stopped early for futility were undertaken in women in Africa, with both citing lack of adherence as 
the cause for no effectiveness. None of the early RCTs were undertaken in other high-risk women 
populations, such as female sex workers and adolescent females. 
Based on the results of the RCTs, in July 2012, the WHO called for demonstration projects to be 
carried out to better understand the acceptability, patterns of use, and sustainability of PrEP112. At 
the same time, they introduced oral PrEP into normative guidance, recommended for 
serodiscordant couples (couples, where one partner is HIV positive and the other is HIV negative), 
men who have sex with men (MSM) and transgender women (TGW) as part of demonstration 
projects113.   
Early demonstration projects, including open label extensions (OLE) of original RCTs, helped to set 
the direction of PrEP implementation research111. Priority areas of investigation included exploring 
approaches to strengthen drug adherence and program uptake and retention; behavioural 
disinhibition (in this case, reductions in condom use on PrEP); drug safety and resistance; priority 
populations for PrEP scale-up; and cost-effectiveness; as well as exploring PrEP effectiveness for 
populations not addressed in the RCTs111,114. 
Importantly, the OLE projects of two of the RCTs, iPrEx and Partners PrEP, were able to establish that 
the drug adherence levels need to achieve the same levels of protection against HIV are different 
between women and men. The iPrEx OLE115 undertaken in MSM and TGW, established that only 4 
out of the 7 weekly doses of PrEP are required to achieve almost full protection against HIV. The 
study was also able to link levels of drug adherence, through blood drug concentration, to levels of 
HIV risk reduction, as set out in Table 2. 
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% of iPrEx 
OLE115 trial 
participants  
Estimated 
drug dosing 
(adherence) 
TFV-DP in DBS 
(fmol/punch) Estimated HIV incidence 
Estimated HIV 
relative risk 
reduction 
compared to no 
adherence 
26% None <2.5 4.7/100 PY (95% CI: 2.8 to 
7.2)  
 
27% <2 
tablets/week 
2.5 to < 350 2.2/100 PY (95% CI: 1.1 to 
4.1) 
53% 
12% 2 to 3 
tablets/week 
>=350 to < 700 0.6/100 PY (95% CI: 0.0 to 
2.5) 
87% 
22% 4 to 6 
tablets/week 
>=700 to 1249 0 /100 PY (95% CI: 0.0 to 0.6) 100% 
5% Daily >=1250 0 /100 PY (95% CI: 0.0 to 1.1) 100% 
Table 2: Detailed adherence-effectiveness outcomes estimated from the iPrEx OLE trial115.  
The iPrEx OLE demonstration project was carried out among MSM and TGW in multiple geographic locations. The table 
links the estimated daily dosing of PrEP (adherence) in trial participants with estimated levels of HIV risk reduction achieved. 
The table shows the proportion of trial participants exhibiting different adherence behaviours (estimated number of daily 
pills taken a week), measured by drug concentrations found in participants’ dried blood spots. For each adherence group an 
estimated HIV incidence is given and corresponding relative HIV risk reduction compared with no PrEP adherence. TFV-DP in 
DBS = Tenofovir-diphosphate in dried blood spots. PY = person years. The data in the table are reproduced from Grant et 
al115. 
  
The Partners PrEP OLE (called Partners Demonstration Project)116 carried out in serodiscordant 
couples, using PrEP as a bridge to viral suppression in the HIV positive partner using ART, was able to 
relate levels of drug adherence to levels of HIV risk reduction through multi-variate regression 
(rather than blood drug concentration levels). The estimates for women in the trial are set out in 
Table 3. 
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% of Partners 
Demonstration Project116 
female trial participants 
Estimated drug dosing 
(adherence) 
Estimated HIV relative risk 
reduction in HIV incidence 
compared to no adherence 
82% ≥4 Doses/week 89% (95% CI: 79%–99%), p=0.03 
71% ≥6 Doses/week 88% (95% CI: 73%–106%), p=0.17 
(not statistically significant) 
Table 3:  Estimated HIV risk reduction associated with PrEP adherence levels of ≥4 and ≥6 doses a week for females in the 
Partners Demonstration Project116.  
The table shows the estimated daily dosing of PrEP (adherence) associated with estimated levels of HIV risk reduction 
achieved in the project, calculated through multivariate analysis. The Partners Demonstration Project was undertaken in 
sero-discordant couples in Kenya and Uganda. 
Unlike in men, for whom 4 out of 7 weekly doses are estimated to achieve full protection against 
HIV, for women, the results of the Partners Demonstration Project116, along with more recent 
pharmacokinetic117 and modelling studies118 suggest that at least 6 out of 7 weekly, if not 7, doses of 
PrEP are needed to achieve full protection against HIV. It is postulated that this relates to differences 
in between-tissue drug transport systems between the lower female genital tract in women and 
colorectal tissue in men, resulting in stronger PrEP drug concentrations in colorectal tissue than the 
lower female genital tract118,119. 
In 2014, normative guidance was revised to recommend PrEP for MSM102, based primarily on the 
results of the iPrEx Study among MSM and TGW105, and later in 2015 to include all people at 
substantial risk of HIV infection, defined as incidence of greater than 3 per 100 person years, as part 
of a combination approach to HIV prevention103. This guidance was updated with the latest clinical 
and drug formulation recommendations in 201685. To date, more than 100 PrEP demonstration 
projects are underway or have been carried out across populations and countries globally to address 
the priority areas for implementation research120 and many countries, including in sub-Saharan 
Africa, have started rolling out PrEP ‘implementation programmes’ for highest-risk populations121–123. 
Drug safety and resistance 
Oral PrEP, using either TDF or TDF/FTC, is considered to be safe across populations and geographies, 
including during pregnancy and whilst using hormonal contraceptives85,124. Mild adverse events, such 
as gastrointestinal symptoms, are reported on PrEP, and though usually disappear after the first 
month, have caused limited PrEP interruption in demonstration projects124. Subclinical decreases in 
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renal function are reported on PrEP, usually disappearing with drug continuation, as well as 
subclinical decreases in liver function and bone density124. Quarterly renal testing for the first 12 
months is recommended as standard on PrEP, as well as annually thereafter85. 
Antiretroviral drug resistance, which may be acquired through HIV acquisition in persons with sub-
optimal drug adherence, has, despite early fears and challenging levels of drug adherence in 
demonstration programs, been rare on PrEP85,124. Whilst seroconversion and resistance is closely 
monitored in PrEP programmes, the potential for drug resistant infections (against drugs that are 
included as first line ART) is not generally considered prohibitive to wide PrEP program scale 
up85,125,126. 
PrEP program cascade 
An illustrative conception of the PrEP program cascade127–129 is set out below in Figure 5. The 
cascade depicts the programme stages from recruitment to programme retention at a defined end 
point. It should be noted that the stages of the cascade and their definitions are not standardised 
across OLE, demonstration and implementation projects120. As such there is no single reference 
cascade meaning that direct comparisons between cascade stages across studies can be challenging. 
Furthermore, as PrEP is intended to cover seasons of risk, rather than for long term use85, it does not 
always make sense to compare retention after lengthy time horizons across studies (as it does with 
ART retention), as periods of risk may be shorter depending on the population in question. This lens 
should be taken when considering PrEP program uptake, retention and adherence (key stages of the 
cascade to help ascertain the effectiveness of a PrEP programme85) throughout this manuscript. 
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1.2.3 PrEP programme uptake and retention, and drug adherence by population in SSA 
Whilst only a subset of the more than 100 PrEP demonstration projects underway have published 
results, perhaps the biggest challenge observed globally to date in PrEP demonstration as well as 
implementation programs is in ensuring high levels of programme uptake and retention, and drug 
adherence85,111,124,130. This section gives an overview of PrEP uptake, retention and adherence by 
population in sub-Saharan Africa. 
 
Serodiscordant couples 
Programme uptake, retention and adherence have, in general, been reported to be higher among 
serodiscordant couples observed in studies globally131,132. The Partners Demonstration Project (OLE 
of Partners PrEP RCT) among serodiscordant couples in Kenya and Uganda reported 97% HIV-
negative partners initiating PrEP, 51% retained in the program to the end point of 6 months 
following partner initiation on ART, and 71% participants reporting at least 80% PrEP drug 
adherence.  
 
Figure 5: Illustrative PrEP program cascade from recruitment to program retention at a given time end point 
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MSM and TGW 
Uptake, retention and adherence have been mixed among studies for MSM and TGW, with program 
indicators generally lower in contexts where there is widespread stigma against these 
populations133. The iPrEx OLE study133 for MSM and TGW across regions globally (USA, Peru, Ecuador, 
Thailand, South Africa, USA) had levels of uptake ranging between 67% (Peru) and 95% (Ecuador), 
with average 93% retention and 70% clinically significant adherence measured through TDF blood 
concentration at 12-weeks (retention and adherence not reported disaggregated by country). This is 
contrasted with the IPCP-Kenya demonstration project, which reported only 22% 12 week and 15% 
6-month PrEP programme retention among MSM134.
People who inject drugs 
Few demonstration projects have been completed for people who inject drugs (PWID), though the 
OLE135 of the Bangkok Tenofovir Study for PWID in Thailand has so far reported 35% uptake (among 
the original study’s participants who remained HIV negative), that only 30% of participants were 
retained at 12 months and 26% participants are regularly adhering to PrEP according to participant 
diaries. 
High-risk women 
Given the challenges of the PrEP RCTs in achieving levels of HIV-protective PrEP adherence in 
women, as well as that none took place in defined high-risk groups such as FSW or AGYW, a large 
number of the PrEP demonstration projects and implementation studies are taking place for women 
across the spectrum of HIV risk120. The currently ongoing, planned and completed PrEP OLE, 
demonstration and implementation projects for women in sub-Saharan Africa are set out in 
Appendix 1, including a description of the studies’ specific research questions. 
Female sex workers: Emerging results from demonstration projects among FSW in sub-Saharan 
Africa reveal challenges in programme retention, consistent with the challenges faced by FSW in 
adhering to ART and wider health services related to stigma, unstable routines, criminalization of 
their work, disempowerment and disenfranchisement and discrimination by healthcare 
providers4,136. The TaPS demonstration project137 for FSW in Johannesburg, South Africa, reported 
PrEP uptake of 98%, and self-reported adherence of 70-85% among those retained in the 
programme, but only 22% 12-month retention levels. The SAPPH-IRe trial138 among FSW in 
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Zimbabwe reported 38% uptake, and an average of 4 months’ programme retention and did not 
report on adherence (as is the case for the following studies where adherence is not mentioned). In 
Kenya, the IPCP trial134 reported 66% uptake and 14% 6-month retention among FSW. PrEP retention 
in trials among FSW in West Africa has been slightly more encouraging, with 83% uptake and 67% 
retention at 12 months in Senegal139 and 88% uptake and at 12 months 47% retention, with 57% 
participants self-reporting 100% adherence in Benin140.  
AGYW: Similar retention challenges have been observed in studies among AGYW. For young women 
15-29 years in Kenya, IPCP141 reported 86% uptake and 10% 6-month retention. The EMPOWER 
Study142 in South Africa and Tanzania for AGYW aged 15-24 years reported 97% PrEP uptake and 34% 
retention at 6 months. The challenging retention levels seen in AGYW are consistent with the 
increased challenges that young people have in adhering to treatment compared to adults, as seen 
in the case of ART136. 
Other high-risk women: The HPTN 067/ADAPT trial143 in South African women aged 18 years and 
older reported 93% uptake, and compared daily, time-driven (twice per week and a post-sex dose), 
and event-driven (one tablet before and after sex), and reported 75%, 56% and 52% of sex events 
respectively covered by PrEP after 6 months, and adherence to the prescribed regimen of 75%, 65% 
and 53% respectively. Use of PrEP as a 6-week short course for the female partners of Mozambican 
miners returning home144, was successful in obtaining 97% uptake, 91% retention at week 6 and 42% 
of those women retained at week 6 having drug concentration levels consistent with at least 4 out of 
7 pills a week. Early results from the SEARCH study145 among adults 15 years and older in rural 
Uganda so far report 43% uptake among women and 47%, with clinic distance reported as a barrier 
to uptake and retention. Early results from the PrIYA study146 of PrEP for women 15-45 years 
delivered through maternal child health and family planning clinics in Kisumu, Kenya has so far 
reported 38%, 21%, and 10% retention at 1, 3 and 6 months respectively. Although many other 
studies are underway across high-risk female populations, they are yet to release their results120.  
A table of the ongoing, planned and completed PrEP OLE, demonstration and implementation 
projects among women in Sub-Saharan Africa is set out in Appendix 1.  
 
1.2.4 Open policy questions regarding PrEP for high-risk women in SSA 
This section gives an overview of the open policy questions relating to PrEP programmes for women 
at high risk of HIV in sub-Saharan Africa. The section concludes by categorizing the open questions as 
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those that can be assessed through standalone modelling studies, and those that need to be 
evaluated in conjunction with RCTs, OLE, demonstration and implementation trials. 
Strategies to improve PrEP uptake, retention and adherence 
Given the challenges observed in the original PrEP RCTs, a focus of OLE, demonstration and 
implementation studies for high-risk women in SSA is evaluation of strategies to improve PrEP 
program uptake, retention and drug adherence. On the supply side, this includes evaluating peer-
based as well as more general information campaigns; community outreach; exploring platforms for 
scaling up PrEP availability (including schools, sexual and reproductive health clinics, antenatal 
clinics); tailored services to the needs of different high-risk women populations including 
differentiated care models and mobile services to meet the needs of mobile populations such as sex 
workers; ensuring PrEP is affordable and freely available; and addressing structural barriers such as 
policies that preclude discussion of sexuality education and HIV prevention in education settings, 
stigma or legal barriers to provision of PrEP to young people111,120,136,147–150.  
On the demand side, this includes evaluating approaches to strengthen risk awareness; 
empowerment of women and their communities with correct information about PrEP and HIV 
prevention; working to ensure PrEP providers have supportive attitudes; integration of PrEP 
provision with other sexual and reproductive health and social services; integration with 
empowerment and gender-based violence reduction programmes (strengthening demand for PrEP 
as well as HIV prevention in general); and offering PrEP through approaches that are sensitive to 
local cultural and religious norms111,120,136,147–150. Specific approaches being explored to strengthen 
retention and adherence include adherence counselling; approaches (such as text messaging and 
smart phone applications) to remind participants to take medication; structural interventions to 
address social determinants of non-retentive and non-adherent behaviour (e.g. cash transfers, 
working with police to support FSW programmes, building self-empowerment, efficacy and social 
cohesion); the use of ‘adherence buddies’; direct follow up with defaulters; and medication refill 
groups that alternate drug collection among group members111,120,136,147–150. 
Alternative PrEP dosing strategies and formulations are also being explored, with the aim of 
improving programme uptake, retention, adherence and thereby effectiveness (as set out in the 
next section). 
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Different PrEP dosing strategies  
Once PrEP had been proven effective with drug adherence, OLE, demonstration and implementation 
projects have been exploring different dosing strategies to assess the effectiveness of non-daily PrEP 
HIV prevention, to see if this helps improve adherence to the intended drug regimen. Such 
alternative dosing strategies include on demand (before and after sex) and time-driven (usually few 
doses a week plus a dose after sex)120. Given the different PrEP dosing strategies being explored 
among OLE, demonstration and implementation projects, comparison of drug adherence between 
studies should be according to regimen rather than directly comparable.   
To date, the results of different dosing strategies have been mixed, according to population. The 
HPTN/067 – ADAPT trial143 of different dosing strategies in South African women aged 18 years and 
older found that daily dosing resulted in a higher coverage of sex events, strengthened adherence to 
the dosing regimen and blood drug concentrations. The IPERGAY study for Canadian and French 
MSM on the other hand found that event-driven dosing (in this case 2 tablets 2-24 hours before sex, 
1 tablet 24 hours later and 1 tablet 48 hours later) found 43% correct use of PrEP according to 
adherence regimen and 86% relative HIV risk reduction after 2 years151. These differences in 
effectiveness of non-daily dosing of PrEP may relate to the differences in drug levels needed to 
achieve similar levels of protection against HIV between women and men, as well as different risk 
awareness, behavioural, structural and contextual considerations between populations152. It was 
also noted that the frequency of sex acts in the IPERGAY study were sufficiently high such that many 
participants had drug levels consistent with the at least 4 doses a week needed to achieve full 
protection noted through the iPrEx OLE study152. Throughout this thesis, it has been specifically 
noted where referenced studies involve non-daily dosing strategies. 
 
Different PrEP formulations 
To date, PrEP formulated for daily oral consumption through tablet form, ‘oral PrEP’, is the only 
formulation with regulatory approval for use outside of trial settings (although the most recent US 
Food and Drug Administration approval of the tenofovir alafenamide/emtricitabine oral PrEP option 
is not yet indicated for women having receptive vaginal sex)153. Long-acting PrEP microbicide 
formulations are under investigation through randomized controlled trials and OLEs, with the 
Dapivirine ring the most progressed153. Longer-acting formulations intend to strengthen PrEP 
program outcomes by avoiding the need to take pills on a daily basis, which has proven a barrier in 
many studies107,108,124. The latest results of the DREAM154 OLE study in South African and Ugandan 
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women aged 20 years and older showed 90% retention at 12 months, 90% of women using the 
Dapivirine ring at least some of the time and 63% HIV risk reduction estimated through modelling, 
an improvement on the 30% risk reduction through the original clinical trial form of the study, the 
RING Study155. As of August 2019, regulatory approval is being sought for the Dapivirine ring153. 
Other long-acting formulations of PrEP are also under investigation, the most advanced of which are 
injectable formulations being explored through the HPTN 083156 and HPTN 084157 clinical trials. 
These trials are taking place respectively for MSM and TGW in the Americas, Asia and South Africa, 
and young women in SSA, using the antiretroviral cabotegravir in comparison to daily oral PrEP 
(using TDF/FTC), with results expected 2021-2022. Given that for the duration of this PhD PrEP 
implementation has predominantly focused on the roll out of oral PrEP120, the focus of the PhD is on 
the oral formulation. However, much of the work contained herein can be easily adapted to assess 
other formulations if they are approved. 
Behavioural disinhibition 
Since the commencement of PrEP RCTs, there has been concern around behavioural disinhibition or 
risk compensation – in particular, reductions in condom use (also termed condom migration) – 
following the introduction of PrEP, and its impact on the ability for PrEP to reduce HIV 
risk114,124,149,150,158–160. These concerns remained as the results of the early RCTs showed poor 
adherence in some groups, which led to worries that the levels of protection against HIV would be 
insufficient to counterbalance reduced levels of protection against HIV through reductions in 
condom use, as well as increase exposure to STIs, some of which increase the likelihood of HIV 
acquisition22,150,158–160. These concerns regarding behavioural disinhibition mirror those surrounding 
the introduction of previous innovative HIV prevention measures, including the introduction of STI-
efficacious microbicides161,162 from almost two decades ago, voluntary medical male 
circumcision163,164 a decade ago, and treatment as prevention in recent years165,166.  
Concerns around behavioural disinhibition relate especially to women across the spectrum of HIV 
risk in SSA, as well as others, who have limited agency over condom use10,25,167, with worries that 
they would readily reduce condom use once PrEP is offered, further exposing themselves to STIs, 
without achieving protective levels of PrEP efficacy. This is also particularly relevant to FSW, who in 
many situations may receive increased payment for condomless sex50,52,55,57,58 (up to four times the 
amount in some settings168), or women engaging in transactional sex, who may receive greater 
benefits where condoms are not used29,43,45,169.  
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None of the early RCTs reported reductions in condom use170, neither did the early OLE projects and 
demonstration projects124. Qualitative surveys among young women in South Africa, however, 
reported appetite to reduce condom use on PrEP149,171, and more recent PrEP demonstration and 
implementation programmes in developed country contexts for MSM are starting to report 
decreased condom use and increases in STIs172–175. In particular, community-level behavioural 
disinhibition (reductions in condom use in individuals not taking PrEP, but in the same community as 
those who are) have recently been reported among MSM, TGM and bisexual male communities in 
Sydney and Melbourne, Australia, associated with rapid PrEP scale for MSM, TGW and bisexual 
men176. Given that few of the demonstration and implementation projects underway in high-risk 
women in SSA have published results120, it is too early to rule out behavioural disinhibition as a 
reality for high-risk women taking PrEP in SSA. There are also more limited concerns about increases 
in other risky behaviours on PrEP, such as increased numbers of sexual partners, however concerns 
surrounding reductions in condom use have predominated, potentially in relation to the more direct 
motivations for condomless sex, as well as results of PrEP studies to date85,177. 
In response, many mathematical modelling studies of PrEP over the past decade have assessed the 
impact of reduced condom use following PrEP commencement, and concluded that this would lead 
to lower levels of HIV risk reduction, as well lower PrEP cost-effectiveness126,137,178–182. Concerns 
around behavioural disinhibition in relation to the introduction of other new HIV prevention 
interventions, such as the STI-efficacious microbicide, had previously been assessed through 
mathematical modelling studies, quantifying the extent to which the intervention may be of benefit, 
even with sub-optimal product adherence161,183. However, at the time of commencing this PhD (and 
to date, other than the study that arose through this PhD), no mathematical modelling study had 
been undertaken to understand the extent to which reductions in condom consistency on PrEP 
could take place without increasing HIV risk, including for high-risk women in SSA, should it become 
an implementation reality.  
Scale-up of PrEP for individuals beyond those at highest HIV risk 
With PrEP proven an effective HIV prevention intervention for those achieving defined levels 
adherence115, 116, policy makers in many countries in SSA (such as South Africa121, Zimbabwe181 and 
Kenya182) are now considering how best roll out PrEP among at-risk populations, considering impact 
and cost-effectiveness in resource constrained environments4,85,150,186. Among high-risk women in 
countries in SSA, FSW are being prioritised due to their elevated risk, and in some cases 
AGYW121,181,182,187,188. However, women in SSA are on a spectrum of risk, with heterogeneous risk 
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factors, including in numbers of partners, HIV and STI prevalence in partner populations, condom 
use, ART and VMMC coverage among partners of different types, periods of risk, making it difficult 
to target PrEP appropriately4,12,189–191. Additionally, female population groups with lower HIV 
incidence rates are larger in number than higher risk groups such as FSW, meaning that the greatest 
number of new infections in absolute terms are occurring in comparatively lower-risk 
groups16,17,191,192. The limited information available on the PrEP program cascade outcomes (including 
uptake, retention and adherence) also varies by female population and context, as with the number 
of secondary infections resulting from each infection in a high-risk woman group, altogether making 
it challenging to know how to most effectively scale-up PrEP beyond highest-risk groups120,150,186.  
Many of the PrEP demonstration and implementation projects have used screening tools to identify 
those at significant risk85, though have received criticism for having better sensitivity than specificity, 
and not being sufficiently focused to identify those that would most benefit from PrEP193,194. There is 
also now growing momentum from community groups to move from targeted programs for key 
population groups towards universal access to PrEP as part of a rights-based approach to 
health195,196. 
Many mathematical modelling studies have assessed the impact and cost-effectiveness of PrEP for 
high-risk populations in sub-Saharan Africa182,197–200, between population groups (between key 
populations or key populations and men/ women in the general population)200–202, as well as relative 
to other HIV prevention interventions203–205. The studies conclude PrEP to be less cost-effective than 
other prevention interventions such as condoms, but cost-effective as part of a combination 
prevention approach for those at greatest risk182,197–205. Modelling studies have not systematically 
accounted for the low levels of PrEP program adherence and retention reported across different 
high-risk women groups in SSA182,197–205. None of the studies to date have addressed the scale-up of 
PrEP across high-risk women population groups in SSA, considering heterogeneities in risk factors, 
PrEP program outcomes, population size, and their effect on population-level impact and cost-
effectiveness considerations to guide local strategies for PrEP roll-out.  
1.2.5 Summary of open policy questions around PrEP implementation for high-risk women in SSA 
As this review illustrates, there are many outstanding policy questions surrounding PrEP 
implementation for high-risk women in sub-Saharan Africa. These include: 
1. Which strategies can be undertaken to improve PrEP uptake, retention and adherence?
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2. How effective are alternative PrEP dosing strategies and formulations in strengthening 
programme outcomes? 
3. The extent to which behavioural disinhibition may outweigh the potential HIV-protective 
benefits of PrEP, should it become an implementation reality?  
4. How to prioritise PrEP scale-up across high-risk women, weighing considerations of impact and 
cost-effectiveness in resource constrained environments? 
Open questions 1 and 2 will be predominantly answered through RCTs, OLE, demonstration and 
implementation trials, with the aid of mathematical modelling studies to help assess outcomes, 
especially when undertaken alongside the trials. 
Open questions 3 and 4 can be explored independently of trials using mathematical modelling 
methods. As this PhD is not attached to an intervention trial, it will focus on open questions 3 and 4 
using modelling approaches.  
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1.3 Modelling for HIV policy making 
Mathematical models play an important role in public health by providing policy makers with 
evidence to inform decision making 206–208. They are quantitative frameworks that draw upon data, 
evidence and processes from a number of different disciplines (for example, demography, biology, 
economics, epidemiology, anthropology, behavioural sociology) to generate evidence of past or 
projected impact and cost-effectiveness of programmes or interventions. They can be evaluated 
over very short (hours, days, weeks) to very long (multiple decades) time horizons.  
Mathematical models allow policymakers to assess the impact of policy options under consideration, 
which may be impractical or unethical to test in implementation settings or over longer time 
horizons206,209. Undertaken alongside implementation studies, they can be used to evaluate the 
impact and, when combined with costing data, the cost-effectiveness of interventions or program 
approaches207,210. Mathematical models allow policy makers to explore the role of heterogeneity in 
risk, program or implementation factors on a study’s outcome; or the effect of factors within or 
external to a study207,211. They also provide evidence to assess non-linearities between HIV risk 
factors or HIV infection and programme outcomes, to weigh the effects of circular interactions (for 
example, behavioural disinhibition following introduction of PrEP), and to explore how different time 
horizons of evaluation affect decision making212.  
This section gives an overview of the use of mathematical modelling in HIV policy making in five 
areas. It presents an overview of different model types used in HIV policy making; how models 
account for uncertainty; how models are fit to observed data; how they have been used to date in 
HIV policy making; and the challenges around their use. 
 
1.3.1 Overview of different model types for use in HIV policy making 
Mathematical models are simplified representations of complex realities and situations209. There are 
many possible (not necessarily mutually exclusive) forms that a model can take to address policy 
questions in relation to an infectious disease such as HIV.  
This sub-section gives an overview of the different forms that models can take in addressing 
questions of relevance to HIV policy making. It is split into two parts. First, an overview of the key 
considerations of more direct relevance to policy makers213. Second, an overview of other model 
considerations faced by modellers in ensuring the model is appropriate to addresses the policy 
question at hand209,213. 
46 
 
Overview of key model considerations of direct relevance to policy makers 
Static vs dynamic models 
Static models do not account for feedback loops affecting the force of infection (rate at which 
susceptible individuals are infected) over time209. Instead, the force of infection takes a 
predetermined value and does not capture the downstream effects of population interaction. For 
example, if modelling the risk of HIV infection to a FSW through sexual intercourse with male clients, 
the likelihood that the client population is HIV infected (i.e. the HIV prevalence) does not change 
over time. If the model shows the FSW’s risk of infection going up over time, static models do not 
capture the downstream effects on clients’ HIV prevalence, and in turn, this onward effect on FSWs’ 
future risk of infection.  
Static models of HIV risk are typically employed when the time horizon for evaluation of the policy 
question is short, and assumes the probability of exposure to the infectious diseases is constant for 
the time period under examination and therefore unaffected by programme, policy or other 
epidemiological or social changes214. They are generally structurally more straightforward, less data- 
and time-intensive to develop209,215 and often form the basic building blocks for more complex 
models209. 
An example of a static model is the Bernouilli formulation of HIV risk216–218, where the probability of 
the HIV virus being transmitted through each sexual contact is treated as an independent risk event. 
This formulation of HIV risk is a Bayesian statistical approach, which assumes that model parameters 
are based on prior distributions which are used to make statistical inferences about that chance of 
an event happening219. The other main statistical approach for calculating risk is the frequentist 
approach, which defines the likelihood of an event based on the limit of its relative frequency over a 
large number of trials219. A simple formulation of the Bernouilli model of risk is as follows: 
𝜋𝜋 = 1 − (𝑝𝑝( 1 − 𝛽𝛽) + (1 − 𝑝𝑝))𝐶𝐶 
(1.1) 
Where, using the same example of a FSW’s risk from her clients, 𝜋𝜋 is the HIV risk to a FSW per unit of 
time, 𝑝𝑝 is the prevalence of HIV in the client population, 𝛽𝛽 is the average probably of HIV 
transmission during a sex act with an HIV-infected client, and 𝐶𝐶 is the total number of sex acts per 
unit of time. 
From this formulation, we can explore a simplified, intuitive version of the fundamental concept in 
infectious disease modelling, 𝑅𝑅0, the basic reproduction number, which represents the average 
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number of secondary infections arising from a single infectious person when introduced to a fully 
susceptible population220. 
𝑅𝑅0 = 𝛽𝛽𝐶𝐶𝛽𝛽, 
(1.2)
Where 𝛽𝛽 is the average duration of infectiousness in an individual. In HIV, the average duration of 
infectiousness is affected by whether or not an individual becomes virally supressed on ART, and 
indeed 𝛽𝛽, the risk of transmission per sex act with an HIV-infected partner, would change according 
to the stage of infection, which affects the level of infectiousness. This is a simplified version of the 
basic reproduction in the context of a homogeneous population, with more sophisticated, real 
world-like derivations calculable according model type and its complexity220,221.  
𝑅𝑅 0 is important in the analysis of infectious diseases as it represents the threshold for stability of a 
disease-free equilibrium. In a fully susceptible population, if 𝑅𝑅 0 > 1, then an infectious disease will  
persist in a population, and if 𝑅𝑅 0 < 1, it dies out. Although inevitably a simplification of complex 
realities, 𝑅𝑅 0 is an important measure at the start of an epidemic, to help predict the rate of 
infection invasion in a population, the potential magnitude of the outbreak and the impact of disease 
prevention and control interventions. 𝑅𝑅 0 takes comparatively less prominence when infectious 
diseases are at endemic equilibrium, such as in the HIV contexts in sub-Saharan Africa4 that will be 
explored through this thesis, but rather is used to help quantify the efforts needed to bring 𝑅𝑅 0 < 1 
for the disease to be on a trajectory to elimination222. 
Unlike static models, dynamic models, on the other hand, account for feedback loops affecting the 
force of infection and therefore can account for changes over time owing to population interactions 
and evolving contextual factors209. They are therefore able to more fully gauge the extent of an 
intervention’s impact across populations223. Continuing with the example of a FSW and male client 
population, the likelihood that the client population is HIV infected (i.e. the HIV prevalence) will 
change over time as a result of the interactions between (in this simple case) the FSW and her 
clients.  
Dynamic models are typically represented by a system of differential or difference equations, 
evaluated numerically using programming tools with increased data requirements214,215. They are 
usually more time-intensive and expensive to devise, calibrate and solve, and often require critical 
assumptions to be made about current and future trends215,224.  
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A simple dynamic model of static equation (1.1) can be approximated using the Kermack-McKendrick 
SIR system of differential equations209,225,226,227, where 𝑆𝑆(𝑡𝑡) is the number of susceptible individuals 
in a population at time 𝑡𝑡, 𝐼𝐼(𝑡𝑡) the number of infected, and 𝑅𝑅(𝑡𝑡), the number removed from the 
population. 
For FSW we have: 
𝑑𝑑𝑆𝑆𝑓𝑓(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑎𝑎𝑓𝑓𝑁𝑁𝑓𝑓0 − 𝜆𝜆𝑚𝑚(𝑡𝑡)𝑆𝑆𝑓𝑓(𝑡𝑡) −𝑚𝑚𝑓𝑓𝑆𝑆𝑓𝑓(𝑡𝑡) 
𝑑𝑑𝐼𝐼𝑓𝑓(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝜆𝜆𝑚𝑚(𝑡𝑡)𝑆𝑆𝑓𝑓(𝑡𝑡) − (𝑟𝑟 + 𝑚𝑚𝑓𝑓)𝐼𝐼𝑓𝑓(𝑡𝑡) 
𝑑𝑑𝑅𝑅𝑓𝑓(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑚𝑚𝑓𝑓𝑆𝑆𝑓𝑓(𝑡𝑡) + (𝑟𝑟 + 𝑚𝑚𝑓𝑓)𝐼𝐼𝑓𝑓(𝑡𝑡) 
And for the client population: 
𝑑𝑑𝑆𝑆𝑚𝑚(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑎𝑎𝑚𝑚𝑁𝑁𝑚𝑚0 − 𝜆𝜆𝑓𝑓(𝑡𝑡)𝑆𝑆𝑚𝑚(𝑡𝑡) −𝑚𝑚𝑚𝑚𝑆𝑆𝑚𝑚(𝑡𝑡) 
𝑑𝑑𝐼𝐼𝑚𝑚(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝜆𝜆𝑓𝑓(𝑡𝑡)𝑆𝑆𝑚𝑚(𝑡𝑡) − (𝑟𝑟 + 𝑚𝑚𝑚𝑚)𝐼𝐼𝑚𝑚(𝑡𝑡) 
𝑑𝑑𝑅𝑅𝑚𝑚(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑚𝑚𝑚𝑚𝑆𝑆𝑚𝑚(𝑡𝑡) + (𝑟𝑟 + 𝑚𝑚𝑚𝑚)𝐼𝐼𝑚𝑚(𝑡𝑡) 
 
With per capita forces of infection: 
𝜆𝜆𝑚𝑚(𝑡𝑡) = 𝛽𝛽𝑓𝑓𝑐𝑐𝑓𝑓 𝐼𝐼𝑚𝑚(𝑡𝑡)𝑁𝑁𝑚𝑚(𝑡𝑡)     and 𝜆𝜆𝑓𝑓(𝑡𝑡) = 𝛽𝛽𝑚𝑚𝑐𝑐𝑚𝑚 𝐼𝐼𝑓𝑓(𝑡𝑡)𝑁𝑁𝑓𝑓(𝑡𝑡). 
With total population sizes: 
𝑁𝑁𝑓𝑓(𝑡𝑡) = 𝑆𝑆𝑓𝑓(𝑡𝑡) + 𝐼𝐼𝑓𝑓(𝑡𝑡)  and 𝑁𝑁𝑚𝑚(𝑡𝑡) = 𝑆𝑆𝑚𝑚(𝑡𝑡) + 𝐼𝐼𝑚𝑚(𝑡𝑡). 
And the equations balanced using 
𝑐𝑐𝑓𝑓 = 𝑐𝑐𝑚𝑚𝑁𝑁𝑓𝑓/𝑁𝑁𝑚𝑚 
(1.3) 
Where 𝑎𝑎 is the rate of recruitment into the population, 𝑐𝑐 is the per capital rate of partner change, 𝑡𝑡0 
is at time zero, 𝑚𝑚 the non-AIDS related mortality rate, 𝛽𝛽 is the average probably of HIV transmission 
per sex act and 𝑟𝑟 the AIDS-related mortality rate. The subscript 𝑓𝑓 denotes females, and 𝑚𝑚 denotes 
males, and 𝑁𝑁𝑓𝑓0 and 𝑁𝑁𝑚𝑚0 are the initial population sizes of FSW and males respectively. 
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For deterministic compartmental models (see later section for description) of infectious diseases, 𝑅𝑅0 
can be calculated using a Next Generation Matrix approach, as set out by Diekmann228, van den 
Driessche and Watmough229, Jones230, Mukandavire231 and others, using the linearized matrices. 
Following van den Driessche and Watmough229 approach, we have: 
𝐹𝐹 = �𝜕𝜕𝐹𝐹𝐼𝐼(𝑥𝑥0)
𝜕𝜕𝑥𝑥𝑗𝑗
� and 𝑉𝑉 = �𝜕𝜕𝑉𝑉𝐼𝐼(𝑥𝑥0)
𝜕𝜕𝑥𝑥𝑗𝑗
�, 
(1.4) 
Where 𝐹𝐹𝐼𝐼 is the rate at which newly infected individuals enter the infected compartment, 𝐼𝐼; 𝑉𝑉𝐼𝐼 is the 
transfer of individuals out of and into the infected compartment by individuals 𝑗𝑗 in classes 𝑅𝑅 and 𝑆𝑆 
respectively; and 𝑥𝑥0 is the disease-free equilibrium state. Then, for FSW: 
𝐹𝐹𝑓𝑓 = 𝛽𝛽𝑓𝑓𝑐𝑐𝑓𝑓𝑆𝑆𝑓𝑓(𝑡𝑡) 𝐼𝐼𝑚𝑚(𝑡𝑡)𝑁𝑁𝑚𝑚(𝑡𝑡)  and 𝑉𝑉𝑓𝑓 = �𝑚𝑚𝑓𝑓𝑆𝑆𝑓𝑓(𝑡𝑡) − 𝑎𝑎𝑓𝑓𝑁𝑁𝑓𝑓0(𝑟𝑟 + 𝑚𝑚𝑓𝑓)𝐼𝐼𝑓𝑓(𝑡𝑡) �. 
(1.5) 
With disease free equilibrium when 𝑆𝑆𝑓𝑓0 = 𝑎𝑎𝑓𝑓𝑁𝑁𝑓𝑓0𝑚𝑚𝑓𝑓 . 
The Next Generation Matrix 𝐹𝐹𝑉𝑉−1gives the expected number of secondary cases in compartment 𝐼𝐼 
by an individual in compartment 𝑗𝑗. 𝑅𝑅0f, the number of new female infections produced by a typical 
infected male at disease free equilibrium is determined by the spectral radius (i.e. dominant 
eigenvalue) of the system, as follows (noting, here 𝑁𝑁𝑓𝑓0 = 𝑆𝑆𝑓𝑓0): 
𝑅𝑅0f = 𝛽𝛽𝑓𝑓𝑐𝑐𝑓𝑓𝑆𝑆𝑓𝑓0𝑆𝑆𝑚𝑚0(𝑟𝑟 + 𝑚𝑚𝑓𝑓) 
(1.6) 
Similarly, for males: 
𝐹𝐹𝑚𝑚 = 𝛽𝛽𝑚𝑚𝑐𝑐𝑚𝑚𝑆𝑆𝑚𝑚(𝑡𝑡) 𝐼𝐼𝑓𝑓(𝑡𝑡)𝑁𝑁𝑓𝑓(𝑡𝑡)  and 𝑉𝑉 = �𝑚𝑚𝑚𝑚𝑆𝑆𝑚𝑚(𝑡𝑡) − 𝑎𝑎𝑚𝑚𝑁𝑁𝑚𝑚0(𝑟𝑟 + 𝑚𝑚𝑚𝑚)𝐼𝐼𝑚𝑚(𝑡𝑡) �. 
(1.7) 
With disease-free equilibrium when 𝑆𝑆𝑚𝑚0 = 𝑎𝑎𝑚𝑚𝑁𝑁𝑚𝑚0𝑚𝑚𝑚𝑚 , and  
𝑅𝑅0m = 𝛽𝛽𝑚𝑚𝑐𝑐𝑚𝑚𝑆𝑆𝑚𝑚0𝑆𝑆𝑓𝑓0(𝑟𝑟 + 𝑚𝑚𝑚𝑚) 
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(1.8) 
Then, for the system, 𝑅𝑅0, the expected number of secondary infections by an infected individual is: 
𝑅𝑅0 = �𝑅𝑅0f𝑅𝑅0m = � 𝛽𝛽𝑓𝑓𝑐𝑐𝑓𝑓𝛽𝛽𝑚𝑚𝑐𝑐𝑚𝑚(𝑟𝑟+𝑚𝑚𝑓𝑓)(𝑟𝑟+𝑚𝑚𝑚𝑚) ,    
 (1.9) 
Which is the average number of secondary infections arising from a primary infection. When 𝑅𝑅0 < 1 
the disease-free equilibrium is locally asymptotically stable, and when 𝑅𝑅0 > 1 the disease will persist 
in the population.  
Comparisons of static and dynamic models are explored through the 2nd research chapter of this 
thesis. 
 
Stochastic vs deterministic 
Stochastic models capture uncertainty in transition between the different states represented by the 
model. They are formulated using probabilistic random variables, such that for the same set of initial 
conditions, a stochastic model’s outcome will vary209. They can be modelled as individual-based 
models, tracking the path of an individual through a model, with chance affecting whether they get 
infected, or compartmental models (see later section for description), where the individual are 
treated as a group or compartment, with chance determining what happens to the group in 
total209,232. Stochastic models should be repeated a large number of times to build up a picture for 
the decision maker to assess, overall, the likely outcomes of an approach of interest209. Monte Carlo 
models are example stochastic models, which use parameter values randomly drawn according to 
set distributions, and with repeated runs can be used to ascertain the likelihood of an outcome 
happening210. Such models are often used in accounting for data uncertainty in models but tend to 
be difficult to simulate without the use of computing resources209. 
Deterministic models have a set pathway, such that with the same parameter values and initial 
conditions, the results of a model’s simulation will always be the same232. They tend to be more 
straightforward to calculate, and, in general, to describe to and be understood by policy makers, but 
are a more simplified version of real-world dynamics209,213. Stochastic models are particularly 
appropriate for use with small population sizes, where chance may play an importance role in a 
population’s behaviour through an intervention or in population interactions, and therefore 
parameter and initial condition specification209. Deterministic models may be more appropriate with 
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larger population sizes where the effects of chance over a large number of interactions become 
much less significant, and the system conditions can be appropriately reflected by a set of states 
determined upfront based on parameter averages 233.  
Overview of key model considerations in determining appropriate model structure 
Capturing population heterogeneity 
Accounting for the appropriate level of model heterogeneity is a key concern of modellers in 
developing models to assess policy questions213. It is important that models appropriately represent 
a policy problem at hand by accounting for the key underlying heterogeneities that affect model 
outcomes221. This includes heterogeneities in epidemiological, risk and behavioural characteristics, in 
the dynamics of interaction between populations, progression through programme stages (e.g. 
intervention uptake, retention and adherence) and in relation to the policy question at hand (e.g. 
different scenarios under consideration)234,235. This level of model detail has to be balanced with the 
availability of data of reasonable quality, to ensure that model parameterization reasonably reflects 
the underlying population and programme under consideration, and does not inadvertently 
introduce inaccuracies in model outcomes209,210. 
Many of the choices faced by modellers in in determining the appropriate model structure to assess 
a policy question come about explicitly due to heterogeneity. For example, modellers must consider 
whether it is important that heterogeneity in transition between model states be represented 
stochastically rather than deterministically; or heterogeneity in partner mixing represented through 
individual-based network models rather than approximated using population averages (further 
description of these approaches are laid out later in this section). Heterogeneity adds complexity to 
models213. However, if models fail to capture important heterogeneities, their conclusions risk 
misleading policy makers209,213. 
Compartmental vs distributional 
Compartmental models divide a pathway into a set of states with parameters attached to govern 
individuals’ or populations’ transition between these set of states210. They are most appropriate 
when a policy problem or disease states can be broken down into distinct stages, and parameters 
(determined through stochastic or deterministic approaches) assigned to them209,210. An illustration 
of a compartmental model is set out in Figure 6. It sets out the pathway of HIV negative individuals 
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through a PrEP programme, and if they become HIV infected, their pathway through stages of 
disease progression (denoted by CD4 count) in the absence of ART, on ART, and following ART drop 
out. In compartmental models, each arrow between the compartments in Figure 6 would be 
parameterised to describe the chance of progression between model compartments. 
Distributional models, on the other hand, represent progression through disease states or a policy 
pathways using pre-determined distributions. Gradations of disease severity or pathway stages are 
used to assess the progression of individuals through these distributed states210.  
 
 
Discrete or continuous time 
The transition of individuals or populations through model states can be assessed either through 
discrete timesteps or continuously. When modelled through discrete time, progress through model 
states can only happen after defined time steps (e.g. 1 day, 3 months or 12 months). As such, model 
progression can be abrupt, rather than happening on an ongoing basis210. Discrete models allow 
model policy makers to understand the numbers of individuals in a given model state based on the 
number in that state at the previous point in time209. Discrete models are suited where transition 
through disease states or the policy pathway happen only after defined periods, and data is available 
to parameterise the model corresponding to larger discrete timesteps210. Discrete models can be 
evaluated in simple computing tools such as Microsoft Excel161.  
Modelling using continuous time on the other hand allows for transition between states to be 
continuous and happen on an ongoing basis through infinitely small timesteps221. These models can 
be evaluated at any point in time and are better suited where process happen in an ongoing 
manner221. Unlike with discrete models, it may not always be possible to describe the numbers of 
Figure 6: Illustrative compartmental model showing the pathway of HIV negative individuals through a PrEP programme, and 
when HIV infected, their pathway through stages of disease progression (denoted by CD4 count) in the absence of ART, on ART, 
and following ART drop out. 
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individuals in a given model state based on the number in that state at the previous point in time209. 
Continuous models usually need to be evaluated using computing tools, as they are evaluated using 
differential calculus210. However, in practice, many models such as the SIR models set out in 
equation (1.3) can equally be evaluated using discrete and continuous time using the same 
computing tools236.  
For example, the differential SIR model in equation (1.3) can be written in discrete form237, using 
difference equation formulation, as follows:  
For FSW: 
𝑆𝑆𝑓𝑓𝑡𝑡+1 = 𝑎𝑎𝑓𝑓𝑁𝑁𝑓𝑓0 − 𝜆𝜆𝑚𝑚𝑡𝑡𝑆𝑆𝑓𝑓𝑡𝑡 − 𝑚𝑚𝑓𝑓𝑆𝑆𝑓𝑓𝑡𝑡  
𝐼𝐼𝑓𝑓𝑡𝑡+1 = 𝜆𝜆𝑚𝑚𝑡𝑡𝑆𝑆𝑓𝑓𝑡𝑡 − (𝑟𝑟 + 𝑚𝑚𝑓𝑓)𝐼𝐼𝑓𝑓𝑡𝑡  
𝑅𝑅𝑓𝑓𝑡𝑡+1 = 𝑚𝑚𝑓𝑓𝑆𝑆𝑓𝑓𝑡𝑡 + (𝑟𝑟 + 𝑚𝑚𝑓𝑓)𝐼𝐼𝑓𝑓𝑡𝑡  
And for the client population: 
𝑆𝑆𝑚𝑚𝑡𝑡+1 = 𝑎𝑎𝑚𝑚𝑁𝑁𝑚𝑚0 − 𝜆𝜆𝑓𝑓𝑡𝑡𝑆𝑆𝑚𝑚𝑡𝑡 − 𝑚𝑚𝑚𝑚𝑆𝑆𝑚𝑚𝑡𝑡 
𝐼𝐼𝑚𝑚𝑡𝑡+1 = 𝜆𝜆𝑓𝑓𝑡𝑡𝑆𝑆𝑚𝑚𝑡𝑡 − (𝑟𝑟 + 𝑚𝑚𝑚𝑚)𝐼𝐼𝑚𝑚𝑡𝑡 
𝑅𝑅𝑚𝑚𝑡𝑡+1 = 𝑚𝑚𝑚𝑚𝑆𝑆𝑚𝑚𝑡𝑡 + (𝑟𝑟 + 𝑚𝑚𝑚𝑚)𝐼𝐼𝑚𝑚𝑡𝑡 
With per capita forces of infection: 
𝜆𝜆𝑚𝑚𝑡𝑡 = 𝛽𝛽𝑓𝑓𝑐𝑐𝑓𝑓 𝐼𝐼𝑚𝑚𝑡𝑡𝑁𝑁𝑚𝑚𝑡𝑡     and 𝜆𝜆𝑓𝑓𝑡𝑡 = 𝛽𝛽𝑚𝑚𝑐𝑐𝑚𝑚 𝐼𝐼𝑓𝑓𝑡𝑡𝑁𝑁𝑓𝑓𝑡𝑡. 
With total population sizes: 
𝑁𝑁𝑓𝑓𝑡𝑡 = 𝑆𝑆𝑓𝑓𝑡𝑡 + 𝐼𝐼𝑓𝑓𝑡𝑡  and 𝑁𝑁𝑚𝑚𝑡𝑡 = 𝑆𝑆𝑚𝑚𝑡𝑡 + 𝐼𝐼𝑚𝑚𝑡𝑡 . 
And the equations balanced using 
𝑐𝑐𝑓𝑓 = 𝑐𝑐𝑚𝑚𝑁𝑁𝑓𝑓𝑡𝑡/𝑁𝑁𝑚𝑚𝑡𝑡 
(1.10) 
Here, 𝑡𝑡 is time. As the time steps in discrete models become infinitesimally small, they tend towards 
continuous-time models209,238. That is, where the size of the timestep, 𝛿𝛿𝑡𝑡 becomes infinitesimally 
small: lim
𝛿𝛿𝑡𝑡→0 𝑆𝑆𝑡𝑡+𝛿𝛿𝑡𝑡−𝑆𝑆𝑡𝑡𝛿𝛿𝑡𝑡 → 𝑑𝑑𝑆𝑆(𝑡𝑡)𝑑𝑑𝑡𝑡 , lim𝛿𝛿𝑡𝑡→0 𝐼𝐼𝑡𝑡+𝛿𝛿𝑡𝑡−𝐼𝐼𝑡𝑡𝛿𝛿𝑡𝑡 → 𝑑𝑑𝐼𝐼(𝑡𝑡)𝑑𝑑𝑡𝑡  and lim𝛿𝛿𝑡𝑡→0 𝑅𝑅𝑡𝑡+𝛿𝛿𝑡𝑡−𝑅𝑅𝑡𝑡𝛿𝛿𝑡𝑡 → 𝑑𝑑𝑅𝑅(𝑡𝑡)𝑑𝑑𝑡𝑡     
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(1.11)
In other words, the system of equations in (1.10) tends towards the system of equations in (1.3). 
Individual-based network vs population averages 
Network models can be used to describe the system or network of contacts between individuals 
with sexual partnerships, with the risk of infection dependent on the individuals with whom a person 
is connected209. Such models can be a powerful tool for understanding the role of specific networks 
in disease spread. However, they require very detailed, individual-level parameterization, which is 
often not feasible to collect in practice, and the results of network models often not broadly 
generalisable at population level210. Models otherwise, and more often, use population averages to 
describe to parameterise and describe transition through model stages, capturing heterogeneity 
through model stratification according to key heterogenous characteristics or transition 
parameters210.  
1.3.2 Accounting for uncertainty 
There are two main types of uncertainty to be accounted for in modelling infectious diseases – 
parametric (about the model parameters) and structural (about the model’s structure). 
Parametric uncertainty 
Uncertainty in the underlying data used to parameterise a model can be estimated through 
Frequentist or Bayesian approaches. Both aim to give policy and decision makers a level of 
understanding around the uncertainty in model outcomes due to uncertainty in model inputs. 
Frequentist inference approaches assume that parameters have fixed (unknown) values and cannot 
be ascribed underlying distributions with associated probabilities239. They involve deriving parameter 
estimates using approaches such as maximum likelihood functions, to obtain the best fit model to 
observed data (e.g. HIV prevalence), then generating multiple samples from the best fit model using 
methods such as bootstrapping, to re-estimate parameters and then quantify uncertainty in 
underlying data sets240,241. They are used to produce (e.g. 95%) confidence intervals, indicating that 
over large number of samples, (e.g. 95%) of confidence intervals calculated would contain this range 
of values239. 
55 
𝑁𝑁𝑚𝑚0
Bayesian inference approaches are used to assess uncertainty around model parameter inputs as 
well as outputs242,243. They assume prior distributions for parameters, and combine them with 
likelihoods derived through methods such as Monte Carlo simulations to build up parameter 
sets242,244. These simulated parameter sets are run through the model and typically fitted to 
observed data ranges (e.g. HIV prevalence)245,240. Uncertainty in model outcomes is then described 
by calculating (e.g. 95%) credible intervals based on this data, which signifies that there is (e.g. 95%) 
certainty that the true value lies within this range246,247. Bayesian inference approaches are 
nowadays more typically used in estimating parameter uncertainty and fitting models to data where 
prior distributions can reasonably estimated for parameters248,244, and since 2006 have been used in 
UNAIDS’s core modelling approaches for estimating uncertainty in national HIV estimates 
(Estimation and Projection Package, EPP, using Bayesian Melding and Spectrum using Monte Carlo 
methods)249,250. 
Two common Bayesian methods for accounting for model uncertainty and fitting to data using 
different approaches for deriving likelihoods are illustrated in Figure 7 and Figure 8. First, the 
Markov Chain Monte Carlo (MCMC) approach, where a chain is constructed through a ‘walk’ over a 
defined parameter space, constantly checking the closeness of the model outcome for each new 
parameter explored with a target outcome, and adjusting its path so that it converges towards the 
target outcome251,252. The example uses equation (1.3), and for illustrative purposes, simulates 
MCMC chains only on the parameters 𝛽𝛽𝑓𝑓 and 𝛽𝛽𝑚𝑚 (the probably of HIV transmission during a sex act 
with an HIV infected partner to women and men respectively), and uses the following model 
parameters: [𝑁𝑁𝑓𝑓0 = 1000, 𝐶𝐶𝑚𝑚  = 37, 𝐶𝐶𝑓𝑓 = 4, 𝐼𝐼 𝑚𝑚0  = 0.24, 𝑚𝑚𝑓𝑓  = 0.0005, 𝑚𝑚𝑓𝑓  = 0.0006, 𝑟𝑟 = 0.0002,
𝛽𝛽𝑓𝑓 ,𝛽𝛽𝑚𝑚𝜖𝜖[0,0.01], with starting values for the chain of 0.0001] over 1000 iterations. Figure 7 below 
sets of the MCMC chains simulated for 𝛽𝛽𝑓𝑓 and 𝛽𝛽𝑚𝑚, and Figure 8 the histograms of the posterior 
distributions generated. 
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Figure 7: MCMC chain for equation (1.3), for parameters 𝜷𝜷𝒇𝒇 and 𝜷𝜷𝒎𝒎.  
The x-axis shows the number of iterations and y-axis the parameter values explored. The MCMC chains were simulated 
using the following parameter values: [𝑁𝑁𝑓𝑓0 = 1000,𝐶𝐶𝑚𝑚 = 37, 𝐶𝐶𝑓𝑓 = 4, 𝐼𝐼𝑚𝑚0𝑁𝑁𝑚𝑚0 = 0.24, 𝑚𝑚𝑓𝑓 = 0.0005, 𝑚𝑚𝑓𝑓 = 0.0006, 𝑟𝑟 =0.0002, 𝛽𝛽𝑓𝑓,𝛽𝛽𝑚𝑚𝜖𝜖[0,0.1] with starting values for the chain of 0.0001] over 1000 iterations.  
 
Figure 8: Histograms of the posterior distributions derived for parameters 𝜷𝜷𝒇𝒇 and 𝜷𝜷𝒎𝒎 from equation (1.3) using MCMC.  
The x-axis shows the parameter values and y-axis the frequency. The MCMC chains were simulated using the following 
parameter values: [𝑁𝑁𝑓𝑓0 = 1000,𝐶𝐶𝑚𝑚 = 37, 𝐶𝐶𝑓𝑓 = 4, 𝐼𝐼𝑚𝑚0𝑁𝑁𝑚𝑚0 = 0.24, 𝑚𝑚𝑓𝑓 = 0.0005, 𝑚𝑚𝑓𝑓 = 0.0006, 𝑟𝑟 = 0.0002, 𝛽𝛽𝑓𝑓,𝛽𝛽𝑚𝑚𝜖𝜖[0,0.01] 
with starting values for the chain of 0.0001], over 1000 iterations.  
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The Latin Hypercube Sampling (LHS) is a type of Monte Carlo simulation that works by dividing the 
cumulative density function of each parameter into equal spaces, and sampling randomly from each 
of the spaces253,254,255. These sampled parameter values are run through the model and those sets of 
sampled parameters within a range of observed data are taken as fits and used to build up 
uncertainty intervals around model outcomes253,254,255. Compared to other Monte Carlo-based 
approaches, LHS is considered to be particular efficient computationally254,255. As an illustration, 
Figure 9 sets out the resulting distribution (range, standard deviation and range) of model outcomes 
(HIV prevalence in females (left) and males (right)) through LHS performed on parameters 𝛽𝛽𝑓𝑓 and 𝛽𝛽𝑚𝑚 
using equation (1.3) and the parameter sets as described above for the MCMC simulation. 
 
Figure 9: Graphs showing the range (min, max), median and standard deviation using all sampled parameters for 𝜷𝜷𝒇𝒇 and 
𝜷𝜷𝒎𝒎 from equation (1.3) using LHS.  
The range is shown in light blue, the standard deviation in dark blue and the median in black. The x-axis is the time steps 
and the y- axis HIV prevalence (%) for females (left had side) and males (right hand side). The LHS were run using the 
following parameter values: [𝑁𝑁𝑓𝑓0 = 1000,𝐶𝐶𝑚𝑚 = 37, 𝐶𝐶𝑓𝑓 = 4, 𝐼𝐼𝑚𝑚0𝑁𝑁𝑚𝑚0 = 0.24, 𝑚𝑚𝑓𝑓 = 0.0005, 𝑚𝑚𝑓𝑓 = 0.0006, 𝑟𝑟 = 0.0002, 
𝛽𝛽𝑓𝑓,𝛽𝛽𝑚𝑚𝜖𝜖[0,0.01] with starting values for the chain of 0.0001], over 1000 iterations.  
 
Structural uncertainty 
As noted above, a model’s structure should be driven by its intended use, and ideally represent the 
key policy or programme states under evaluation, as well as important heterogeneities in relation to 
populations, their interactions and underlying epidemiology, as well as data availability235. 
Uncertainty in model structure is usually assessed through introducing greater, and also lesser, 
complexity in the structure of the model, and then comparing outcomes256–259. For example, 
modellers can start with simpler structural versions of a model and progressively add more 
structural heterogeneity, to gain understanding into how model structural complexity affects a 
model’s outcome235,258.  
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In practice, however, it is difficult to separately address model structural uncertainty in the absence 
of assessing parametric uncertainty. For example, introducing greater model structural 
heterogeneity also necessitates greater heterogeneity in parameterization256. One technique called 
Bayesian Model Averaging, an extension of Bayesian inference methods260, has been developed to 
concurrently address structural and parametric uncertainty in stochastic modelling 261. The 
technique averages over a set of models that are supported by the underlying data, requires 
specification of prior distributions of competing models and then averages over the class of models 
deemed to be most appropriate261. However, in practice, the requirements for performing such 
analyses are too vast and require too many assumptions to be practicable260,261.  
 
1.3.3 Fitting models to data 
Fitting models to observed data aims to improve the accuracy of model predictions209. Model fitting 
is undertaken by ensuring that the sets of parameters used by the model to describe the as-is 
situation give rise to observed basic model outcomes (e.g. populations’ prevalence or incidence)262. 
Where models are evaluated over time horizons, their accuracy can be strengthened if they can be 
fit to observed data at several point in the past, thereby appropriately depicting the past epidemic 
course. This is undertaken with the hope that when the model with fitted parameter sets is then 
used to evaluate a policy question (e.g. introduction of an intervention, or a counterfactual), its 
outcomes will be more likely to be grounded in implementation realities262.  
There are a wide range of approaches for fitting models to data, usually based on minimizing the 
distance between model predictions and observed data using goodness of fit statistics263. Examples 
of fitting approaches include least square approaches where parameter sets are adopted that lead 
to the least sum of squares between predicted and observed outcome data; or maximum likelihood 
approaches where parameter sets are adopted that maximise the likelihood of observing the 
outcome data209. 
Where approaches are concurrently being used to estimate uncertainty in model outcomes, credible 
intervals around model parameters can be obtained at the same time as the best fitting parameter 
values209. This can be done through a variety of approaches, including the Bayesian MCMC and Latin 
Hypercube Sampling approaches previously described, using algorithms to generate parameter sets 
and select those as ‘fits’ that lead to model outcomes within observed data ranges244,255.  
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1.3.4 Use of models in HIV policy making  
Mathematical models have been used to inform HIV policy making since the early days of the HIV 
epidemic response85,264–269. Their key uses in HIV policy making include informing normative 
guidance setting85,113,270; informing resource allocation across populations, interventions and 
geographies at global, regional, national and sub-national levels based on consideration of impact 
and cost-effectiveness201,271–273; supporting assessment of the results of intervention trials197,274,275; 
and informing strategy development, target setting and resource mobilization investment 
cases68,69,74,276,277. These models range from those which can be applied across multiple countries or 
tailored to multiple different implementation contexts93,202,272, to those built specifically to address 
particular policy questions at hand161,256,278. Whist very far from an exhaustive list, Table 4 illustrates 
a number of the mathematical models that have been used in informing policy and decision making 
at global, regional, national and subnational levels in recent years. For each model, the table sets out 
its key usages in policy and decision making, the model type, the approach that was used in 
accounting for data uncertainty and fitting to data, and the computing tool that the model was 
programmed in. 
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Model name Key usage in policy and decision making Model type 
Approach for assessing 
uncertainty and fitting to 
data 
Programme/ 
Package 
EPP279,280 Used by UNAIDS and countries in 
estimating and projecting national HIV 
prevalence in countries with generalised 
epidemics 
Dynamic, compartmental SI 
(susceptible, infected) model 
Bayesian, MC Melding  Java, R Studio 
Spectrum281 (suite of 
models including 
AIDS Impact Model 
(AIM) and Goals) 
Used by UNAIDS and countries, in 
conjunction with EPP, to estimate national 
HIV prevalence, as well as to assess the 
consequences (impact, cost) of the HIV 
epidemic and assess intervention choices. 
Used to inform the Global Fund 2017-2022 
Strategy targets and 5th and 6th 
replenishment investment cases276,269,68 
and UNAIDS Fast Track Strategy69. 
AIM is discrete, 
compartmental model282 
Goals is compartmental, 
based on Bayesian risk 
formulation273  
Bayesian, MC methods Java, Delphi 
Imperial College 
Model201,202 for sub-
Saharan Africa 
Used by researchers and countries to 
evaluate the consequences (impact, cost) 
of intervention choices on countries’ HIV 
epidemics, by population and sub-national 
location. Used to inform the Global Fund 
2017-2022 Strategy targets and 5th and 6th 
replenishment investment cases276,269,68. 
Dynamic compartmental 
model 
Bayesian, LHC methods Not specified202,201 
EMOD (Epidemic 
Modelling)283,87,284 
Used by researchers to evaluate the 
consequences (impact, cost) of 
intervention choices on countries’ HIV 
epidemics 
Discrete, stochastic, 
individual-based SIR model 
Bayesian methods C++ 
Optima272 Used by the World Bank to evaluate the 
consequences (impact, cost) of 
intervention choices on countries’ HIV 
Dynamic, differential 
compartmental model, with 
force of transmission based 
Bayesian methods MATLAB and 
Python 
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epidemics. Used to confirm Spectrum’s 
UNAIDS Fast Track Strategy modelling69.  
on Bayesian risk 
formulation.  
Modes of 
Transmission285,286,287 
Used by UNAIDS and countries to evaluate 
the consequences (impact, cost) of HIV 
prevention intervention choices  
Static, compartmental 
model based on Bayesian 
risk formulation. 
Not calibrated.  Uncertainty 
assessed using simple 
Bayesian approach involving 
uniform sampling from user-
prescribed plausibility ranges 
Excel 
HIV Synthesis 
Model288,289 
Used by researchers to evaluate the 
consequences (impact, cost) of 
intervention choices on countries’ HIV 
epidemics 
Individual-based, stochastic 
model 
Approximate Bayesian 
Computation methods 
SAS 
Thembisa290,291 Used by researchers to evaluate the 
consequences (impact, cost) of 
intervention choices on the South African 
HIV epidemic. Also used as data source for 
UNAIDS’s South African HIV estimates, and 
as demographic projection model for the 
country. 
Compartmental, discrete 
model 
Bayesian methods C++ and Excel/ VBA 
versions 
13 modelling studies 
assessed in 
systematic review of 
cost-effectiveness of 
PrEP197 
Modelling evidence used in WHO’s 2016 
normative guidance to provide PrEP for all 
individuals at substantial risk of HIV85 
Of 13 studies, 11 
deterministic transmission 
models, 2 stochastic Markov 
simulations   
Various Various 
Modelling studies 
assessed in 
determination of 
WHO’s 2015 and 
2016 treat all 
Strategy270,85  
Modelling evidence used in WHO’s 2015 
and 2016 normative guidance to provide 
ART for all people living with HIV 
Stochastic and deterministic 
transmission models 
(Granich292); deterministic 
transmission (Kato293); 
Literature review of 12 
studies: 9 deterministic 
compartmental, 3 individual-
Various  Various 
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based microsimulation 
(Eaton et al87) 
Table 4: Table illustrating a number of the mathematical models that have been used to inform policy and decision making at global, regional, national and subnational levels in recent 
years. 
The for each model, the table sets out its key usages in policy and decision making, the type of model, the approach that was used in accounting for data uncertainty and fitting to data, and 
the computing tool that the model was programmed in. The models listed in the table are far from exhaustive.   
63 
 
1.3.5 Challenges in use of models for policy making  
A predominant challenge and barrier to the use of models for policy making, as well as cause of 
misuse, is a perception that models are too complex to understand; referred to as intimidating ‘black 
box’ processes with challenges in assessing their applicability to real-life settings206,210,294–298. These 
challenges of model complexity span the models themselves, as well as challenges on the part of 
both modellers and policy makers. 
Model complexity can come from many sources including the level of heterogeneity captured in the 
model (e.g. populations and their interactions, risk factors, program and disease transition 
states)206,6,299; the model structure (e.g. simple static models may be more accessible to policy 
makers than simple dynamic models, which require a greater level of mathematical 
understanding215) and level of sophistication in data uncertainty and calibration tools6,300,301; and the 
accessibility of the tool in which the model computations are undertaken (e.g. Excel may be more 
accessible than computer programmes that require vast training)210,215.  Models that can be more 
easily understood, parameterized, run, and correctly interpreted by policy makers themselves, or 
with the partial support of modellers, may increase the likelihood of their uptake and use to inform 
decision making, as well as ownership by policy makers302,303. 
Challenges on the part of the modellers include the need to clearly distil key pieces of information 
around model structure, parameterisation and interpretation to ensure that the model being 
developed is appropriate to the context and question at hand6,301,234; and appropriately 
communicate the meaning and limitations of its results (including alignment with observed data and 
the results of other studies) through an approach that is accessible to policy makers that may not 
have advanced analytical training206,295,296,301.  On the part of policy makers, challenges include the 
need to engage with modellers to clearly communicate the rationale, scope and objectives of the 
modelling assignment296,301; key epidemiological, population, program and implementation 
characteristics that affect the policy question206; as well as availability and quality of data to 
parameterise the model, to ensure that the model can be structured appropriately296,304. 
 
Addressing challenges to do with modelling complexity  
In recent years, to facilitate the use of models to inform policy making, several frameworks have 
been put forward to guide the information exchange and facilitate dialogue between modelers and 
policy makers to address these communication challenges206,295–298,303–307.  
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Recommendations in the literature around model structural complexity suggest that to improve 
uptake in decision making, models should adopt only the minimum level of complexity needed to 
appropriately represent the policy question at hand, in view of the availability of data, important 
interactions between populations, heterogeneities in risk factors, program and disease transition 
states210,306,308–311. Einstein is quoted in stating: ‘‘Everything should be made as simple as possible, but 
not simpler’’309. In response to the lack of specificity of existing guidance around the requisite level 
of model structural complexity, a 2015 HIV Modelling Consortium dialogue between modellers and 
policy makers concluded that there is a need to better understand the minimum level of complexity 
to address policy questions295.  
Prudden et al. explored the importance of heterogeneity in population grouping according to risk 
factor in the context of low level, generalised epidemics, and concluded that the lack of 
heterogeneity in UNAIDS’s simple static Modes of Transmission model may underestimate the 
importance of different vulnerable groups (e.g. women engaged in transactional sex, and brothel-
based vs. non-brothel based FSW) in an HIV reponse285. Mishra et al. also explored the simple, static 
model Excel-based Modes of Transmission tool used extensively to prioritise HIV prevention 
interventions between groups at country-level285–287 They concluded that because the static model 
does not capture the dynamic effects of partner interaction, the model underestimates the 
contribution of epidemic drivers to HIV transmission over time286. 
When are simple, static models appropriate to guide policy making in HIV? 
Simple, static models form the basic building blocks for more complex models209. They can be 
manipulated through simple methodological approaches that may be comparatively accessible to 
policy makers, and used to deduce broad principles to help guide decision making210,264. They rely on 
a snap-shot of data without accounting for the downstream effects of population interaction209,215. 
They typically are more straightforward structurally, are less data- and time-intensive to develop, 
can often be programmed in simpler programming tools such as Excel209,215. Simple, static models 
therefore have appeal for use in policy making, making them easier tool with which to engage policy 
makers, and in view of data limitations in implementation contexts302,303.  
A key attribute of static models that differentiates them from structurally more complex models is 
their lack of ability account for time-dependent changes209,215. Unlike static models, dynamic models 
account for changes over time owing to population interactions and evolving contextual 
factors215,224. They are usually structurally more complex, have significantly increased data 
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requirements and need to be evaluated using more advanced programming tools215,214. As a result, 
dynamic model are more time-intensive and costly to develop, usually require assumptions to be 
made about relationships and parameters that are not empirically available, and may be less 
accessible to policy makers215,224. Dynamic models are extensively used across models to inform 
policy making at global, national and sub-national levels87,197,201,202,272,280,281,290,292,293 including the 
majority of those set out in Table 4.  
To date, there has been limited assessment of the conditions under which simple static models are 
robust enough to guide policy making in HIV224,285,286,295. In this vein, as previously stated, Mishra et 
al. have assessed the static Modes of Transmission model and concluded that by not capturing the 
dynamic effects of partner interaction, the model underestimates the contribution of epidemic 
drivers to HIV transmission over time286. Foss et al. have incorporated dynamic features into a static 
model of HIV risk when exploring the impact of an STI-efficacious microbicide, and compared the 
models’ projections at an end timepoint161,183. They concluded that the static model may over- or 
under-state the magnitude of microbicide efficacy depending on the product’s HIV-risk reduction 
characteristics and behavioural disinhibition161,183.  
To the best of my knowledge, no study has yet examined the extent to which the conclusions of 
static models remain robust to the incorporation of dynamic effects when considering the 
introduction of a new HIV prevention intervention. Considering the opportunity for mathematical 
modelling to address some of the key outstanding questions in relation to PrEP introduction for high-
risk women in sub-Saharan Africa, such studies would provide an opportune case study for exploring 
the conditions under which static models can provide adequate insights to inform HIV policy making. 
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1.4 PhD aims and objectives 
1.4.1 Summary of open questions to be addressed by thesis 
In view of the urgent need to address the disproportionate and vast scale of new HIV infections 
across the spectrum of high-risk women in sub-Saharan Africa as set out in section 1.1, this thesis 
aims to address the open policy questions 3 and 4 from section 1.2 that can be directly addressed 
through mathematical modelling approaches, and the open methodological question around the 
contexts in which static models can provide adequate insights to support policy making concerning 
the introduction of a new HIV prevention intervention. 
Specifically, this PhD research will aim to use mathematical modelling to inform policy making 
around the scale-up of PrEP for high-risk women in sub-Saharan Africa. It will intend to do so by 
accounting for the heterogenous behavioural and epidemiologic risk factors and PrEP programme 
outcomes across women at a spectrum of risk in sub-Saharan Africa, exploring: 
- The extent to which behavioural disinhibition may outweigh the potential HIV-protective
benefits of PrEP
- Strategies for scale-up of PrEP across women at a spectrum of risk in sub-Saharan Africa,
weighing impact and cost-effectiveness considerations in resource constrained environments
- The conditions under which static models remain robust to the incorporation of dynamic model
effects when evaluating the introduction of a new HIV prevention intervention
Accordingly, the aims and objectives of this PhD are set out on the following page. 
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1.4.2  Aim and objectives 
Aim: to use mathematical modelling to inform policy making around the scale-up of PrEP for women 
across a spectrum of high HIV risk in sub-Saharan Africa, accounting for heterogeneities in HIV risk 
factors and potential PrEP programme outcomes 
Objectives: 
The specific objectives are to: 
1. Assess the potential effectiveness of PrEP in reducing HIV infections among high-risk women in
sub-Saharan Africa
2. Explore the extent to which behavioural disinhibition may outweigh the potential benefits of
PrEP
3. Assess the robustness of conclusions made on the basis of static modelling techniques to
incorporation of dynamic effects, to contribute to understanding around the importance of
modelling complexity to inform HIV policy making
4. Explore strategies for the scale-up of PrEP across high-risk women at population-level, weighing
considerations around HIV infection reduction and cost-effectiveness
5. Evaluate strategies for PrEP scale-up in more than one country setting in sub-Saharan Africa, to
explore how the approach to PrEP scale-up may differ by epidemic and implementation context
The next chapter sets out the methods adopted in responding to the aim and objectives of this 
thesis. 
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Chapter 2 
2. Thesis Methods 
 
2.1  Overview of Thesis Methods 
This thesis adopts mathematical modelling approaches to inform HIV policy making. First, a simple 
static model of HIV risk to FSW is developed using the established Bernouilli1–4 formulation. It is used 
to assess the impact of behavioural disinhibition on PrEP’s ability to avert HIV infections, accounting 
for heterogeneities in FSWs’ initial condom consistency and PrEP adherence. The static model is then 
evolved into a more complex dynamic model formulation, using a system of difference equations, to 
account for the downstream effects of population interactions. The outcomes of the static and 
dynamic models are compared over different time horizons and epidemic contexts, to explore the 
conditions under which the policy conclusions based on the two models are consistent. Finally, the 
static model is refined to represent women across a more broadly defined spectrum of HIV risk: 
women 15-24 years, 25-34 years and 35-49 years, in addition to FSW. These models are used to 
explore the cost-effectiveness and population-level impact of PrEP scale-up from FSW to women in 
the general population, in order to highlight policy considerations as countries consider rolling out 
PrEP beyond those at highest individual risk.  
The models are parameterised to case study countries spanning a range of high HIV burden contexts 
in sub-Saharan Africa: South Africa, Zimbabwe and Kenya, using published biological, 
epidemiological and sexual behavioural data. The models are solved using both analytical and 
numerical mathematical approaches, and using both Microsoft Excel (for Office 365) and the R 
programming environment5. The static and dynamic models are fitted to data using Bayesian Monte 
Carlo Filtering with Latin Hypercube Sampling assuming uniform prior distributions. The following 
sections present more detailed information on the methods used in each Research Paper. 
 
2.2  Research Paper 1 
2.2.1 Research Paper Objectives  
Research Paper 1 aims to address PhD Objectives 1 and 2; specifically: 
1. To assess the potential effectiveness of PrEP in reducing HIV infections among high-risk women 
in sub-Saharan Africa 
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2. To explore the extent to which behavioural disinhibition may outweigh the potential benefits of 
PrEP  
 
2.2.2 Rationale for Research Paper Setting 
The setting for Research Paper 1 is PrEP for FSW in South Africa – specifically in Hillbrow, inner-city 
Johannesburg. This setting and population was chosen in order to be able to explore the modelling 
in this first analysis applied to a particularly high HIV burden setting and population – Hillbrow has 
particularly high HIV-burden among sub-Saharan African settings, and FSW are a particularly high 
HIV risk female population within this context, with up to 72% HIV prevalence6–8. 
In addition, it is hoped that this case study will help inform policy decision making around PrEP scale-
up in South Africa, in line with PrEP roll out for FSW in South Africa under the National Sex Worker 
HIV Plan (2016-2019)9. This is a pertinent case study for examining the potential impact of 
behavioural disinhibition considering heterogeneities in PrEP programme outcome, given the 
challenges FSWs face in negotiating condom use10 and the financial incentives they may receive for 
condomless sex with clients11, as well as the challenges in PrEP retention observed in TaPS12, a 2015-
2017 PrEP and early antiretroviral treatment (ART) demonstration project undertaken among the 
Hillbrow FSW community. 
 
2.2.3 Overview of Methods 
Research Paper 1 builds on the approach of Foss et al.13 in assessing the effectiveness of and 
potential implications of behavioural disinhibition (reductions in condom use) following introduction 
of an STI-efficacious microbicide. Research Paper 1 uses the established Bernoulli model of HIV 
transmission1–4 where the probability of the HIV virus being transmitted through each sexual contact 
is treated as an independent risk event.  
To be able to explore the consequences for FSWs of behavioural disinhibition on PrEP, condoms are 
assumed to be used with consistency that may vary with the introduction of PrEP (𝛾𝛾0 prior to PrEP 
introduction and 𝛾𝛾1 after its introduction). Condoms were assumed to have an HIV risk reduction 
efficacy, 𝜀𝜀, including slippage and breakage, with the risk reduction effectiveness of condom 
following a linear relationship between use and efficacy (𝜀𝜀𝛾𝛾). At the time of undertaking Research  
Paper 1, the exact effectiveness relationship between adherence and PrEP efficacy remained under 
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investigation14–16, so the model took an overall level of ‘PrEP effectiveness’, 𝑏𝑏𝛼𝛼, corresponding to a 
level of FSW PrEP adherence, 𝛼𝛼. No partner populations are assumed to be taking PrEP.  
To start, a single partner population is considered, in which the proportion HIV infected is 𝑝𝑝. For a 
given time period, ℎ, a FSW is assumed to have an average 𝑚𝑚 partners, and an average of 𝑛𝑛 sex acts 
with each partner. Parameter ℎ is taken as 3 months, corresponding to the minimum period after 
which an individual on PrEP must return to the provider to perform an HIV test to check for 
seroconversion (amongst other indicators) 17. For simplicity these equations assume an overall 
average probability of HIV transmission, 𝛽𝛽, per sexual contact with an HIV infected partner. It is 
assumed that all sex acts are peno-vaginal on the basis of available epidemiological data for FSWs in 
Hillbrow18. The models for all Research Papers in this thesis are parameterised using sexual 
behaviour, biological, epidemiological and PrEP programme data from the literature. The HIV risk 
from a single partner population to FSW with consistency of condom use 𝛾𝛾1, adhering to PrEP at 
level 𝛼𝛼 is given by: 
𝜋𝜋(𝛾𝛾1,𝛼𝛼) = 1 − �𝑝𝑝� 1 − 𝛽𝛽(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1)�𝑛𝑛 + (1 − 𝑝𝑝)�𝑚𝑚
(2.1) 
In the absence of PrEP(𝑖𝑖. 𝑒𝑒 𝛼𝛼 = 0) the HV risk is: 
𝜋𝜋(𝛾𝛾0, 0) = 1 − �𝑝𝑝� 1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0)�𝑛𝑛 + (1 − 𝑝𝑝)�𝑚𝑚
(2.2) 
It is therefore beneficial to take PrEP as part of a combination HIV prevention approach, even if 
reductions in condom use occur, as long as 𝜋𝜋(𝛾𝛾1,𝛼𝛼) < 𝜋𝜋(𝛾𝛾0, 0), simplifying to: 
�𝑝𝑝� 1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0)�𝑛𝑛 + (1 − 𝑝𝑝)�𝑚𝑚 < �𝑝𝑝� 1 − 𝛽𝛽(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1)�𝑛𝑛 + (1 − 𝑝𝑝)�𝑚𝑚
(2.3) 
From (2.3), the condition for PrEP to be beneficial in terms reducing HIV risk is: (1 − 𝜀𝜀𝛾𝛾1)(1 − 𝜀𝜀𝛾𝛾0) < (1 − 𝑏𝑏𝛼𝛼) 
(2.4) 
In other words, if the relative HIV risk reduction in condom use following the introduction of PrEP is 
less than the HIV risk reduction afforded by PrEP. Equation (2.4) can also be arranged to give: 
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𝑏𝑏𝛼𝛼 > 𝜀𝜀(𝛾𝛾0 − 𝛾𝛾1)(1 − 𝜀𝜀𝛾𝛾1)  
(2.5) 
Equation (2.5) gives the level of PrEP effectiveness that must be attained for PrEP to be of benefit in 
reducing HIV risk, considering any change in condom consistency. Equation (2.5) also illustrates that 
PrEP will be beneficial at any level of adherence 𝛼𝛼 > 0 where  𝛾𝛾0 = 𝛾𝛾1, that is condom consistency 
remains unchanged. This is independent of the number of partners, sex acts and partner HIV 
prevalence. 
The critical level of PrEP effectiveness corresponding to adherence level 𝛼𝛼∗, which serves as the 
break-even point for beneficence of PrEP for HIV prevention with regard to any change in condom 
consistency is: 
𝑏𝑏𝛼𝛼∗ = 𝜀𝜀(𝛾𝛾0 − 𝛾𝛾1∗)(1 − 𝜀𝜀𝛾𝛾1∗)
(2.6) 
Considering the extreme scenario of 100% reduction in condom consistency on PrEP, HIV risk will not 
be increased as long as the achieved effectiveness of PrEP exceeds that of condoms at the 
consistency prior to PrEP introduction: 
𝜀𝜀𝛾𝛾0 < 𝑏𝑏𝛼𝛼  ≤ 1 
(2.7) 
This is the condition under which PrEP will always be beneficial as an additional HIV prevention 
approach in reducing HIV risk. 
Simple rearrangement of equation (2.6) gives the break-even value of condom consistency after 
introduction of PrEP such that HIV risk is not increased: 
𝛾𝛾1
∗ = (𝜀𝜀𝛾𝛾0 − 𝑏𝑏𝛼𝛼  )
𝜀𝜀(1 − 𝑏𝑏𝛼𝛼  )
(2.8) 
Accounting for increased STI exposure through reductions in condom use 
Since reductions in condom use will result in increased exposure to STIs, a number of which are 
cofactors for increased HIV transmission19, the analysis is expanded to explore the increased risk of 
HIV transmission resulting from any increased exposure to STIs. The probability that at least one 
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person in the partnership has an STI following the introduction of PrEP, 𝑠𝑠1,  is assumed to increases 
proportionally to the absolute change in condom consistency. Thus, 𝑠𝑠1 = 𝑠𝑠0�1 + (𝛾𝛾0 − 𝛾𝛾1)�, where 
𝑠𝑠0 is the probability that at least one person in the partnership has an STI prior to the introduction of 
PrEP. Parameter 𝛿𝛿 is the multiplicative increase in per sex act probability of HIV transmission in the 
presence of an STI. The HIV risk equations (2.1) and (2.2) become, respectively, on PrEP: 
𝜋𝜋(𝛾𝛾1,𝛼𝛼, 𝑠𝑠1) = 1 − �𝑠𝑠1𝑝𝑝� 1 − 𝛿𝛿𝛽𝛽(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1)�𝑛𝑛 + (1 − 𝑠𝑠1)𝑝𝑝� 1 − 𝛽𝛽(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1)�𝑛𝑛 +(1 − 𝑝𝑝)�𝑚𝑚,
(2.9) 
and in the absence of PrEP: 
𝜋𝜋(𝛾𝛾0, 0, 𝑠𝑠0) = 1 − �𝑠𝑠0𝑝𝑝� 1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0)�𝑛𝑛 + (1 − 𝑠𝑠0)𝑝𝑝� 1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0)�𝑛𝑛 + (1 − 𝑝𝑝)�𝑚𝑚.
(2.10) 
PrEP is thus beneficial in reducing HIV risk if 𝜋𝜋(𝛾𝛾1,𝛼𝛼, 𝑠𝑠1) < 𝜋𝜋(𝛾𝛾0, 0, 𝑠𝑠0), which simplifies to: 
𝑠𝑠0� 1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0)�𝑛𝑛 + (1 − 𝑠𝑠0)� 1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0)�𝑛𝑛 < 𝑠𝑠1� 1 − 𝛿𝛿𝛽𝛽(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1)�𝑛𝑛 + (1 −
𝑠𝑠1)� 1 − 𝛽𝛽(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1)�𝑛𝑛.
(2.11) 
Two partner populations – clients and regular partners 
The HIV risk equations are extended to account for risk arising from two distinct partner 
populations: clients ("𝑐𝑐") and regular partners("𝑟𝑟"). The HIV risk equations (2.1) and (2.2) become, 
respectively, on PrEP: 
𝜋𝜋(𝛾𝛾1,𝛼𝛼, 𝑠𝑠1, 𝑐𝑐, 𝑟𝑟) = 1 − �𝑠𝑠1𝑝𝑝𝑐𝑐�1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾1𝑐𝑐)(1 − 𝑏𝑏𝛼𝛼)�𝑛𝑛𝑐𝑐 + (1 − 𝑠𝑠1)𝑝𝑝𝑐𝑐�1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾1𝑐𝑐)(1 −
𝑏𝑏𝛼𝛼)�𝑛𝑛𝑐𝑐 + (1 − 𝑝𝑝𝑐𝑐)�𝑚𝑚𝑐𝑐 ∗ �𝑠𝑠1𝑝𝑝𝑟𝑟�1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾1𝑟𝑟)(1 − 𝑏𝑏𝛼𝛼)�𝑛𝑛𝑟𝑟 + (1 − 𝑠𝑠1)𝑝𝑝𝑟𝑟�1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾1𝑟𝑟)(1 −
𝑏𝑏𝛼𝛼)�𝑛𝑛𝑟𝑟 + (1 − 𝑝𝑝𝑟𝑟)�𝑚𝑚𝑟𝑟,
(2.12) 
and in the absence of PrEP: 
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𝜋𝜋(𝛾𝛾0, 0, 𝑠𝑠0, 𝑐𝑐, 𝑟𝑟) = 1 − �𝑠𝑠0𝑝𝑝𝑐𝑐�1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0𝑐𝑐)�𝑛𝑛𝑐𝑐 + (1 − 𝑠𝑠0)𝑝𝑝𝑐𝑐�1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0𝑐𝑐)�𝑛𝑛𝑐𝑐 +(1 − 𝑝𝑝𝑐𝑐)�𝑚𝑚𝑐𝑐 ∗ �𝑠𝑠0𝑝𝑝𝑟𝑟�1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0𝑟𝑟)�𝑛𝑛𝑟𝑟 + (1 − 𝑠𝑠0)𝑝𝑝𝑟𝑟�1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0𝑟𝑟)�𝑛𝑛𝑟𝑟 + (1 − 𝑝𝑝𝑟𝑟)�𝑚𝑚𝑟𝑟.
(2.13) 
Thus, it is beneficial to take PrEP as part of a combination HIV prevention approach, even if 
reductions in condom use occur, as long as 𝜋𝜋(𝛾𝛾1,𝛼𝛼, 𝑠𝑠1, 𝑐𝑐, 𝑟𝑟) < 𝜋𝜋(𝛾𝛾0, 0, 𝑠𝑠0, 𝑐𝑐, 𝑟𝑟). 
In this setting, condom consistency with regular partners is low18 and in many cases clients pay more 
for condom-less sex20. Change in condom consistency on PrEP is therefore likely to be more 
pronounced with clients. To explore this, Research Paper 1 assesses the percentage reduction in 
condom consistency with male clients tolerated, for HIV risk not to increase on PrEP, holding 
condom consistency with regular partners constant using equations (2.12) and (2.13). The Paper 
assesses whether the results remain the same, accounting or not for increased STI exposure through 
decreased condom use. In order to explore whether changes in condom use with clients or regular 
partners present the biggest HIV risk in such settings, the Research Paper examines whether there is 
a significant difference in the percentage reduction in condom consistency with male clients 
tolerated for HIV risk not to increase, if PrEP use reduces condom use to zero with regular partners.  
To account for heterogeneity in PrEP programme outcomes, these equations are evaluated over a 
range of PrEP effectiveness levels, in increments of 10% spanning 35% to 95%. These levels were 
chosen as they span the range of HIV risk reduction estimated through the iPrEx OLE21 study (53% 
corresponding to adherence levels of <2 tablets a week; 87% corresponding to 2-3 tablets a week, up 
to 100% corresponding to 4-6 tablets a week), with a lower effectiveness bound of 35% chosen, 
given the iPrEx OLE study was undertaken in a different study population (MSM and TGW). At the 
time of undertaking this study, there were no data available connecting levels of PrEP adherence in 
women to levels of HIV risk reduction (and even the data now available through the Partners 
Demonstration OLE project are less granular22). 
Programming tool 
The numerical analysis for Research Paper 1 is undertaken in Microsoft Excel, as it is in general 
considered a user-friendly analytical tool that is more accessible to policy makers than advanced 
programming tools23. Optimization is undertaken using Solver in Excel. 
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Uncertainty analysis 
Simple uncertainty analyses are undertaken through basic approaches that may be more 
reproducible by policy makers, without requiring complex programming tools. Accordingly, the 
calculations are repeated across boundary cases: high risk and low risk, parameterised using high 
and low risk values for sexual behaviour and the transmission probability parameters. 
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2.3  Research Paper 2 
2.3.1 Research Paper Objectives  
Research Paper 2 aims to address PhD Objective 3; specifically: 
3. To assess the robustness of conclusions made on the basis of static modelling techniques to
incorporation of dynamic effects, to contribute to understanding around the importance of
modelling complexity to inform HIV policy making
2.3.2 Rationale for Research Paper Setting 
For ease of comparison with the model from Research Paper 1, the same setting and population are 
retained for Research Paper 2 – FSW in Hillbrow, inner city Johannesburg. 
2.3.3 Overview of Methods 
The static model from Research Paper 2 is first refined and then compared with a matched dynamic 
version of the model.  
For the static model, the average number of partners that a FSW has per unit time, ℎ, is renamed 𝐶𝐶 
instead of 𝑛𝑛, as it was in Research Paper 1, in line with convention24. Parameter 𝐶𝐶 was not used in 
the first Research Paper to avoid confusion with the use of the subscript 𝑐𝑐 to denote clients.  
To facilitate ease of comparison between models, the equations consider only a single FSW partner 
population, male partners, denoted by subscript 𝑚𝑚 and FSW are denoted by the subscript 𝑓𝑓. For 
clarity, 𝛽𝛽𝑓𝑓 is the average probability of HIV transmission to a FSW, per sexual contact with an HIV 
infected male partner, and  𝛽𝛽𝑚𝑚 the average probability of HIV transmission to a male, per sexual 
contact with an HIV infected FSW. 
In refining the risk equations used in Research Paper 1, the equations for Research Paper 2 
additionally account for antiretroviral (ART) and male circumcision coverage. Parameters  𝜗𝜗𝑚𝑚 and 
𝜗𝜗𝑓𝑓are the proportion of HIV+ male partners and FSW that are on ART respectively, and 𝜚𝜚 is the 
average reduction in the probability of HIV transmission due to viral suppression on ART. The 
proportion of male population circumcised is denoted by 𝜏𝜏 and 𝜎𝜎𝑓𝑓and 𝜎𝜎𝑚𝑚 are the average reduction 
in probability HIV transmission to FSW and male partners respectively, when the male partner has 
been circumcised.  
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The static model formulation of HIV risk to FSW per time step ℎ is: 
𝜋𝜋𝑠𝑠𝑡𝑡𝑎𝑎𝑡𝑡𝑠𝑠𝑐𝑐 = 1 − �1 + 𝑝𝑝(𝜓𝜓𝑓𝑓 + 𝜔𝜔𝑓𝑓 − 1)�𝐶𝐶𝑚𝑚
Where  
𝜓𝜓𝑓𝑓 = (1 − 𝜏𝜏)
⎝
⎜
⎜
⎜
⎛
(1 − 𝜗𝜗)𝑠𝑠 � 1 − 𝛿𝛿𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛+(1 − 𝜗𝜗)(1 − 𝑠𝑠) � 1 − 𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛+𝜗𝜗𝑠𝑠 � 1 − (1 − 𝜚𝜚)𝛿𝛿𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛+𝜗𝜗(1 − 𝑠𝑠) � 1 − (1 − 𝜚𝜚)𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛⎠⎟
⎟
⎟
⎞
and 𝜔𝜔𝑓𝑓 = 𝜏𝜏
⎝
⎜
⎜
⎜
⎛
(1 − 𝜗𝜗)𝑠𝑠 � 1 − (1 − 𝜎𝜎)𝛿𝛿𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛+(1 − 𝜗𝜗)(1 − 𝑠𝑠) � 1 − (1 − 𝜎𝜎)𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛+𝜗𝜗𝑠𝑠 � 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛+𝜗𝜗(1 − 𝑠𝑠) � 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛⎠⎟
⎟
⎟
⎞
With γ = γ0 before the introduction of PrEP, and γ1 after the introduction of PrEP; s = s0 before the introduction of PrEP and s1 after the introduction of PrEP; and  s1 = s0(1 + (  γ0 −  γ1)). 
(2.14) 
The static model is then evolved into dynamic model formulation using difference equations. The 
use of discrete time formulation was chosen to allow for comparison with the static model, which is 
evaluated in discrete time steps. The Bernoulli risk formulation (2.14) is taken as the force of 
infection on FSW, and an equivalent Bernoulli risk formulation of HIV risk taken as the force of 
infection on the male partner population. No male partners are assumed to be taking PrEP. 
Under the dynamical compartmental approach using the SIR formulation, populations of size 𝑁𝑁 are 
divided into HIV-susceptible individuals, 𝑆𝑆, and infected individuals, 𝐼𝐼. As individuals, who are 
removed from the system, 𝑅𝑅, cannot return to the system, their respective equations are not set out 
below.  Instead of a static HIV prevalence, 𝑝𝑝, for each population, prevalence changes over time 
according to the proportion of HIV infected individuals, 𝜆𝜆 = 𝐼𝐼/𝑁𝑁. 
The dynamic model system assumes population mortality rates 𝜇𝜇𝑓𝑓 and 𝜇𝜇𝑚𝑚 in FSWs and male 
partners respectively, and AIDS-related death rates of 𝜉𝜉𝑓𝑓 and 𝜉𝜉𝑚𝑚 respectively. The rate of 
recruitment into both populations are 𝜃𝜃𝑓𝑓 and 𝜃𝜃𝑚𝑚 respectively. 
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The model is run from 1980 to 2035, with an initial prevalence of HIV at the start of the epidemic in 
1980 of 𝑝𝑝𝑓𝑓0 in FSWs and 𝑝𝑝𝑚𝑚0  in male partners. Under the baseline scenario, Epidemic Equilibrium, 
PrEP is introduced for FSWs in 2015 in line with the introduction of normative guidance in 2015 
recommending that PrEP be made available to all persons at substantial risk of HIV25. The baseline 
scenario is called Epidemic Equilibrium, as in 2015 the HIV epidemics in these populations in South 
Africa had stabilised6,7,26,27.  
To account for the stage of the HIV epidemic in the model comparisons, the analyses are repeated 
20 years earlier, when the HIV epidemics in FSWs and their partner populations were still 
increasing6,7,26,27. Under this scenario, Increasing Epidemic, PrEP is hypothetically introduced in 1995. 
Given that little is known about the rate of increase in condom use in these populations over time, 
change in condom use from the start of the HIV epidemic is approximated by a linear increase in 
consistency between 1980 and the year prior to the introduction of PrEP (2014 for the Epidemic 
Equilibrium analyses, and 1994 for the Increasing Epidemic scenarios).  
To account for changes in ART coverage over time, in the dynamic model, ART coverage is taken to 
be zero between 1980 and 2003. Linear scale up assumed from 2003, in line with the wide-scale 
introduction in South Africa28,29 in 2003, to levels in 2012 for male partners27 and 2014 for FSW6 (the 
latest data available for each population to parameterise the model up to the final point of fitting in 
2014). 
The model accounts for changes in male circumcision levels in the context of the 2007 WHO and 
UNAIDS guidance on the scale-up of VMMC for HIV prevention30 and the 2010 South African 
government’s introduction of their VMMC policy and programme.27 Due to the limited data 
availability on circumcision levels in Hillbrow (or by proxy, Gauteng, the South African Province in 
which it lies), with national survey data only available for 200331 and 201227, circumcision levels are 
assumed to be constant at 2003 levels between 1980 and 2003, and then increase linearly to 2012 
levels and are then constant thereafter (likewise as these are the latest available data to 
parameterise the model up to the final point of model fitting in 2014). 
For the dynamic model, the force of infection from male partners to FSW is: 
Π𝑚𝑚 = 1 − �1 + 𝜆𝜆𝑚𝑚(𝜓𝜓𝑓𝑓 + 𝜔𝜔𝑓𝑓 − 1)�𝐶𝐶𝑚𝑚
Where 𝜆𝜆𝑚𝑚 = 𝐼𝐼𝑚𝑚𝑁𝑁𝑚𝑚
(2.15) 
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The force of infection from FSW to male partners is: 
Π𝑓𝑓 = 1 − �1 + 𝜆𝜆𝑓𝑓(𝜓𝜓𝑚𝑚 + 𝜔𝜔𝑚𝑚 − 1)�𝐶𝐶𝑓𝑓
Where 𝜆𝜆𝑓𝑓 = 𝐼𝐼𝑓𝑓𝑁𝑁𝑓𝑓  and: 
𝜓𝜓𝑚𝑚 = (1 − 𝜏𝜏)
⎝
⎜⎜
⎛
�1 − 𝜗𝜗𝑓𝑓�𝑠𝑠� 1 − 𝛿𝛿𝛽𝛽𝑚𝑚(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛𝑓𝑓+�1 − 𝜗𝜗𝑓𝑓�(1 − 𝑠𝑠)� 1 − 𝛽𝛽𝑚𝑚(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛𝑓𝑓+𝜗𝜗𝑓𝑓𝑠𝑠� 1 − (1 − 𝜚𝜚)𝛿𝛿𝛽𝛽𝑚𝑚(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛𝑓𝑓+𝜗𝜗𝑓𝑓(1 − 𝑠𝑠)� 1 − (1 − 𝜚𝜚)𝛽𝛽𝑚𝑚(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛𝑓𝑓⎠⎟⎟
⎞
and 
𝜔𝜔𝑚𝑚 = 𝜏𝜏
⎝
⎜⎜
⎛
�1 − 𝜗𝜗𝑓𝑓�𝑠𝑠� 1 − (1 − 𝜎𝜎𝑚𝑚)𝛿𝛿𝛽𝛽𝑚𝑚(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛𝑓𝑓+�1 − 𝜗𝜗𝑓𝑓�(1 − 𝑠𝑠)� 1 − (1 − 𝜎𝜎𝑚𝑚)𝛽𝛽𝑚𝑚(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛𝑓𝑓+𝜗𝜗𝑓𝑓𝑠𝑠� 1 − (1 − 𝜎𝜎𝑚𝑚)(1 − 𝜚𝜚)𝛿𝛿𝛽𝛽𝑚𝑚(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛𝑓𝑓+𝜗𝜗𝑓𝑓(1 − 𝑠𝑠)� 1 − (1 − 𝜎𝜎𝑚𝑚)(1 − 𝜚𝜚)𝛽𝛽𝑚𝑚(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛𝑓𝑓⎠⎟⎟
⎞
(2.16) 
With population sizes: 
𝑁𝑁𝑚𝑚 = 𝑆𝑆𝑚𝑚 + 𝐼𝐼𝑚𝑚,  and 𝑁𝑁𝑓𝑓 = 𝑆𝑆𝑓𝑓 + 𝐼𝐼𝑓𝑓 
(2.17) 
Balancing equation: 
𝐶𝐶𝑓𝑓 = 𝐶𝐶𝑚𝑚𝑁𝑁𝑓𝑓/𝑁𝑁𝑚𝑚 
(2.18) 
Difference equations: 
𝑆𝑆𝑓𝑓 𝑡𝑡+1 = 𝜃𝜃𝑓𝑓𝑁𝑁𝑓𝑓 0 + 𝑆𝑆𝑓𝑓 𝑡𝑡 − 𝛱𝛱𝑚𝑚𝑆𝑆𝑓𝑓 𝑡𝑡 − 𝜇𝜇𝑓𝑓𝑆𝑆𝑓𝑓 𝑡𝑡  
𝐼𝐼𝑓𝑓 𝑡𝑡+1 = 𝐼𝐼𝑓𝑓 𝑡𝑡 + 𝛱𝛱𝑚𝑚𝑆𝑆𝑓𝑓 𝑡𝑡 − (𝜇𝜇𝑓𝑓 + 𝜉𝜉𝑓𝑓)𝐼𝐼𝑓𝑓 𝑡𝑡  
𝑆𝑆𝑚𝑚 𝑡𝑡+1 = 𝜃𝜃𝑚𝑚𝑁𝑁𝑚𝑚 0 + 𝑆𝑆𝑚𝑚 𝑡𝑡 − 𝛱𝛱𝑓𝑓𝑆𝑆𝑚𝑚 𝑡𝑡 − 𝜇𝜇𝑚𝑚𝑆𝑆𝑚𝑚 𝑡𝑡 
𝐼𝐼𝑚𝑚 𝑡𝑡+1 = 𝐼𝐼𝑚𝑚 𝑡𝑡 + 𝛱𝛱𝑓𝑓𝑆𝑆𝑚𝑚 𝑡𝑡 − (𝜇𝜇𝑚𝑚 + 𝜉𝜉𝑚𝑚)𝐼𝐼𝑚𝑚 𝑡𝑡 
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(2.19) 
The dynamic model is fitted to HIV prevalence data for both FSW and male partner populations 
between 1980 and 2014, which are then used to parameterise both the static and dynamic models. 
Numerical optimizations are run to determine the lowest level in condom consistency tolerated 
following the introduction of PrEP without HIV risk increasing. See following sections ‘Programming 
tool’ and ‘Uncertainty analysis and model fitting’ for more methodological details. 
To account for heterogeneity in risk factors, FSWs’ initial condom consistencies32,13 the parameter 
sets are fitted individually for initial condom consistencies (prior to introduction of PrEP) of 10%, 
40% and 70%, spanning the range reported by this population.32  
At the time of undertaking this study, available data relating levels of PrEP adherence to HIV risk 
reduction in women were limited to recognition that up to 100% risk reduction on PrEP necessitates 
higher levels of adherence in women (6/7 tablets a week) than in men (4/5 in MSM and TGW)33. As 
such, the analysis spans a spectrum of potential levels of PrEP use-effectiveness (HIV risk reduction 
corresponding to a level of adherence): 25%, 55% and 85%. PrEP use-effectiveness  of 85% was 
simulated as the highest level, as it equates to the threshold at which PrEP will always increase the 
level of HIV protection irrespective of the level of condom use, using equation 2.6 from the static 
model analysis in Research Paper 1 and the risk reduction efficacy of condoms as 85%34,35.  
The percentage reduction in condom consistency that can be tolerated was calculated across these 
levels of initial condom consistency and PrEP use-effectiveness.  
Programming tool 
The equations were evaluated in R5, a more flexible programming platform that is a facilitates the 
evaluation of more complex model formulations, such as dynamical systems. Optimisations 
algorithms are run using R FME package36 for the dynamic model and R rootSolve package37 for the 
static model. 
Uncertainty analysis and model fitting 
The dynamic model is fitted to HIV prevalence data for both FSW and male partner populations 
between 1980 and 2014 using Bayesian Monte Carlo methods with Latin Hypercube Sampling (R 
FME package36), run on 50,000 parameter sets, yielding at least 200 fits for each scenario explored. 
Both the static and dynamic models are parameterised and evaluated using the same set of fitted 
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parameters, allowing for the evaluation of uncertainty ranges in both models. Monte Carlo filtering 
with Latin Hypercube Sampling assuming uniform prior distributions was chosen as the Bayesian 
method for accounting for parametric uncertainty and model fitting, as it feels to me a discernible 
and intuitive approach, which may be easier to explain to policy makers, and where each stage of 
the calculations can be easily extracted and communicated. Other methods for calculating the 
likelihood function in Bayesian approaches such as, for example, the Markov Chain random walk in 
MCMC, may be seen as a more ‘black box’ and less accessible by policy makers. 
To explore a level of model structural sensitivity, the Research Paper explores the model’s sensitivity 
to heterogeneity in the number of parameters. This is undertaken by removing all parameters 
related ART, circumcision and STIs, re-running the analyses and comparing the conclusions. 
To further explore the sensitivity of the model to stage of the epidemic (in addition to PrEP being 
introduced in 1995 the Increasing Epidemic and 2015 in the Epidemic Equilibrium scenarios), a 
further scenario is evaluated, where PrEP is introduced when the epidemics are fully endemic in the 
populations, called the Fully Endemic scenario. The underlying epidemic curves for each of these 
scenarios are show in the Annex to this thesis, in Supplementary Materials to Research Paper 2. 
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2.4 Research Paper 3 
2.4.1 Research Paper Objectives  
Research Paper 3 aims to address PhD Objectives 4 and 5; specifically: 
4. To explore strategies for the scale-up of PrEP across high-risk women at population-level, 
weighing considerations around HIV infection reduction and cost-effectiveness  
5. To evaluate strategies for PrEP scale-up in more than one country setting in sub-Saharan Africa, 
to explore how the approach to PrEP scale-up may differ by epidemic and implementation 
context 
 
2.4.2 Rationale for Research Paper Setting 
In order to evaluate strategies for PrEP scale-up in more than one country setting in sub-Saharan 
Africa and assess how model outcomes change by epidemic and implementation context, Research 
Paper 3 applies modelling to three HIV endemic countries in SSA that span a range of HIV burden 
levels in the region: South Africa (20.4% adult HIV prevalence), Zimbabwe (12.7% adult HIV 
prevalence) and Kenya (4.7% adult HIV prevalence)38. These countries were chosen as, in addition to 
spanning a range of HIV burden levels in the region, they each have adopted a national PrEP 
strategy39–41 and have been at the forefront of PrEP roll-out in sub-Saharan Africa42. 
 
2.4.3 Overview of Methods 
The HIV epidemics in South Africa, Zimbabwe and Kenya are stable generalized high-prevalence 
epidemics8,26. Given that to date, few PrEP demonstration programs have achieved significant 
retention in women in this context beyond the first 12 months43–50, as well as that PrEP is intended 
to cover seasons of HIV risk, the analyses of Research Paper 3 are conducted over a one-year 
timeframe. Based on the conclusions of Research Paper 2 that static models are sufficiently robust 
to model the introduction of an HIV prevention intervention over short-medium time horizons in 
contexts where the HIV epidemics are well established, Research Paper 3 adopts a static model of 
HIV risk. 
 
 
101 
Simple tools to help guide PrEP programme decision making 
First, simple tools are developed to help guide policy makers and PrEP programmers make decisions 
around the scale-up of PrEP for high-risk women using a basic set of information that may typically 
be available in implementation settings51.  
In this Research Paper, we do not explore the effects of behavioural disinhibition, since this has been 
addressed through Research Papers 1 and 2. Accordingly, condom use is denoted 𝛾𝛾 independent of 
PrEP status. Additionally, the basic HIV risk equations (2.1) and (2.2) are refined to capture 12-month 
PrEP programme retention levels, 𝑟𝑟. HIV risk equations (2.1) and (2.2) therefore become, 
respectively: 
On PrEP: 
𝜋𝜋(𝛾𝛾, 𝑏𝑏𝛼𝛼) = 1 − �𝑝𝑝 � 1 − 𝛽𝛽𝑓𝑓(1 − 𝑟𝑟𝜃𝜃𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛 + (1 − 𝑝𝑝)�𝐶𝐶  , 
(2.20) 
and in the absence of PrEP: 
𝜋𝜋(𝛾𝛾, 0) = 1 − �𝑝𝑝 � 1 − 𝛽𝛽𝑓𝑓(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛 + (1 − 𝑝𝑝)�𝐶𝐶  . 
(2.21) 
Heatmaps to estimate HIV incidence in women 
Heatmaps are developed to help decision makers estimate the annual HIV incidence in women by 
number of monthly sex acts, average condom use and underlying epidemic setting, assuming a 
simple partner population and the simple risk equation set out in equation (2.21). Heterogeneity in 
epidemic setting is accounted for by assessing HIV prevalence in male partner populations of 5%, 
10%, 20% and 40% (giving rise to one heatmap each). These prevalence levels are chosen to 
illustrate different epidemic settings, as across many sub-Saharan African contexts, 5% HIV 
prevalence may be consistent with HIV prevalence in males 15-24 years, 5-20% the HIV prevalence in 
males 25-49 years, and 20-40% the HIV prevalence in the clients of FSW (depending on the 
setting)8,38. Heatmaps are chosen as a user-friendly tool to represent the outcomes of multiple 
interacting scenarios for policy makers52–54. 
Within each heatmap, heterogeneity in number of sex acts and average condom use are accounted 
for by varying the average number of monthly sex acts between 0 and 40 (an upper bound for 
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women in this context55–59) and illustratively varying condom use between 0% and 100%.  On the 
heatmaps, the threshold for a resulting annual incidence of 3 per 100 person years is marked, 
signifying the threshold for PrEP eligibility according to WHO guidelines60. To account for 
heterogeneity in the other risk factors in equation (2.21) within the heatmaps, parameters sets for 
𝑟𝑟,𝛽𝛽, 𝜀𝜀 and 𝑛𝑛 (corresponding to levels of 𝑚𝑚) spanning the spectra reported for women in SSA were 
obtained from the literature, and used to simulate equation (2.21) across all permutations and 
combinations, giving yield to 720,000 distinct parameter sets. 
Simple rule to assess relative cost-effectiveness of PrEP scale-up from a group of high- to lower-risk 
women 
A simple rule is then developed to help policy makers estimate the relative cost at which PrEP will be 
equally as cost-effective between two groups of women with different HIV risk factors and 
behaviours. In the absence of willingness-to-pay thresholds, cost-effectiveness is assessed by 
comparing estimates of cost per infection averted between populations. 
It is assumed that one woman comes from a comparatively higher-risk population (e.g. FSW) and the 
other from a comparatively lower-risk female population, with the women denoted 𝐻𝐻and 𝐿𝐿 
respectively. 𝜋𝜋𝐻𝐻 and 𝜋𝜋𝐿𝐿 are the respective HIV risks for each woman. Let $𝑋𝑋𝐻𝐻 and $𝑋𝑋𝐿𝐿be the 12-
month unit costs of PrEP for each woman (the incremental cost of PrEP for a woman retained in a 
PrEP program over a 12-month period). 
Then the cost of averting one HIV infection with PrEP per year for each woman is $𝑋𝑋𝐻𝐻
𝜋𝜋𝐻𝐻(𝛾𝛾,0)−𝜋𝜋𝐻𝐻(𝛾𝛾,𝛼𝛼𝐻𝐻)
and $𝑋𝑋𝐿𝐿
𝜋𝜋𝐿𝐿(𝛾𝛾,0)−𝜋𝜋𝐿𝐿(𝛾𝛾,𝛼𝛼𝐿𝐿) respectively. 
PrEP will become equally cost-effective in the lower-risk group as it is in the higher-risk group where: 
$𝑋𝑋𝐿𝐿
𝜋𝜋𝐿𝐿(𝛾𝛾,0)−𝜋𝜋𝐿𝐿(𝛾𝛾,𝛼𝛼𝐿𝐿) = $𝑋𝑋𝐻𝐻𝜋𝜋𝐻𝐻(𝛾𝛾,0)−𝜋𝜋𝐻𝐻(𝛾𝛾,𝛼𝛼𝐻𝐻) , 
(2.22) 
or when: 
$𝑋𝑋𝐿𝐿$𝑋𝑋𝐻𝐻 = 𝜋𝜋𝐿𝐿(𝛾𝛾,0)−𝜋𝜋𝐿𝐿(𝛾𝛾,𝛼𝛼𝐿𝐿)𝜋𝜋𝐻𝐻(𝛾𝛾,0)−𝜋𝜋𝐻𝐻(𝛾𝛾,𝛼𝛼𝐻𝐻) . 
(2.23) 
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To derive a simple formulation of (2.23) that may be more intuitive for policy makers and 
programmers in real-world settings, equations (2.20) and (2.21) are simplified through a first order 
Binomial expansion61. Using the example of equation (2.20), provided 𝛽𝛽(1 − 𝑟𝑟𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾) ≪ 1 we 
have: 
𝜋𝜋(𝛾𝛾, 𝑏𝑏𝛼𝛼) ≈ 1 − �𝑝𝑝 � 1 − 𝑛𝑛𝛽𝛽𝑓𝑓(1 − 𝑟𝑟𝜃𝜃𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)� + (1 − 𝑝𝑝)�𝐶𝐶
≈ 1 − �1 − 𝑝𝑝𝑛𝑛𝛽𝛽𝑓𝑓(1 − 𝑟𝑟𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝐶𝐶  ,
and provided 𝑝𝑝𝑛𝑛𝛽𝛽𝑓𝑓(1 − 𝑟𝑟𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾) ≪ 1: 
𝜋𝜋(𝛾𝛾, 𝑏𝑏𝛼𝛼) ≈ 𝐶𝐶𝑝𝑝𝑛𝑛𝛽𝛽𝑓𝑓(1 − 𝑟𝑟𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾). 
(2.24) 
Thus the risk reduction on PrEP is approximately: 
𝐶𝐶𝑝𝑝𝑛𝑛𝛽𝛽(1 − 𝜀𝜀𝛾𝛾) − 𝐶𝐶𝑝𝑝𝑛𝑛𝛽𝛽(1 − 𝑟𝑟𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾) 
Which simplifies to: 
𝐶𝐶𝑝𝑝𝑛𝑛𝛽𝛽(1 − 𝜀𝜀𝛾𝛾)𝑟𝑟𝑏𝑏𝛼𝛼. 
(2.25) 
Therefore, when 𝛽𝛽(1 − 𝑟𝑟𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾) ≪ 1 and 𝑝𝑝𝑛𝑛𝛽𝛽(1 − 𝑟𝑟𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾) ≪ 1,the condition for equal 
cost-effectiveness in equation (2.23) between two female populations with different risk levels 
becomes: 
$𝑋𝑋𝐿𝐿$𝑋𝑋𝐻𝐻 = 𝐶𝐶𝐿𝐿𝑛𝑛𝐿𝐿𝑝𝑝𝐿𝐿(1−𝜀𝜀𝛾𝛾𝐿𝐿)𝑟𝑟𝐿𝐿𝑏𝑏𝛼𝛼𝐿𝐿𝐶𝐶𝐻𝐻𝑛𝑛𝐻𝐻𝑝𝑝𝐻𝐻(1−𝜀𝜀𝛾𝛾𝐻𝐻)𝑟𝑟𝐻𝐻𝑏𝑏𝛼𝛼𝐻𝐻
(2.26) 
In a simplified form for policy makers, the relative cost of PrEP at which it will be equally as cost-
effective to roll out PrEP for lower-risk women compared to higher-risk women is summarised below 
in equation (2.27).  
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(2.27) 
Now that the equations have been refined to account for PrEP programme retention, use-
effectiveness of PrEP is defined as the HIV-risk reduction through use of PrEP at a given level of 
adherence, for a population with a given average program retention level. 
Heatmaps to estimate the relative unit cost at which PrEP scale-up from higher- to lower-risk women 
is cost-effective 
Heatmaps are developed to help decision makers estimate the relative unit cost at which it will be 
cost-effective to scale up PrEP from a comparatively higher- to comparatively lower-risk woman, 
using a limited set of data typically available at country level51 and equation (2.23). Heterogeneity in 
epidemic setting is accounted for by accounting for HIV prevalence in the higher-risk women’s 
partner population of 20% and 40%, and for each, simulating 4 cases for the lower-risk women’s 
partner population at 1/4, 1/2, 3/4 and 1 times the prevalence of the higher-risk women’s partner 
population (i.e. 5%, 10%, 15% and 20%; and 10%, 20%, 30% and 40% respectively). These levels of 
male partner HIV prevalences span a range of the levels seen across SSA settings8,38. This gives rise to 
two groups of four heatmaps. 
Heterogeneity in condom use and number of sex acts a month are accounted for by varying the 
relative condom use between the lower- and higher-risk women between 0% and 150%, and the 
relative number of sex acts a month between the lower- and higher-risk women between 0% and 
150%. In view of limited data available on PrEP retention and levels of HIV risk-reduction from PrEP 
demonstration and implementation projects for women, this study used the most granular available 
data at the time of the analysis from projects among women in SSA. Accordingly, it was assumed 
that the higher-risk group had 22% 12-month PrEP program retention levels and all women retained 
had PrEP adherence levels of 70-85% (corresponding to risk-reduction of 73-99%62), consistent with 
the South African TAPS demonstration project in FSW43. PrEP program retention for the lower-risk 
group was simulated between ±25% of the 22% retention levels of the higher-risk group (i.e. 16.5%-
27.5%), consistent with the difference between AGYW (the group with the largest difference in 
retention levels among females across available studies at the time of the analysis) and FSW 
retention in Kenya44. For lower-risk women retained in the PrEP program, it was assumed that PrEP 
adherence was the same as the higher-risk group (in the absence of available PrEP adherence data at 
the time of the study, other than from the TaPS project among FSW)43.  
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Using the same approach as for the first set of heatmaps to account for heterogeneity in the other 
risk factors in equation (2.23) within the heatmaps, parameters sets for the remaining parameters 
spanning the spectra reported for women in SSA were obtained from the literature, and used to 
simulate equation (2.23) across all permutations and combinations, giving yield to 7,920,000 distinct 
parameter sets. 
 
Assessment of strategies to guide PrEP-scale up across women on a spectrum HIV risk  
To assess strategies to guide PrEP scale-up across women on a spectrum of risk, in addition to FSW, 
Research Paper 3 considers women at HIV risk to include the following groups: 15-24 years, women 
25-34 years and women 35-49 years. These three groups of women in the general population are 
included in addition to FSW (who are well recognised at high risk of HIV), as HIV incidence data from 
all three country case study settings (South Africa63,64, Zimbabwe65 and Kenya38) reveal elevated 
levels of incidence among each of these groups, with the incidence patterns between the groups 
also varying by country. Whilst broad groupings, they have the advantage of being intuitive and easy 
to operationalize in country settings. The set of high-risk women groups considered in the analysis, 𝑗𝑗,  
is therefore 𝑗𝑗: = {FSW, adolescent girls and young women aged 15-24 years (AGYW), women 25-34 
years and women 35-49 years}. 
Based on available data from the literature, AGYW are assumed to have partners drawn from their 
own age group and also the 25-34 years age group, given that 17% and 14% women 15-19 years 
report relationships with men at least 10 years older in Zimbabwe66 and Kenya67 respectively, and 
36% South African women 15-19 years report relationships with men at least 5 years older7. Women 
25-34 years and women 35-49 years are assumed to have partners drawn from their own age 
groups. FSW are assumed to have partners drawn from two populations: regular partners and 
clients. The set of partner populations across high-risk women groups, 𝑖𝑖,  is 𝑖𝑖: = {men 15-24 years, 
men 25-34 years, men 35-49 years, men 15-49 years (regular partners of FSW), and clients of FSW}. 
As above, FSW are assumed to have 12-month PrEP program retention and adherence levels 
consistent with the South African TaPS demonstration project.43 All other high-risk women groups 
were assumed to have program retention levels between ±25% of FSW retention levels,44 and the 
same adherence levels as FSW retained in the program. To explore the role of adherence, the 
analyses were repeated with 25% lower HIV risk-reduction across all groups (see section 
‘Uncertainty analyses’). 
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To assess strategies for the scale-up of PrEP across these groups of high-risk women, risk equations 
(2.20) and (2.21) are modified to account for HIV risk at population-level, rather than individual-
level, and to account for multi-partner populations. 
The total population size of high-risk women group of type 𝑗𝑗 is 𝑁𝑁𝑗𝑗, in which the prevalence of HIV is 
𝑝𝑝𝑗𝑗 . The coverage of PrEP in the population 𝑗𝑗 is 𝜔𝜔𝑗𝑗. High-risk women are assumed to have 𝐶𝐶𝑠𝑠 number 
of partners from each population a year, with whom they have an average of 𝑛𝑛𝑠𝑠 sex acts a year each. 
Condoms are assumed to be used with partners from each population with consistency 𝛾𝛾𝑠𝑠𝑗𝑗.  
Parameter 𝑠𝑠𝑠𝑠𝑗𝑗  is the probability that at least one person in the partnership between high risk woman 
from population 𝑗𝑗 and partner from population 𝑖𝑖 has an STI and  𝜗𝜗𝑠𝑠 is the proportion of HIV+ 
partners from population 𝑖𝑖 that are virally suppressed on ART. The proportion of male partners from 
population 𝑖𝑖 that are circumcised is denoted by 𝜏𝜏𝑠𝑠   
Upon introduction, high-risk women from population 𝑗𝑗 are assumed to adhere to PrEP at an average 
level 𝛼𝛼𝑗𝑗, which corresponds to a level of HIV risk reduction, 𝑏𝑏𝛼𝛼𝑗𝑗 . They are assumed to have 12-month 
program retention levels 𝑟𝑟𝑗𝑗. Sex acts are assumed to be peno-vaginal, the predominant pathway of 
HIV transmission to heterosexual women in sub-Saharan Africa68.  
Where high-risk women from population 𝑗𝑗 have partners drawn from a single male population, their 
HIV risk for a 12-month period, is in the absence of PrEP is given by: 
Π(0) = 1 − �𝑝𝑝(𝜓𝜓(1−𝜏𝜏),0 + 𝜓𝜓𝜏𝜏,0) + (1 − 𝑝𝑝)�𝐶𝐶
Where: 
𝜓𝜓(1−𝜏𝜏),0 = (1 − 𝜏𝜏)�(1 − 𝜗𝜗)𝑠𝑠( 1 − 𝛿𝛿𝛿𝛿)𝑛𝑛 + (1 − 𝜗𝜗)(1 − 𝑠𝑠)( 1 − 𝛿𝛿)𝑛𝑛 + 𝜗𝜗𝑠𝑠( 1 − (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿)𝑛𝑛+ 𝜗𝜗(1 − 𝑠𝑠)( 1 − (1 − 𝜚𝜚)𝛿𝛿)𝑛𝑛�
𝜓𝜓𝜏𝜏,0 = 𝜏𝜏�(1 − 𝜗𝜗)𝑠𝑠( 1 − (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿)𝑛𝑛 + (1 − 𝜗𝜗)(1 − 𝑠𝑠)( 1 − (1 − 𝜎𝜎)𝛿𝛿)𝑛𝑛 + 𝜗𝜗𝑠𝑠( 1 −(1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿)𝑛𝑛 + 𝜗𝜗(1 − 𝑠𝑠)( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿)𝑛𝑛�, 
with 𝛿𝛿 = 𝛽𝛽𝑓𝑓(1 − 𝜀𝜀𝛾𝛾). 
(2.28) 
When women are enrolled on PrEP, their HIV risk for a 12-month period is: 
Π(𝑟𝑟𝑏𝑏𝛼𝛼) = 1 − �𝑝𝑝(𝜓𝜓(1−𝜏𝜏),𝑟𝑟𝑏𝑏𝛼𝛼 + 𝜓𝜓𝜏𝜏,  𝑟𝑟𝑏𝑏𝛼𝛼) + (1 − 𝑝𝑝)�𝐶𝐶  .
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Here: 
𝜓𝜓(1−𝜏𝜏), 𝑟𝑟𝑏𝑏𝛼𝛼 = (1 − 𝜏𝜏)�(1 − 𝜗𝜗)𝑠𝑠( 1 − 𝛿𝛿𝛿𝛿)𝑛𝑛 + (1 − 𝜗𝜗)(1 − 𝑠𝑠)( 1 − 𝛿𝛿)𝑛𝑛 + 𝜗𝜗𝑠𝑠( 1 − (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿)𝑛𝑛+ 𝜗𝜗(1 − 𝑠𝑠)( 1 − (1 − 𝜚𝜚)𝛿𝛿)𝑛𝑛�
𝜓𝜓𝜏𝜏, 𝑟𝑟𝑏𝑏𝛼𝛼 = 𝜏𝜏�(1 − 𝜗𝜗)𝑠𝑠( 1 − (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿)𝑛𝑛 + (1 − 𝜗𝜗)(1 − 𝑠𝑠)( 1 − (1 − 𝜎𝜎)𝛿𝛿)𝑛𝑛 + 𝜗𝜗𝑠𝑠( 1 −(1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿)𝑛𝑛 + 𝜗𝜗(1 − 𝑠𝑠)( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿)𝑛𝑛�, 
with 𝛿𝛿 = 𝛽𝛽𝑓𝑓(1 − 𝑟𝑟𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾) 
(2.29) 
Where high-risk women from population 𝑗𝑗 have partners drawn from two male populations, 
denoted 1 and 2, their HIV risk for a 12-month period, in the absence of PrEP is: 
Π(0) = 1 − �𝑝𝑝1(𝜓𝜓(1−𝜏𝜏),01 + 𝜓𝜓𝜏𝜏,01 ) + (1 − 𝑝𝑝1)�𝐶𝐶1�𝑝𝑝2(𝜓𝜓(1−𝜏𝜏),02 + 𝜓𝜓𝜏𝜏,02 ) + (1 − 𝑝𝑝2)�𝐶𝐶2
Where 
𝜓𝜓(1−𝜏𝜏),01 = (1 − 𝜏𝜏1)�(1 − 𝜗𝜗1)𝑠𝑠1( 1 − 𝛿𝛿𝛿𝛿1)𝑛𝑛1 + (1 − 𝜗𝜗1)(1 − 𝑠𝑠1)( 1 − 𝛿𝛿1)𝑛𝑛1+ 𝜗𝜗1𝑠𝑠1( 1 − (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + 𝜗𝜗1(1 − 𝑠𝑠1)( 1 − (1 − 𝜚𝜚)𝛿𝛿1)𝑛𝑛1�
𝜓𝜓𝜏𝜏,01 = 𝜏𝜏1�(1 − 𝜗𝜗1)𝑠𝑠1( 1 − (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + (1 − 𝜗𝜗1)(1 − 𝑠𝑠1)( 1 − (1 − 𝜎𝜎)𝛿𝛿1)𝑛𝑛1+ 𝜗𝜗1𝑠𝑠1( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + 𝜗𝜗1(1 − 𝑠𝑠1)( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿1)𝑛𝑛1�
With 𝛿𝛿1 = 𝛽𝛽𝑓𝑓(1 − 𝜀𝜀𝛾𝛾1) 
And, 
𝜓𝜓(1−𝜏𝜏),02 = (1 − 𝜏𝜏2)�(1 − 𝜗𝜗2)𝑠𝑠2( 1 − 𝛿𝛿𝛿𝛿2)𝑛𝑛2 + (1 − 𝜗𝜗2)(1 − 𝑠𝑠2)( 1 − 𝛿𝛿2)𝑛𝑛2+ 𝜗𝜗2𝑠𝑠2( 1 − (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + 𝜗𝜗2(1 − 𝑠𝑠2)( 1 − (1 − 𝜚𝜚)𝛿𝛿2)𝑛𝑛2�
𝜓𝜓𝜏𝜏,02 = 𝜏𝜏2�(1 − 𝜗𝜗2)𝑠𝑠2( 1 − (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + (1 − 𝜗𝜗2)(1 − 𝑠𝑠2)( 1 − (1 − 𝜎𝜎)𝛿𝛿2)𝑛𝑛2 +
𝜗𝜗2𝑠𝑠2( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + 𝜗𝜗2(1 − 𝑠𝑠2)( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿2)𝑛𝑛2�  
With 𝛿𝛿2 = 𝛽𝛽𝑓𝑓(1 − 𝜀𝜀𝛾𝛾2) 
(2.30) 
Where women are enrolled on PrEP, their HIV risk for a 12-month period is: 
Π(rj𝑏𝑏αj) = 1 − �𝑝𝑝1(𝜓𝜓(1−𝜏𝜏), 𝑟𝑟𝑏𝑏𝛼𝛼1 + 𝜓𝜓𝜏𝜏, 𝑟𝑟𝑏𝑏𝛼𝛼1 ) + (1 − 𝑝𝑝1)�𝐶𝐶1�𝑝𝑝2(𝜓𝜓(1−𝜏𝜏), 𝑟𝑟𝑏𝑏𝛼𝛼2 + 𝜓𝜓𝜏𝜏, 𝑟𝑟𝑏𝑏𝛼𝛼2 ) + (1 − 𝑝𝑝2)�𝐶𝐶2
Where 𝑗𝑗 = 1, with: 
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𝜓𝜓(1−𝜏𝜏), 𝑟𝑟𝑏𝑏𝛼𝛼1 = (1 − 𝜏𝜏1)�(1 − 𝜗𝜗1)𝑠𝑠1( 1 − 𝛿𝛿𝛿𝛿1)𝑛𝑛1 + (1 − 𝜗𝜗1)(1 − 𝑠𝑠1)( 1 − 𝛿𝛿1)𝑛𝑛1+ 𝜗𝜗1𝑠𝑠1( 1 − (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + 𝜗𝜗1(1 − 𝑠𝑠1)( 1 − (1 − 𝜚𝜚)𝛿𝛿1)𝑛𝑛1�
𝜓𝜓𝜏𝜏, 𝑟𝑟𝑏𝑏𝛼𝛼1 = 𝜏𝜏1�(1 − 𝜗𝜗1)𝑠𝑠1( 1 − (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + (1 − 𝜗𝜗1)(1 − 𝑠𝑠1)( 1 − (1 − 𝜎𝜎)𝛿𝛿1)𝑛𝑛1+ 𝜗𝜗1𝑠𝑠1( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + 𝜗𝜗1(1 − 𝑠𝑠1)( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿1)𝑛𝑛1�
With:  
𝛿𝛿1 = 𝛽𝛽𝑓𝑓(1 − 𝑟𝑟𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1) 
And, 𝑗𝑗 = 2, with: 
𝜓𝜓(1−𝜏𝜏), 𝑟𝑟𝑏𝑏𝛼𝛼2 = (1 − 𝜏𝜏2)�(1 − 𝜗𝜗2)𝑠𝑠2( 1 − 𝛿𝛿𝛿𝛿2)𝑛𝑛2 + (1 − 𝜗𝜗2)(1 − 𝑠𝑠2)( 1 − 𝛿𝛿2)𝑛𝑛2+ 𝜗𝜗2𝑠𝑠2( 1 − (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + 𝜗𝜗2(1 − 𝑠𝑠2)( 1 − (1 − 𝜚𝜚)𝛿𝛿2)𝑛𝑛2�
𝜓𝜓𝜏𝜏, 𝑟𝑟𝑏𝑏𝛼𝛼2 = 𝜏𝜏2�(1 − 𝜗𝜗2)𝑠𝑠2( 1 − (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + (1 − 𝜗𝜗2)(1 − 𝑠𝑠2)( 1 − (1 − 𝜎𝜎)𝛿𝛿2)𝑛𝑛2+ 𝜗𝜗2𝑠𝑠2( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + 𝜗𝜗2(1 − 𝑠𝑠2)( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿2)𝑛𝑛2�
With 𝛿𝛿2 = 𝛽𝛽𝑓𝑓(1 − 𝑟𝑟𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾2) 
(2.42) 
To assess the relative impact and cost-effectiveness of PrEP scale-up, FSW are taken as the 
benchmark against which other high-risk women groups are assessed, as they are priority groups for 
PrEP roll-out in the three country settings39,40,41 in view of their very high levels of HIV risk6,58,68,69. 
The following analytical relations are derived to guide the PrEP scale-up analysis. 
Let $𝑌𝑌𝑗𝑗 be the unit cost per high risk woman from population 𝑗𝑗 ≠ 𝐹𝐹𝑆𝑆𝐹𝐹 retained in a PrEP program 
for population 𝑗𝑗, with 12-month retention level 𝑟𝑟𝑗𝑗, and $𝑌𝑌𝐹𝐹𝑆𝑆𝐹𝐹 the equivalent unit cost for a FSW PrEP 
program per FSW retained with 12-month retention level 𝑟𝑟𝐹𝐹𝑆𝑆𝐹𝐹. 
The program’s cost to avert 1 infection per year due to PrEP in each population is $Yj
Πj(0)−Πj(rj𝑏𝑏αj) and $YFSW
ΠFSW(0)−ΠFSW(rFSWbαFSW) respectively. 
Building on equation (2.23), a PrEP program for high risk population 𝑗𝑗 ≠ 𝐹𝐹𝑆𝑆𝐹𝐹 will then be equally as 
cost-effective per infection averted due to PrEP, as it is for FSW, where:  
$Yj$YFSW = Πj(0)−Πj(rjbαj)ΠFSW(0)−ΠFSW(rFSWbαFSW)
(2.31)
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(2.32) 
To determine the coverage, 𝜔𝜔𝑗𝑗, of PrEP in high-risk woman population 𝑗𝑗 ≠ 𝐹𝐹𝑆𝑆𝐹𝐹 needed to achieve 
the same risk reduction as coverage 𝜔𝜔𝐹𝐹𝑆𝑆𝐹𝐹 in FSW, we have: 
 𝜔𝜔𝑗𝑗𝑁𝑁𝑗𝑗(1 − 𝑝𝑝𝑗𝑗) �Π𝑗𝑗(0) − Π𝑗𝑗(𝑟𝑟𝑗𝑗𝑏𝑏𝛼𝛼𝑗𝑗 )� = 𝜔𝜔𝐹𝐹𝑆𝑆𝐹𝐹𝑁𝑁𝐹𝐹𝑆𝑆𝐹𝐹(1 − 𝑝𝑝𝐹𝐹𝑆𝑆𝐹𝐹)�Π𝐹𝐹𝑆𝑆𝐹𝐹(0) − Π𝐹𝐹𝑆𝑆𝐹𝐹(𝑟𝑟𝐹𝐹𝑆𝑆𝐹𝐹𝑏𝑏𝛼𝛼𝐹𝐹𝐹𝐹𝐹𝐹 )� 
(2.33) 
Which is when: 
𝜔𝜔𝑗𝑗 = 𝜔𝜔𝐹𝐹𝑆𝑆𝐹𝐹 𝑁𝑁𝐹𝐹𝑆𝑆𝐹𝐹(1 − 𝑝𝑝𝐹𝐹𝑆𝑆𝐹𝐹)�Π𝐹𝐹𝑆𝑆𝐹𝐹(0)− Π𝐹𝐹𝑆𝑆𝐹𝐹(𝑟𝑟𝐹𝐹𝑆𝑆𝐹𝐹𝑏𝑏𝛼𝛼𝐹𝐹𝐹𝐹𝐹𝐹)� 
𝑁𝑁𝑗𝑗(1 − 𝑝𝑝𝑗𝑗) �Π𝑗𝑗(0) − Π𝑗𝑗(𝑟𝑟𝑗𝑗𝑏𝑏𝛼𝛼𝑗𝑗)�
(2.34) 
These levels of coverage would be at a relative total cost of: 
$𝑌𝑌𝑗𝑗𝜔𝜔𝑗𝑗𝑁𝑁𝑗𝑗(1−𝑝𝑝𝑗𝑗)$𝑌𝑌𝐹𝐹𝐹𝐹𝐹𝐹𝜔𝜔𝐹𝐹𝐹𝐹𝐹𝐹𝑁𝑁𝐹𝐹𝐹𝐹𝐹𝐹(1−𝑝𝑝𝐹𝐹𝐹𝐹𝐹𝐹)
(2.46) 
If PrEP were to be scaled up at equal coverage in both populations, then the relative number of 
infections averted per year in high-risk woman population 𝑗𝑗 ≠ 𝐹𝐹𝑆𝑆𝐹𝐹with respect to the FSW 
population would be: 
𝑁𝑁𝑗𝑗(1−𝑝𝑝𝑗𝑗)(Π𝑗𝑗(0)−Π𝑗𝑗(𝑟𝑟𝑗𝑗𝑏𝑏𝛼𝛼𝑗𝑗))
𝑁𝑁𝐹𝐹𝐹𝐹𝐹𝐹(1−𝑝𝑝𝐹𝐹𝐹𝐹𝐹𝐹)(Π𝐹𝐹𝐹𝐹𝐹𝐹(0)−Π𝐹𝐹𝐹𝐹𝐹𝐹(𝑟𝑟𝐹𝐹𝐹𝐹𝐹𝐹𝑏𝑏𝛼𝛼𝐹𝐹𝐹𝐹𝐹𝐹))
(2.36) 
This is equivalent to the relative total maximum number of infections averted per year if PrEP 
programs were scaled up to all HIV negative women in each population. 
For each $100𝑘𝑘 available for PrEP programming for each population, the estimated number of 
infections averted a year in each population would be, in high-risk women 𝑗𝑗 ≠ 𝐹𝐹𝑆𝑆𝐹𝐹: 
$100𝑘𝑘$𝑌𝑌𝑗𝑗 (Π𝑗𝑗(0) − Π𝑗𝑗(𝑟𝑟𝑗𝑗𝑏𝑏𝛼𝛼𝑗𝑗)), 
In FSW: 
$100𝑘𝑘$𝑌𝑌𝐹𝐹𝐹𝐹𝐹𝐹 (𝛱𝛱𝐹𝐹𝑆𝑆𝐹𝐹(0) − 𝛱𝛱𝐹𝐹𝑆𝑆𝐹𝐹(𝑟𝑟𝐹𝐹𝑆𝑆𝐹𝐹𝑏𝑏𝛼𝛼𝐹𝐹𝐹𝐹𝐹𝐹)) 
(2.35)
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(2.37) 
The proportion of the potential total number of infections that could be averted a year in each 
population with $100𝑘𝑘, in high-risk women 𝑗𝑗 ≠ 𝐹𝐹𝑆𝑆𝐹𝐹, is: 
 $100𝑘𝑘.(Π𝑗𝑗(0)−Π𝑗𝑗(𝑟𝑟𝑗𝑗𝑏𝑏𝛼𝛼𝑗𝑗))$𝑌𝑌𝑗𝑗.𝑁𝑁𝑗𝑗(1−𝑝𝑝𝑗𝑗).Π𝑗𝑗(0)  
In FSW: 
 
$100𝑘𝑘.(𝛱𝛱𝐹𝐹𝐹𝐹𝐹𝐹(0)−𝛱𝛱𝐹𝐹𝐹𝐹𝐹𝐹(𝑟𝑟𝐹𝐹𝐹𝐹𝐹𝐹𝑏𝑏𝛼𝛼𝐹𝐹𝐹𝐹𝐹𝐹))$𝑌𝑌𝐹𝐹𝐹𝐹𝐹𝐹 .𝑁𝑁𝐹𝐹𝐹𝐹𝐹𝐹(1−𝑝𝑝𝐹𝐹𝐹𝐹𝐹𝐹).𝛱𝛱𝐹𝐹𝐹𝐹𝐹𝐹(0)  
(2.38) 
Estimation of current PrEP unit costs per person retained after 12-months 
In order to be able to compare the relative costs at which PrEP scale-up from FSW to another high-
risk group is equally cost-effective to current relevant unit costs between the populations, estimates 
of the current cost of PrEP per person retained after 12-months for each high-risk women group 
were developed. These estimates of the current costs of PrEP for each group of high-risk women in 
each of South Africa, Zimbabwe and Kenya were developed by Dr Gabriela Gomez, a Health 
Economist. The following costing methodology was developed by Dr Gomez:  
To estimate the cost of PrEP to each high-risk group of women, FSW were assumed to be offered 
PrEP through programmes with outreach and community mobilisation components. All other 
women were assumed to be offered PrEP through sexual and reproductive health services, with 
services for AGYW having larger counselling components. Cost data were reviewed from PrEP OLE, 
demonstration and implementation projects and previous PrEP costing publications in Kenya70,71 and 
South Africa43 (None were available from Zimbabwe).  
Cost estimates were disaggregated into service delivery and drug costs. The reported drug costs 
were replaced by a range of $57-80 per year. The lower bound is the internationally traded value of 
USD3.75 with a 25% top up of freight and distribution costs in country (15% shipping and handling 
charges, and 10% for drug distribution costs)72. The high bound is the highest reported price for 
drugs in the demonstration projects - 30 days of TDF/FTC at $6.75. For Zimbabwe, in addition to drug 
costs, non-tradable components of the South African estimates were transferred using purchasing 
power parities73 following standard methods74. All previously published costs were adjusted to 
$201775. The amounts and detailed assumptions underpinning the estimated unit costs for each 
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high-risk women group by country are set out in the Annex to this thesis, in Supplementary 
Materials to Research Paper 3. 
Analyses to inform strategies for PrEP scale-up 
The following analyses were undertaken to inform strategies for PrEP scale-up across high-risk 
women in each country context.  
First, the maximum unit costs of PrEP for non-FSW high-risk women relative to FSW is estimated, for 
scale-up to be equally as cost-effective as it is in FSW, for all three countries using equation (2.32). 
These are compared to the current estimated relative unit costs of PrEP between for non-FSW high-
risk women and FSW as set out in the ‘Estimation of current PrEP unit costs per person retained after 
12-months’ section above.
Then, the number of infections that could be averted a year due to PrEP in each high-risk women 
population group are estimated, in each country, for every $100,000 available for PrEP programming 
using equation (2.37). The proportion of HIV infections that could be averted a year for every 
$100,000 allocated to each group is estimated using equation (2.38). 
Finally, given the differences in relative population sizes between the high-risk women groups in 
each country, the relative number of HIV infections that could be averted a year with PrEP at equal 
coverage levels across all high-risk women groups is each country is estimated using equation (2.36). 
Programming tool 
The equations for Research Paper 3 were also evaluated in R5, as flexible programming platform that 
facilitates fitting the model equations to incidence data and for running and storage of the results of 
multiple country and population simulations. 
Uncertainty analysis 
Parametric uncertainty: Data ranges to parameterise the models for each high-risk women group are 
fitted to the latest national estimates of HIV incidence by population and country using Bayesian 
Monte Carlo methods with Latin Hypercube Sampling assuming uniform prior distributions using the 
R PSE Package76, giving yield to at least 200 sets of parameter fits for each high-risk woman 
population modelled and allowing for the evaluation of uncertainty ranges. 
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Two further parametric uncertainty analyses are undertaken, to assess the sensitivity of the model 
results to the PrEP adherence levels assumed for all non-FSW high-risk women groups, given the 
particular uncertainty around the data parameterization. At the time of undertaking the analysis, 
there were no PrEP adherence data available for women other than for FSW under the TaSP 
demonstration project in South Africa43. As such, for non-FSW high-risk women groups PrEP 
adherence was taken to be the same as in FSW. To explore the sensitivity of the results to this 
assumed level of PrEP adherence, the analyses were repeated with 1) 25% lower (not higher, as the 
existing upper bound is 99%) HIV risk-reduction across all groups; and 2) 25% lower HIV risk-
reduction across AGYW, women 25-34 years and women 35-49 years (but unchanged among FSW). 
Structural sensitivity: Whist the literature only provides evidence of women aged 15-25 years having 
male partners from an older population group in these three settings, we explored how the model 
outcomes change if women aged 25-34 years are also assumed to have male partners from an older 
population group (35-49 years) with higher HIV prevalence. This model structural sensitivity analysis 
was parameterised illustratively assuming 50% the number of partners a year from the male 
population 35-49 years as had by women 35-49 years (in addition to their partnerships with males 
25-34 years). 
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Chapter 3 
3. Research Paper 1: When are declines in condom use 
while using PrEP a concern? Modelling insights from a 
Hillbrow, South Africa case study
3.1   Introduction to Research Paper 1 
Research Paper 1 aims to respond to objectives 1 and 2 of the thesis by assessing how behavioural 
disinhibition may affect the potential HIV risk reduction of PrEP for high-risk women. It addresses 
this question considering a spectrum of different baseline condom consistencies (prior to the 
introduction of PrEP) and for different levels of HIV risk reduction achieved on PrEP. The study aims 
to assist policy makers in identifying and focusing programming efforts on women likely to be at 
increased risk of HIV should behavioural disinhibition occur in PrEP programs. 
This study is applied to a particularly high HIV risk population and high HIV risk setting - to FSW, who 
typically have significantly elevated levels of HIV risk compared to women in the general population1, 
and to the setting of Hillbrow, in inner Johannesburg, South Africa. Specifically, in this context, 
female sex workers are estimated to have extremely high HIV prevalence levels of 72%2, with high 
prevalence levels of HIV among men in the general population (26% (95% confidence interval: 23-
29%) among men aged 25-49) 3. 
At the time this study was undertaken, PrEP had yet to be rolled out in South Africa, and was being 
explored through demonstration projects, such as the TaPS4 demonstration project for female sex 
workers in Hillbrow, which serves as the setting for this modelling study. No studies had yet equated 
levels of PrEP adherence to levels of HIV risk reduction in women, nor determined whether the 
levels of PrEP adherence needed to be the same between men and women to achieve the same 
levels of HIV risk reduction. This study was the first to use mathematical models to explore the effect 
of different levels of PrEP adherence-associated HIV risk reduction in women on PrEP programme 
outcomes, with the aim of informing policy on PrEP roll-out.  
Given the lack of data available at the time to equate level of PrEP adherence with levels of HIV risk 
reduction in women, this study refers to data from a demonstration project in MSM and TGW to 
indicatively link levels of HIV risk reduction to numbers of PrEP tablets taken a week by female sex 
workers5. It has since been recognised that 100% risk reduction on PrEP necessitates higher levels of 
adherence in women (6 out of 7 tablets a week, mode of transmission through heterosexual 
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intercourse) than in men (4 out if 5 in MSM and TGW, mode of transmission through anal 
intercourse).6  
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Abstract 
 
Objectives: To assess whether decreased levels of condom use following introduction of oral pre-
exposure prophylaxis (PrEP) might limit HIV risk reduction for female sex workers (FSWs). 
Design: A static mathematical model of HIV risk. 
Methods: We compared HIV risk estimates before and after the introduction of PrEP to determine 
the maximum tolerated reductions in condom use with regular partners and clients for HIV risk not 
to change. The model incorporated the effects of increased STI exposure owing to decreased 
condom use. Noting that condom use with regular partners is generally low, we also estimated the 
change in condom use tolerated with clients only, to still achieve 50% and 90% risk reduction on 
PrEP. The model was parameterised using data from Hillbrow, Johannesburg. Sensitivity analyses 
were performed to ascertain the robustness of our results. 
Results: Reductions in condom use could be tolerated by FSWs with lower baseline condom use 
(<50%), or where PrEP effectiveness achieved is reasonably high (>65%). For scenarios where 75% 
PrEP effectiveness is attained, 50% HIV risk reduction on PrEP would be possible even with 100% 
reduction in condom use from consistent condom use as high as 70% with clients. Increased 
exposure to STIs through reductions in condom use had limited effect on the reductions in condom 
use tolerated for HIV risk not to increase on PrEP. 
Conclusions: PrEP is likely to be of benefit in reducing HIV risk, even if reductions in condom use 
does occur. Efforts to promote consistent condom use will be critical for FSWs with high initial levels 
of condom use, but with challenges in adhering to PrEP. 
 
Conflicts of Interest and Source of Funding: The authors declare no conflicts of interest. 
Contributions: HG and CW designed the study.  All authors input into the analyses and contributed to 
the writing of the paper. 
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Introduction 
Oral pre-exposure prophylaxis (PrEP) is a promising approach to HIV prevention. It is hoped that 
PrEP might become an effective addition to combined HIV prevention and help to significantly 
reduce HIV risk for vulnerable groups. This would be especially critical for those populations with low 
ability to negotiate condom use due to gender and societal power imbalances, such as young 
women in heterosexual relationships7  and sex workers8. Proof of concept has been demonstrated9 
in four out of the six randomized controlled trials conducted to date, in which higher levels of HIV 
risk reduction were associated with higher levels of adherence. Open label extension studies9–12 have 
confirmed PrEP’s importance as a prevention tool, with up to 100% risk reduction estimated in the 
Open Label Extension (OLE) of the iPrEx trial13 for men and transgender women who have sex with 
men adhering to PrEP for at least four out of seven doses a week.  
Nonetheless, the two randomised controlled trials14,15 stopped early for futility cited lack of 
adherence by the study populations as the cause. Additional implementation concerns have been 
raised, including antiretroviral (ARV) resistance development resulting from sub-optimal drug 
adherence levels16, contraindications17, challenges in acceptability18, barriers to access and 
programme retention19, and behaviour change20–24. Noting both the positive trial results as well as 
implementation concerns, in July 2012 the World Health Organisation (WHO) 25 called for countries 
to undertake demonstration projects to gain insight into acceptability, patterns of use, and 
sustainability of PrEP.  
Data since gathered has informed WHO’s September 2015 PrEP guidance26 recommending oral PrEP 
for all people at substantial risk of HIV (incidence >3 per 100 person years). However, concerns 
remain27–31 regarding the potential limiting effects of a particular form of behaviour change - 
reductions in condom use (“condom migration”) - on PrEP. Reductions in condom use not only 
increase the chance of HIV exposure, but also the exposure to and transmission of sexually 
transmitted infections (STIs). Increased exposure to STIs increases both the susceptibility of an HIV 
negative partner, as well as the infectiousness of an HIV positive partner, and thereby HIV 
transmission32. Whilst no trial to date has reported decreased condom use, the high rate of 
pregnancies reported in the trials18, results of behavioural surveys33 and qualitative research19 
indicate that efforts to tackle condom migration may need to be considered in the design of PrEP 
programmes. 
In response to these concerns and to inform PrEP programme design, this study examines the extent 
to which condom migration is likely to impact PrEP effectiveness in programmes for female sex 
workers (FSWs). We focus on the FSW population working in Hillbrow, Johannesburg, some of whom 
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are participating in a PrEP demonstration programme undertaken by the Wits Reproductive Health 
and HIV Institute (WRHI)34. The FSW populations in this setting present extremely high baseline HIV 
prevalence (estimated to be up to 72%2,35), elevated levels of STIs2,36, low levels of condom use with 
often high HIV risk37 regular partners, and known challenges in condom negotiation with clients, 
where in such settings FSWs may receive a quarter of the average price for transactional sex if 
condoms are insisted upon23.  
Our study aims to inform rapidly changing policy in South Africa where in November 2015, South 
Africa’s Medicines Control Council approved the use of the fixed-dose combination of TDF/FTC as 
PrEP38. Locally-adapted guidelines39 were published in early 2016 and PrEP was recently included in 
South Africa’s National Sex Worker HIV Plan (2016–2019)40. PrEP roll out for sex workers started in 
June 2016.  
  
 
 
125 
 
Methods 
This work builds on that in Foss et al41, where an adaption of an HIV risk equation was used to assess 
microbicides as a new HIV prevention method. This study uses the established Bernoulli model of 
HIV transmission42–45 where the probability of the HIV virus being transmitted through each sexual 
contact is treated as an independent risk event. We employed static rather than dynamic 
mathematical modelling to obtain clear deductions regarding the contribution of the parameters 
being explored to HIV risk, and for the derivation of rules of thumb that can be broadly understood 
and applied to HIV prevention efforts focused on FSWs. Whilst previous studies41,46,47 have used 
mathematical modelling to predict the impact of condom migration on the effectiveness of ARV-
based microbicides, this is the first study to consider its impact on oral PrEP, in particular for FSWs. 
The HIV risk equations for a population of HIV-negative FSWs and their partners prior to, and 
following introduction of, PrEP are outlined in the Supplementary Methods. To explore the 
consequences for FSWs of condom migration on PrEP, condoms are assumed to be used with 
consistency that may vary with the introduction of PrEP (𝛾𝛾0 prior to PrEP introduction and 𝛾𝛾1 after 
its introduction). We assumed condoms to have an HIV risk reduction efficacy, 𝜀𝜀, including slippage 
and breakage. Whilst the risk reduction effectiveness of condoms is generally assumed to follow a 
linear relationship between use and efficacy (𝜀𝜀𝛾𝛾), the exact effectiveness relationship between 
adherence and PrEP efficacy remains under investigation48–50 (although one study suggested a linear 
relationship51), so we assume an overall level of ‘PrEP effectiveness’, 𝑏𝑏𝛼𝛼, corresponding to a level of 
FSW PrEP adherence, 𝛼𝛼. No partner populations are assumed to be taking PrEP.  
 
Single partner population 
We started the analysis by considering a single partner population, in whom the proportion HIV 
infected is 𝑝𝑝. For a given time period, a FSW is assumed to have n partners, each with whom she has 
an average of 𝑚𝑚 sex acts. For simplicity these equations assume an overall average probability of HIV 
transmission, 𝛽𝛽, per sexual contact with an HIV infected partner.  
We used the HIV risk equations to derive two key threshold conditions: 1) the level of PrEP 
effectiveness that must be attained for PrEP to be of benefit in reducing HIV risk, considering any 
change in condom consistency; and 2)  the ‘break-even’ level of condom consistency after 
introduction of PrEP such that HIV acquisition risk is not increased.  
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Single partner population, accounting for increased STI exposure  
We expanded our analysis to explore the increased risk of HIV transmission resulting from exposure 
to STIs, should condom migration occur and PrEP use be inconsistent. Parameter s is taken as the 
probability that at least one person in the partnership has an STI, and 𝛿𝛿 the multiplicative increase in 
per sex act probability of HIV transmission in the presence of an STI.  
We derived the percentage reduction in condom consistency tolerated for HIV risk not to increase 
on PrEP and compared these results to those not accounting for increased STI exposure, to see 
whether conclusions remain robust. 
 
Two partner populations, accounting for increased STI exposure  
We then extended the HIV risk equations to account for risk arising from two distinct partner 
populations: clients ("𝑐𝑐") and regular partners("𝑟𝑟"). In this setting, condom consistency with regular 
partners is low52 and clients sometimes pay more for condom-less sex37. As such, any change in 
condom consistency on PrEP is likely to be more profound with clients, and therefore its impact on 
HIV risk. We thus examined the percentage reduction in condom consistency with clients tolerated 
for HIV risk not to increase on PrEP, holding condom consistency with regular partners constant 
(using Appendix 2: Supplementary Materials equations S14 and S15). We assessed whether the 
results remain the same, accounting or not for increased STI exposure through decreased condom 
use. To gauge whether, in such settings, changes in condom use with clients or regular partners 
present the biggest HIV risk, we assessed whether there is a significant difference in the percentage 
reduction in condom consistency with clients tolerated for HIV risk not to increase, if PrEP use 
reduces condom use to zero with regular partners.  
The equations were solved numerically using Solver in Microsoft Excel 2013 (set to perform 10,000 
iterations per calculation) to ascertain the maximum change in condom consistency that can be 
tolerated for PrEP to remain of benefit, considering increased exposure to STIs, across a range of 
possible attained PrEP effectiveness levels. 
 
Data and model parameterisation 
The HIV risk equations were parameterised using sexual behaviour data from Hillbrow, Johannesburg 
collected by WRHI, as well as biological and epidemiological data from other literature (Supplementary 
Methods: Table S1). As there is uncertainty about the PrEP effectiveness corresponding to levels of 
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drug adherence, calculations were carried out for a range of simulated values of PrEP effectiveness 
for a given adherence value (𝑏𝑏𝛼𝛼). The values simulated roughly span the range of risk reduction 
estimated through the iPrEx OLE13 study (between 44% corresponding to fewer than 2 tablets a week 
and 100% corresponding to at least 4 tablets a week). We started from a slightly lower baseline of 35% 
to reflect, conservatively, that this study was conducted in a different study population. 
It was assumed that all sex acts are peno-vaginal on the basis of available epidemiological data for 
FSWs in Hillbrow52. Three months was chosen as the period of HIV risk evaluation, as this corresponds 
to the period after which an HIV test must be performed on PrEP to check for seroconversion (amongst 
other indicators)38,53. 
 
Sensitivity analysis 
Two categories of sensitivity analysis were performed. Firstly, the calculations were repeated for two 
boundary cases: high risk (HR) and low risk (LR) FSWs, parameterised using high and low risk values 
in the HIV risk equation for the sexual behaviour parameters (% partners HIV infected, number of 
partners and average number of sex acts per three months, probability at least one person in the 
partnership has an STI) and the transmission probability parameters (condom HIV risk reduction 
efficacy, probability of HIV transmission through peno-vaginal sex, multiplicative increase in per sex 
act probability of HIV transmission in the presence of an STI). 
A second set of sensitivity analyses were undertaken to explore the case that any condom migration 
brings with it increases in STI prevalence, and therewith risk of HIV transmission. In spite of high 
levels of STI treatment in the FSW population34, to obtain conservative results in terms of change in 
condom consistency tolerated following the introduction of PrEP, we assumed that STIs are present 
in all partnerships where reductions in condom consistency occur, and that these STIs are 
transmitted through the sex act if not already present in both partners. The probability that at least 
one person in the partnership has an STI following the introduction of PrEP is therefore assumed to 
increase at the same rate as the change in condom consistency.   
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Results 
Single partner population 
We deduced that where the level of PrEP effectiveness achieved equals or exceeds that of condoms 
(i.e. condom efficacy * baseline condom consistency), PrEP will be of equal or greater benefit in 
reducing HIV risk and therefore condom use could be reduced to zero without HIV risk increasing. 
Where the level of PrEP effectiveness is less than the effectiveness originally achieved with 
condoms, we see that greater drops in condom consistency can be tolerated for those FSW with 
lower baseline condom consistencies. 
Figure 1 shows the break-even condom consistency after introduction of PrEP such that HIV risk is 
not increased. Large relative reductions in condom consistency on PrEP are anticipated to be 
especially well tolerated where higher levels of PrEP effectiveness achieved (>65%). For FSWs whose 
baseline consistencies are low (<55%), or where there is not anticipated to be a large relative drop in 
condom consistency on PrEP, even the achievement of low levels of PrEP effectiveness will reduce 
HIV risk.  
Figure 1: Break-even condom consistencies following introduction of PrEP. 
In the case of a single partner population, the figure describes the break-even condom consistencies (the levels that condom 
use could be reduced to, following introduction of PrEP) such that HIV risk is not increased on PrEP. These break-even levels 
are shown for baseline condom consistencies between 30% and 100%, and corresponding to six different levels of achieved 
PrEP effectiveness ranging from 35% to 85% (85% corresponding to the level of condom efficacy assumed in this study).  
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Single partner population, accounting for increased STI exposure  
The results show that reductions in condom consistency on PrEP are especially well tolerated for 
FSWs with lower baseline condom consistencies (<50%) and where higher levels of PrEP 
effectiveness are achieved (>65%). Even for the lowest level of 35% PrEP effectiveness simulated 
(which would correspond to adherence to fewer than two tablets a week according to iPrEx OLE13 
estimates), the percentage reduction in condom consistency tolerated steadily increases upwards 
from a minimum reduction of 17% (corresponding to 90% baseline condom consistency) to 100% 
migration (corresponding to 30% baseline condom consistency).  
Where PrEP effectiveness of 85% can be achieved (which would correspond to adherence of 2-3 
tablets a week according to iPrEx OLE13 estimates; and the exact level of assumed condom 
protection efficacy simulated for the base case), 100% condom migration can uniformly be tolerated 
across all baseline condom consistencies simulated.  
The percentage change in condom consistency possible is almost the same (<1% difference) whether 
STIs are accounted for or not in the HIV risk equations (Supplementary Results: Table S2, shown 
graphically in Figure 2). This is because, whilst inclusion of STI parameters in the mathematical HIV 
risk equations does result in increased HIV risk levels on an absolute basis, it does not significantly 
affect change in risk on a relative basis. 
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Figure 2: Percentage reduction in condom consistency tolerated with a single partner population for HIV risk not to 
increase on PrEP, accounting for the effect of STIs on HIV risk.  
For different baseline condom consistencies between 30 and 95%, the figure describes the percentage reduction in condom 
consistency that could be tolerated on PrEP corresponding to six different levels of achieved PrEP effectiveness, ranging 
from 35% to 85% (85% corresponding to the level of condom efficacy assumed in this study). 
Sensitivity analysis 
Looking at the boundary cases of high and low risk FSW reveals only small variations in the 
percentage reduction in condom consistency tolerated (accounting for STIs or not in the equations). 
This is especially true at lower levels of PrEP effectiveness and higher baseline condom consistencies 
(4-8% reduced reduction in condom consistency tolerated), although this is slightly more 
pronounced at higher levels of PrEP effectiveness (up to 22% reduced reduction).  
Should condom migration bring with it increases in STI prevalence in the population, there would be 
modest reductions in the percentage reduction in condom consistency tolerated (at most 22% 
reductions in relative terms compared to the base case results, or between 2% and 20% less in 
absolute terms), though the differences in the results are smaller especially where PrEP 
effectiveness achieved is lower (<65%) and initial condom consistency is high (>70%), or where PrEP 
effectiveness achieved is higher (≥65%) and initial condom consistency is below ~80%. 
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Two partner populations, accounting for increased STI exposure  
Table 1 demonstrates the percentage reductions in condom consistency with clients tolerated to 
achieve 50% or 90% levels of reduction in HIV risk on PrEP, condom consistency with regular 
partners held constant (at 10%54).  
Achievement of 50% reduction in HIV risk on PrEP is feasible across all simulated PrEP effectiveness 
levels (55%, 75%, 95%) and baseline condom consistencies (30-90%). As seen for single partner 
populations, reductions in condom consistency are best tolerated for FSWs with lower baseline 
levels with clients or where higher PrEP effectiveness levels are achieved.  
A FSW with initial condom consistency of 30% with clients could reduce her consistency by one third 
and still achieve 50% reduction in HIV risk, if she were able to attain 55% PrEP effectiveness 
(corresponding to below 2-3 doses a week per iPrEx OLE13). A FSW achieving 95% PrEP effectiveness 
(corresponding to around 4 doses a week per iPrEx OLE13) could tolerate 100% condom migration to 
achieve HIV risk reductions in excess of 50%; and so too for those FSWs achieving 75% PrEP 
effectiveness for baseline condom consistencies with clients of up to 70%. 
Across the parameters simulated, the higher level of 90% risk reduction on PrEP could only be 
achieved in the case where PrEP is 95% effective (corresponding to around 4 doses a week per iPrEx 
OLE13). In this case, an initially 90% condom consistent FSW could reduce her condom use with 
clients by more than half; and for FSWs with baseline condom consistencies with clients of 70% and 
lower, 100% condom migration on PrEP could be tolerated. 
Again, there is negligible observable (<1%) difference whether or not STIs are accounted for in the 
HIV risk equations.  
In the case that PrEP leads to full condom migration with regular partners, rather than remaining 
consistent at 10%, there is a small further reduction in condom consistency tolerated (between 1-8% 
across the scenarios simulated, see Supplementary Results Table S4)). 
 
Sensitivity analysis 
Looking at the boundary cases of high and low risk FSW reveals small variation in the percentage 
reduction in condom consistency tolerated for the lower level of PrEP effectiveness of 55%. The 
variation is more pronounced for higher levels of PrEP effectiveness (75% and 95%), with up to 
around one third change in percentage reduction in condom consistency tolerated across the 
parameter ranges simulated.  
 
 
132 
 
In the case that condom migration brings with it increases in STI prevalence in the population, there 
are reductions in relative terms of 14%-26% compared to the base case results, and in absolute 
terms the reductions are almost uniformly within the range of variation seen through examining the 
boundary cases of high and low risk FSW. 
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Table 1: Maximum tolerated % reduction in condom consistency with clients (consistency with regular partners held constant) to still achieve 50% or 90% reductions in HIV risk on PrEP, for 
different levels of PrEP effectiveness achieved.  
For each level of PrEP effectiveness demonstrated, the table shows the % reduction in condom consistency that could be tolerated, from varying levels of initial condom consistency, to achieve 
either 50% or 90% HIV risk reduction. The results are shown for both the case that STIs are accounted for in the HIV risk equations, as well as the case that they are not. The results are shown 
for the base case parameterization of the model, as well as the boundary cases explored through the first sensitivity analysis of high and low risk FSW. They assume that condom consistency 
with regular partners remains constant at 10% before and after introduction of PrEP. The results corresponding to the case that condom consistency with regular partners drops from 10% to 
0% following the introduction of PrEP is shown in Table S4 in the Appendix 2: Supplementary Materials. 
 ‘–‘ indicates that achievement of the risk reduction is not possible. ‘*’ indicates full migration will still result in higher levels of risk reduction. ‘Base’ refers to the main calculated results 
undertaken using the baseline parameter values. HR stands for high risk and LR stands for low risk FSW, and the results calculated in the sensitivity analysis for the boundary parameter cases. 
A graphic depiction of the results corresponding to achievement of 50% HIV risk reduction on PrEP is given in Supplementary Equations, Figure S1.
90% 90% 90%
Accounting for 
STIs
Not accounting 
for STIs
Accounting for 
STIs
Not accounting 
for STIs Accounting for STIs
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STIs
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Accounting for 
STIs
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Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR)
90% 6% (-3%,-3%) 6% (-3%,3%) - - - - 57% (-27%,26%) 57% (-28%,39%) - - - - 100% (*,*) 100% (*,*) 56% (-27%,19%) 57% (-28%,37%)
80% 8% (-3%,-5%) 8% (-3%,2%) - - - - 76% (-31%,24%) 77% (-31%,23%) - - - - 100% (*,*) 100% (*,*) 75% (-29%,20%) 76% (-31%,24%)
70% 10% (-3%,-6%) 11% (-4%,2%) - - - - 100% (*,*) 100% (*,*) - - - - 100% (*,*) 100% (*,*) 100% (*,*) 100% (*,*)
50% 18% (-4%,-13%) 19% (-5%,2%) - - - - 100% (*,*) 100% (*,*) - - - - 100% (*,*) 100% (*,*) 100% (*,*) 100% (*,*)
30% 37% (-6%,-29%) 38% (-7%,0%) - - - - 100% (*,*) 100% (*,*) - - - - 100% (*,*) 100% (*,*) 100% (*,*) 100% (*,*)
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Discussion 
This study provides insights into the risks associated with condom migration following the 
introduction of PrEP into a comprehensive HIV prevention programme for FSWs. The study 
demonstrates that the success of PrEP will rest upon its ability to achieve high enough PrEP 
adherence in FSWs such that the increased protection achieved outweighs the increased HIV risk 
owing to condom migration and increased STIs exposure. The added value for decision makers of our 
study lies upon our ability to quantify these trade-offs. 
This study has demonstrated that where a FSW’s adherence to PrEP achieves a level of effectiveness 
that exceeds that of condoms, PrEP will always reduce HIV risk. Condom migration is anticipated to 
be especially well tolerated where baseline levels of condom consistency are low (<50%) or where a 
reasonably high level of PrEP effectiveness (>65%) can be achieved. Should FSWs’ condom 
consistency with regular partners remain low (~10%) or be reduced to zero on PrEP, reductions in 
condom consistency with clients could uniformly be tolerated whilst still achieving 50% HIV risk 
reduction (assuming achieved PrEP effectiveness of at least 55%). This is especially noteworthy 
having considered probabilities of up to 60% likelihood of STI exposure in a partnership if condom 
migration were to occur.   
From a programming point of view, strategies to identify FSWs with initially higher condom-
consistent behaviour but anticipated to adhere less well to PrEP will be important, and efforts to 
promote condom consistency and give adherence support critical. Considering that full condom 
migration with regular partners does not substantially increase HIV risk on PrEP (assuming initially 
low consistency with regular partners holds true), efforts to encourage condom consistency with 
clients will be critical.  
The study has demonstrated that the break-even point at which PrEP is beneficial in terms of HIV risk 
reduction is driven primarily by the behavioural parameters of condom consistency and drug 
adherence, as well as by the efficacy of condoms, and much less by epidemiological parameters. This 
is noteworthy in programme design, as efforts to improve and sustain behaviours relating to PrEP 
adherence and condom consistency will have the greatest influence on programme outcomes over 
epidemiologic context.  
There are, however, a number of caveats to the study. This work does not speak to acceptable PrEP 
adherence levels, given the risk of ARV resistance, noting that PrEP users in the middle adherence 
spectrum are anticipated to be at greatest risk55. This study does not account for a partner’s stage of 
HIV infection or ARV use in partner populations. The former may increase HIV risk if partners are 
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likely to be recently infected and thus highly viremic, whereas the latter would likely decrease 
overall risk; however neither would be expected to impact comparative estimates of change in HIV 
risk.  
Use of a static rather than dynamic model limits the study to an analysis of FSW HIV risk in isolation 
of the dynamics of infections between FSWs, their partners and clients and in turn to FSWs. These 
results, whilst suitable to indicate rules of thumb to guide HIV prevention efforts, cannot provide 
insight into the downstream impact of the intervention and condom migration on the HIV epidemic 
in South Africa. Finally, the data used to characterise the FSW population in Hillbrow is limited by 
being self-reported (susceptible to underreporting) and age, as little has been published since the 
end of the 1990s, when the HIV epidemic was less evolved56, although studies are underway.  
Most importantly, this study indicates that, assuming oral PrEP is proven effective in FSW 
populations through ongoing trials, in many situations oral PrEP is likely to be of benefit in reducing 
HIV risk even if behaviour change were to be a programme reality. It provides guidance around the 
characteristics of FSWs for whom condom migration may be more of an issue (those with initially 
high-levels of condom consistency with clients, anticipated to adhere poorly to PrEP and significantly 
migrate away from condoms); and those FSWs for whom PrEP is likely to be an important addition to 
combined HIV prevention measures (those with initially low condom consistency with clients, or 
anticipated to adhere reasonably well to PrEP). Importantly for the latter group, PrEP will provide 
additional protection against HIV transmission from regular partners, with whom there is otherwise 
little protection given low baseline condom levels. Finally, the analytic approach followed in this 
study could easily be adapted to other vulnerable populations beyond FSW.  
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3.4    Implications for Thesis 
The results of Research Paper 1 indicate that for high HIV risk women in a high HIV burden setting, 
PrEP is likely to be of benefit in reducing new infections, even if behavioural disinhibition occurs. This 
conclusion in made having considered a range of women’s baseline condom consistencies and levels 
of HIV risk reduction achieved on PrEP. However, it cautions policy makers that strategies to support 
continued condom use will be especially critical for women who had high levels of condom use prior 
to PrEP introduction but anticipated to have difficulties in adhering to PrEP. 
This agrees with the work by Foss et al41 in relation to an HIV- and STI-efficacious microbicide, which 
also found that there are likely to be contexts in which reductions in condom use can be tolerated 
(depending on the efficacy and use-effectiveness of the microbicide), and that particular concern 
should be paid to individuals with high baseline levels of condom use anticipated to have challenges 
in using microbicides consistently. Research Paper 1 goes further by exploring the effect of 
reductions in condom consistency among two different partner populations of FSW. This Research 
Paper found that condom consistency with regular partners could be reduced to zero, and 
reductions in condom consistency with clients still be tolerated whilst achieving 50% HIV risk 
reduction, with levels of PrEP use-effectiveness of at least 55%. This is noteworthy given the 
incentives for FSW to reduce condom consistency with clients37, and challenges with condom use 
between FSW and regular partners52. 
This analysis was undertaken using a simple static model, evaluated in Microsoft Excel, which has the 
advantage of being relatively easily replicable for application to other contexts or populations. The 
use of a simple static model also allowed for the deduction of simple rules of thumb to guide HIV 
prevention programming. 
However, as the static model does not account for the dynamics of population interactions, the 
conclusions of this study cannot account for the downstream effects of PrEP use and behavioural 
disinhibition on the wider HIV epidemic over time. Accordingly, Research Paper 2, explores the 
extent to which the conclusions made on the basis of a static model hold when the dynamics of 
population interactions are accounted for using a dynamic model, evaluated over different time 
horizons and in epidemic contexts. 
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Chapter 4 
4. Research paper 2: Is Modelling complexity always 
needed? Insights from modelling PrEP introduction in South 
Africa 
 
4.1    Introduction to Research Paper 2 
Research Paper 2 aims to respond to thesis objective 3 by assessing the extent to which the 
conclusions made in Research Paper 1 hold, when the dynamics of population interaction are 
accounted for through incorporation of dynamic modelling effects. To test these conclusions, the 
paper matches the static model used in Research Paper 1 with a dynamic model of HIV transmission 
between high-risk women and their partner population. It considers two epidemic scenarios: first, 
where the underlying HIV epidemic is at equilibrium (as it is now in many countries in sub-Saharan 
Africa1), and then, where the underlying HIV epidemic is still increasing (as it was in earlier years in 
many epidemics in sub-Saharan Africa1).  
The study compares the models’ predictions of the reductions in condom use that can be tolerated 
following the introduction of PrEP, without HIV risk increasing over a 20-year time horizon. It also 
assesses the extent to which the main policy conclusions made in Research Paper 1 hold when 
assessed through the dynamic model formulation. These policy conclusions were as follows: 
1. Condom use can be reduced to zero without increasing HIV risk, if the level of HIV risk reduction 
achieved through PrEP is at least high as the maximum risk reduction possible through condom 
use. 
2. Reductions in condom consistency are especially well tolerated where:  
i. Higher levels of PrEP use-effectiveness are achieved (e.g. ≥65%) 
ii. Or where initial condom consistencies are low (e.g. <50%). 
3. Even with the achievement of low levels of PrEP use-effectiveness (e.g. ≤45%), reductions in 
condom consistency are possible without increasing HIV risk. 
For consistency, the models are applied to same population and setting as in Research Paper 1, to 
female sex workers in Hillbrow, inner Johannesburg, South Africa. 
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It is hoped that the conclusions of Research Paper 2 will help contribute to the wider understanding 
of the conditions under which static models, which may be more user-friendly for policy makers, are 
sufficiently robust to inform decision making around the introduction of a new HIV prevention 
intervention to a population at risk. 
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Abstract 
Background: Mathematical models can be powerful policymaking tools. Simple, static models are 
user-friendly for policymakers. More complex, dynamic models account for time-dependent 
changes, but are complicated to understand and produce. Under which conditions are static models 
adequate? We compare static and dynamic model predictions of whether behavioural disinhibition 
could undermine the impact of HIV pre-exposure prophylaxis (PrEP) provision to female sex workers 
in South Africa.  
Methods: A static model of HIV risk was developed and adapted into a dynamic model. Both models 
were used to estimate the possible reduction in condom use, following PrEP introduction, without 
increasing HIV risk. The results were compared over a 20-year time-horizon, in two contexts: at 
epidemic equilibrium and during an increasing epidemic. 
Results: Over time-horizons of up to five years, the models are consistent. Over longer timeframes, 
the static model overstates the tolerated reduction in condom use where initial condom use is 
reasonably high (≥50%) and/or PrEP effectiveness is low (≤45%), especially during an increasing 
epidemic.  
Conclusions: Static models can provide useful deductions to guide policymaking around the 
introduction of a new HIV intervention over short-medium time-horizons of up to five years. Over 
longer timeframes, static models may not sufficiently emphasize situations of programmatic 
importance, especially where underlying epidemics are still increasing.  
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Background 
Mathematical models play an important role in policy making for public health.2–4 They can be used 
to assess the impact of different policy options, which may be impractical to test in implementation 
settings or over longer time horizons.2 Nonetheless, there is often hesitation among policy makers to 
rely on models, perceived to be an intimidating ‘black box’ process of uncertain applicability to real-
world settings.5,6 This may be owing to complexity in model structure, uncertainty around model 
assumptions or challenges in model communication.7 As a consequence, potentially useful models 
may be underemployed or in some cases inappropriately used to inform decision making.5 
Simple models have a comparative appeal for use in policy making. They can be used to deduce 
broad principles to guide decision-making through an approach that is easier for policy makers to 
understand and critique.8,5 For this reason, we previously used a simple, static model of HIV risk to 
assess the potential effect of behavioural disinhibition (in this case: reductions in the use of 
condoms) following the introduction of pre-exposure prophylaxis (PrEP) among female sex workers 
(FSW) in South Africa.9 Simple models have been used to obtain insights into a number of other 
pertinent HIV policy questions – from resource prioritization across low and middle income 
countries10 to the scale up of microbicides11,12, the cost-effectiveness of male circumcision in sub-
Saharan Africa13,14, declining HIV test positivity15 and projecting HIV diagnoses among children and 
adolescents in New York State16. 
To date there has been limited assessment of the conditions under which models of simple 
structural form are sufficient to guide policy making in HIV.17–21 A key element of modelling 
complexity is the extent to which model conclusions account for time-dependent changes. Static 
models take a snap-shot approach and cannot capture the downstream effects of population 
interaction. They are typically structurally more straightforward, and less data- and time-intensive to 
develop.22,23 By comparison, dynamic models account for changes over time owing to population 
interactions and evolving contextual factors. Dynamic models are typically represented by a system 
of differential or difference equations, evaluated numerically using programming tools with 
increased data requirements. 22,24 As a result, they are more time-intensive and expensive to devise 
and calibrate, and often require critical assumptions to be made about current and future trends.21,22  
Other key considerations in the design of models to inform policy making include the extent to 
which models can be devised, computed and appropriately interpreted by policy makers themselves, 
or whether external technical support is required.2,21,25 Simpler models, such as those calculated in 
Microsoft Excel, that can be developed and owned by policy makers themselves, may improve their 
uptake to inform decision making. However, accessibility needs to be balanced against the risk of 
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inaccuracies through model over-simplification, leading to misleading model outcomes or 
interpretation, and the derivation of incorrect policy conclusions.3  
Modelling studies17,21,26,27 have proposed broad frameworks to guide the development of models for 
policy making, noting that models should adopt only the minimum level of complexity needed to 
appropriately represent the policy question at hand, in view of the availability of data, the 
importance of accounting for interactions between population groups, the time horizon of 
assessment and epidemiological context. However, none have given specific guidance around the 
characteristics or contexts in which simpler models suffice. Given that simple, static models form the 
basic building blocks for more complex models,23 it is important to determine conditions under 
which they can reliably provide an accessible approach to guide policy making. 
In 2009 Foss et al12 incorporated dynamic features into a static model of HIV risk11 to explore the 
impact of microbicide STI-efficacy. In 2014 Mishra et al18,28 assessed the static UNAIDS Modes of 
Transmission model,10 used by many countries to prioritise HIV prevention interventions between 
groups at population-level. These studies12,18,28 concluded that by not capturing dynamic effects of 
partner interaction, the static model underestimates the contribution of epidemic drivers to HIV 
transmission over time. Other studies have used static and dynamic models to explore different 
aspects of a policy question but have not compared model outcomes.14,29 To the best of our 
knowledge, no study has examined the extent to which the conclusions of static models remain 
robust to the incorporation of dynamic effects over multiple time-horizons, when assessing the 
introduction of a new HIV intervention to a population group. 
To contribute to wider understanding of the role of simple, static models in decision making, we 
modify our previous model of HIV risk for female sex workers (FSW) in Hillbrow, South Africa9 to 
incorporate the dynamics of partner interaction over time. We assess the consistency of policy 
conclusions derived between the static and dynamic model formulations. We make this comparison 
over different time-horizons, as well as by HIV epidemic stage, to determine whether the underlying 
maturity of population epidemics affects the time-dependency of results. The introduction of PrEP 
for FSW in South Africa is a pertinent case study, in view of growing concerns around sub-optimal 
drug adherence30,31 and behavioural disinhibition,31,32 highlighting the need to understand trade-offs 
associated with PrEP outside of trial settings.33 
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Methods 
Model structures and parameterisation 
The static model was developed using the Bernoulli formulation of HIV risk,9 where the probability of 
HIV being transmitted through each sexual contact is an independent risk event. The sexual partners 
of FSWs are assumed to come from a single population in which the proportion HIV infected is 𝑝𝑝. To 
assess the effect of changes in condom consistency following the introduction of PrEP, condoms 
were assumed to be used with consistency 𝛾𝛾0 prior to PrEP introduction and 𝛾𝛾1 after its 
introduction. As the relationship between PrEP adherence and effectiveness is yet to be defined for 
women,34 the model assumes an achieved level of PrEP use-effectiveness, 𝑏𝑏𝛼𝛼, corresponding to a 
level of PrEP adherence, 𝛼𝛼. It was assumed that the probability that at least one person in the 
partnership has an STI increases proportionally to decreases in condom consistency, to account for 
changes in HIV risk through increased STI exposure. The static model accounts for the effects of ART 
and circumcision coverage (in the partner population) on FSWs’ HIV risk. The term ‘use-
effectiveness’ is used to describe the HIV risk-reduction achieved through a level of use of an 
efficacious HIV prevention intervention (e.g. PrEP or condoms). 
A dynamic version of the static model was developed using difference equations, taking the 
Bernoulli risk formulation as the force of infection on FSWs per timestep, and an equivalent 
formulation for male partner population. Instead of a static HIV prevalence, 𝑝𝑝, the dynamic model 
system allows prevalence to change over time as the proportion of HIV infected individuals, 𝐼𝐼/𝑁𝑁, 
where 𝐼𝐼 is the number of HIV infected individuals and 𝑁𝑁 the total population size. The dynamic 
system accounts for population recruitment and loss due to natural and AIDS-related death. The 
models were parameterised based on sexual behaviour, biological and epidemiological data from 
the literature (Appendix 3: Supplementary Materials Table 1) and programmed in R.  
The dynamic model was fitted to HIV prevalence data for both FSW and partner populations 
between 1980 and 2014 using Monte Carlo methods with Latin Hypercube Sampling (R FME 
package35), run on 50,000 parameter sets. This yielded at least 200 fits for each scenario explored. 
Both models were then parameterised and evaluated using the same set of fitted parameters, 
allowing for the evaluation of uncertainty ranges in both models. PrEP was introduced in 2015 in line 
with its introduction to FSWs in Hillbrow under the TaPS demonstration project.36 
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Analyses 
Percentage reduction in condom consistency tolerated on PrEP 
For each model, optimisation algorithms were run (dynamic model: R FME package35; static model: R 
rootSolve package37) to ascertain the lowest level of condom consistency possible (𝛾𝛾1∗) for HIV risk 
not to increase following the introduction of PrEP. This was used to calculate the threshold 
percentage reduction in condom consistency (𝛾𝛾0 − 𝛾𝛾1∗)/𝛾𝛾0 that can be tolerated. For the dynamic 
model, this optimisation was repeated over time horizons of 3 months to 20 years.  
 
Accounting for behavioural heterogeneity: differences in initial condom consistencies and PrEP use-
effectiveness  
Given the importance of accounting for heterogeneity in FSWs’ initial condom consistencies,9,11 the 
parameter sets were fitted individually for initial condom consistencies (prior to introduction of 
PrEP) of 10%, 30%, 50% and 70%, spanning the range reported by this population.9  
Unlike for men who have sex with men (MSM) and transgender women (TGW), where studies have 
been able to relate the number of weekly doses of PrEP to levels of HIV risk reduction, the same has 
not yet been possible for women, for whom it is only recognised that 100% risk reduction on PrEP 
necessitates higher levels of adherence (6/7 tablets a week in women as opposed to 4/5 in MSM and 
TGW).38 As such, we chose to span a spectrum of potential levels of PrEP use-effectiveness: 25%, 
45%, 65% and 85%. 85% was simulated as the highest level, as it equates to the maximum use-
effectiveness of condoms as in Grant and colleagues.9  
The percentage reduction in condom consistency that can be tolerated was calculated across these 
levels of initial condom consistency and PrEP use-effectiveness.  
 
Accounting for stage of HIV epidemic 
To assess whether the results change by underlying stage of HIV epidemic, the analyses were 
repeated 20 years earlier, when the HIV epidemics in FSWs and their partner populations were still 
increasing. Under this scenario, Increasing Epidemic, initial condom consistency was fixed in 1994 
and PrEP hypothetically introduced in 1995. This is in comparison to the base case analysis, Epidemic 
Equilibrium, where initial condom consistency was fixed in 2014 and PrEP introduced in 2015 once 
the epidemics had started to stabilise.  
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Additional analyses 
To assess whether the inclusion of ART, circumcision and STIs in the models affected our 
conclusions, we conducted a model structural sensitivity analysis, removing all related parameters 
from the models and rerunning the analyses. To assess whether our conclusions were sensitive to 
PrEP being introduced when the epidemics are fully endemic in the populations (Fully Endemic 
scenario), we repeated the analysis with PrEP introduced in 2030 (Appendix 3: Supplementary 
Materials Figure 1). 
Appendix 3: Supplementary Materials contains further information on the model structure, 
parameterization and calibration. 
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Results 
The lowest levels of condom consistency that can be tolerated by FSW on PrEP (without their HIV 
risk increasing) at Epidemic Equilibrium and in the context of an Increasing Epidemic, are shown in 
Figure 1 and Figure 2 respectively.  
In Figures 1 and 2, the three rows, from top to bottom, represent FSW initial condom consistencies 
(at point of introduction of PrEP) of 30%, 50% and 70% respectively. The three columns represent, 
from left to right, PrEP use-effectiveness of 25%, 45% and 65% respectively. For each combination of 
initial condom consistency and PrEP use-effectiveness, boxplot graphs depict the lowest level of 
condom consistency tolerated on PrEP (vertical-axis). The far-left boxplot on the horizontal-axis of 
each of the graphs is the lowest level of condom consistency estimated using the static model. The 
boxplots to the right of it are the lowest level of condom consistencies estimated using the dynamic 
model, at time points of 3 months, 1 year, 2 years, 5 years, 10 years and 20 years, from left to right. 
The boxplots depict uncertainty in the estimated lowest level of condom consistency tolerated, with 
the black line representing the median value, the coloured section the interquartile range (25-75% of 
the values) and the whiskers the maximum and minimum values. The differences between the static 
and dynamic model outcomes can be understood by comparing how similar the lowest level of 
condom consistency estimated by the static model is to the lowest level of condom consistency 
estimated by the dynamic model over time.  
Whilst Figures 1 and 2 depict the key trends in model differences for each scenario, more detailed 
plots including FSW initial condom consistency of 10% and PrEP use-effectiveness of 85% are shown 
in Appendix 3: Supplementary Materials, Figures S5 and S7 for the Epidemic Equilibrium and 
Increasing Epidemic scenarios respectively. The Appendix 3: Supplementary Materials also contain 
the equivalent boxplot graphs for the second model outcome: percentage reduction in condom 
consistency tolerated on PrEP (Appendix 3: Supplementary Materials Figures S6 and S8), the model 
fits to HIV prevalence (Appendix 3: Supplementary Materials Figures S1-S4), as well as all underlying 
data (Appendix 3: Supplementary Materials Tables S2-S10). 
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Figure 1: Boxplots showing the lowest level of condom consistency tolerated on PrEP (for HIV risk not to increase) predicted through the static and dynamic models – PrEP introduced at 
HIV Epidemic Equilibrium.  
The results are shown distinctly for initial condom consistencies (at point of introduction of PrEP) of 30%, 50% and 70%, and simulated for levels of achieved PrEP use-effectiveness at HIV risk reduction of 25%, 45% 
and 65%. In the case of the static model, the lowest levels of condom consistency tolerated on PrEP are point estimates. In the case of the dynamic model, the lowest levels of condom consistency tolerated on PrEP 
are given after 3 months, 1 year, 2 years, 5 years, 10 years and 20 years on PrEP. The boxplots depict uncertainty in the lowest level of condom consistency tolerated, with the black line representing the median of all 
fits, the coloured section the interquartile range and the whiskers the maximum and minimum values. 
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Figure 2: Boxplots showing the lowest level of condom consistency tolerated on PrEP (for HIV risk not to increase) predicted through the static and dynamic models – PrEP introduced 
with Increasing Epidemic.  
The results are shown distinctly for initial condom consistencies (at point of introduction of PrEP) of 30%, 50% and 70%, and simulated for levels of achieved PrEP use-effectiveness at HIV risk reduction of 25%, 45% 
and 65%. In the case of the static model, the lowest levels of condom consistency tolerated on PrEP are point estimates. In the case of the dynamic model, the lowest levels of condom consistency tolerated on PrEP 
are given after 3 months, 1 year, 2 years, 5 years, 10 years and 20 years on PrEP. The boxplots depict uncertainty in the lowest level of condom consistency tolerated, with the black line representing the median of all 
fits, the coloured section the interquartile range and the whiskers the maximum and minimum values. 
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Comparison of static and dynamic model outcomes 
Under the scenario that PrEP is introduced at Epidemic Equilibrium, the percentage reductions in 
condom consistency estimated by the static and dynamic models are very similar up to a time-
horizon of one year. By five years, the model predictions remain consistent to within 25% relative 
difference between medians (<35% between credible intervals (CrIs)), and by 20 years to within 35% 
between medians (≤100% between CrIs) (Appendix 3: Supplementary Materials Table S2a). The 
differences between the percentage reductions in condom consistency predicted by the static and 
dynamic models are less consistent over time where initial condom consistency is higher (≥50%) and 
PrEP use-effectiveness is lower (≤45%). This is consistent with our previous work based on the static 
model, which indicated that reductions in condom consistency should be of greatest concern for 
FSW with high initial condom consistencies achieving low levels of PrEP use-effectiveness9. However, 
the results suggest that the magnitude of concern predicted by the static model was understated 
over the long-term. 
Under the Increasing Epidemic scenario, the differences between the percentage reductions in 
condom consistency predicted by the models are more pronounced over time. By five years the 
relative difference between model medians is less than 10% (<25% between CrIs) at high levels of 
PrEP use-effectiveness (85%) but up to 100% (100% between CrIs) at low levels of PrEP use-
effectiveness (25%). By 20 years, the differences between the models start to decrease in response 
to the natural plateau of the underlying epidemics (Appendix 3: Supplementary Materials Table S2b).  
For both epidemic scenarios, removing ART, circumcision and STIs from the models under the 
structural sensitivity analysis led to bigger differences between model outcomes in situations where 
PrEP use-effectiveness is low (≤45%) and initial condom consistency is at least 30% (<45% relative 
difference between CrIs by 5 years, and <50% relative difference by 20 years) (Appendix 3: 
Supplementary Materials Tables S3a and Sb, Figures S9-S12). Introducing PrEP in 2030 under the 
Fully Endemic rather than in 2015 in the Epidemic Equilibrium scenario led to differences under the 
same situations, although the magnitude of differences was smaller (<25% relative difference 
between CrIs by 5 years, and <35% between by 20 years) (Appendix 3: Supplementary Materials 
Table S4, Figures S13 and S14). Additional analysis comparing the model outcomes by scenario is set 
out in Appendix 3: Supplementary Materials, Additional Assessment of Results section. 
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Comparison of policy conclusions between static and dynamic models 
To explore the contexts in which the qualitative conclusions made on the basis of static models may 
be appropriate to guide HIV policy making, we list three policy conclusions derived based on the 
static model9, and assess their validity under dynamic model formulation. 
1. Condom use can be reduced to zero without increasing HIV risk, if the level of HIV risk reduction 
achieved through PrEP is at least high as the maximum risk reduction possible through condom 
use 
This conclusion holds under the dynamic model in the Epidemic Equilibrium scenario, as well as in 
the Increasing Epidemic scenario, other than at high levels of initial condom consistency (70%), 
where after five years the dynamic model predicts that a reduction in condom consistency to zero 
may start to lead to an increase in HIV risk (Figures 1 & 2; Appendix 3: Supplementary Materials 
Table S2a &S2b and Figures S6 & S8). 
 
2. Reductions in condom consistency are especially well tolerated where:  
i. Higher levels of PrEP use-effectiveness are achieved (e.g. ≥65%) 
Figure 3 shows the lowest levels of condom consistency tolerated calculated using the static and 
dynamic models for PrEP use-effectiveness levels of 65% and 85%. The lowest levels of condom 
consistency are shown for initial condom consistencies of 10% (in blue), 30% (in orange), 50% (in 
pink), and 70% (in green). The dotted lines represent median estimates and shaded areas represent 
the 95% CrIs. The top row depicts the Epidemic Equilibrium scenario, and bottom row the Increasing 
Epidemic scenario. 
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Figure 3: Lowest level of condom consistency tolerated at higher levels of PrEP use-effectiveness, for both scenarios 
Epidemic Equilibrium and Increasing Epidemic.  
The lowest levels of condom consistency tolerated on PrEP are depicted for PrEP use-effectiveness levels of 65% (left) and 85% (right). Each 
graph shows the lowest level of condom consistency estimated by the static model, and by the dynamic model over a time horizon of 3 
months to 20 years, corresponding to initial condom consistencies of 10%, 30%, 50% and 70%. The first row of graphs corresponds to the 
scenario Epidemic Equilibrium and the second row of graphs corresponds to the scenario Increasing Epidemic. The dotted lines are median 
estimates and shaded areas are 95% CrIs (colour coding in legend).  Where the median results corresponding to lower initial condom 
consistencies cannot be seen on the graph, it indicates that the estimated lowest level of condom consistency is 0%. Where the 95% CrI 
cannot be seen on the graph, it indicates that the 95% CrI is very close to or exactly the same as the median. 
With PrEP use-effectiveness of at least 65%, the static model predicts that median reductions in 
condom use of at least 85% will be possible without increasing HIV risk. The dynamic model broadly 
supports this conclusion, with less than 25% relative difference between the model medians and CrIs 
after five years, and less than 35% relative difference after 20 years in the Epidemic Equilibrium 
scenario. Importantly, under the Increasing Epidemic scenario, these differences are much more 
pronounced, with up to 60% relative difference between medians and CrIs after five years, and up to 
65% relative difference (85% between 95% CrIs) after 20 years.  
For initial condom consistencies of up to 50%, the static model predicts that FSW on PrEP with use-
effectiveness of at least 65% can stop using condoms completely without increasing HIV risk. This is 
consistent with the dynamic model conclusions under the Epidemic Equilibrium scenario. Under the 
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Increasing Epidemic scenario, this only holds where PrEP use-effectiveness is at least 85% (rather 
than 65%) (Figure 3; Appendix 3: Supplementary Materials Table S2a & Sb).  
ii. Or where initial condom consistencies are low (e.g. <50%).
Figure 4 shows the lowest levels of condom consistency tolerated after PrEP introduction, calculated 
using the static and dynamic models for initial condom consistencies (before PrEP introduction) of 
10% and 30%. The lowest levels of condom consistency tolerated are shown corresponding to PrEP 
use-effective of 25% (in green), 45% (in pink), 65% (in orange), and 85% (in blue). The dotted lines 
represent median estimates and shaded areas represent the 95% CrIs. The top row depicts the 
Epidemic Equilibrium scenario, and bottom row the Increasing Epidemic scenario. 
Figure 4: Lowest level of condom consistency tolerated at lower levels of initial condom consistency, for both scenarios 
Epidemic Equilibrium and Increasing Epidemic. 
The lowest levels of condom consistency tolerated on PrEP are depicted for initial condom consistencies of 10% (left) and 30% (right). Each 
graph shows the lowest level of condom consistency estimated by the static model, and by the dynamic model over a time horizon of 3 
months to 20 years, corresponding to PrEP use-effectiveness levels of 25%, 45%, 65% and 85%. The first row of graphs corresponds to the 
scenario Epidemic Equilibrium and the second row of graphs corresponds to the scenario Increasing Epidemic. The dotted lines are median 
estimates and shaded areas are 95% CrIs (colour coding in legend).  Where the median results corresponding to specific levels of PrEP 
effectiveness cannot be seen on the graph, it indicates that the lowest level of condom consistency tolerated is 0%. Where the 95% CrI 
cannot be seen on the graph, it indicates that the 95% CrI is very close to or exactly the same as the median. 
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Under the Epidemic Equilibrium scenario the dynamic model supports the outcomes of the static 
model especially well in the short term, with relative difference between medians of less than 5% 
after five years (<25% between the 95% CrIs), and less than 5% relative difference by 20 years 
(<70% between 95% CrIs). Under the Increasing Epidemic scenario, the model differences are large 
over time, e.g. estimates from the dynamic model of the lowest level of condom consistency 
tolerated are up to double the levels estimated by the static model after 5 years  (Figure 4; Appendix 
3: Supplementary Materials Table S2a & S2b). 
 
3. Even with the achievement of low levels of PrEP use-effectiveness (e.g. ≤45%), reductions in 
condom consistency are possible without increasing HIV risk.  
As with the static model, under the Epidemic Equilibrium scenario the dynamic model predicts that 
some decreases in condom consistency on PrEP will always be possible without increasing HIV risk 
over the 20-year time horizon, even for lower levels of PrEP use-effectiveness of up to 45%. This 
holds true under the Increasing Epidemic scenario up to a five-year time horizon. 
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Discussion 
Main findings of this study 
This study demonstrates that there are contexts in which static models can provide useful 
deductions to guide policy making around the introduction of a new HIV intervention. Static models 
may have advantages to guide programming over short-medium time horizons in certain settings. 
However, over longer timeframes, static models may not sufficiently emphasize situations of 
programmatic importance, especially in contexts where underlying epidemics are not at equilibrium. 
PrEP is likely to be of benefit in reducing HIV risk in high-burden settings, even if moderate 
reductions in condom use occur. 
 
What is already known on this topic 
It is well established that dynamic models are more appropriate to address policy questions where it 
is important to account for the downstream effects of population interactions and evolving 
contextual factors over time.5,6,26,27 Both static and dynamic models have been used to inform policy 
making in the field of HIV.10,11,13,39,40 Existing studies have cautioned that static models may 
underestimate the contribution of epidemic drivers to HIV transmission over time.18,28 However, to 
date, no study has assessed the epidemic contexts and timeframes over which simple static models 
may suffice to inform decision making in the field of HIV, especially in the context of the introduction 
of new prevention interventions. 
 
What this study adds 
This study compares the outcomes of a static model with the outcomes of a matched dynamic 
model, applied to different epidemic contexts across time horizons. Both models are used to assess 
the absolute and percentage reductions in condom consistency that can be tolerated, without HIV 
risk increasing, following introduction of PrEP for FSW. We found that over short-medium time-
horizons of up to five years, the static model approximates the outcomes of the dynamic model 
fairly consistently. Over longer timeframes of up to 20 years, there are contexts in which the 
reductions in condom use predicted by the static model do not hold under the dynamic model 
formulation; particularly where initial condom consistency is reasonably high (≥50%) and/or PrEP 
use-effectiveness is low (≤45%). The differences between the two models are greater where the 
underlying HIV epidemic is increasing (Figure 1 & 2, Appendix 3: Supplementary Materials Tables S2a 
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& S2b). The structural sensitivity analysis (removing model parameters relating to ART, circumcision 
and STIs) showed bigger differences between model outcomes in situations where PrEP use-
effectiveness is low (≤45%) and initial condom consistency is at least 30%. Introducing PrEP where 
the underlying HIV epidemic is fully endemic in 2030 (rather than at equilibrium in 2015) led to 
differences under the same situations, although smaller in magnitude. The difference between the 
models’ outcomes arise predominantly from the dynamic model’s ability to capture changes in HIV 
prevalence over time, which is highlighted where PrEP use-effectiveness is insufficiently high enough 
to mask greater reductions in condom use. 
Nonetheless, the broad-stroke policy conclusions predicted by the static model hold under the 
dynamic model formulation. Specifically, in high HIV burden contexts, PrEP for FSW is likely to be of 
benefit in reducing HIV risk even if reductions in condom use occur; that reductions in condom 
consistency can be better tolerated by FSW achieving high levels of PrEP effectiveness or with low 
baseline condom consistencies; and efforts to promote condom use will be especially critical for FSW 
with high levels of baseline condom consistency but who are anticipated to adhere less well to PrEP.  
Simple, static models have a structural advantage over dynamic models, as they can usually be more 
easily analytically manipulated to deduce conclusions to guide policy making. These take-aways are 
often additional to those that can be gleaned through numeric and graphic assessment of either 
model’s outcomes. Noting that model results are usually discounted over longer time-horizons due 
to uncertainty in underlying assumptions or implementation contexts, there may be merits for using 
static models to guide the introduction of new HIV interventions over short-medium time horizons, 
especially where the underlying HIV epidemic is well-evolved. Static models may also be better 
suited to guide the roll out of interventions intended for short term-use, such as PrEP, which is 
intended to cover seasons of risk.31 
In contexts with increasing epidemics, dynamic models may be more appropriate to guide the 
programming of interventions for long-term use. Building on the conclusions in Mishra and 
colleagues,18 this study underscores that decision maker reliance on the magnitude of intervention 
effectiveness assessed through static models, such as the UNAIDS Modes of Transmission model,10 
should be cautioned in contexts where HIV prevalence is increasing, e.g. in the relevant sub-
epidemics in Eastern Europe, South East Asia, the Middle East and South America, especially in 
relation to high burden (e.g. key) populations.  
Future studies could extend this model comparison to other infectious diseases to understand the 
conditions under which static models are sufficient to inform policy making. This may be especially 
pertinent for diseases where there is limited understanding of key components required in dynamic 
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model construction (e.g. transmission dynamics or their quantification), but comparably better 
understanding of the narrower information set needed to formulate static models. 
Limitations of this study 
There are several limitations to this study. The models used in this analysis are simplified 
formulations of static and dynamic models, to facilitate comparison. They do not account for 
different levels of PrEP coverage or population heterogeneity, relying instead on population 
averages. For the same reason, these two populations were explored in isolation without accounting 
for interactions with wider societal groups. Assessment of the effects of behavioural disinhibition are 
limited to FSW, not the downstream effects on partner populations. 
The analysis does not explicitly explore potentially important correlations between risk factors and 
PrEP effectiveness. However, the impact of correlations between initial condom consistency and 
PrEP adherence can be easily deduced through the scenarios explored (Figures 1 & 2). 
The data used to characterise the FSW and their partner population in Hillbrow, South Africa, is 
limited by age and in some cases reliance on self-reports of sexual behaviour, which are susceptible 
to under-reporting. Data uncertainty is addressed to some extent through the uncertainty analysis.  
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4.4    Implications for Thesis 
Research Paper 2 concludes that broad-stroke conclusions of Research Paper 1 regarding the 
reductions in condom consistency tolerated without HIV risk increasing following the introduction of 
PrEP for high-risk women do indeed hold under dynamic formulation. Specifically, in high HIV burden 
contexts, PrEP for high-risk women is likely to be of benefit in reducing HIV risk even if reductions in 
condom use occur; reductions in condom consistency can be better tolerated by FSWs achieving 
high levels of PrEP effectiveness or with low baseline condom consistencies; and efforts to promote 
condom use will be especially critical for FSW with high levels of baseline condom consistency but 
who are anticipated to adhere less well to PrEP. 
However, the paper concludes that over longer time horizons (upwards of 5 years) the static model 
under-emphasises the specific situations that may be of programmatic importance. Specifically, 
where a high-risk woman’s initial condom consistency is reasonably high (≥50%) and/or PrEP use-
effectiveness is low (≤45%), the levels of reduction in condom use predicted by the static model do 
not hold under the dynamic formulation. This is especially the case where the underlying HIV 
epidemic is still increasing. 
The results of Research Paper 2 indicate that there are merits in using static models to inform policy 
making around the introduction of an HIV prevention intervention in high-burden contexts over 
short-medium time horizons, especially where the underlying HIV epidemic is well-evolved. This is a 
pertinent conclusion, considering the relative benefits of static models over dynamic models for use 
in policy making (including ease of communication, understanding, adoption and critiquing), as well 
as that some HIV prevention interventions are intended for short-term use (as in the case of PrEP, 
which is intended for seasons of risk). However, in contexts with increasing epidemics, dynamic 
models are more appropriate to guide the programming of HIV prevention interventions for long-
term use. 
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Chapter 5 
5. Research paper 3: Time to scale up PrEP beyond the 
highest-risk populations? Modelling insights from high-risk 
women in sub-Saharan Africa 
 
5.1    Introduction to Research Paper 3 
Research paper 3 aims to respond to thesis objectives 4 and 5 by exploring strategies for PrEP scale 
up across high-risk women at population-level, weighing overall HIV infection reduction and cost-
effectiveness. To explore how these strategies may differ by epidemic and implementation context, 
Research Paper 3 applies this analysis to 3 country contexts in sub-Saharan Africa with different 
epidemic profiles and levels of HIV burden: South Africa (20.4% adult HIV prevalence1), Zimbabwe 
(12.7% adult HIV prevalence1) and Kenya (4.7% adult HIV prevalence1). 
The contexts in which the models are being applied are stable generalised high prevalence HIV 
epidemics2. The timeframe for the analysis was taken to be 1 year, given that PrEP is intended to 
cover seasons of risk and that few PrEP demonstration programs have achieved significant retention 
in women in this context beyond the first 12 months.3,4 Given the conclusions of Research Paper 2 
that static models are sufficiently robust to guide decision making around the introduction of an HIV 
prevention intervention in high HIV burden contexts over short-medium time horizons where the 
underlying HIV epidemic is well-evolved, and in view of their comparative merits to inform policy 
making, this study adopted static rather than dynamic models of HIV risk. 
At the time of undertaking this study, PrEP roll out in all three countries was focused on the highest-
risk individuals, including female sex workers5–7, who face significantly higher individual HIV risk2 
than women in the general population. As such, female sex workers were considered the benchmark 
for assessment of cost-effectiveness and infections averted when assessing PrEP scale-up across a 
more broadly defined group of women at risk in these contexts8–10: to adolescent girls and young 
women aged 15-24 years (AGYW), to women 25-34 years, and to women 35-49 years. 
It is hoped that the conclusions of Results Paper 3 will help inform priority setting as policy makers in 
sub-Saharan Africa consider scaling-up PrEP across a more broadly defined group of women at risk, 
accounting for both population-level impact and cost-effectiveness.   
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Abstract  
Background: HIV burden in sub-Saharan Africa remains highest in women. PrEP is an effective HIV 
prevention measure, currently prioritized for those at highest risk, such as female sex workers (FSW), 
for whom it is most cost-effective. However, the greatest number of HIV infections in sub-Saharan 
Africa occur in women in the general population. As countries consider wider PrEP scale-up, there is 
need to weigh population-level impact with cost-effectiveness to inform priority-setting in the 
context of resource constraints.  
Methods: We developed mathematical models of HIV risk to women and derived tools to guide PrEP 
programming. The models were fitted to South Africa, Zimbabwe and Kenya, which span a range of 
HIV burdens in sub-Saharan Africa. The impact, cost and cost-effectiveness of PrEP scale-up for 
adolescent girls and young women (AGYW), women 25-34 years and women 35-49 years were 
assessed, accounting for the low program retention levels reported in demonstration projects. 
Findings: PrEP could avert substantially more infections a year among women in general population 
than among FSW. The greatest number of infections could be averted annually among AGYW in 
South Africa (24-fold the number as for FSW). In Zimbabwe, the greatest number of infections could 
be averted among women 25-34 years (8-fold that as for FSW), and in Kenya similarly between 
AGYW and women 25-34 years (3-fold that as for FSW).  
Conclusions: PrEP has the potential to substantially reduce the numbers of new HIV infections in 
HIV-endemic countries in sub-Saharan Africa, even considering low levels of PrEP program retention 
in women. This will necessitate PrEP being made widely available beyond those at highest individual 
risk, including to women in the general population. Wide scale roll out will require continued 
integration of PrEP into a range of national services and at community level, in order to significantly 
bring down the costs and improve cost-effectiveness. 
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Background 
Women remain the most affected by the global HIV epidemic. In sub-Saharan Africa, the region with 
the greatest HIV burden, 59% of new adult infections are among women2. In 2017, a quarter of all 
new infections in the region were among adolescent girls and young women (AGYW) aged 15-24 
years2, whilst female sex workers (FSW) are up to 20 times more likely to be HIV positive than 
women in the general population11. 
Oral pre-exposure prophylaxis (PrEP) has shown HIV prevention efficacy in randomised controlled 
trials12. It is hoped PrEP will address some of the drivers of HIV in women, which include lack of 
agency to negotiate sex and condom use2. Aside from women in sero-discordant relationships13, 
PrEP demonstration projects have faced challenges in retaining women3,4,14, raising concerns about 
the ability of programs to avert infections when scaled-up2. A recently completed PrEP 
demonstration project among FSW in South Africa reported 22% 12-month program retention 
rates3. In spite of promising 3-month retention levels15, early results from programming in Kenya4,16 
and Zimbabwe17 show even lower retention rates in AGYW than FSW.  
As PrEP is rolled out in countries in line with 2016 normative guidance, its use has been prioritised 
for populations at substantial risk of HIV18. Among women in sub-Saharan Africa, PrEP is being 
prioritized for FSW and, in certain contexts, AGYW19 (including through PEPFAR DREAMS 
programmes20,21). PrEP programs are being hosted by services tailored for groups at highest risk of 
infection, or in general services with screening tools used to identify those most at risk18,22. 
Increasingly, there is pressure for countries to move away from focused programs for key 
populations, towards universal access to PrEP as part of a rights-based approach to health23. The 
language of PrEP programming is shifting to refer to populations that could benefit from PrEP, rather 
than to focus on individual risk23. 
Whilst FSW are typically the women at highest HIV risk19, HIV incidence among women in the general 
population varies significantly by age range across countries in sub-Saharan Africa19. To date, six of 
the seven finalised population-based HIV impact assessments (PHIA) undertaken in PEPFAR-
supported sub-Saharan African countries reveal higher levels of incidence in women 25-34 years or 
35-49 years than in AGYW24–30. Policy makers are now having to weigh the potential benefits and 
challenges of scaling up PrEP for groups of women at lower individual levels of risk, but in whom the 
total number of new infections is greater due to vast differences in population sizes2.  
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Decisions around PrEP scale-up are taking place in a context of limited external resources for HIV, 
constraints in domestic budgets and a global push for countries to prioritize resources to reach the 
90-90-90 treatment targets2. These decisions mirror those previously faced by policy makers in 
determining whether to scale up antiretroviral treatment for individuals at higher CD4 counts, 
balancing comparatively lower benefits for individuals with potential for greater population-level 
prevention effects18.  
Several modelling studies have evaluated the cost-effectiveness and impact of PrEP for high-risk 
populations in sub-Saharan Africa31–33; between key populations or key populations and men/ 
women in the general population33–35; relative to other HIV prevention interventions36–38; and 
relative to the scale up of antiretroviral treatment (ART)39–41. Studies typically find PrEP to be less 
cost-effective than other established prevention interventions, such as condoms, or scaling up early 
ART, but cost-effective as part of a combination prevention approach for those at greatest risk. 
Studies have not systematically accounted for the low levels of PrEP program retention recently seen 
in women in sub-Saharan Africa31–38,42,43. No study to date has assessed the scale-up of PrEP from 
higher- to lower-risk women population groups in sub-Saharan Africa, weighing cost-effectiveness 
on an individual basis with the need to avert the greatest number of infections at a population level.  
It is in this context we undertake our study, which aims to highlight key considerations to feed into 
policy decision making, as countries consider scaling-up PrEP across a more broadly defined group of 
women at risk in sub-Saharan Africa, accounting for individual- and population-level impact and 
cost-effectiveness. We use case studies of three HIV-endemic countries in sub-Saharan Africa: South 
Africa, Zimbabwe and Kenya. These countries were chosen as they span a range of HIV burden levels 
in the region, each have adopted a national PrEP strategy5–7, and have been at the forefront of PrEP 
roll-out in sub-Saharan Africa23.  
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Methods 
As the contexts in which the models are being applied are stable generalised high prevalence HIV 
epidemics2, we adopted static mathematical models of HIV risk44–46. Static models have the 
advantage of being a comparatively easier tool for use and communication with policy makers, and 
have been shown to be robust to inform policy making around the introduction of new HIV 
interventions over short-medium time horizons in stabilised epidemics47.  
The mathematical models take the Bernoulli formulation of HIV risk47, where the sexual partners of 
high-risk women are assumed to come from population 𝑖𝑖 in which the proportion HIV infected is 𝑝𝑝𝑠𝑠. 
High-risk women are assumed to have 𝐶𝐶𝑠𝑠 partners from each population per year, with whom they 
have an average 𝑛𝑛𝑠𝑠 sex acts per year each. Condoms are assumed to be used with partners from 
each population with consistency 𝛾𝛾𝑠𝑠. Upon introduction, high-risk women from group 𝑗𝑗 are assumed 
to adhere to PrEP at an average level 𝛼𝛼𝑗𝑗, which corresponds to a level of HIV risk reduction, 𝜃𝜃𝛼𝛼𝑗𝑗 . We 
used the estimates for women from the Partners Demonstration Project48 to relate levels of PrEP 
adherence to levels of HIV risk reduction. High-risk women from group 𝑗𝑗 enrolled in PrEP projects are 
assumed to have a 12-month retention level 𝑟𝑟𝑗𝑗.  The models account for STI levels, levels of viral load 
suppression due to ART in HIV positive partners, and male circumcision. Analyses were conducted 
over a one-year timeframe, as PrEP is intended to cover ‘seasons’ of HIV risk (rather than long-term 
use), and few PrEP demonstration programs have achieved significant retention in women in this 
context beyond the first 12 months3,4. All models were programmed in R version 3.3.2.  
 
Simple tools to help guide PrEP programme decision making 
First, three simple tools were developed to inform programme decision making using a basic set of 
information typically available to PrEP programmes49.  
 
Heatmaps to estimate HIV incidence in women 
Heatmaps were developed to help decision makers estimate the annual HIV incidence in women by 
number of monthly sex acts, average condom use and underlying epidemic setting. We 
demonstrated four different example epidemic settings: underlying HIV prevalence in partner 
populations of 5%, 10%, 20% and 40%. In many sub-Saharan African contexts, 5% HIV prevalence is 
illustrative of HIV prevalence in males 15-24 years, 5-20% the HIV prevalence in males 25-49 years, 
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and 20-40% the HIV prevalence in the clients of FSW (Appendix 4: Supplementary Materials: Table 
S2). 
 
Simple rule to draw insights around relative cost-effectiveness of PrEP 
A simple rule was developed to help policy makers draw qualitative program insights around 
conditions under which it may be equally cost-effective to roll out PrEP in a lower-risk group (e.g. 
AGYW) as in a higher-risk group (e.g. FSW). Cost-effectiveness is defined as the incremental cost of 
PrEP for a woman retained at level 𝑟𝑟𝑗𝑗 in a PrEP program over a 12-month period, divided by the risk 
reduction achieved on PrEP when adhered to at level 𝛼𝛼 with retention 𝑟𝑟𝑗𝑗 over the 12-month period. 
In the absence of willingness-to-pay thresholds, relative cost-effectiveness was assessed by 
comparing these estimates of cost per infection averted between populations. 
 
Heatmaps to estimate the relative unit cost at which PrEP scale-up from higher- to lower-risk women 
is cost-effective 
Heatmaps were developed to help decision makers estimate the relative unit cost at which it will be 
cost-effective to scale up PrEP from a comparatively higher- (e.g. FSW) to comparatively lower-risk 
woman (e.g. AGYW), also using the number of monthly sex acts, average condom use and underlying 
epidemic setting. Different epidemic settings were illustrated by taking HIV prevalence in the higher-
risk women’s partner population of either 20% or 40%. For each of these scenarios, HIV prevalence 
in the lower-risk women’s partner population was then simulated at 1/4, 1/2, 3/4 and 1 times the 
prevalence of the higher-risk women’s partner population (i.e. 5%, 10%, 15% and 20%; and 10%, 
20%, 30% and 40% respectively). These scenarios span a range of epidemic settings in sub-Saharan 
Africa19. 
It was assumed that the higher-risk group had 22% PrEP program retention levels and all women 
retained had PrEP adherence levels of 70-85% (corresponding to risk-reduction of 73-99%48), 
consistent with the South African TAPS demonstration project in FSW3. PrEP program retention for 
the lower-risk group was simulated between ±25% of the 22% retention levels of the higher-risk 
group (i.e. 16.5%-27.5%), consistent with the difference between AGYW and FSW retention in 
Kenya4. For lower-risk women retained in the PrEP program, it was assumed that PrEP adherence 
was the same as the higher-risk group.  
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Country case studies  
Assessment of cost-effectiveness and impact of scaling-up PrEP  
To highlight key considerations to feed into decision making as countries consider scaling-up PrEP 
beyond those at highest-individual risk, we assessed the cost-effectiveness and impact of scaling-up 
PrEP for women across a spectrum of high HIV risk in South Africa, Zimbabwe and Kenya. Given the 
significantly higher individual HIV risk faced by FSW2 FSW were taken as the benchmark for 
assessment. In comparison, we considered the scale-up of PrEP to three groups at high HIV risk in 
the general population8–10: AGYW (aged 15-24 years), women 25-34 years and women 35-49 years. 
No further targeting of PrEP was assumed. Women aged 50+ were not evaluated given the paucity 
of information available to parameterise and fit the models in all three country contexts24,50–53.  
FSW were assumed to have partners drawn from two populations: regular partners and clients. 
AGYW were assumed to have partners drawn from their own age group and the 25-34 years age 
group, given that 17% and 14% women 15-19 years report relationships with men at least 10 years 
older in Zimbabwe51 and Kenya52 respectively, and 36% South African women 15-19 years report 
relationships with men at least 5 years older8. Women 25-34 years and women 35-49 years were 
assumed to have partners drawn from their own age groups given the lack of data to suggest 
otherwise. However, this assumption was explored further through the structural sensitivity 
analysis. Data ranges to parameterise the models were drawn from the literature and fitted to the 
latest national estimates of HIV incidence by group1,24,54–60 using Bayesian Monte Carlo Filtering with 
Latin Hypercube Sampling, assuming uniform prior distributions, yielding at least 200 fits across the 
four groups for each country. 
FSW were assumed to have 12-month PrEP program retention and adherence levels consistent with 
the South African TAPS demonstration project3. AGYW, women 25-34 years and women 35-49 years 
were assumed to have program retention levels between ±25% of these 12-month FSW retention 
levels4, and the same adherence levels as FSW retained in the program. To explore the role of 
adherence, the parametric uncertainty analyses were repeated with 1) 25% lower HIV risk-reduction 
across all groups, and 2) 25% lower HIV risk-reduction across AGYW, women 25-34 years and women 
35-49 years (but unchanged among FSW). 
We estimated the unit costs of PrEP program delivery per person retained after 12-months (Table 1). 
We assumed FSW were offered PrEP through programmes with outreach and community 
mobilisation components and all other women were offered PrEP through sexual and reproductive 
health services, with AGYW having larger counselling components. Service delivery costs were taken 
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from demonstration projects and previous costing publications in Kenya61,62 and South Africa3. For 
Zimbabwe, non-tradable components of the South African estimates were transferred using 
purchasing power parities63 following standard methods64. Drug costs were assumed to be USD57-80 
per year, spanning internationally traded values with freight and distribution65, and highest reported 
prices in demonstration projects. All published costs were adjusted to USD 201766.  
Country Population  
Unit cost  
(min - max) 
Service delivery 
excl. drugs 
Drugs only  
(min - max) 
South Africa FSW 190 - 210 130 57 – 80 
South Africa AGYW (15-24 years) 149 - 169 89 57 – 80 
South Africa Women (25-34 years) 128 - 148 68 57 – 80 
South Africa Women (35-49 years) 87 - 107 27 57 – 80 
Zimbabwe FSW 293 - 317 237 57 – 80 
Zimbabwe AGYW (15-24 years) 219 - 243 163 57 – 80 
Zimbabwe Women (25-34 years) 181 - 204 124 57 – 80 
Zimbabwe Women (35-49 years) 106 - 130 50 57 – 80 
Kenya FSW 399 - 423 343 57 – 80 
Kenya AGYW (15-24 years) 358 - 382 302 57 – 80 
Kenya Women (25-34 years) 294 - 318 238 57 – 80 
Kenya Women (35-49 years) 185 - 209 129 57 – 80 
Table 1: Cost estimates per person retained on PrEP after 12-months by population and country. Costs in USD 
2017.  
 
Structural sensitivity analysis 
Whist the literature only provides evidence of women aged 15-25 years having male partners from 
an older population group in these three settings, we explored how the model outcomes change if 
women aged 25-34 years are also assumed to have male partners from an older population group 
(35-49 years) with higher HIV prevalence. This model structural sensitivity analysis was 
 
 
177 
 
parameterised illustratively assuming 50% the number of partners a year from the male population 
35-49 years as had by women 35-49 years (in addition to their partnerships with males 25-34 years). 
 
Further information on model structure, parameterization, calibration and costs are set out in the 
Appendix 4: Supplementary Materials. 
  
178 
Results 
Simple tools to help guide PrEP programme decision making 
Heatmaps to estimate HIV incidence in women 
The estimated annual HIV incidence in women, by number of monthly sex acts and average condom 
use, is shown in Figure 1. The estimates are shown for four cases: underlying HIV prevalence in 
partner population of 5%, 10%, 20% and 40%.  
Figure 1: Women’s estimated HIV incidence by risk factor.  
The heatmaps show the estimated annual HIV incidence in women according to their number of sex acts per month 
(number of partners multiplied by average number of sex acts with each per month), and average condom use. The 
estimated annual HIV incidence is shown by colour (according to the colour key on the right-hand side of the graph) in 
incidence increments of 1% or 1 per 100 person years. An annual incidence of at least 3% or 3 per 100 person years is 
coloured light orange and corresponds to the WHO recommended threshold for PrEP eligibility18. The 4 heatmaps 
correspond respectively (left to right, top to bottom) to underlying partner HIV prevalence of 5%, 10%, 20% and 40%. The 
heatmaps are calculated using equation (S1.1) from the Appendix 4: Supplementary Materials, assuming that a women’s 
partners are drawn from a single population and no women are on PrEP. 
Figure 1 shows that where women’s partners come from a population with HIV prevalence of up to 
5%, women will be below the 3%18 WHO-recommended HIV incidence threshold for PrEP where the 
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number of sex acts a month is up to 10 and average condom use is at least 50% (areas shaded yellow 
in the heatmap). As the underlying HIV prevalence in the partner population increases, women will 
need higher levels of condom consistency or to engage in fewer sex acts a month to be below the 
WHO incidence threshold for PrEP (areas shaded orange-red). Where women’s partner population 
have a prevalence of 40%, women will almost uniformly be above the threshold for PrEP.  
Simple rule to draw insights around relative cost-effectiveness of PrEP 
To help policy makers draw qualitative program insights around conditions under which it may be 
equally cost-effective to roll out PrEP in a lower-risk group as in a higher-risk group, we derived the 
simple rule set out in Equation 1. This rule can be approximated based on information typically 
estimated by PrEP programs49. The relative measures stated are for lower-risk women compared to 
higher-risk women.  
Equation 1: Simple rule to draw insights around the relative cost at which PrEP will be equally as cost-effective to scale 
up in a lower-risk group as it will be in the high-risk group.  
All relative measures refer to the low-risk group in comparison to the high-risk group and pertain to the same time period. 
The relative cost of PrEP is the unit cost of PrEP per individual retained in the program over the given time period. The 
number of sex acts is the number of partners multiplied by the average number of sex acts with each over the given time 
period. The use-effectiveness of PrEP is the HIV-risk reduction through use of PrEP at a given level of adherence, for a 
population with a given average program retention level49. This rule holds under the condition that the prevalence in the 
partner population multiplied by the average number of sex acts with each partner per unit of time, multiplied by the basic 
risk of HIV transmission through peno-vaginal sex, the average proportion of sex acts not protected with condoms and PrEP 
is much less than 1. This simple rule can be approximated using data collected in PrEP programs49. Further details on the 
derivation of this rule and associated conditions are given in the Appendix 4: Supplementary Materials.
Heatmaps to estimate the relative unit cost at which PrEP scale-up from higher- to lower-risk women 
is cost-effective 
The relative cost at which PrEP will be equally as cost-effective to scale up in the lower-risk group as 
it will be in the higher-risk group, is demonstrated in four scenarios shown in Figure 2: underlying 
HIV prevalence in the lower-risk women’s partner population of 10%, 20%, 30% and 40%, and with 
HIV prevalence in the higher-risk women partner population of 40% (approximately that of FSW 
clients in higher-burden settings). The equivalent figure corresponding to a lower HIV prevalence in 
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the higher-risk women’s partner population of 20% is given in Appendix 4: Supplementary Materials 
– Figure S4.
Figure 2: Relative unit cost at which it is cost-effective to scale up PrEP from a higher- to lower-risk women group.  
The heatmaps show the relative unit cost at which it is cost-effective to scale up PrEP from a higher- to a lower-risk group. 
The relative unit cost at which PrEP is cost-effective is shown by the relative average condom use in the lower-risk group 
compared to the higher-risk group (x-axis), and the relative number of sex acts a month for women in the lower-risk group 
compared to the higher-risk group (y-axis). The unit cost of PrEP in the lower-risk group relative to the higher-risk group at 
which PrEP is equally cost-effective between the two groups is shown by colour, according to the colour key on the right-
hand side of the graph. A colour within the yellow spectrum denotes that the relative unit cost of PrEP in the lower-risk 
group relative to the higher-risk group has to be less than 1 for it to be equally as cost cost-effective. A colour within the 
green spectrum denotes that the relative unit cost of PrEP in the lower-risk group relative to the higher-risk group will be 
greater than 1 for it to be equally as cost cost-effective. The 4 heatmaps correspond respectively (left to right, top to 
bottom) to underlying partner HIV prevalence of 10%, 20%, 30% and 40% in the lower-risk group’s partner population and 
all of them corresponding to 40% HIV prevalence in the higher-risk women’s partner population. The heatmaps are 
calculated using equation (S1.5) from the Appendix 4: Supplementary Materials, assuming that women’s partners are 
drawn from a single population each. The higher-risk group are assumed to have 12-month PrEP program retention levels 
of 22%3 and adherence levels of 70-85% (corresponding to a risk reduction of 73-99%48). The PrEP program retention levels 
for the lower-risk group were simulated between +/- 25% the retention of the higher-risk group4. For those lower-risk 
women retained in the PrEP program, it was assumed that PrEP adherence was the same as the higher-risk group. 
Where HIV prevalence in the lower-risk women’s partner population is 10%, the results show that 
irrespective of both women’s condom use, the unit cost of PrEP in the lower-risk group will have to 
be much lower than in the higher-risk group for PrEP roll-out to be equally as cost-effective (areas 
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shaded yellow), other than where the numbers of monthly sex acts in the lower-risk group exceeds 
that of the higher-risk group (areas shaded green). As HIV prevalence increases in the lower-risk 
women’s partner population relative to the higher-risk women’s partner population, PrEP will be 
equally cost-effective between the two groups at increasingly higher unit costs for the lower-risk 
group relative to the higher-risk group.  
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Country case studies 
The model fits to HIV incidence for South Africa, Zimbabwe and Kenya are given in Appendix 4: 
Supplementary Materials: Figures 1-3.  
Figure 3 shows the maximum unit cost of PrEP for AGYW, women 25-34 years and women 35-49 
years, relative to the unit cost of PrEP for FSW, for scale-up to be equally as cost-effective as it is in 
FSW. This is shown for South Africa (blue), Zimbabwe (orange) and Kenya (green). As comparators, 
the estimated current relative unit costs are shown (cream).  
Figure 3: Relative unit cost of PrEP for scale-up to be equally as cost-effective as for FSW.  
The boxplot shows the maximum unit cost of PrEP per year for AGYW, women 25-34 years or women 35-49 years relative to 
the unit cost of PrEP for FSW, for PrEP scale-up in these populations to be equally as cost-effective as it is for FSW (bright-
coloured boxes). The maximum relative unit costs are shown, grouped left to right, for AGYW, women 25-34 years or 
women 35-49 years. Within each age grouping, the results are show by country, left to right, for South Africa (in blue), 
Zimbabwe (in orange) and Kenya (in green). The maximum relative unit costs are calculated using equation (S2.5) from 
Appendix 4: Supplementary Materials and assume that 12-month PrEP program retention in AGYW, women 25-34 years or 
women 35-49 years is within +/-25% of retention levels for FSW, taken to be 22%, in line with the results of the TAPS 
demonstration project3. As comparisons, current estimates of the unit costs of PrEP for AGYW, women 25-34 years and 
women 35-49 years, relative to the unit cost of PrEP for FSW are shown for all countries (in cream), calculated using data 
from Table 1. The abbreviations used in the graph are as follows: AGYW denotes adolescent girls and young women 15-24 
years, S Africa denotes South Africa and Zim denotes Zimbabwe. 
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For example, in the case of AGYW in South Africa, Figure 3 shows that PrEP will be equally cost-
effective for AGYW as for FSW at a maximum median relative unit cost of 23.3 % (95% CrI: 13.3%, 
36.8%)  (furthest left blue boxplot). The current estimated unit cost of PrEP in AGYW relative to FSW 
in South Africa is median 79.8 % (95% CrI: 73.0%, 87.0 %) (furthest left cream boxplot). If the cost of 
PrEP for AGYW dropped by median 70.8% (95% CrI: 53.2%, 83.4 %) it would be equally as cost-
effective as for FSW (Appendix 4: Supplementary Materials: Table S3).  
Otherwise, across all other scenarios in all three countries, the unit cost of PrEP for AGYW, women 
25-34 years and women 35-49 years would have to drop between median 71.8-91.0% (95% CrIs
spanning: 50.8%, 96.5%) to be equally as cost-effective.
Figure 4 illustrates the estimated number of infections that could be averted a year due to PrEP in 
each high-risk women population group, in each country, for every $100,000 available for PrEP 
programming. Additional analyses, including the proportion of HIV infections that could be averted a 
year for every $100,000 allocated to each population group are shown in Appendix 4: Supplementary 
Materials: Tables S4, S5 and Figure S5. 
Figure 4: Boxplot of the number of HIV infections that could be averted a year due to PrEP, for each $100k available for 
PrEP programming.  
The boxplot shows, for each $100k available for PrEP programming a year for FSW, AGYW, women 25-34 years and women 
35-49 years, the total number of infections that could be averted a year due to PrEP. The number of infections that could be 
averted a year for each $100k available for PrEP are shown, grouped left to right, for FSW, AGYW, women 25-34 years or 
women 35-49 years. Within each age grouping, the results are shown by country, left to right, for South Africa (in blue),
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Zimbabwe (in orange) and Kenya (in green). The number of infections averted a year is calculated using equation (S2.10) 
from Appendix 4: Supplementary Materials and assumes that 12-month PrEP program retention in AGYW, women 25-34 
years or women 35-49 years is within +/-25% of retention levels for FSW, taken to be 22%, in line with the results of the 
TAPS demonstration project3. The unit costs of PrEP for each high-risk women group are as stated in Table 1. These 
estimates hold until PrEP saturation (determined by retention levels and population size) has been reached in the smallest 
population group – in this case, FSW. After this point, no additional financial resources will be able to reduce infections per 
year in this population group. 
Given the differences in relative population sizes, Figure 5 demonstrates the relative number of 
infections that could be averted a year with PrEP at equal coverage levels in AGYW, women 25-34 
years and women 35-49 years as in FSW. These results correspond to Table S8 in the Appendix 4: 
Supplementary Materials. 
Figure 5: Violin plot of the relative number of infections averted a year on PrEP with equal program coverage as in FSW.  
The violin plot shows the relative number of infections that could be averted a year in HIV negative AGYW, women 25-34 
years or women 35-49 years, compared to in FSW, if PrEP were scaled up at the same coverage levels as in HIV negative 
FSW. The relative number of infections that could be averted are shown, grouped left to right, for South Africa (in blue), 
Zimbabwe (in orange) and Kenya (in green). In the violin plots, the white dots represent the median values, the thick black 
vertical lines represent the interquartile range, the vertical length of the violin represents the range of values and the width 
of the violin represents the frequency with which those values occur. The relative number of infections that could be averted 
are calculated using equation (S2.9) from Appendix 4: Supplementary Materials and assumes that 12-month PrEP program 
retention in AGYW, women 25-34 years or women 35-49 years is within +/-25% of retention levels for FSW, taken to be 
22%, in line with the results of the TAPS demonstration project3. The abbreviations used in the graph are as follows: AGYW 
denotes adolescent girls and young women 15-24 years, 25-34 yr denotes women 25-34 years and 35-49 yr denotes women 
35-49 years in each country. 
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In comparison to the number of infections averted annually in FSW in South Africa, a median 24 times 
(95% CrI:12, 45) the number of HIV infections could be averted in AGYW, median 14 times (95% CrI:7, 
27) in women 25-34 years, and median 8 times (95% CrI:4, 17) in women 35-49 years, if PrEP were 
rolled out at the same coverage levels across populations.  
In Zimbabwe, a median 4 times (95% CrI:2, 9) the number of annual HIV infections could be averted 
in AGYW, median 8 times (95% CrI:3, 14) in women 25-34 years, and median 3 times (95% CrI:2, 5) in 
women 35-49 years, in comparison to FSW with equal PrEP program coverage.  
In Kenya, a median 3 times (95% CrI:2, 8) the number of HIV infections could be averted in AGYW, 
median 3 times (95% CrI:1, 5) in women 25-34 years, and median 1 times (95% CrI:1, 3) in women 35-
49 years, in comparison to FSW with equal PrEP program coverage. 
 
Sensitivity analyses 
Repeating the analyses shown in Figure 3 (relative unit cost for PrEP to be equally as cost effective) 
and Figure 5 (relative number of infections averted a year with equal program coverage) with 25% 
reduced adherence-related HIV risk-reduction across all female groups led to <0.01% change across 
the scenarios (Appendix 4: Supplementary Materials: Tables S9 and S10). Repeating these analyses 
with 25% reduced adherence-related HIV risk reduction among all non-FSW women groups led to 
<0.3% change across the scenarios (Appendix 4: Supplementary Materials: Tables S11 and S12). 
Repeating the analyses in Figures 3 and 5 under the structural sensitivity analysis, exploring the case 
that women 25-34 years have partners from the 35-49 year age group in addition to their own age 
group, led to <1% change across scenarios (Appendix 4: Supplementary Materials: Tables S13 and S14). 
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Discussion 
This is the first study to assess the potential impact and cost-effectiveness of PrEP scale-up across 
different high-risk women population groups among countries in sub-Saharan Africa, to highlight key 
considerations for policy decision making. PrEP should be offered to women at highest HIV risk, such 
FSW, for whom it is most cost-effective. However, only by extending PrEP to women at 
comparatively lower risk will new HIV infections reduce substantially.  
We developed three simple tools to guide PrEP programming, applicable to any setting using a basic 
set of information typically available to implementers. First, heatmaps (Figure 1) to estimate the 
annual HIV incidence in women, by number of monthly sex acts, average condom use and underlying 
epidemic setting. Second, a simple rule (Equation 1) to gain qualitative program insights around the 
relative cost at which PrEP will be equally as cost-effective between two groups of women with 
different HIV risk factors and behaviours. Third, heatmaps (Figure 2) applying the relative cost-
effectiveness estimates to different epidemic settings. 
By adapting the models to three countries spanning the spectrum of high HIV burden contexts in 
sub-Saharan Africa, we have seen that the unit costs of PrEP delivery for AGYW, women 25-34 years 
and women 35-49 years would have to reduce considerably (by estimated median 70.8-91.0%  
across scenarios) for scale-up to these populations to be as cost-effective as for FSW. Indeed, on an 
individual basis, PrEP is most cost-effective for FSW than any other high-risk women population 
group, with a greater number of infections averted a year for every $100k available for PrEP 
programming in all three country contexts (Figure 4).  
However, rolling out PrEP widely for women in the general population has potential to substantially 
impact on the countries’ HIV epidemics. In South Africa, PrEP has the potential to avert 
approximately 24 times the number of infections annually in AGYW as in FSW when scaled up at 
equal coverage levels, and approximately 14 and 8 times the number in women 25-34 and 35-49 
years respectively. In Zimbabwe approximately 8 times the number of infections could be averted 
annually in women 25-34 years as in FSW, and approximately 4 and 3 times the number in AGYW 
and women 35-49 years respectively. In Kenya, approximately 3 times the number of infections 
could be averted annually in AGYW and in women 25-34 years as in FSW, and around the same 
number in women 35-49 years as in FSW. The wide variability in the violin plot estimates of the 
relative number of infections averted by population group (Figure 5) highlight that decisions around 
PrEP scale-up will need to depend on the specific characteristics of the groups under consideration.  
 
 
187 
 
By quantifying the impact that can be achieved through PrEP scale-up across high-risk women 
groups in each of the three country contexts, this study highlights the potential importance of PrEP 
roll-out at population level, even considering low levels of program retention and adherence. It 
underscores the value of universal access to PrEP in sub-Saharan Africa as part of a rights-based 
approach to health. Policy makers will need to weigh these prospects against affordability, in view of 
current program costs, budget constraints and program sustainability (although given PrEP is 
intended to cover seasons of risk, rather than for long term use, it may be more feasibly scaled back 
over time as population incidence decreases). 
Scaling up PrEP for women in the general population has the potential to drive cost reductions 
through economies of scale, in turn improving cost-effectiveness, allowing more women to be 
reached with the same budget. Doing so will require countries to continue to integrate PrEP into a 
range of health, non-health and community services for women in the general population5–7, which 
in some instances (e.g. education) may be challenging in local cultural contexts. Advocates’ efforts 
will be important in further reducing drug prices, as will the prioritization of resources for prevention 
by decision makers. Long-acting PrEP formulations, currently under investigation67–69, may also help 
improve cost-effectiveness, if they are able to increase HIV prevention use-effectiveness through 
improved product adherence and retention in comparison to daily oral pill formulations.  
 
Limitations 
This study was conducted using static mathematical models, given their comparative ease for use in 
policy making. Static models can be more easily tailored to individual settings, necessitating a 
narrower and more readily available set of data in comparison to the more complex dynamic models 
typically used to inform HIV decision making. However, they do not capture downstream infections 
averted in partner populations and the wider society. Many studies have shown that introducing HIV 
prevention interventions to high-risk groups has greatest impact on reducing onwards transmission 
early in epidemics when prevalence is low and the basic reproductive rate is high, than in endemic 
high-burden contexts70,71, such as those in which our model is applied2. Therefore, if the study were 
extended to look at the impact of PrEP beyond its recipients, these estimated infections averted 
would be minima, costs per infection averted maxima, and modest changes would be expected 
comparing the relative impact between high-risk populations.  
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Much of the data used to characterise high-risk women are limited by age and lack of reliable data 
on numbers of partners and numbers of sex acts. Sexual behaviour data is subject to under-
reporting, and when collected for the general population through demographic health surveys, 
reporting as percentages makes it difficult to derive meaningful limits or statistic distributions for the 
underlying data. HIV incidence and prevalence data are not always available for the same population 
for the same year. As PHIA surveys72 in PEPFAR-supported sub-Saharan African countries continue to 
be rolled out over the coming years, these data will become more readily and consistently available 
to repeat these analyses across high-burden countries. Cost estimates are limited by assumptions on 
how subgroups are reached. Whilst a strength of this study is heterogeneity in programmatic costs, 
our estimates are limited by the scarcity of empirical data in these settings. Data uncertainty is 
addressed to some extent through the uncertainty analysis. 
This study parameterises models using population averages for broadly defined groups for whom 
data is readily available in the literature. It does not account for significant behavioural 
heterogeneity that exists within each of these groups nor in differences in HIV burden at local-levels, 
potentially masking important risk groups and population interactions. Accordingly, reported 
population mixing between women 15-19 years and men 5-10 years older in these countries was 
approximated to be represented by AGYW (15-24 years) drawing partners from male populations 
15-24 years and 25-34 years. Lack of available data to parameterize women 50 years+ meant that it 
was not possible to explore the scale-up of PrEP to this population group. Where available data 
permits, these analyses could be tailored to reflect greater or different heterogeneity between sub-
populations and at sub-national level. Lastly, the study also does not explicitly account for other PrEP 
program cascade factors, such as uptake. Doing so would affect the relative estimates of PrEP 
effectiveness where at least one of the female populations have materially different levels of 
program uptake than the others. 
 
Conclusion  
PrEP has the potential to significantly reduce the numbers of new HIV infections in HIV-endemic 
countries in sub-Saharan Africa, even considering low levels of PrEP program retention in women. 
This will necessitate PrEP being made widely available beyond those at highest individual risk, 
including to women in the general population. Wide-scale roll out will require integration of PrEP 
into a wide range of national services and at community level, in order to significantly bring down 
the costs and improve cost-effectiveness.  
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5.4    Implications for Thesis 
The conclusions of Research Paper 3 indicate that PrEP has the potential to significantly reduce the 
numbers of HIV infections at population-level, if it is scaled up widely for women beyond those at 
highest individual risk. This is noteworthy, considering the low levels or PrEP program retention 
accounted for: 22% retention after 1 year in female sex workers, and within ±25% of this (i.e. 16.5%-
27.5%) for all other women. 
The female population groups in which PrEP has the potential to reduce the greatest number of 
infections differs by country according to their underlying incidence profiles. In South Africa, it is 
estimated that PrEP has the potential to avert the most number of infections in AGYW as compared 
to FSW (approximately 24 times the number annually), followed by women 25-34 years 
(approximately 14 times the number) and then women 35-49 years (approximately 8 times the 
number). By contrast, in Zimbabwe, it is estimated that the greatest number of infections could be 
averted annually in women 25-34 years (approximately 8 times the number as in FSW), followed by 
AGYW and women 35-49 years (approximately 4 and 3 times the number as in FSW respectively). In 
Kenya, roughly the same number of new infections could be averted annually in AGYW and women 
25-34 years (approximately 3 times the number of infections as in FSW respectively), followed by 
women 35-49 years (approximately the same number as in FSW). 
Policy makers will have to balance this important potential for infection reduction at population 
level, with their ability to pay for PrEP scale-up. Using current estimates of cost of PrEP delivery by 
population group, and given the significantly greater HIV risk faced by FSW in comparison to other 
female groups in the general population, PrEP provision remains significantly more cost-effective for 
FSW across the three country contexts explored. The unit cost of PrEP delivery for AGYW, women 
25-34 years and women 35-49 years would need to drop significantly by between median 70.8%-
91.0% across all three country contexts to be as cost-effective as for FSW. 
Scaling up PrEP at population level by integration into a range of national and community services 
has the potential to drive cost reductions, improving cost-effectiveness on an individual basis for 
AGYW, women 25-34 years and women 35-49 years. However, achieving cost-parity with the cost of 
PrEP for FSW (other than potentially for AGYW in South Africa) is likely to be challenging for these 
countries in the near term. 
Policy makers in sub-Saharan Africa can easily adapt the models and tools used in this Research 
Paper to estimate the relative cost-effectiveness and potential impact of PrEP for different risk 
populations by country context. It is hoped that this information will then help these decision 
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makers weigh available resources with the potential for impact of PrEP at population level in an 
effort to maximise HIV infections averted.   
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Chapter 6 
 
6. Discussion 
 
6.1  Main findings 
This PhD thesis set out to address the following aim and objectives: 
Aim: to use mathematical modelling to inform policy making around the scale-up of PrEP for women 
across a spectrum of high HIV risk in sub-Saharan Africa, accounting for heterogeneities in HIV risk 
factors and PrEP programme outcomes 
Objectives: 
1. To assess the potential effectiveness of PrEP in reducing HIV infections among high-risk women 
in sub-Saharan Africa 
2. To explore the extent to which behavioural disinhibition may outweigh the potential benefits of 
PrEP  
3. To assess the robustness of conclusions made on the basis of static modelling techniques to 
incorporation of dynamic effects, to contribute to understanding around the importance of 
modelling complexity to inform HIV policy making 
4. To explore strategies for the scale-up of PrEP across high-risk women at population-level, 
weighing considerations around HIV infection reduction and cost-effectiveness  
5. To evaluate strategies for PrEP scale-up in more than one country setting in sub-Saharan Africa, 
to explore how the approach to PrEP scale-up may differ by epidemic and implementation 
context 
 
An assessment of the research conclusions in relation to the thesis objectives is set out in the 
following section. 
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Objective 1: To assess the potential effectiveness of PrEP in reducing HIV infections among high-risk 
women in sub-Saharan Africa 
This objective was assessed in Chapters 3, 4 and 5 as a critical step on the modelling pathway to 
investigation of subsequent thesis objectives, e.g. around the effects of behavioural disinhibition and 
strategies for PrEP scale-up. The modelling undertaken in all three chapters, through both static and 
dynamic model formulations, concluded that PrEP has the potential to reduce new HIV infections 
among women across a spectrum of risk in sub-Saharan Africa. However, its ability to do so is 
dependent on women’s PrEP programme cascade metrics, including PrEP programme uptake, 
retention and adherence. PrEP will only be effective at reducing HIV risk for a woman if it is made 
available to her, she has access to it, commences taking the drug, is retained in the programme 
during her season of risk and adheres to it. It also depends on the level of any behavioural 
disinhibition following commencement of PrEP relative to other HIV risk factors and her use-
effectiveness of PrEP (level of HIV risk reduction achieved through taking PrEP with given retention 
and adherence levels). The analytical derivations in Research Paper 1 (Chapter 2, Equation 2.7) have 
illustrated that as long as the use-effectiveness of PrEP is at least the same as that achieved with 
condoms prior to introduction of PrEP, PrEP will always be beneficial in reducing HIV risk. Once the 
precise relationship between PrEP adherence and use-effectiveness has been established for 
women, this will facilitate understanding of the levels of weekly PrEP pill adherence needed 
compared to baseline levels of condom consistency (for which there is a linear relationship between 
use and effectiveness) to achieve the same levels of HIV risk reduction.  
 
Objective 2: To explore the extent to which behavioural disinhibition may outweigh the potential 
benefits of PrEP 
This objective was assessed first through Research Paper 1 (in Chapter 3) using a static model and 
the results then verified through Paper 2 (in Chapter 4) using a dynamic model formulation. The 
papers conclude that should behavioural disinhibition occur, the extent to which the protective 
effects of PrEP will outweigh increased HIV risk through reductions in condom use depends on the 
use-effectiveness of PrEP and the change in use of condoms following PrEP commencement. The 
effects of behavioural disinhibition would be more pronounced for women at higher underlying risk 
of HIV owing to other non-condom related risk factors. 
The methodological approaches undertaken through both Research Papers agree in their broad-
stroke policy conclusions to guide decision making at country level. These are, that in high HIV 
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burden contexts, PrEP for high-risk women is likely to be of benefit in reducing HIV risk even if 
reductions in condom use occur; that reductions in condom consistency can be better tolerated by 
high-risk women achieving high levels of PrEP use-effectiveness or with low baseline condom 
consistencies; and efforts to promote condom use will be especially critical for high-risk women with 
high levels of baseline condom consistency but who are anticipated to adhere less well to PrEP.  
The exact use-effectiveness threshold at which PrEP is a beneficial additional HIV prevention 
approach for high-risk women (considering any reductions in condom consistency following PrEP 
introduction) depends on other underlying epidemiological and behavioural HIV risk factors. In the 
case of FSW in inner-city Johannesburg, if PrEP is introduced in a context where the underlying HIV 
epidemic has reached HIV equilibrium, over short-medium time horizons of up to 5 years, it is 
estimated that up to 85% reduction in condom consistency can be tolerated, as long as 65% use-
efficacy is achieved with PrEP. 65% PrEP use-efficacy corresponds to adherence levels of more than 4 
tablets out of 7 a week, according to the Partners Demonstration Project analysis in women1. If the 
underlying epidemic were still to be increasing in inner-city Johannesburg, the level of reduction in 
condom consistency tolerated with 65% PrEP use-effectiveness would drop from 85% to 34% after 5 
years on PrEP.   
As highlighted in our recent Commentary for the Lancet HIV (Appendix 5), there are further aspects 
in relation to behavioural disinhibition on PrEP that would benefit investigation. These include 
community-level behavioural disinhibition (reductions in condom use in those not using PrEP, which 
has recently been reported among MSM communities in Australia2); patterns of behavioural 
disinhibition in relation to intermittent PrEP regimens (i.e. between and after episodes of PrEP); and 
alternate strategies for STI prevention among PrEP takers with low baseline condom use. 
 
Objective 3: To assess the robustness of conclusions made on the basis of static modelling techniques 
to incorporation of dynamic effects, to contribute to understanding around the importance of 
modelling complexity to inform HIV policy making 
This objective was assessed through Research Paper 2 (Chapter 4). Research Paper 2 compared the 
results of matched static and dynamic model formulations in exploring the impact of the 
introduction of a new HIV prevention intervention (in this case, PrEP) for women at high HIV-risk in 
SSA, using the case study of FSW in inner-city Johannesburg. Research Paper 2 explored the extent 
to which the broad-stroke conclusions made on the basis of the static model held under the dynamic 
model formulation. The paper explores the extent to which specific numeric predictions of the 
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reductions in condom consistency tolerated on PrEP made through the static model remained robust 
under the dynamic model formulation. This was assessed different epidemic contexts (where the 
underlying HIV epidemics in the respective populations are still increasing, at equilibrium, and fully 
endemic in the populations) and over time horizons of three months to 20 years. 
Research Paper 2 concluded that the overarching policy conclusions made on the basis of the static 
model remained true under the dynamic model formulation. This is a noteworthy conclusion given 
the comparative advantages of static models for use by policy makers3,4.  
Regarding the consistency of the numeric predictions between the two models, Research Paper 2 
found that over short-medium time-horizons of up to five years, the static model approximates the 
outcomes of the dynamic model fairly consistently. However, over longer timeframes of up to 20 
years, the static models may underemphasize situations of programmatic importance, especially in 
contexts where underlying epidemics are increasing. In particular, the model comparison found that 
the reductions in condom use predicted by the static model do not hold under the dynamic model 
formulation where initial condom consistencies are reasonably high (≥50%) and/or PrEP use-
effectiveness is low (≤45%), with the differences greater where the underlying HIV epidemic is 
increasing. The difference between the models’ outcomes arise principally from the dynamic 
model’s ability to capture changes in HIV prevalence over time, highlighted where PrEP use-
effectiveness is insufficiently high enough to mask greater reductions in condom use. 
 
Objective 4: To explore strategies for the scale-up of PrEP across high-risk women at population-level, 
weighing considerations around HIV infection reduction and cost-effectiveness  
This objective was explored through Research Paper 3 (Chapter 5), which assessed the potential 
individual-level cost-effectiveness and population-level impact (number of infections averted) of 
PrEP, for women across a spectrum of high risk: AGYW, women 25-34 years, women 35-49 years and 
FSW. In the absence of willingness to pay thresholds, relative cost-effectiveness was assessed by 
comparing estimates of cost per infection averted between high-risk women populations. Research 
Paper 3 devised three simple tools to guide implementers in assessing strategies for PrEP scale-up at 
country level, applicable to any setting, using a basic set of information available to implementers5.  
The first tool helps implementers estimate the annual HIV incidence in women, using information on 
average number of monthly sex acts, average condom use and underlying epidemic setting. The 
second tool helps implementers to estimate the relative cost at which PrEP will be equally as cost-
effective between two groups of women according to their HIV risk factors and risk behaviours. The 
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third simple tool helps implementers assess the relative unit cost at which PrEP will be equally as 
cost-effective for lower-risk women as women at comparatively higher-risk, also using information 
on average number of monthly sex acts, average condom use and underlying epidemic setting. 
The Research Paper then assessed strategies for PrEP scale-up across these four groups of high HIV-
risk women in three different country implementation contexts in SSA. It concluded that to maximise 
cost-effectiveness, PrEP should be offered to women at highest HIV risk, such FSW. However, to 
maximise the number of HIV infections averted at population-level, and significantly impact the HIV 
epidemics in SSA, PrEP should be rolled out for women in the general population at comparatively 
lower HIV-risk, but in whom the number of HIV infections are in total greater annually, due to vast 
differences in population size. The relative magnitude of potential infections averted on PrEP 
annually in each of the 4 high-risk women groups differs by country context, according to underlying 
HIV risk factors (epidemiological and behavioural), relative population sizes and PrEP programme 
outcomes in each of the groups. As such, so would the order of prioritization of high-risk women 
groups for PrEP scale-up in each of these country contexts. 
Wide-scale roll out of PrEP for groups of women in the general population has the potential to drive 
cost reductions through economies of scale, improving cost-effectiveness and allowing more women 
to be reached with the same financial resources. This will require the integration of PrEP into a range 
of health, non-health and community services for women, which in some instances may be 
challenging considering local cultural contexts (e.g. integration into education settings for AGYW).  
Accordingly, strategies for scale-up of PrEP for women across a spectrum of high HIV-risk can be 
determined using the analytical tools developed for this study, allowing decision makers to assess 
relative cost-effectiveness and relative number of infections averted at population level. These 
strategies will also need to account for the contextual considerations outlined in the study, including 
potential scope for PrEP cost-reduction through economies of scale, potential for integration of PrEP 
into a wide range of national services and at community level to research each of these groups of 
women and other relevant contextual, political and cultural factors. 
 
Objective 5: To evaluate strategies for PrEP scale-up in more than one country setting in sub-Saharan 
Africa, to explore how the approach to PrEP scale-up may differ by epidemic and implementation 
context 
This objective was explored through Research Paper 3 (Chapter 5), which applied analytical tools to 
assess the potential cost-effectiveness and population-level impact of PrEP across the 4 groups of 
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women at high risk of HIV in three different implementation contexts in SSA. Specifically, strategies 
for PrEP scale-up were applied to three HIV endemic countries in SSA that span a range of HIV 
burden levels in the region: South Africa (20.4% adult HIV prevalence), Zimbabwe (12.7% adult HIV 
prevalence) and Kenya (4.7% adult HIV prevalence)6. The analysis showed that in all three country 
contexts, PrEP is most cost-effective for FSW, for whom HIV risk is higher than all the other female 
population groups considered. 
Looking at the potential impact of PrEP population-level in reducing the greatest number of new HIV 
infections annually, the relative magnitude of potential infections averted across the 4 high-risk 
women groups differs by country context. In South Africa, PrEP has the potential to avert 
approximately 24 times the number of infections annually in AGYW as in FSW when scaled up at 
equal coverage levels, and approximately 14 and 8 times the number in women 25-34 and 35-49 
years respectively. In Zimbabwe, approximately 8 times the number of infections could be averted 
annually in women 25-34 years as in FSW, and approximately 4 and 3 times the number in AGYW 
and women 35-49 years respectively. In Kenya, approximately 3 times the number of infections 
could be averted annually in AGYW, 3 times in women 5-34 years as in FSW, and the same number in 
women 35-49 years. 
PrEP has the potential to avert significant numbers of new HIV infections annually in each of these 
countries with high HIV incidence among women, even considering low levels of PrEP program 
retention seen in among women in sub-Saharan African settings. This will necessitate PrEP being 
made widely available beyond those at highest individual risk. In each of these three countries, 
strategies for PrEP scale-up for women across risk-groups in the general population will account for 
the relative number of infections that could be averted annually between each group, resource 
availability, the potential scope for PrEP cost-reduction through economies of scale, political will, the 
potential for PrEP to be integrated into a wide range of national services and at community level to 
research each of these groups of women and other relevant contextual and cultural factors. 
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6.2  Contributions of Thesis 
The contributions of this thesis are summarised below, grouped as 1) contributions to HIV policy 
making and PrEP programming, and 2) contributions to methods. 
 
6.2.1 Contributions to HIV policy making and PrEP programming 
This thesis has demonstrated that PrEP is likely to be a beneficial HIV prevention tool for women 
across a spectrum of high HIV-risk in sub-Saharan Africa, accounting for heterogeneities in HIV risk 
factors and PrEP programme outcomes. This holds, even if reductions in condom use occur on PrEP. 
This is an important take away, given the critical need for the scale-up of new HIV prevention 
approaches to address the incredibly high levels of HIV incidence in women across a spectrum of HIV 
risk in SSA7, the concerns that behavioural disinhibition may outweigh the HIV-protective effects of 
PrEP8–12 and in view of the low levels of PrEP programme retention and drug adherence observed in 
studies to date for women at high-HIV risk in SSA13–20. 
This research guides PrEP programmers and policy makers that in high HIV burden contexts, 
reductions in condom consistency can be better tolerated by women achieving high levels of PrEP 
use-effectiveness or with low baseline condom consistencies. It has demonstrated that efforts to 
promote condom use will be especially critical for high-risk women with high levels of baseline 
condom consistency but who are anticipated to adhere less well to PrEP.  
This research has built on the work by Foss et al21 in relation to the introduction of an HIV- and STI-
efficacious microbicide, which also found that there are likely to be contexts in which reductions in 
condom use can be tolerated (depending on the efficacy and use-effectiveness of the microbicide), 
and that particular concern should be paid to individuals with high baseline levels of condom use 
anticipated to have challenges in using microbicides consistently. This thesis has gone further, 
however, in several ways. First, it explored the effect of reductions in condom consistency with two 
different partner populations of FSW, finding that condom consistency with regular partners could 
be reduced to zero, and reductions in condom consistency with clients still be tolerated whilst 
achieving 50% HIV risk reduction, with levels of PrEP use-effectiveness of at least 55%. This is of note 
given the incentives for FSW to reduce condom consistency with clients22, and challenges with 
condom use between FSW and regular partners23. It has accounted for an important element of the 
PrEP programme cascade, retention, within the Bernoulli HIV risk equation, finding that in spite of 
the low levels of retention among women observed among demonstration projects13,14,20, PrEP has 
the potential to substantially impact the annual number of new HIV infections annually among 
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women in sub-Saharan Africa. It has also explored the epidemic contexts and timeframes over which 
the results of the static model formulation hold, having accounted for the dynamics of population 
interactions (further assessment of this below). 
To help assess strategies for PrEP scale-up in resource-constrained environments beyond women at 
highest HIV-risk in sub-Saharan African society, accounting for heterogeneities in women’s risk 
factors and PrEP programme outcomes, this research has contributed a number of analytical tools, 
three country case studies and noted associated implementation considerations. It has 
demonstrated that PrEP will always be most cost-effective for those women, such as FSW, who are 
at highest HIV risk in sub-Saharan African contexts. However, to maximise the number of HIV 
infections averted at population-level, and significantly impact the HIV epidemics in SSA, PrEP will 
need to be rolled out for women within the general population.  
Having assessed PrEP roll out across 4 population groups across a spectrum of risk in SSA (AGYW, 
women 25-34 years, women 35-49 years and FSW), this research has demonstrated that strategies 
for PrEP scale-up for women across risk-groups in the general population need to be informed by 1) 
the relative number of infections that could be averted annually between each group with PrEP, 2) 
the relative cost-effectiveness of PrEP between these population groups; 3) resource availability and 
the potential scope for PrEP cost-reduction through economies of scale, and 4) the potential for PrEP 
to be integrated into a wide range of national services and at community level to reach each of these 
groups of women, as well as other relevant contextual, political and cultural factors.  
Case studies are illustrated for three countries in SSA, South Africa, Zimbabwe and Kenya, all of 
which are currently weighing PrEP roll out beyond those at highest individual HIV-risk24–26, and 
represent different implementation settings across a spectrum of HIV burden in the region7. It is 
hoped that this research will help inform in-country deliberations around PrEP scale-up. 
More generally, this research provides decision makers with a number of relatively simple analytical 
and pictorial tools to guide programming in implementation contexts. These include the simple 
analytical relations outlined in Research Paper 1 (Chapter 3) to guided assessment of the conditions 
under which reductions in condom use will be tolerated on PrEP. They also include the tools set out 
in Research Paper 3 to help PrEP implementers estimate the annual HIV incidence in women and the 
relative cost at which PrEP will be equally as cost-effective between two groups of women at 
different levels of HIV risk, using a limited set of information typically available in implementation 
settings5. Many of the static models used in this PhD could relatively easily be carried out or adapted 
by implementers with limited analytical background and limited experience with programming tools 
– for example the relatively simple Excel-based static model from Research Paper 1. 
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To the best of my knowledge this research is the first to have assessed 1) the extent to which 
behavioural disinhibition can be tolerated without increasing HIV risk following the introduction of 
PrEP, and 2) the scale-up of PrEP across high-risk women population groups in SSA, whilst 
considering heterogeneities in HIV risk factors and PrEP program outcomes. The analytical 
approaches carried out in this research could easily be adapted to assess new PrEP formulations as 
they become available27, or indeed adapted to other new HIV prevention interventions, populations 
or implementation settings.  
Finally, this research will give assurance that static models of HIV risk are likely to be robust in 
assessing the introduction of new HIV prevention interventions in high-burden settings where the 
underlying HIV epidemics are at equilibrium, especially over short-medium time horizons of up to 5 
years. There is therefore scope for static models, which are simpler to devise, parametrise and 
communicate, to be used more routinely to inform decision making in such contexts. Where such 
tools are to be implemented in contexts where the underlying HIV epidemics are still increasing, 
policy makers are advised to instead rely on dynamic modelling tools. 
 
6.2.2 Contributions to methods 
To the best of my knowledge, this research is the first to examine the extent to which the 
conclusions of static models remain robust to the incorporation of dynamic effects when considering 
the introduction of a new HIV prevention intervention, across differing time horizons and epidemic 
contexts. This methodological question was explored using the topical open question surrounding 
tolerated reductions in condom use following the introduction of PrEP8–12, and using the pertinent 
case study of FSW in inner-city Johannesburg, a population at very high levels of HIV28. 
This research has demonstrated that over short-medium time-horizons of up to five years, the static 
model approximates the outcomes of the dynamic model fairly consistently. However, over longer 
timeframes of up to 20 years, the static models may underemphasize situations of programmatic 
importance, especially in contexts where underlying epidemics are not at equilibrium. In particular, 
the model comparison found that the predictions of the static model do not hold well under the 
dynamic model formulation over longer time horizons in specific contexts - where initial condom 
consistencies are reasonably high (≥50%) and/or PrEP use-effectiveness is low (≤45%), with the 
differences greater where the underlying HIV epidemic is increasing. The difference between the 
models’ outcomes arises principally from the dynamic model’s ability to capture changes in HIV 
prevalence over time, highlighted where PrEP use-effectiveness is insufficiently high enough to mask 
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greater reductions in condom use. Importantly, the key policy conclusions made on the basis of the 
static model held well under the dynamic model formulation.  
This research will contribute to the evolving and limited literature base seeking to assess the 
minimum level of modelling complexity needed to appropriately address HIV policy questions29–31. It 
provides reassurance that in high HIV-burden contexts where the underlying HIV epidemics are at 
equilibrium, static models are sufficiently robust to inform decision making around the introduction 
of new HIV prevention interventions over short-medium time horizons. This is noteworthy 
considering the comparative advantages of simpler models outlined in this thesis, including that they 
are typically easier to communicate to, be understood and owned by policy makers; their reduced 
data requirements and speed of development compared to dynamic models; and their ease of use 
to deduce broad principles to help guide decision making3,4,30–33. 
These conclusions have direct implications for the use of existing simple static models used to guide 
decision making in HIV, in view of the epidemic context and timeframe the analysis is applied to. For 
example, it underscores the conclusions of Mishra and colleagues34 that the UNAIDS Models of 
Transmission model, used to inform HIV prevention resource allocation at country and sub-national 
levels, should be cautioned in epidemic contexts where HIV prevalence is increasing beyond very 
short timeframes.  
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6.3    Limitations 
This section focuses on overarching limitations across the body of research undertaken in this thesis. 
 
6.3.1 Accounting for uncertainty and fitting to data in Research Paper 1 
Research Paper 1 adopted a simple static model that could easily be evaluated in Excel, along with a 
very simple approach to assess parametric uncertainty, with the idea that the simplicity of the 
approach would more intuitive to and more easily understood by policy makers. This was 
undertaken by taking maximum and minimum values of each parameter from the literature and 
repeating the analyses with exclusively maximum value and exclusively minimum values, to give 
upper and lower bounds for model outcomes. The HIV risk model was not fitted to HIV incidence 
data.  
This approach to accounting for parametric uncertainty, whilst being a simple approach that was 
hoped to be intuitive to and replicable by policy makers, is rudimentary. In general, this approach 
cannot be relied upon to give true upper and lower bounds due to the interactions of non-linear 
modelling terms. More appropriate yet simple Bayesian approaches, though slightly less intuitive, 
could include assigning each parameter an underlying distribution, drawing a large number of 
samples from each, and use these parameter sets to build up uncertainty ranges around model 
outcomes. 
As the risk model was not fitted to HIV incidence data, there cannot be confidence that the specific 
numeric outcomes of the model apply well to the implementation context for FSW in inner-city 
Johannesburg. The static model adopted in Research Paper 2, which was fitted to data, did confirm 
the broad overall trends (not specific numeric values) of the static model used in Research Paper 1. 
However, simple fitting approaches could have been used, such as undertaking the refined approach 
to parametric uncertainty suggested above, and selecting only parameter sets that gave outcomes 
(in the absence of the PrEP intervention) matching estimates of HIV incidence for the population. 
 
6.3.2 Model structural uncertainty  
The uncertainty analyses undertaken in all three Research Papers overall focused more strongly on 
parametric rather than model structural uncertainty. Model structural uncertainty was accounted 
for to some extent in Research Paper 1 by exploring one vs two partner population groups for FSW 
(though the outcomes not specifically compared) and comparing the model outcomes with or 
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without accounting for STIs in the model equations. In Research Paper 2, model structural 
uncertainty was explored by assessing the model’s sensitivity to heterogeneity in the number of 
parameters. This was undertaken by removing all parameters related ART, circumcision and STIs, re-
running the analyses and comparing the conclusions. In Research Paper 3, model structural 
uncertainty explored the assumption (based on available data) that only AGYW have partners drawn 
from an older age group, and looked at how the results change if women 25-34 years were assumed 
to have partners also from the 35-49 year group. 
Where model structural uncertainty is not fully explored, this means that there cannot be 
confidence the model outcomes are not affected by the choice of model structure. One important 
model structural uncertainty analysis that could be undertaken is exploring model sensitivity to 
heterogeneity in populations and their interactions, for example, by more fully exploring multiple or 
greater age disaggregation around partner populations (where relevant) and including the 
underlying general population in models – see below for further interrogation of population 
heterogeneity. 
6.3.3 Population and demographic heterogeneity 
Population heterogeneity 
All the models developed for this research adopted simplified representations of heterogeneity in 
population groups and their interactions. For example, whilst Research Papers 1 and 3 adopted two 
partner populations for FSW, regular partners and clients, Research Paper 2 assumed only clients. In 
practice, research has shown that FSW’s partner populations usually include at least a third group, 
regular clients or boyfriends23,28,35. This is an important partner group in terms of HIV risk, as they are 
often individuals at high HIV-risk and with whom condom consistency is typically low as a reflection 
of the regular nature of the relationship23,28,35. In Research Paper 3, for the main analysis, AGYW and 
FSW are assumed to have partners drawn from two populations and women 25-34 years and 35-49 
years partners drawn from single populations each. In none of the Research Papers were other 
underlying population groups accounted for, such as women and men in the general population for 
Research Papers 1 and 2, and women and men 50+ years in Research Paper 3. Furthermore, FSW, as 
well as the three additional general population female groups addressed in Research Paper 3 are far 
from homogenous groups7,23,36–38. Though Research Paper 3 accounted for risk heterogeneity 
through uncertainty analysis, further disaggregation of these groups may reveal important trends to 
inform programming. 
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Women in serodiscordant couples were not included in within the broader definition of women at 
high HIV-risk in this research. Whilst they are at significantly elevated risk of HIV, this was 
undertaken considering that many countries are rolling out distinct programmes in conjunction with 
ART services to give PrEP to the HIV negative partner as a short-term bridge to HIV viral suppression 
in the HIV positive partner25,39–41, so many not be considered for PrEP resource allocation within the 
same category as ‘other’ high-risk women, as well as women in serodiscordant relationship’s 
comparatively improved outcomes through the PrEP programme cascade vis-à-vis other groups of 
high-risk women42,43. This was a subjective choice, and it could be argued that women in 
serodiscordant relationships should have been included in the group of women defined as at high 
HIV-risk for the purposes of the analyses undertaken. The models adopted across the Research 
Chapters could easily be adapted to include women in serodiscordant relationships in future work. 
In reality, individuals at risk have partners drawn from many different populations, and by not 
accounting for these heterogeneous populations and their partner formations, important routes of 
HIV transmission may be under accounted for, and therefore the research may fail to bring out 
important groups to be prioritized for HIV prevention interventions. The level of population 
heterogeneity accounted for in a model is a difficult balance between addressing important 
populations for programming, with availability of data to parameterise these groups and their 
interactions. It must also consider the ability of policy makers and implementers to implement 
recommendations that in reality may be too focused on narrow population groups that are either 
difficult to identify in practice or by doing so risks having adverse effects such as perpetuating stigma 
around narrowly defined risk groups. 
 
Demographic heterogeneity 
This research also has limitations in the demographic heterogeneity accounted for. First, the 
research has focused on countries in South and East Africa, due to their comparative elevated levels 
of HV burden at population level, but not addressed any case studies from west and central Africa. 
Nonetheless there are many female populations at high HIV-risk in west and central Africa, who 
could perhaps benefit through such modelling to inform policy making around PrEP. It would also be 
interesting to compare the conditions under which static models are sufficiently robust to inform 
policy making around the introduction of a new HIV prevention intervention for high-risk women, as 
undertaken in Research Paper 2, but in the context of lower-HIV burden settings. 
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Additionally, HIV epidemics are incredibly diverse at sub-national levels, and in many settings, down 
to the level of localities of hundreds of metres, such as the fishing communities on the shores of 
Lake Victoria, where the transactional practice of sex-for-fish is a significant driver of HIV 
transmission44,45. Whilst the research of Research Papers 1 and 2 were undertaken in a specific 
geographic location (Hillbrow in inner-city Johannesburg), the settings for Research Paper 3 were at 
national level. Whilst this was undertaken to inform dialogue at national levels, and the models can 
be easily tailored to more specific geographies. However, doing so risks conclusions being made on 
the basis of population averages and applied to settings with very different epidemiologic, as well as 
other risk factor, realities. For example, in Kenya, at county level alone (a low level of demographic 
disaggregation), the county with the highest average adult HIV prevalence, Siaya (21.0%), has 
prevalence levels 210 times higher than the county with the lowest  average adult HIV prevalence, 
Wajir (0.1%) (2018 estimates)46. 
 
Both these issues of population and demographic heterogeneity are part of a wider challenge in the 
use of mathematical models to inform policy making and programme implementation – that models 
are always a simplified version of reality, and therefore always wrong. The underlying tension in use 
of models to inform decision making in reality is the need to capture sufficient heterogeneity, as well 
as complexity, to accurately reflect the question and context at hand, with the availability of reliable 
data to parameterise models, as well as models and their conclusions being well understood and 
adopted by decision makers, and their outcomes being sufficiently specific, but not too specific to be 
applied in view of the realities of implementation contexts. 
 
6.3.4 Static models and downstream effects of interventions 
As stated throughout the Research Papers, use of static models limits the assessment of the effect of 
an intervention (in this case PrEP) to the population for whom risk is being assessed. Static models 
do not capture the downstream effects of interactions between populations and therefore cannot 
make deductions about the effect of PrEP being taken by a high-risk woman on infections averted in 
their partner populations. In fact, all three Research Papers (including Research Paper 2 which 
compares the outcomes of static and dynamic models) do not assess secondary infections averted in 
partner and wider population groups as a result of PrEP for high-risk women. This is a limitation as 
deductions are made only on the basis of assessing primary, rather than secondary, or even tertiary 
infections prevented. 
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6.3.5 Data availability  
A significant challenge and limitation in parametrising the models in all three Research Papers has 
been the availability, as well as age, of data. Much sexual behaviour data is limited by being self-
reported and therefore subject to under-reporting47,48. Many national surveys (such as demographic 
health surveys) report important data categorically (e.g percentage of women who have 2+ partners 
in the last 12 months49), making it difficult to derive meaningful parameter ranges (e.g. in this case, 
the of the numbers of partners over the last 12 months). Data is not always available disaggregated 
by the three female general population groupings used in Research Paper 3 for all parameters and all 
countries. For example, in Research Paper 3, data to parametrise Zimbabwean AGYW’s number of 
sex acts a year with both partner groups had to be parameterised using South African data, due to 
lack of data availability for their Zimbabwean counterparts.  
Data to parameterise key populations, in this case FSW, is limited by age, as well as under- reporting 
in all three implementation contexts explored. The population most challenging to parametrise are 
the clients of sex workers, as there is very little data on them as a distinct group in these contexts. As 
such, data gaps were filled by relying on data from long-distance truck drivers and male migrant 
worker populations, population groups which are known clients of FSW in these settings50,51. 
PrEP programme cascade data, in particular retention and adherence data is limited by availability in 
SSA for women, especially non-FSW general population groups. At the time of undertaking research 
for the first Research Paper, no data were available for women relating the numbers of weekly PrEP 
doses to levels of HIV risk reduction, so data for MSM and TGW was relied on in the model 
interpretation, which has since been shown to be unrealistic, since women require higher levels of 
PrEP drug levels to achieve the same levels of HIV risk reduction as men52. To date, there is still not 
the same level is disaggregation available for women, as for men, relating number of daily PrEP 
tablets to levels of HIV risk reduction. Also, at the time of undertaking Research Paper 1, no data 
were available relating PrEP cascade factors in general to levels of HIV risk reduction for female 
populations (other than the early RCTs which were stopped early for futility, assumed owing to lack 
of adherence53). Accordingly, the model accounted only for levels of HIV-risk reduction, assumed to 
be associated with unknown levels of PrEP adherence, but in nomenclature this also should have 
referred to other programme cascade factors including retention and uptake. 
Finally, data for fitting models to HIV prevalence and incidence is limited by age, in particular in 
Kenya. As the population-based HIV impact assessment (PHIA) surveys54 are further rolled out over 
the coming years across countries in SSA, updated data will become available. Altogether the 
challenges in availability and them being up-to-date limits the accuracy of the model results.  
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6.4      Key area not addressed through research: structural factors 
Role of structural factors in HIV prevention for high-risk women in SSA 
Structural factors are important drivers of HIV in women in sub-Saharan Africa. At a macro-level 
these drivers arise due to harmful social and economic policies and conditions, cultural norms, 
religious practices, political and legal factors55,56. At community-level these drivers affect women’s 
access to education, economic opportunities and healthcare, affect societal gender norms, 
perpetuate stigma and lead to power imbalances between men and women55,56. At an individual 
level, these factors contribute to HIV acquisition through women engagement in transactional sex 
and sex work, gender-based violence, lack of agency to negotiate partner selection and sex, safe sex, 
uptake of health and HIV prevention services and interventions (such as condoms or PrEP, or the 
treatment of STIs)55,56. 
It is incredibly difficult to assess the contribution of structural factors to HIV transmission, or indeed 
the relative contribution of structural factors versus other behavioural and epidemiologic risk 
factors. Researchers including Remme et al57,58, Shannon et al59 and Cluver et al60,61 have done some 
impressive, formative work to assess the potential impact of one or more concurrent structural 
interventions to address predominantly individual-level as well as community-level structural drivers 
of HIV women (including cash transfers, gender empowerment programmes, free school meals, 
violence reduction programmes) across a spectrum of women at high HIV risk, including AGYW and 
FSW. Their studies report the potential impact and cost-effectiveness of such interventions 
according to epidemic context, as well as the multiplicative impact and cost benefits of more than 
one structural intervention concurrently implemented. They note the additive impact of these 
interventions on outcome and impact indicators of importance to other development sectors 
prioritized in the SDGs62, such as education, economic development and social protection, or to 
other sectors within health, including sexual and reproductive health, mental health, and a wide 
range of communicable diseases57–61. 
At present, the majority of normative core HIV prevention interventions focus on biomedical 
approaches (such as VMMC, ART, PEP, condoms, harm reduction services), including the mainstay of 
UNAIDS’s five pillar programmes of HIV prevention63, with PrEP being the newest addition. In the 
policy space, it is comparatively easier to justify HIV prevention funding for biomedical rather than 
structural interventions, as their effect on individual HIV risk is well documented, their effect 
typically easier to quantify through intervention trials, and they tend to be more straightforward to 
implement64–67. When rolled out at wide scale through implementation programmes, the impact of 
biomedical interventions can be more directly measured over short time horizons (e.g. VMMC 
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performed, condoms delivered, viral suppression due to ART), making them easier for international 
donors and domestic politicians to justify to their funders and funding bases64–67. By contrast, 
structural interventions to affect macro-level policy and cultural change can take many years, and 
their effect difficult to attribute and quantify55,56. Indeed, the majority of donor financing for HIV is 
spent on biomedical interventions68,69. However, biomedical interventions tend address the 
proximate symptoms of the drivers of HIV, not their upstream causes. 
Through my time spent working on HIV prevention programmes in Kenya and South Africa, as well as 
through keen interest in the literature, it has been my overwhelming sense that structural factors, 
have perhaps the greatest influence on HIV acquisition among women in SSA. However, as a policy 
maker, I have repeatedly felt under-equipped with concrete, numerical evidence to make the case 
for the importance of addressing structural factors and for structural programmes to be scaled up at 
global, national and local levels. 
If I were to undertake research again to address the disproportionate HIV incidence among women 
across a spectrum of risk in SSA using mathematical modelling, I would therefore focus on structural 
factors where there is a comparative paucity of evidence55. Specifically, I would aim to contribute to 
quantification of the effect of structural factors at macro-, community- and individual-levels on HIV 
transmission, as well as the potential impact and cost-effectiveness of structural interventions to 
address these drivers, looking across the HIV, health and wider development sectors in assessing the 
contribution of structural interventions to broader global development goals62. I would especially 
focus on interventions to address macro-level factors, since these are the origin of structural drivers 
down to individual level55 and have been comparatively under-explored compared to individual- and 
community-level drivers55,67,66. Modelling could also be used to assess the complementarity of 
structural interventions to support and enhance the use of PrEP to address HIV risk among women 
across a spectrum of risk in SSA.  
This modelling could be done in conjunction with trials or demonstration projects, or as standalone 
research, by algebraically characterising the effect of structural interventions upon relevant parts of 
the HIV risk equation and prevention cascade, as well as equivalent risk equations and cascades for 
the health and cross-sectoral outcomes under exploration. For example, in the case of HIV, certain 
structural interventions could be considered to act upon condom use, the rate of partner change, 
the basic risk of transmission (e.g. if it reduces the risk of physiological trauma through 
intercourse70), the prevalence of HIV and STIs in partner populations (e.g. if it affects the population 
from which partners are drawn), and PrEP programme cascade metrics (e.g. uptake, retention and 
adherence). In the absence of empirical data to parametrise models, potential impact ranges for 
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structural interventions could be derived by simulating parameters across data ranges elicited 
through expert opinion71–73. Considering the outcomes of Research Chapter 2, if this research were 
applied to contexts where the underlying epidemics are stable among relevant partner populations, 
and the structural interventions deemed to affect change over shorter time horizons (such as 
through individual-level empowerment programmes, which have demonstrated behavioural changes 
over a number of months55), this modelling could be undertaken using static risk equations. 
Otherwise, and especially for structural interventions that affect change of longer time horizons 
(such as certain legal or policy changes55), dynamic models will be more appropriate. 
Having done so, I would then be able to equip myself with a stronger evidence for making the 
appropriate case in my work for the prioritization of resources for interventions to address macro-, 
community- and individual-level structural factors, through the HIV sector, as well as in conjunction 
with other sectors, to address the unacceptably high burden of HIV incidence among women in SSA, 
as well as in other populations and geographies globally.  
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6.5      Areas for further research 
Considering the aims and results of this thesis’s research, its limitations and the outlined area of 
research not addressed by this thesis, the following are suggested areas for further research. These 
areas of research are grouped as research to inform HIV policy making and PrEP programming, and 
research to inform methods. 
 
Research to inform HIV policy making and PrEP programming 
- The dynamic model formulation set out in Research Paper 2 could be refined to assess the 
potential effects of community behavioural disinhibition following the introduction of PrEP for 
high-risk women in SSA. Whilst community-level behavioural disinhibition has thus far only been 
reported in MSM communities2, the fact that few PrEP OLE, demonstration and implementation 
projects among women in SSA have been completed and reported results to date, means this 
cannot be ruled out as a potential consequence of PrEP introduction for women across a 
spectrum of risk in SSA. 
- The potential effects of behavioural disinhibition in relation to strategies for intermittent (rather 
than daily) PrEP use among women at high risk of HIV in SSA could be explored using either the 
static or dynamic model outlined in Research Papers 1 and 2, depending on whether the 
timeframe for evaluation is up to 5 years, or longer. 
- The South Africa, Zimbabwean and Kenyan case studies outlined in Research Paper 3 could be 
further refined with in-country policy makers in the context of country-specific HIV prevention 
or PrEP budgets, considering the actual scope for PrEP cost-reduction through economies of 
scale, the potential for PrEP integration into a wide range of national services and at community 
level, and relevant contextual, political and cultural factors in order to finalise in-country 
strategies for PrEP scale-up. 
- The methods outlined in Research Paper 3 could be used to assess strategies for PrEP scale-up 
in other country contexts or across other populations at risk of HIV. This could be undertaken by 
policy makers, requiring only limited support from modellers. The models could be applied 
across contexts with greater population and geographic heterogeneity to evaluate PrEP scale-up 
across more narrowly defined risk groups and geographic locations.  
- The methods outlined in Research Paper 3 could also be applied to assess strategies for the 
scale-up of newer, long-acting PrEP formulations, such as microbicides, injections and implants. 
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Given that longer-acting formulations intend to improve PrEP program outcomes by 
strengthening critical stages of the PrEP cascade, such as uptake and retention74–76, it will be 
important that these cascade stages are reflected in the model equations. The model equations 
would need be adapted to include, for example, PrEP uptake, in addition to retention and use-
effectiveness. 
 
Research to inform methods 
- The static versus dynamic model comparison undertaken in Research Paper 2 could be repeated 
in lower-HIV burden contexts, such as west and central Africa, or concentrated epidemic 
settings, such as in the relevant Asian and eastern and central European settings, to assess the 
broader epidemic conditions under which static models are sufficiently robust to inform policy 
making around the introduction of a new HIV prevention intervention for populations at risk of 
HIV. 
- The static versus dynamic model comparison undertaken in Research Paper 2 could be explored 
in the context of declining epidemics in underlying population groups, for applicability to 
current and future contexts where the epidemics are on a trajectory to decline. Extrapolating 
the conclusions of Research Paper 2, I would hypothesise that the changing rates of HIV 
prevalence in declining epidemics would mean that beyond short timeframes, dynamic models 
are most appropriate for estimating the impact of new HIV interventions. However, this would 
need to be confirmed through such research. 
- The mathematical properties of the static and dynamic models in Research Paper 2 could be 
compared to further understand the differences in model limit behaviour. For example, the 
basic reproduction number could be derived for the dynamic model based on first principles 
and for the static model based the intuitive approach (as outlined in the section on static vs 
dynamic models in the Background chapter) to determine the relationship between equilibria 
states; compare what they highlight about epidemic control efforts; and understand the extent 
to which the dynamic model is controlled by model parameters versus initial conditions. 
- The static versus dynamic model comparison undertaken in Research Paper 2 could be applied 
to other infectious diseases, such as tuberculosis, where there is a more limited understanding 
of transmission dynamics, and thus harder to meaningfully build and parameterise dynamic 
transmission models. Should there be contexts in which static models are sufficiently robust to 
inform policy making for these diseases, this information would support policy makers and 
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modellers in building and adopting simpler models for decision making, which may be less data 
and time intensive and therefore cheaper to devise, and more user friendly. 
- The role of model complexity could be explored in relation to other methodological attributes 
considered in model development to inform HIV policy making. One such example would be to 
explore the contexts in which discrete models are sufficiently robust in relation to their 
continuous counterparts. This would be an interesting study, since simple discrete models (such 
as those in the family of SIR models) can be evaluated using simple computing tools, such as 
excel, by counting the number of individuals in each compartment after each time step. 
Equivalent matched models evaluated in continuous time, however, require the use of more 
advanced programming approaches, as well as adopting more complex methodological 
approaches (such as advanced calculus), for model solving, with which policy makers may be 
less comfortable. If such studies were undertaken across a range of model attributes, this would 
allow for an overall framework to be developed to guide policy makers and modellers around 
the minimum level of modelling complexity need to appropriately inform decision making in HIV 
and beyond. 
- Rather than looking at the barriers to use of models to inform policy making from a model 
structure point of view, research could be undertaken to explore the barriers and best-practice 
approaches for effectively communicating models of all levels of complexity through 
approaches that encourage policy maker understanding, ownership and uptake. 
- The results of Research Paper 2 could be further verified through other types of model 
structural uncertainty analyses, for example by exploring whether further population 
heterogeneity affects the Research Paper’s conclusions, e.g. by accounting for FSW regular 
partners and boyfriends in addition to clients, as well as men and women in the general 
population. 
- Modelling approaches could be developed to quantify of the effect of structural factors at 
macro-, community- and individual-levels on HIV transmission, as well as the potential impact 
and cost-effectiveness of structural interventions to address these drivers, particularly the 
under-explored area of macro-level structural drivers. Impact and cost-effectiveness could 
usefully be assessed beyond the HIV sector alone, across other health and non-health sectors, 
to assess the contribution of structural interventions to broader global development goals62. 
The models developed through this research could be adapted to assess the complementarity of 
structural interventions to support and enhance the use of PrEP to address HIV risk among 
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women across a spectrum of risk in SSA. This modelling could then be used to inform resource 
allocation across sectors at global, national and sub-national levels. 
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6.6      Conclusion 
PrEP is likely to be of benefit in reducing HIV risk in women across a spectrum of HIV-risk in sub-
Saharan Africa, even if reductions in condom use occur. This conclusion is made having accounted 
for heterogeneities in women’s HIV risk factors and PrEP programme outcomes, including the low 
levels of PrEP programme retention and adherence reported in studies. PrEP will be most cost-
effective for individuals at great HIV risk, such as FSW. However, it has potential to significantly 
reduce the number of new infections at population-level if made widely available beyond those at 
highest individual risk, including to women in the general population. Strategies for PrEP scale-up 
will need to weigh the potential cost-effectiveness and population-level impact of PrEP with the 
potential for PrEP integration into a wide range of national services and at community level, in order 
to significantly bring down the costs and improve cost-effectiveness in resource-constrained 
environments.  
Static models can be sufficiently robust to inform policy making around the introduction of new HIV 
prevention interventions in high HIV-burden settings over short-medium time horizon of up to 5 
years, where underlying HIV epidemics have reached equilibrium. Over longer timeframes, and in 
contexts where the underlying HIV epidemics are still evolving (other than over short time horizons 
of less than a year), static models may under-emphasize situations of programmatic importance and 
dynamic models will be more appropriate to guide decision making. 
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Appendix 1: Ongoing, planned and completed PrEP OLE, demonstration and implementation 
projects among women in Sub-Saharan Africa 
Ongoing, Planned and Completed PrEP Open Label, Demonstration and Implementation Projects in Women in Sub-Saharan Africa                                                                                                                                                                                     
Trial/Project Sponsor/ Funder Type/Category Location Population Design/Key questions Status 
Status 
Details 
HPTN 082: 
Evaluation of daily 
oral PrEP as a 
primary prevention 
strategy for young 
African women: A 
Vanguard Study 
Wits RHI, 
HPTN; 
DAIDS, 
NIAID, NIMH 
Demonstration 
Project 
South Africa; 
Zimbabwe 
AGYW aged 
16-25 years 
The goal of this study is to evaluate whether HIV-
uninfected sub-Saharan African women ages 16-25 who 
are at high risk for HIV infection will initiate PrEP and 
achieve sufficient adherence using scalable adherence 
support interventions to achieve HIV prevention benefits 
from this promising biomedical prevention intervention. 
Ongoing Ongoing; 
started June 
2016. 
Expected 
completion 
October 
2018. 
MTN-034/IPM 
045/REACH 
MTN; IPM; 
NIH; NIAID, 
NIMH, 
NICHHD 
Clinical Trial South Africa, 
Kenya, 
Zimbabwe, 
Uganda 
AGYW aged 
16-17 years 
Participants will be randomized to product sequence and 
will use a silicone elastomer vaginal matrix ring (VR) 
containing 25 mg of dapivirine (DPV) to be replaced each 
month for a total period of 6 months of use, as well as take 
oral emtricitabine/tenofovir (FTC/TDF) tablets daily for a 6 
month product use period. The primary purpose of this 
trial is to collect safety and adherence data over the course 
of study product use. The study will also examine the 
acceptability of the study products. 
Ongoing Ongoing; 
started 
January 
2019. 
EMPOWER 
(Enhancing Methods 
of Prevention and 
Options for Women 
Exposed to Risk) 
Consortium 
Wits RHI, 
LSHTM; 
USAID 
Demonstration 
Project 
South Africa, 
Tanzania 
AGYW aged 
16-24 years 
An initiative of STRIVE, a research consortium investigating 
the social norms and inequalities that drive HIV, that 
integrates violence prevention and combination 
prevention, including PrEP. Aims to assess whether it is 
feasible, acceptable, and safe to offer oral PrEP as part of a 
combination prevention package that addresses gender-
based violence (GBV) and HIV. 
Completed Completed; 
ended 
December 
2017. 
IMPAACT 2009 
(DAIDS ID 30020): 
Pharmacokinetics, 
Feasibility, 
Acceptability and 
Safety of Oral Pre-
Exposure 
Prophylaxis for 
International 
Maternal 
Pediatric 
Adolescent 
AIDS Clinical 
Trials 
(IMPAACT) 
Network 
Observational 
study 
Zimbabwe, 
South Africa, 
Malawi, Uganda 
AGYW aged 
16-24 years 
Parallel, observational cohort study of HIV-uninfected 
pregnant adolescents and young women (aged 16-24). The 
study is designed to characterize adherence over time 
among women who initiate once daily oral PrEP during 
pregnancy and continue in the first 6 months following 
delivery, and to compare pregnancy outcomes among 
women who take PrEP and women who decline PrEP 
during the antenatal period. 
Ongoing Ongoing; 
started 
February 
2019. 
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Primary HIV 
Prevention during 
Pregnancy and 
Breast Feeding in 
Adolescents and 
Young Women 
POWER (Prevention 
Options for Women 
Evaluation Research) 
University of 
Washington 
ICRC, 
Carnegie 
Mellon, 
DTHF, 
Harvard U., 
KEMRI, RTI, 
Wits RHI; 
USAID 
Demonstration 
project 
Kenya, South 
Africa 
AGYW aged 
16-24; women 
25-29 years 
Assesses women’s preferences for using microbicides and 
PrEP through demonstration projects with strategic pilots 
of delivery strategies, first with oral PrEP. Project will 
characterize choice, uptake, early adherence and identify 
cost-effective delivery models, including assessment of 
repeat HIV testing, decision-making within partnerships, 
and the interface with reproductive health services. 
Ongoing Ongoing; 
started July 
2015. 
Expected 
completion 
June 2020. 
CAPRISA 082: 
Prospective Study of 
HIV Risk Factors and 
Prevention Choices 
in Young Women in 
KwaZulu-Natal, 
South Africa 
USAID; 
CAPRISA 
Observational 
study 
South Africa AGYW aged 
18-24; women 
25-30 years 
Observational study looking at: 1) demographics, 2) HIV 
risk perception and behavioural assessment, 3) 
acceptability assessment of expanded HIV prevention 
options. Data on PrEP uptake, adverse events, usage, 
barriers, PrEP cycling, adherence by pill count and drug 
levels will be collected. 
Completed Completed; 
study closed 
February 
2018. 
CAPRISA 084: A 
demonstration 
project of daily oral 
PrEP as part of 
sexual reproductive 
health 
services for young 
women at high risk 
of acquiring HIV in 
KwaZulu- Natal 
USAID; 
CAPRISA 
Demonstration 
project 
South Africa AGYW aged 
18-24; women 
25-31 years 
This PrEP demonstration project will identify in two high 
HIV burden districts in KwaZulu-Natal: who is likely to use 
PrEP; how PrEP will be used (understanding pill taking 
practices); barriers to consistent adherence; how PrEP will 
change current behavioural practices for HIV prevention 
(risk compensation); and what support and training is 
required for service providers. 
Completed Completed; 
study closed 
November 
2018. 
Gender-Specific 
Combination HIV 
Prevention for Youth 
in High Burden 
Settings (MP3-
Youth) 
NIH Demonstration 
Project 
Kenya AGYW, 
adolescent 
men 
To evaluate the feasibility and acceptability of a gender-
specific combination HIV prevention package for youth in 
high burden settings. The study aims to pilot a combination 
package of gender-specific interventions in western Kenya 
in a mobile health delivery format using integrated services 
delivery. Interventions include: Male-Specific Intervention 
Package (HIV counselling and testing; facilitated linkage to 
Completed Completed; 
study closed 
April 2016. 
 
 
226 
 
care for HIV-positive; condoms; VMMC); Female-Specific 
Intervention Package (HIV counselling and testing; 
facilitated linkage to care for HIV-positive; 
contraception/family planning; PrEP; conditional cash 
transfer). 
Church of Scotland 
Demonstration 
Project 
Church of 
Scotland 
Hospital 
Demonstration 
Project 
South Africa Adolescent 
girls, Pregnant 
Women 
Aims to recruit pregnant teenagers at their first ANC visit 
and enrol them into comprehensive support program, 
including PrEP, with the aim of improving outcomes for the 
mothers and babies.  Central focus will be assisting young 
mothers to return to school, prevent acquisition of HIV and 
postponing further pregnancies. Other adherence 
strategies will be investigated as well. 
Planned Planned. 
PrEP 
Implementation for 
Mothers in 
Antenatal Care 
(PrIMA) 
NIH, NIAID Cluster 
randomized 
controlled trial 
Kenya Adolescent 
women, 
women, 
serodiscordant 
couples 
This cluster randomized controlled trial aims to determine 
the best model for optimized PrEP delivery in pregnancy by 
using existing highly accessed MCH systems as a platform 
for efficiently delivering PrEP to pregnant women. 
Twenty ANC clinics in Western Kenya (Siaya and Homa Bay 
counties) were randomized, ten to universal and ten to 
targeted PrEP administration. 
Overall, 4000 women will be enrolled (200 women per 
clinic) and followed through nine months postpartum. The 
primary outcome is HIV incidence at nine months 
postpartum and additional outcomes (PrEP uptake, PrEP 
continuation and adherence). We are also collecting data 
on psychosocial factors that may influence uptake, 
adherence, and retention, birth and infant outcomes, 
partner HIV-status knowledge, and sexual behaviour 
information. 
Ongoing Ongoing; 
started in 
May 2016. 
Expected 
completion 
June 2020. 
3Ps for Prevention 
Study (Perception, 
Partners, Pills) 
DTHF; 
University of 
Washington; 
funded by 
NIMH, 
BMGF 
Demonstration 
project 
South Africa AGYW Demonstration project in Masiphumilele (Cape Town) 
assessing uptake to oral PrEP and effect of conditional 
incentives based on drug levels on adherence to oral PrEP. 
Through BMGF supplemental funding, PrEP demand 
creation campaign is being developed with McCann South 
Africa and PrEP uptake will be enumerated. 
Ongoing Ongoing; 
started 
February 
2017. 
DREAMS PEPFAR, 
BMGF, Nike 
Foundation 
Implementation 
Project 
Kenya, South 
Africa, eSwatini, 
Uganda, 
Lesotho, 
Tanzania, 
AGYW Partnership to reduce HIV infections among AGYW; 
extends beyond health sector to address poverty, gender 
inequality, sexual violence, lack of education; PrEP 
implementation component included. 
Ongoing Ongoing. 
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Zambia, 
Zimbabwe 
Monitoring Pre-
Exposure 
Prophylaxis in Young 
Adult Women 
(MPYA) 
NIMH Demonstration 
Project 
Kenya AGYW This protocol describes a longitudinal study of young 
Kenyan women at high risk for HIV who will be offered HIV 
pre-exposure prophylaxis (PrEP) for up to two years. 
Adherence will be monitored in all women with the next 
generation Wisepill; half will be randomized to receive 
short message service (SMS) reminders. The technical 
function, acceptability, cost, and validity of the next 
generation Wisepill device coupled to SMS reminders will 
be determined among this cohort of young Kenyan 
women. Additionally, SMS will be used for longitudinal 
assessment of risk perception and its alignment with PrEP 
adherence. 
Ongoing Ongoing; 
started June 
2016. 
Expected 
completion 
May 2020. 
MSF AGYW PrEP 
Demo Program 
MSF Open Label 
Study 
South Africa AGYW Clinic-based SRH club for delivery of PrEP to young women 
in Khayelitsha. 
Ongoing Ongoing; 
started June 
2017. 
Choices For 
Adolescent Methods 
Of Prevention In 
South Africa 
(CHAMPS) 
NIAID Demonstration 
Project 
South Africa AGYW, 
Adolescent 
Men 
CHAMPS consists of three pilot projects: three pilots: 
MACHO interrogates adolescent men’s attitude to 
circumcision; Pluspills investigates PrEP; UChoose 
investigates preferred types of prevention utilizing 
contraception as the surrogate in 16-17 year-old women. 
Completed Completed; 
still 
providing 
PrEP. 
I-TECH DREAMS 
Project 
CDC/PEPFAR Implementation 
Project 
Namibia AGYW, 
Pregnant 
women 
I-TECH, International Training and Education Center for 
Health at the University of Washington, is funded by 
CDC/PEPFAR to implement a DREAMS- like intervention in 
two regions of Namibia. The DREAMS-like intervention 
includes provision of PrEP to 15-24 year old AGYW. 
Ongoing Ongoing; 
started 
October 
2017. 
Expected 
completion 
February 
2019. 
PrEP 
Implementation in 
Young Women and 
Adolescent girls- 
DREAMS Innovation 
Challenge (PrIYA) 
DREAMS 
managed by 
JSI  
Implementation 
Project 
Kenya AGYW, 
Pregnant 
women 
PrIYA is an implementation project to integrate delivery of 
oral PrEP in Maternal and Child Health and Family Planning 
clinics and to evaluate how to efficiently reach women who 
might benefit from PrEP. PrIYA is funded through the 
DREAMS Innovation Challenge. 
Completed Completed 
March 
2019. 
UNICEF PrEP Demo 
Program 
UNITAID Demonstration 
Project 
Brazil, South 
Africa, Thailand 
Sexually active 
adolescents 
Combination HIV prevention interventions including oral 
PrEP. 
Planned Planned. 
PEPFAR PEPFAR Implementation 
Project 
17 Countries in 
SSA, 3 Asian, 2 
At risk 
individuals 
Provides PrEP to adults and adolescents at risk of HIV 
infection. 
Ongoing Ongoing. 
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Caribbean, 1 
European 
LVCT Health and 
SWOP Kenya (IPCP-
Kenya) 
LVCT, SWOP; 
WHO, 
UNAIDS, 
Georgetown, 
LSHTM, 
Imperial 
College; 
funded by 
BMGF 
Demonstration 
Project 
Kenya FSW (18 and 
older), MSM 
(18 and older), 
young women 
at high HIV risk 
(15 -29) 
Introduces PrEP to combination prevention interventions. 
Feasibility study assessing consumer perceptions, cost, 
delivery options, potential barriers and opportunities for 
introduction and adherence completed. Acceptability 
among target populations, cost, menu of combination 
interventions and feasible delivery options established. 
Delivers PrEP as part of combination prevention to 2,100 
participants over 12 months in preliminary stages. The 
project will define criteria for PrEP indication among 
targeted populations, adherence strategies, health system 
requirements and model impact of PrEP  in Kenya. 
Completed Completed 
October 
2017. 
Benin 
Demonstration 
Project with CHU de 
Québec (Canada) 
BMGF Demonstration 
Project 
Benin FSW To assess feasibility and usefulness of integrating TasP and 
PrEP to combination prevention package offered to FSWs 
in Benin; identify best way to successfully implement TasP 
and PrEP in this setting and to ensure their adoption by 
national policymakers as part of the HIV prevention 
package for FSWs. 
Completed Completed; 
still 
providing 
PrEP. 
Senegal 
Demonstration 
Project with Reseau 
Africain De 
Recherche Sur Le 
Sida, University of 
Washington, and 
Westat 
BMGF Demonstration 
Project 
Senegal FSW Two phase project including a formative research phase 
followed by a prospective study of PrEP with TDF/FTC to 
assess changes in HIV incidence and prevalence in FSW 
followed at IHS, and Pikine, Mbao, Rufisque and 
Diamniadio Health Centers over 12 months during the 
implementation of PrEP and compare that to detailed 
historical data in this population dating back to 1985. 
Completed Completed; 
ended 
December 
2016. 
The TAPS 
Demonstration 
Project 
BMGF Demonstration 
project 
South Africa FSW Evaluates whether oral PrEP and immediate treatment can 
be rolled out within a combination prevention and care 
approach tailored to needs of 400 HIV-negative and 300 
HIV-positive FSW. Study sites include Hillbrow and Pretoria. 
Completed Completed; 
no longer 
providing 
PrEP to 
former 
participants. 
Sisters Antiretroviral 
therapy Programme 
for Prevention of 
HIV 
–an Integrated 
Response (SAPPH- 
Ire)
DFID; UNFPA Demonstration 
Project 
Zimbabwe FSW, AGYW Seeks to enhance HIV treatment and prevention among 
highway-based sex workers at 7 sites by increasing uptake 
and frequency of testing, demonstrate acceptability and 
feasibility of delivering PrEP, maximize retention in care, 
promote timely initiation of ART for those eligible, and 
maximize adherence to both ART and PrEP. The evaluation 
will be in a representative population-based sample of 
Completed Completed. 
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2,800 sex workers, with an estimated 1,000 to 1,500 
targeted to take PrEP, after 18 months. 
LINKAGES Malawi PEPFAR, 
USAID 
Demonstration 
Project 
Malawi FSW, MSM TBD Ongoing Ongoing. 
Pangaea SHAZ! Hub 
Drop-in Centre 
PEPFAR Implementation 
Project 
Zimbabwe FSW, Young 
Women Who 
Sell Sex, MSM, 
TGW, 
Adolescents, 
Women, Men 
Serodiscordant 
Couples, 
Pregnant 
women 
This is a youth drop-in centre based in Chitungwiza (30km) 
from the capital, Harare. The site also serves as a research 
site. 
Ongoing Ongoing. 
Bridge to Scale 
Implementation 
Project (Jilinde 
Project) 
BMGF, 
Jhpiego 
Implementation 
Project 
Kenya FSW, MSM, 
AGYW, 
Discordant 
Couples, 
General 
population, 
PWID 
This project aims to outline and demonstrate an effective 
model for Pre- exposure Prophylaxis (PrEP) scale-up as an 
HIV-prevention intervention in low-resource settings. 
Ongoing Ongoing; 
started 
November 
2016. 
MSF Swaziland PrEP 
Demonstration 
Project 
MSF Demonstration 
Project 
eSwatini FSW, MSM, 
TGW, TGM, 
Adolescents, 
Women, Men, 
Serodiscordant 
couples 
This study is working to expand the evidence base related 
to the feasibility, acceptability, and tolerability of daily oral 
pre-exposure prophylaxis (PrEP) among key populations in 
Eswatini. 
Ongoing Ongoing; 
started 
September 
2017. 
Results 
expected 
June 2019. 
Expanding Options 
for HIV Prevention 
Through Pre- 
exposure 
Prophylaxis in 
Hhohho Region, 
Swaziland 
(Sihlomile) 
Heidelberg 
Institute of 
Public 
Health; 
Mylan 
Demonstration 
Project 
eSwatini FSW, MSW, 
MSM, 
TGW, AGYW, 
Adolescent 
Men, High Risk 
Women & 
Men, 
Serodiscordant 
couples 
An 18-month observation cohort study with the overall aim 
to assess the operationalization of oral Pre-exposure 
prophylaxis (PrEP) in Swaziland as an additional HIV 
combination prevention method among population groups 
and individuals at high risk of HIV infection. 
Ongoing Ongoing; 
started 
August 
2017. 
Expected 
completion 
January 
2019. 
SAUTI USAID, 
PEPFAR 
Demonstration 
Project 
Tanzania FSW, 
Serodiscordant 
couples, 
The aim of the proposed project is to generate data on the 
implementation models, uptake, feasibility and 
acceptability HIV self-testing and PrEP in Tanzania through 
Ongoing Ongoing; 
started 
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partners of 
FSW 
community services provision to inform future policy and 
program development. The project goal is to achieve the 
UNAIDS first 90, and ensure populations with high risk of 
acquiring HIV remain negative.  This project will target 
KVPs in selected areas. 
October 
2017. 
LINKAGES Swaziland: 
Providing Access to 
HIV Pre Exposure 
Prophylaxis (PrEP) 
for those at High 
Risk in Swaziland 
PEPFAR, 
USAID 
Demonstration 
Project 
eSwatini FSW, Women, 
Men, MSM, 
TGW, TGM, 
AGYW, 
Adolescent 
men, 
Serodiscordant 
couples 
Rates of HIV remain high among women in general, as well 
as key populations such as, adolescent and young women, 
FSW and men who have sex with men. PrEP for HIV 
prevention represents a new option for those at high risk 
and vulnerable to HIV infection to protect themselves from 
HIV. This study proposes to offer PrEP to key populations 
and people at high risk of HIV infection through existing 
service platforms through a demonstration project to 
determine whether it can be scaled up in a national 
programme. 
Ongoing Ongoing; 
started June 
2017. 
Expected 
completion 
January 
2019. 
Technical Support to 
Enhance HIV/AIDS 
Prevention and 
Opportunities in 
Nursing Education 
(TSEPO) 
USAID Implementation 
Project 
Lesotho High Risk 
Individuals 
TBD Ongoing Ongoing. 
Partners 
Demonstration 
Project 
NIMH/NIH, 
USAID and 
BMGF 
Demonstration 
Project 
Kenya, Uganda Men, Women, 
Serodiscordant 
Couples 
Evaluates HIV prevention preferences among 
approximately 1,000 HIV serodiscordant couples, 
adherence to PrEP and ART and interface of reproductive 
health priorities and ART-based prevention. Will 
implement PrEP as “bridge” to ART, providing PrEP to HIV-
negative partner until the HIV- positive partner has 
initiated ART. 
Completed Completed. 
PrEP Operational 
Research Project 
MSF Demonstration 
Project 
Mozambique MSM, FSW Operating in the "corridor," a busy trade route frequented 
by truckers that runs through Mozambique, Malawi, and 
Zimbabwe. MSF is providing HIV 
screening and care to sex workers, drivers, and MSM in the 
region. 
Ongoing Ongoing; 
started in 
2016. 
Expected 
completion 
October 
2018. 
EQUIP PrEP Demo in 
Namibia 
TBD Demonstration 
Project 
Namibia MSM, PWID, 
FSW 
EQUIP has launched a PrEP demonstration project 
specifically focused on treatment approaches that 
effectively respond to Key Population needs and support 
Test & Start services. 
Ongoing Ongoing. 
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SEARCH (Sustainable 
East Africa Research 
in Community 
Health) 
BMGF Demonstration 
Project 
Kenya, Uganda People at high 
risk of HIV 
This is the PrEP extension of the SEARCH study which is 
underway in over 320,000 participants in Kenya and 
Uganda. 
Ongoing Ongoing; 
recruitment 
began April 
2017. 
Seasonal Use of PrEP 
in Mozambique - 
Short course pre- 
exposure 
prophylaxis (PrEP) 
for female partners 
of migrant miners in 
the Gaza Province of 
Mozambique 
BMGF 
through 
WHO 
Demonstration 
Project 
Mozambique Women The overall aim of the proposed study was to assess the 
feasibility and acceptability of providing short term daily 
oral PrEP (once daily FTC/TDF 200mg/300mg) as a potential 
HIV prevention tool to HIV-negative female partners of 
male miners in Gaza Province, Mozambique. Additional 
objectives were also to identify facilitators and barriers to 
uptake and adherence with short term once daily PrEP for 
HIV prevention among female partners of miners; to assess 
safety of PrEP use in terms of adverse events requiring 
discontinuation of PrEP and social harms;  to evaluate 
effect of PrEP on sexual behaviours among participants and 
to assess correlation between self- reported adherence, 
adherence measured by pill count and drug level. 
Completed Completed 
in 2017. 
Table S1: Ongoing, Planned and Completed PrEP Open Label, Demonstration and Implementation Projects in Women in Sub-Saharan Africa.  
For all ongoing, planned or completed PrEP open label demonstration and implementation projects for women in sub-Saharan Africa, the table set out the study name, sponsor/ funder, project 
type, population, key study questions and project status. The table does not include studies for women classified within the populations of people who in inject drugs (PWID) and 
serodiscordant couples. The following acronyms are used: FSW = female sex worker, MSM = men who have sex with men, AGYW = adolescent girls and young women, TGW = transgender 
women, TGM = transgender men, TasP = treatment as prevention. The table is reproduced from AVAC (May 2019 list – latest available in October 2019)1. 
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Supplementary Methods 
The HIV risk from a single partner population to FSW with consistency of condom use 𝛾𝛾1, adhering to 
PrEP at level 𝛼𝛼 is given by: 
𝜋𝜋(𝛾𝛾1,𝛼𝛼) = 1 − �𝑝𝑝� 1 − 𝛽𝛽(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1)�𝑛𝑛 + (1 − 𝑝𝑝)�𝑚𝑚
S1 
In the absence of PrEP(𝑖𝑖. 𝑒𝑒 𝛼𝛼 = 0) the HV risk equation (S1) becomes 
𝜋𝜋(𝛾𝛾0, 0) = 1 − �𝑝𝑝� 1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0)�𝑛𝑛 + (1 − 𝑝𝑝)�𝑚𝑚
S52 
It is more beneficial to take PrEP as a supplementary prevention method if the condition 𝜋𝜋(𝛾𝛾1,𝛼𝛼) <
𝜋𝜋(𝛾𝛾0, 0) is satisfied, which simplifies to 
�𝑝𝑝� 1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0)�𝑛𝑛 + (1 − 𝑝𝑝)�𝑚𝑚 < �𝑝𝑝� 1 − 𝛽𝛽(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1)�𝑛𝑛 + (1 − 𝑝𝑝)�𝑚𝑚
S3 
From equation (S3), the condition for PrEP to be beneficial in terms reducing HIV risk is given by (1 − 𝜀𝜀𝛾𝛾1)(1 − 𝜀𝜀𝛾𝛾0) < (1 − 𝑏𝑏𝛼𝛼) 
S4 
The introduction of PrEP will therefore be of significance if the relative HIV risk reduction factor due 
to condom use after the introduction of PrEP is less than the HIV risk reduction afforded by PrEP. 
Equation (S4) can also be arranged to give: 
𝑏𝑏𝛼𝛼 > 𝜀𝜀(𝛾𝛾0 − 𝛾𝛾1)(1 − 𝜀𝜀𝛾𝛾1)  
S5 
S2
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Equation (S5) gives us the level of effectiveness that must be attained for PrEP to be of benefit in 
reducing HIV risk, considering any change in condom consistency. We also note from equation (S5) 
that the risk reduction for PrEP to be beneficial at any level of adherence 𝛼𝛼 > 0 happens at 𝛾𝛾0 = 𝛾𝛾1: 
condom consistency remains unchanged. It is independent of the number of partners, sex acts and 
partner HIV prevalence. 
From equation (S5) we derive the critical PrEP effectiveness corresponding to critical adherence 
level 𝛼𝛼∗, which serves as the break-even point for beneficence of PrEP for HIV prevention with 
regard to any change in condom consistency: 
𝑏𝑏𝛼𝛼∗ = 𝜀𝜀(𝛾𝛾0 − 𝛾𝛾1∗)(1 − 𝜀𝜀𝛾𝛾1∗)
S6 
Considering the extreme scenario of 100% condom migration on PrEP, this intervention will not 
increase HIV risk for FSWs as long as the achieved effectiveness of PrEP exceeds that of condoms at 
the consistency prior to PrEP introduction: 
𝜀𝜀𝛾𝛾0 < 𝑏𝑏𝛼𝛼  ≤ 1 
S7 
This can also be seen as the condition under which PrEP will always be beneficial as an additional 
HIV prevention approach in reducing HIV risk. 
Simple rearrangement of equation (S6) gives the break-even value of condom consistency after 
introduction of PrEP such that HIV risk is not increased: 
𝛾𝛾1
∗ = (𝜀𝜀𝛾𝛾0 − 𝑏𝑏𝛼𝛼  )
𝜀𝜀(1 − 𝑏𝑏𝛼𝛼 )
S8 
Extension of the simple HIV risk equations (S1) and (S2) to consider the case of two partner 
populations gives the refined HIV risk using PrEP and condoms as: 
Π(𝛾𝛾1,𝛼𝛼) = 1 − �𝑝𝑝𝑐𝑐�1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾1𝑐𝑐)(1 − 𝑏𝑏𝛼𝛼)�𝑛𝑛𝑐𝑐 + (1 − 𝑝𝑝𝑐𝑐)�𝑚𝑚𝑐𝑐
∗ �𝑝𝑝𝑟𝑟�1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾1𝑟𝑟)(1 − 𝑏𝑏𝛼𝛼)�𝑛𝑛𝑟𝑟 + (1 − 𝑝𝑝𝑟𝑟)�𝑚𝑚𝑟𝑟
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S9 
And in the absence of PrEP (i.e.  𝛼𝛼 = 0): 
Π(𝛾𝛾0, 0) = 1 − �𝑝𝑝𝑐𝑐�1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0c)�𝑛𝑛𝑐𝑐 + (1 − 𝑝𝑝𝑐𝑐)�𝑚𝑚𝑐𝑐 ∗ �𝑝𝑝𝑟𝑟�1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0r)�𝑛𝑛𝑟𝑟 + (1 − 𝑝𝑝𝑟𝑟)�𝑚𝑚𝑟𝑟
S10 
Returning to the case of a single partner population, the simple HIV risk equations (S1) and (S2) can 
also be extended to account for the increased risk of HIV transmission resulting from exposure to 
STIs. For a FSW using PrEP and condoms, their HIV risk is refined to: 
𝜋𝜋(𝛾𝛾1,𝛼𝛼) = 1 − �𝑠𝑠𝑝𝑝� 1 − 𝛿𝛿𝛽𝛽(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1)�𝑛𝑛 + (1 − 𝑠𝑠)𝑝𝑝� 1 − 𝛽𝛽(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1)�𝑛𝑛 + (1
− 𝑝𝑝)�𝑚𝑚
S11 
And in the absence of PrEP: 
𝜋𝜋(𝛾𝛾0, 0) = 1 − �𝑠𝑠𝑝𝑝� 1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0)�𝑛𝑛 + (1 − 𝑠𝑠)𝑝𝑝� 1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0)�𝑛𝑛 + (1 − 𝑝𝑝)�𝑚𝑚
S12 
PrEP is thus beneficial in reducing HIV risk, considering possible changes in condom use and 
increased exposure to STIs, if 𝜋𝜋(𝛾𝛾1,𝛼𝛼, 𝛿𝛿) < 𝜋𝜋(𝛾𝛾0, 0, 𝛿𝛿), which simplifies as: 
𝑠𝑠� 1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0)�𝑛𝑛 + (1 − 𝑠𝑠)� 1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0)�𝑛𝑛< 𝑠𝑠� 1 − 𝛿𝛿𝛽𝛽(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1)�𝑛𝑛 + (1 − 𝑠𝑠)� 1 − 𝛽𝛽(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1)�𝑛𝑛
S13 
Finally equations (S11) and (S12) are extended to account for both FSW partner populations, 
considering exposure to STIs. HIV risk using PrEP and condoms is then: 
Π(𝛾𝛾1,𝛼𝛼, 𝛿𝛿) = 1 − �𝑠𝑠𝑝𝑝𝑐𝑐�1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾1𝑐𝑐)(1 − 𝑏𝑏𝛼𝛼)�𝑛𝑛𝑐𝑐 + (1 − 𝑠𝑠)𝑝𝑝𝑐𝑐�1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾1𝑐𝑐)(1 − 𝑏𝑏𝛼𝛼)�𝑛𝑛𝑐𝑐+ (1 − 𝑝𝑝𝑐𝑐)�𝑚𝑚𝑐𝑐
∗ �𝑠𝑠𝑝𝑝𝑟𝑟�1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾1𝑟𝑟)(1 − 𝑏𝑏𝛼𝛼)�𝑛𝑛𝑟𝑟 + (1 − 𝑠𝑠)𝑝𝑝𝑟𝑟�1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾1𝑟𝑟)(1 − 𝑏𝑏𝛼𝛼)�𝑛𝑛𝑟𝑟 + (1
− 𝑝𝑝𝑟𝑟)�𝑚𝑚𝑟𝑟
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S14 
And in the absence of PrEP given by: 
Π(𝛾𝛾0, 0, 𝛿𝛿) = 1 − �𝑠𝑠𝑝𝑝𝑐𝑐�1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0𝑐𝑐)�𝑛𝑛𝑐𝑐 + (1 − 𝑠𝑠)𝑝𝑝𝑐𝑐�1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0𝑐𝑐)�𝑛𝑛𝑐𝑐 + (1 − 𝑝𝑝𝑐𝑐)�𝑚𝑚𝑐𝑐
∗ �𝑠𝑠𝑝𝑝𝑟𝑟�1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0𝑟𝑟)�𝑛𝑛𝑟𝑟 + (1 − 𝑠𝑠)𝑝𝑝𝑟𝑟�1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0𝑟𝑟)�𝑛𝑛𝑟𝑟 + (1 − 𝑝𝑝𝑟𝑟)�𝑚𝑚𝑟𝑟
S15 
Sensitivity analysis 
For the sensitivity analysis exploring the case where the probability that at least one person in the 
partnership has an STI, s, changes following the introduction of PrEP, we take 𝑠𝑠0, to be the 
probability that at least one person in the partnership has an STI prior to the introduction of PrEP 
and 𝑠𝑠1, to be the probability that at least one person in the partnership has an STI following the 
introduction of PrEP.  
In order to obtain conservative results in terms of change in condom consistency tolerated following 
the introduction of PrEP, it is assumed that STIs are present in all partnerships where reductions in 
condom consistency occur following the introduction of PrEP, and these STIs are transmitted 
through the sex act if not already present in both partners. Therefore the probability that at least 
one person in the partnership has an STI following the introduction of PrEP, 𝑠𝑠1, will increase at the 
same rate as the change in condom consistency tolerated for HIV risk not to increase on PrEP. In 
other words, 𝑠𝑠1 = 𝑠𝑠0 ∗ �1 + (𝛾𝛾0 − 𝛾𝛾1)�.  
In order to undertake the sensitivity analyses, equations S11 to S15 are evolved as follows: 
For a single partner population, accounting for the increased risk of HIV transmission resulting from 
exposure to STIs, where the probability that at least one person in the partnership has an STI is 
assumed to change in accordance with change in condom consistency, HIV risk using PrEP and 
condoms (evolution of S11) is: 
𝜋𝜋(𝛾𝛾1,𝛼𝛼, 𝑠𝑠1) = 1 − �𝑠𝑠0�1 + (𝛾𝛾0 − 𝛾𝛾1)�𝑝𝑝� 1 − 𝛿𝛿𝛽𝛽(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1)�𝑛𝑛 + (1
− 𝑠𝑠0�1 + (𝛾𝛾0 − 𝛾𝛾1)�)𝑝𝑝� 1 − 𝛽𝛽(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1)�𝑛𝑛 + (1 − 𝑝𝑝)�𝑚𝑚
S16 
And in the absence of PrEP (evolution of S12) is: 
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𝜋𝜋(𝛾𝛾0, 0, 𝑠𝑠0) = 1 − �𝑠𝑠0𝑝𝑝� 1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0)�𝑛𝑛 + (1 − 𝑠𝑠0)𝑝𝑝� 1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0)�𝑛𝑛 + (1 − 𝑝𝑝)�𝑚𝑚
S17 
PrEP is thus beneficial in reducing HIV risk, considering possible changes in condom use and 
increased exposure to STIs, if (evolution of S13): 
𝑠𝑠0� 1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0)�𝑛𝑛 + (1 − 𝑠𝑠0)� 1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0)�𝑛𝑛< 𝑠𝑠0�1 + (𝛾𝛾0 − 𝛾𝛾1)�� 1 − 𝛿𝛿𝛽𝛽(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1)�𝑛𝑛 + (1
− 𝑠𝑠0�1 + (𝛾𝛾0 − 𝛾𝛾1)�)� 1 − 𝛽𝛽(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1)�𝑛𝑛
S18 
Considering both FSW partner populations, accounting for the increased risk of HIV transmission 
resulting from exposure to STIs, where the probability that at least one person in the partnership has 
an STI is assumed to change in accordance with change in condom consistency, HIV risk using PrEP 
and condoms (evolution of S14) is: 
Π(𝛾𝛾1,𝛼𝛼, 𝛿𝛿, 𝑠𝑠1) = 1
− �𝑠𝑠0�1 + (𝛾𝛾0 − 𝛾𝛾1)�𝑝𝑝𝑐𝑐�1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾1𝑐𝑐)(1 − 𝑏𝑏𝛼𝛼)�𝑛𝑛𝑐𝑐 + (1
− 𝑠𝑠0�1 + (𝛾𝛾0 − 𝛾𝛾1)�)𝑝𝑝𝑐𝑐�1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾1𝑐𝑐)(1 − 𝑏𝑏𝛼𝛼)�𝑛𝑛𝑐𝑐 + (1 − 𝑝𝑝𝑐𝑐)�𝑚𝑚𝑐𝑐
∗ �𝑠𝑠0�1 + (𝛾𝛾0 − 𝛾𝛾1)�𝑝𝑝𝑟𝑟�1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾1𝑟𝑟)(1 − 𝑏𝑏𝛼𝛼)�𝑛𝑛𝑟𝑟 + (1
− 𝑠𝑠0�1 + (𝛾𝛾0 − 𝛾𝛾1)�)𝑝𝑝𝑟𝑟�1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾1𝑟𝑟)(1 − 𝑏𝑏𝛼𝛼)�𝑛𝑛𝑟𝑟 + (1 − 𝑝𝑝𝑟𝑟)�𝑚𝑚𝑟𝑟
S19 
And in the absence of PrEP (evolution of S15) is: 
Π(𝛾𝛾0, 0, 𝛿𝛿, 𝑠𝑠0) = 1 − �𝑠𝑠0𝑝𝑝𝑐𝑐�1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0𝑐𝑐)�𝑛𝑛𝑐𝑐 + (1 − 𝑠𝑠0)𝑝𝑝𝑐𝑐�1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0𝑐𝑐)�𝑛𝑛𝑐𝑐 + (1 − 𝑝𝑝𝑐𝑐)�𝑚𝑚𝑐𝑐
∗ �𝑠𝑠0𝑝𝑝𝑟𝑟�1 − 𝛿𝛿𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0𝑟𝑟)�𝑛𝑛𝑟𝑟 + (1 − 𝑠𝑠0)𝑝𝑝𝑟𝑟�1 − 𝛽𝛽(1 − 𝜀𝜀𝛾𝛾0𝑟𝑟)�𝑛𝑛𝑟𝑟 + (1 − 𝑝𝑝𝑟𝑟)�𝑚𝑚𝑟𝑟
S20 
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Parameter Symbol Baseline value 
(range: low risk- 
high risk) 
References 
Sexual behaviour data   
Proportion of client 
partner population HIV 
infected 
𝑝𝑝𝑐𝑐 0.26 (0.23-0.29) 1(Black African Men, 25-49, 
South Africa) 
Proportion of regular 
partner population HIV 
infected 
𝑝𝑝𝑟𝑟  0.26 (0.23-0.29) 1 (Black African Men, 25-49, 
South Africa) 
Initial condom consistency 
with regular partners 
𝛾𝛾0
𝑟𝑟  0.1   Mid-point of (0.15-0.05) from 
2(main partnerships, per sex act, 
Hillbrow) 
Initial condom consistency 
with clients 
𝛾𝛾0
𝑐𝑐 Varied across a 
spectrum of 
simulated 
values in each 
analysis, from 
30% upwards  
 
Probability at least one 
person in the partnership 
has an STI 
𝑠𝑠 0.15 ( 0.15, 0.3) 3(prevalence of Chlamydia 
trachomatis & Neisseria 
gonorrhoea in Hillbrow FSWs); 
4(FSW STI prevalence, Durban) 
Number of client partners, 
per 3 month period 
𝑛𝑛𝑐𝑐 105 (rounded) 
(78-126) 
2(mean monthly reported 
number of clients per FSW, 
Hillbrow; multiplied by 3) 
Number of regular 
partners, per 3 month 
period 
𝑛𝑛𝑟𝑟 1 (0.37-2) 3(mean reported number of 
current partners, rounded), 
5(number of main sexual 
partners, FSWs Hillbrow) 
Average  number of sex 
acts – per client, per 3 
month period 
𝑚𝑚𝑐𝑐 1 (1-1.2) 3(number of sexual encounters 
per client, Hillbrow) 
Average  number of sex 
acts – per regular partner, 
per 3 month period 
𝑚𝑚𝑟𝑟 24 (mid-point) 
(12-36) 
2(mean monthly frequency of 
sex acts in main partnerships, 
Hillbrow; multiplied by 3) 
Transmission Probabilities   
Condom HIV risk reduction 
efficacy per sex act 
𝜀𝜀 0.85 (0.90-0.80) 6(with consistent use), 7(with 
consistent use) 
Probability of HIV 
transmission, male to 
female, through peno-
vaginal sex 
𝛽𝛽 0.001 
(0.00078,0.0019
9) 
8(basic risk male-to-female 
peno-vaginal), 9(Per-act HIV-1 
transmission probability 95% CI) 
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Multiplicative increase in 
per sex act probability of 
HIV transmission in the 
presence of an STI 
𝛿𝛿 3.7 (2-6); 10(combined study effectiveness 
estimate across STDs, and range 
spanning individual STD 
combined study effect 
estimates) 
PrEP HIV risk reduction 
effectiveness, 
corresponding to 
adherence level 𝛼𝛼 
𝑏𝑏𝛼𝛼 0.35; 0.45; 0.55; 
0.65; 0.75; 0.85; 
0.95 
(see note below 
table) 
Spanning spectrum of trial 
estimates 11–15,16 corresponding 
to varying levels of adherence 
Table S1: Model parameter values.  
The unbracketed numbers shown in the ‘base value’ column are the values that have been used to parameterise the model 
for the base, or core, analyses of this study. The numbers shown in brackets represent the values used in the sensitivity 
analyses looking at the outcomes for high and low risk FSW, with the left-hand bracketed value corresponding to the low 
risk scenario and the right hand bracketed value corresponding to the high risk scenario. 
 
Further notes to Table S1: Specifically, in the case of 𝒃𝒃𝜶𝜶, a range of values were used in the base 
analyses, to represent a spectrum of possible levels HIV risk reduction effectives achieved 
corresponding to differing levels of PrEP adherence (𝜶𝜶).  
In the single partner population analyses these values of 𝒃𝒃𝜶𝜶 were simulated in increments of 10%, 
roughly spanning the range of HIV risk reduction estimated through the iPrEx OLE17 study, which 
provides the most comprehensive evidence base available to date linking PrEP adherence to HIV risk 
reduction through drug concentrations found in participants’ dried blood spots. The study reported 
that: 
- An estimated drug dosing of <2 tables a week led to an estimated HIV risk reduction compared to 
no adherence of 53%;  
- An estimated drug dosing of 2 to 3 tablets a week led to an estimated HIV risk reduction of 87%; 
and 
- An estimated drug dosing of 4 to 6 tablets a week led to an estimated HIV risk reduction of 100%  
However, noting that the iPrEx OLE study was conducted in a different study population (MSM and 
transgender women) than considered in this study, we started 𝒃𝒃𝜶𝜶 from a slightly lower baseline of 
35%. 
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In the two partner population analyses, for simplicity three levels of 𝒃𝒃𝜶𝜶 were simulated: 55%, 75% 
and 95%, roughly spanning the lower and upper values of 𝒃𝒃𝜶𝜶 observed in the iPrEx OLE study, as well 
as the midpoint of these values.  
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Supplementary Results 
Single partner population, accounting for increased STI exposure  
 
Table S2: Percentage reduction in condom consistency tolerated for HIV risk not to increase on PrEP, and corresponding decreased tolerance having accounted for the effect of STIs - for 
various levels of PrEP effectiveness (𝒃𝒃𝜶𝜶) achieved and baseline condom consistencies (𝛾𝛾0).  
For each level of PrEP effectiveness simulated, in the left-hand column, the table shows the % reduction in condom consistency tolerated, where STIs are accounted for in the HIV risk equations. 
The results are shown for the base case parameterization of the model, as well as the boundary cases explored through the first sensitivity analysis of high and low risk FSW.  
In the right hand side columns for each level of PrEP effectiveness simulated, the table shows the absolute difference in % reduction in condom consistency tolerated, in the case that STIs are 
not accounted for in the HIV risk equations. 
‘Base’ refers to the main calculated results undertaken using the baseline parameter values. HR stands for high risk and LR stands for low risk FSW, and the results calculated in the sensitivity 
analysis for the boundary parameter cases. The results corresponding to the Base case where the effect of STIs are considered are shown graphically in Figure 2 in the main text.  
 
 
 
35% PrEP Effectiveness 45% PrEP Effectiveness 55% PrEP Effectiveness 65% PrEP Effectiveness 75% PrEP Effectiveness 85% PrEP Effectiveness
% reduction 
condom 
consistency 
tolerated
Change in 
tolerance, 
considering no 
STI effect
% reduction 
condom 
consistency 
tolerated
Change in 
tolerance, 
considering no 
STI effect
% reduction 
condom 
consistency 
tolerated
Change in 
tolerance, 
considering no 
STI effect
% reduction 
condom 
consistency 
tolerated
Change in 
tolerance, 
considering no 
STI effect
% reduction 
condom 
consistency 
tolerated
Change in 
tolerance, 
considering no 
STI effect
% reduction 
condom 
consistency 
tolerated
Change in 
tolerance, 
considering no 
STI effect
Base (LR, HR) Base (LR, HR) Base (LR, HR) Base (LR, HR) Base (LR, HR) Base (LR, HR) Base (LR, HR) Base (LR, HR) Base (LR, HR) Base (LR, HR) Base (LR, HR) Base (LR, HR)
90% 17% (-4%,4%) 0% (-4%,4%) 25% (-6%,7%) 0% (-6%,7%) 38% (-9%,10%) 0% (-9%,10%) 57% (-13%,15%) 0% (-13%,15%) 92% (-22%,8%) 0% (-22%,8%) 100% (0%,0%) 0% (0%,0%)
85% 21% (-4%,5%) 0% (-4%,5%) 31% (-6%,7%) 0% (-6%,7%) 47% (-9%,11%) 0% (-9%,11%) 71% (-14%,16%) 0% (-14%,16%) 100% (-8%,0%) 0% (-8%,0%) 100% (0%,0%) 0% (0%,0%)
80% 25% (-4%,5%) 0% (-4%,5%) 39% (-7%,8%) 0% (-7%,8%) 58% (-10%,11%) 0% (-10%,11%) 87% (-15%,13%) 0% (-15%,13%) 100% (0%,0%) 0% (0%,0%) 100% (0%,0%) 0% (0%,0%)
75% 31% (-5%,5%) 0% (-5%,5%) 47% (-7%,8%) 0% (-7%,8%) 69% (-11%,12%) 0% (-11%,12%) 100% (-11%,0%) 0% (-11%,0%) 100% (0%,0%) 0% (0%,0%) 100% (0%,0%) 0% (0%,0%)
70% 37% (-5%,6%) 0% (-5%,6%) 56% (-8%,9%) 0% (-8%,9%) 83% (-11%,13%) 0% (-11%,13%) 100% (0%,0%) 0% (0%,0%) 100% (0%,0%) 0% (0%,0%) 100% (0%,0%) 0% (0%,0%)
50% 73% (-7%,8%) 0% (-7%,8%) 100% (0%,0%) 0% (0%,0%) 100% (0%,0%) 0% (0%,0%) 100% (0%,0%) 0% (0%,0%) 100% (0%,0%) 0% (0%,0%) 100% (0%,0%) 0% (0%,0%)
30% 100% (0%,0%) 0% (0%,0%) 100% (0%,0%) 0% (0%,0%) 100% (0%,0%) 0% (0%,0%) 100% (0%,0%) 0% (0%,0%) 100% (0%,0%) 0% (0%,0%) 100% (0%,0%) 0% (0%,0%)
𝜸𝟎
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Single partner population, accounting for increased STI exposure  
– Sensitivity analysis on STI prevalence following introduction of PrEP 
 
Table S3: Percentage reduction in condom consistency tolerated for HIV risk not to increase on PrEP, without and with change in STI prevalence following introduction of PrEP.  
For each level of PrEP effectiveness achieved two sets of results are presented. In the left hand columns, as comparison points for the sensitivity analysis, the left hand column repeat the results 
for each PrEP effectiveness level (accounting for STIs) from Table S2 (in grey). 
In the right hand columns, the results of the sensitivity analysis are presented, for the case that s changes following the introduction of PrEP in accordance with the reduction in condom 
consistency observed. Compared to the original results from Table S2, the table shows the change in % reduction condom migration tolerated in absolute and relative terms from the Base case. 
We also show the absolute % change for the boundary cases of Low Risk and High Risk FSW from the original Base case. (Abs) stands of absolute change and (Rel) stands for relative change. 
‘Base’ refers to the main calculated results undertaken using the baseline parameter values. HR stands for high risk and LR stands for low risk FSW.   
45% PrEP Effectiveness 55% PrEP Effectiveness 65% PrEP Effectiveness 75% PrEP Effectiveness 85% PrEP Effectiveness
% reduction 
condom 
consistency 
tolerated, 
assuming STI 
prevalence does 
not change
% reduction condom 
consistency tolerated, 
assuming STI 
prevalence does not 
change
% reduction 
condom 
consistency 
tolerated, 
assuming STI 
prevalence does 
not change
% reduction 
condom 
consistency 
tolerated, 
assuming STI 
prevalence does 
not change
% reduction 
condom 
consistency 
tolerated, 
assuming STI 
prevalence does 
not change
% reduction 
condom 
consistency 
tolerated, 
assuming STI 
prevalence does 
not change
Base (LR, HR) Base(Abs)
Base
(Rel)
(LR,HR)
(Abs) Base (LR, HR)
Base
(Abs)
Base
(Rel)
(LR,HR)
(Abs) Base (LR, HR)
Base
(Abs)
Base
(Rel) (LR, HR) Base (LR, HR)
Base
(Abs)
Base
(Rel) (LR, HR) Base (LR, HR)
Base
(Abs)
Base
(Rel) (LR, HR) Base (LR, HR)
Base
(Abs)
Base
(Rel) (LR, HR)
90% 17% (-4%,4%) -2% -12% (-4%,-1%) 25% (-6%,7%) -3% -12% (-7%,-2%) 38% (-9%,10% -5% -13% (-10%,-4%) 57% (-13%,15% -10% -18% (-17%,-9%) 92% (-22%,8%) -20% -22% (-28%,-22%) 100% (0%,0%) 0% 0% (0%,0%)
85% 21% (-4%,5%) -3% -15% (-5%,-2%) 31% (-6%,7%) -4% -13% (-8%,-4%) 47% (-9%,11% -7% -15% (-12%,-8%) 71% (-14%,16% -14% -20% (-19%,-16%) 100% (-8%,0%) -12% -12% (-18%,-18%) 100% (0%,0%) 0% 0% (0%,0%)
80% 25% (-4%,5%) -3% -12% (-6%,-4%) 39% (-7%,8%) -6% -16% (-9%,-7%) 58% (-10%,11% -10% -17% (-14%,-13%) 87% (-15%,13% -18% -21% (-22%,-24%) 100% (0%,0%) 0% 0% (0%,-7%) 100% (0%,0%) 0% 0% (0%,0%)
75% 31% (-5%,5%) -5% -16% (-6%,-6%) 47% (-7%,8%) -8% -17% (-10%,-11%) 69% (-11%,12% -14% -20% (-16%,-18%) 100% (-11%,0% -19% -19% (-20%,-28%) 100% (0%,0%) 0% 0% (0%,0%) 100% (0%,0%) 0% 0% (0%,0%)
70% 37% (-5%,6%) -6% -16% (-7%,-9%) 56% (-8%,9%) -10% -18% (-12%,-15%) 83% (-11%,13% -18% -22% (-19%,-25%) 100% (0%,0%) -5% -5% (-4%,-18%) 100% (0%,0%) 0% 0% (0%,0%) 100% (0%,0%) 0% 0% (0%,0%)
50% 73% (-7%,8%) -16% -22% (-14%,-25%) 100% (0%,0%) -16% -16% (-12%,-31%) 100% (0%,0%) 0% 0% (0%,-3%) 100% (0%,0%) 0% 0% (0%,0%) 100% (0%,0%) 0% 0% (0%,0%) 100% (0%,0%) 0% 0% (0%,0%)
30% 100% (0%,0%) 0% 0% (0%,-9%) 100% (0%,0%) 0% 0% (0%,0%) 100% (0%,0%) 0% 0% (0%,0%) 100% (0%,0%) 0% 0% (0%,0%) 100% (0%,0%) 0% 0% (0%,0%) 100% (0%,0%) 0% 0% (0%,0%)
HR
Change in % reduction, 
considering change in STI 
prevalence post PrEP
Change in % reduction, 
considering change in STI 
prevalence post PrEP
Change in % reduction, 
considering change in STI 
prevalence post PrEP
Change in % reduction, 
considering change in 
STI prevalence post 
PrEP
Change in % reduction, 
considering change in STI 
prevalence post PrEP
35% PrEP Effectiveness
Change in % reduction, 
considering change in STI 
prevalence post PrEP
𝜸𝟎
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Two partner population, accounting for increased STI exposure  
 
Figure S1: Percentage reduction in condom consistency tolerated to get risk reduction of 50%. 
Figure S1 shows the % reduction in condom consistency tolerated to get a risk reduction of 50% for three cases of PrEP effectiveness achiever: 55%, 75% and 95%, across a range of initial 
condom consistencies from 30% - 90%. 𝑏𝑏𝛼𝛼 is the level of PrEP effectiveness achieved by a FSW. The results correspond to Table 1 in the main text, for the results accounting for STIs in the HIV 
risk equations. 
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Two partner population, accounting for increased STI exposure  
- In the case that condom consistency with regular partners is reduced from 10% to 0% following the introduction of PrEP 
 
 
Table S4: Maximum tolerated % reduction in condom consistency with clients to still achieve 50% or 90% reductions in HIV risk on PrEP, for different levels of PrEP effectiveness (𝒃𝒃𝜶𝜶) 
achieved and condom consistency with regular partners assumed to be zero. 
For each level of PrEP effectiveness demonstrated, the table shows the % reduction in condom consistency that could be tolerated, from varying levels of initial condom consistency, to achieve 
either 50% or 90% HIV risk reduction. The results are shown for both the case that STIs are accounted for in the HIV risk equations, as well as the case that they are not. The results are shown 
for the base case parameterization of the model, as well as the boundary cases explored through the first sensitivity analysis of high and low risk FSW. 
The difference in assumptions taken to calculate the results for Table S4 compared to Table 1 in the main text is that for Table S4, condom consistency with regular partners is assumed to 
reduce from 10% to 0% following the introduction of PrEP, whereas in Table 1, condom consistency with regular partners is assumed to remain at 10% before and after introduction of PrEP. 
𝒃𝒃𝜶𝜶 is the level of PrEP effectiveness achieved by a FSW.  ‘–‘ indicates that achievement of the risk reduction is not possible. ‘*’ indicates full migration will still result in higher levels of risk 
reduction. ‘Base’ refers to the main calculated results undertaken using the baseline parameter values. HR stands for high risk and LR stands for low risk FSW, and the results calculated in the 
sensitivity analysis for the boundary parameter cases. 
 
 
90% 90% 90%
Accounting for 
STIs
Not accounting 
for STIs
Accounting for 
STIs
Not accounting 
for STIs
Accounting for 
STIs
Not accounting 
for STIs
Accounting for 
STIs
Not accounting 
for STIs
Accounting for 
STIs
Not accounting 
for STIs
Accounting for 
STIs
Not accounting 
for STIs
Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR) Base (LR,HR)
90% 3% (-1%,-3%) 4% (-1%,2%) - - - - 54% (-26%,26%) 55% (-26%,39%) - - - - 100% (*,*) 100% (*,*) 54% (-25%,19%) 54% (-26%,37%)
80% 5% (-1%,-4%) 5% (-1%,2%) - - - - 73% (-29%,27%) 74% (-29%,26%) - - - - 100% (*,*) 100% (*,*) 73% (-28%,19%) 74% (-29%,26%)
70% 7% (-1%,-6%) 8% (-2%,2%) - - - - 98% (*,*) 99% (*,*) - - - - 100% (*,*) 100% (*,*) 97% (*,*) 98% (*,*)
50% 14% (-1%,-13%) 15% (-2%,2%) - - - - 100% (*,*) 100% (*,*) - - - - 100% (*,*) 100% (*,*) 100% (*,*) 100% (*,*)
30% 29% (-1%,-28%) 31% (-3%,0%) - - - - 100% (*,*) 100% (*,*) - - - - 100% (*,*) 100% (*,*) 100% (*,*) 100% (*,*)
55% PrEP Effectiveness 75% PrEP Effectiveness 95% PrEP Effectiveness
% reduction in condom consistency with clients tolerated to get overall HIV risk reduction of
50% 50% 50%
𝜸𝟎
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Two partner population, accounting for increased STI exposure  
- Condom consistency with regular partners assumed to remain at 10% following the introduction of PrEP 
- Sensitivity analysis on STI prevalence following introduction of PrEP 
 
Table S5: Maximum tolerated % reduction in condom consistency with clients (consistency with regular partners held constant) to still achieve 50% or 90% reductions in HIV risk on PrEP, 
for different levels of PrEP effectiveness achieved, assuming STI prevalence does not change with the introduction of PrEP; and change in this % reduction in the case STI prevalence does 
change with the introduction of PrEP.  
For each of the three levels of PrEP effectiveness simulated, two sets of results are presented. In the left hand columns, as comparison points for the sensitivity analysis, the left hand column 
repeats the results (accounting for STIs) from Table 1 in the main paper (in grey) – i.e. the two partner analysis where condom consistency with regular partners is assumed to be unchanged 
(at 10%) following the introduction of PrEP. 
In the right hand columns, the results of the sensitivity analysis are presented, for the case that s changes following the introduction of PrEP in accordance with the reduction in condom 
consistency observed. Compared to the original results from Table 1, we show the change in % reduction condom migration tolerated in absolute and relative terms from the Base case. We 
also show the absolute % change for the boundary cases of Low Risk and High Risk FSW from the original base case. (Abs) stands of absolute change and (Rel) stands for relative change. ‘Base’ 
refers to the main calculated results undertaken using the baseline parameter values. HR stands for high risk and LR stands for low risk FSW.  
90% 90% 90%
Assuming STI 
prevalence does 
not change 
Change in % reduction, 
considering change in STI 
prevalence post PrEP
Assuming STI 
prevalence 
does not 
change 
Change in % reduction, 
considering change in STI 
prevalence post PrEP
Assuming STI 
prevalence does 
not change 
Change in % reduction, 
considering change in STI 
prevalence post PrEP
Assuming STI 
prevalence does 
not change 
Change in % reduction, 
considering change in STI 
prevalence post PrEP
Assuming STI 
prevalence does 
not change 
Change in % reduction, 
considering change in STI 
prevalence post PrEP
Assuming STI 
prevalence does 
not change 
Change in % reduction, 
considering change in STI 
prevalence post PrEP
Base (LR,HR)
Base
(Abs)
Base
(Rel)
(LR,HR)
(Abs) Base (LR,HR)
Base
(Abs)
Base
(Rel)
(LR,HR)
(Abs) Base (LR,HR)
Base
(Abs)
Base
(Rel)
(LR,HR)
(Abs) Base (LR,HR)
Base
(Abs)
Base
(Rel)
(LR,HR)
(Abs) Base (LR,HR)
Base
(Abs)
Base
(Rel)
(LR,HR)
(Abs) Base (LR,HR)
Base
(Abs)
Base
(Rel)
(LR,HR)
(Abs)
90% 6% (-3%,-3%) -1% -14% (-3%,-4%) - - - - - 57% (-27%,26%) -12% -21% (-29%,-11%) - - - - - 100% (*,*) 0% 0% (0%,0%) 56% (-27%,19%) -12% -21% (-29%,-14%)
80% 8% (-3%,-5%) -1% -16% (-3%,-6%) - - - - - 76% (-31%,24%) -18% -24% (-34%,-21%) - - - - - 100% (*,*) 0% 0% (0%,0%) 75% (-29%,20%) -17% -23% (-33%,-24%)
70% 10% (-3%,-6%) -2% -18% (-4%,-8%) - - - - - 100% (*,*) -26% -26% (-41%,-33%) - - - - - 100% (*,*) 0% 0% (0%,0%) 100% (*,*) -26% -26% (-41%,-39%)
50% 18% (-4%,-13%) -4% -22% (-5%,-15%) - - - - - 100% (*,*) 0% 0% (0%,0%) - - - - - 100% (*,*) 0% 0% (0%,0%) 100% (*,*) 0% 0% (0%,-7%)
30% 37% (-6%,-29%) -9% -26% (-9%,-33%) - - - - - 100% (*,*) 0% 0% (0%,0%) - - - - - 100% (*,*) 0% 0% (0%,0%) 100% (*,*) 0% 0% (0%,0%)
Initial 
condom 
consistency
50% 50% 50%
75% PrEP Effectiveness 95% PrEP Effectiveness55% PrEP Effectiveness
% reduction in condom consistency with clients tolerated to get overall HIV risk reduction of
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Two partner population, accounting for increased STI exposure  
- In the case that condom consistency with regular partners is reduced from 10% to 0% following the introduction of PrEP 
- Sensitivity analysis on STI prevalence following introduction of PrEP 
 
Table S6: Maximum tolerated % reduction in condom consistency with clients (consistency with regular partners assumed to reduce to zero following the introduction of PrEP) to still 
achieve 50% or 90% reductions in HIV risk on PrEP, for different levels of PrEP effectiveness achieved, assuming STI prevalence does not change with the introduction of PrEP; and change 
in this % reduction in the case STI prevalence does change with the introduction of PrEP.  
For each of the three levels of PrEP effectiveness simulated, two sets of results are presented. In the left hand columns, as comparison points for the sensitivity analysis, the left hand column 
repeats the results (accounting for STIs) from Table S4 (in grey) – i.e. the two partner analysis where condom consistency with regular partners is assumed to reduce from 10% to 0% following 
the introduction of PrEP. 
In the right hand columns, the results of the sensitivity analysis are presented, for the case that s changes following the introduction of PrEP in accordance with the reduction in condom 
consistency observed (as well as condom consistency with regular partners reducing from 10% to 0% following the introduction of PrEP). Compared to the original results from Table s4, we 
show the change in % reduction condom migration tolerated in absolute and relative terms from the Base case. We also show the absolute % change for the boundary cases of Low Risk and 
High Risk FSW from the original Base case. (Abs) stands of absolute change and (Rel) stands for relative change. ‘Base’ refers to the main calculated results undertaken using the baseline 
parameter values. HR stands for high risk and LR stands for low risk FSW.
90% 90% 90%
Assuming STI 
prevalence does 
not change 
Change in % reduction, 
considering change in STI 
prevalence post PrEP
Assuming STI 
prevalence does 
not change 
Change in % reduction, 
considering change in STI 
prevalence post PrEP
Assuming STI 
prevalence does 
not change 
Change in % reduction, 
considering change in STI 
prevalence post PrEP
Assuming STI 
prevalence does 
not change 
Change in % reduction, 
considering change in STI 
prevalence post PrEP
Assuming STI 
prevalence does not 
change 
Change in % reduction, 
considering change in STI 
prevalence post PrEP
Assuming STI 
prevalence does 
not change 
Change in % reduction, 
considering change in STI 
prevalence post PrEP
Base (LR,HR)
Base
(Abs)
Base
(Rel)
(LR,HR)
(Abs) Base (LR,HR)
Base
(Abs)
Base
(Rel)
(LR,HR)
(Abs) Base (LR,HR)
Base
(Abs)
Base
(Rel)
(LR,HR)
(Abs) Base (LR,HR)
Base
(Abs)
Base
(Rel)
(LR,HR)
(Abs) Base (LR,HR)
Base
(Abs)
Base
(Rel)
(LR,HR)
(Abs) Base (LR,HR)
Base
(Abs)
Base
(Rel)
(LR,HR)
(Abs)
90% 3% (-1%,-3%) 0% -14% (-1%,-3%) - - - - 54% (-26%,26%) -11% -21% (-28%,-10%) - - - - 100% (*,*) 0% 0% (0%,0%) 54% (-25%,19%) -11% -21% (-27%,-13%)
80% 5% (-1%,-4%) -1% -16% (-1%,-5%) - - - - 73% (-29%,27%) -17% -24% (-32%,-20%) - - - - 100% (*,*) 0% 0% (0%,0%) 73% (-28%,19%) -17% -24% (-32%,-23%)
70% 7% (-1%,-6%) -1% -18% (-2%,-7%) - - - - 98% (*,*) -26% -26% (-39%,-33%) - - - - 100% (*,*) 0% 0% (0%,0%) 97% (*,*) -25% -26% (-38%,-37%)
50% 14% (-1%,-13%) -3% -22% (-2%,-13%) - - - - 100% (*,*) 0% 0% (0%,0%) - - - - 100% (*,*) 0% 0% (0%,0%) 100% (*,*) 0% 0% (0%,-10%)
30% 29% (-1%,-28%) -8% -26% (-4%,-29%) - - - - 100% (*,*) 0% 0% (0%,0%) - - - - 100% (*,*) 0% 0% (0%,0%) 100% (*,*) 0% 0% (0%,0%)
55% PrEP Effectiveness 75% PrEP Effectiveness 95% PrEP Effectiveness
% reduction in condom consistency with clients tolerated to get overall HIV risk reduction of
50% 50% 50%
𝜸𝟎
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Supplementary Methods 
 
Model Structure 
 
Static formulation of HIV risk 
Consistent with our previous work,1 the static model of HIV risk takes the Bernoulli formulation, 
where the probability of the HIV virus being transmitted through each sexual contact is treated as an 
independent risk event. In our simplified population model, and to facilitate comparison between 
the static and dynamic models, female sex workers (FSW) are assumed to have a single partner 
population ‘male partners’, in which the proportion HIV infected is 𝑝𝑝. For simplicity, male partners 
are characterised as clients, rather than other partner types (such as regular partners). For a given 
time period, ℎ, FSW are assumed to have 𝐶𝐶𝑚𝑚 0F1 partners, with whom they have an average of 𝑛𝑛𝑚𝑚 sex 
acts each. ℎ is taken as 3 months, corresponding to the minimum period after which an individual on 
PrEP must return to the provider to perform an HIV test to check for seroconversion (amongst other 
indicators).2 We assume an average probability of HIV transmission, 𝛽𝛽𝑓𝑓, per sexual contact with an 
HIV infected male partner. It is assumed that all sex acts are peno-vaginal on the basis of available 
epidemiological data for FSW in Hillbrow.3  
To assess the effect of any change in condom consistency (average proportion of sex acts in which a 
condom is used) following the introduction of PrEP, condoms are assumed to be used with 
consistency 𝛾𝛾0 prior to PrEP introduction and 𝛾𝛾1 after its introduction. We assume condoms to have 
an HIV risk reduction efficacy, 𝜀𝜀, including slippage and breakage. The exact relationship between 
adherence and effectiveness of PrEP remains under investigation, especially for women.4 As such, 
the equations assume an overall achieved level of ‘PrEP use-effectiveness’, 𝑏𝑏𝛼𝛼, corresponding to a 
given level of FSW PrEP adherence, 𝛼𝛼. In its most basic formulation, the Bernoulli model of HIV risk 
to FSW is: 
𝜋𝜋 = 1 − �𝑝𝑝 � 1 − 𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛 𝑚𝑚 + (1 − 𝑝𝑝)�𝐶𝐶𝑚𝑚   
Where γ = γ0 before the introduction of PrEP, and γ1 after the introduction of PrEP.  
1.1 
 
1 Static model parameters are denoted subscripts - f (for female) and m (for male) - as relevant, for ease of comparability with parameters in 
the dynamic model. 
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To account for changes in HIV risk owing to increased sexually transmitted infection (STI) exposure 
resulting through a decrease in condom consistency, it is assumed that 𝑠𝑠1, the probability that at 
least one person in the partnership has an STI following the introduction of PrEP, increases 
proportionally to the absolute change in condom consistency; in other words 𝑠𝑠1 =
𝑠𝑠0�1 + (𝛾𝛾0 − 𝛾𝛾1)�, where 𝑠𝑠0 is the probability that at least one person in the partnership has an STI 
prior to the introduction of PrEP. Parameter 𝛿𝛿 is the multiplicative increase in per sex act probability 
of HIV transmission in the presence of an STI.  
To account for antiretroviral (ART) coverage and male circumcision levels in this setting, 𝜗𝜗𝑚𝑚 is taken 
as the proportion of HIV+ partners that are on ART and 𝜚𝜚 is the average reduction in the probability 
of HIV transmission due to viral suppression on ART. The proportion of male population circumcised 
is denoted by  𝜏𝜏 and 𝜎𝜎𝑓𝑓is the average reduction in probability HIV transmission to women, when the 
male partner has been circumcised.  
Thus the HIV risk to a FSW, for a 3-month timestep, is given by the static model: 
𝜋𝜋𝑠𝑠𝑡𝑡𝑎𝑎𝑡𝑡𝑠𝑠𝑐𝑐 = 1 − �𝑝𝑝𝜓𝜓𝑓𝑓 + 𝑝𝑝𝜔𝜔𝑓𝑓 + (1 − 𝑝𝑝)�𝐶𝐶𝑚𝑚 
 
Or equivalently: 
𝜋𝜋𝑠𝑠𝑡𝑡𝑎𝑎𝑡𝑡𝑠𝑠𝑐𝑐 = 1 − �1 + 𝑝𝑝(𝜓𝜓𝑓𝑓 + 𝜔𝜔𝑓𝑓 − 1)�𝐶𝐶𝑚𝑚  
 
Where: 
𝜓𝜓𝑓𝑓 = (1 − 𝜏𝜏)
⎝
⎜
⎜
⎜
⎛
(1 − 𝜗𝜗)𝑠𝑠 � 1 − 𝛿𝛿𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛+(1 − 𝜗𝜗)(1 − 𝑠𝑠) � 1 − 𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛+𝜗𝜗𝑠𝑠 � 1 − (1 − 𝜚𝜚)𝛿𝛿𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛+𝜗𝜗(1 − 𝑠𝑠) � 1 − (1 − 𝜚𝜚)𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛⎠⎟
⎟
⎟
⎞
 
and 𝜔𝜔𝑓𝑓 = 𝜏𝜏
⎝
⎜
⎜
⎜
⎛
(1 − 𝜗𝜗)𝑠𝑠 � 1 − (1 − 𝜎𝜎)𝛿𝛿𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛+(1 − 𝜗𝜗)(1 − 𝑠𝑠) � 1 − (1 − 𝜎𝜎)𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛+𝜗𝜗𝑠𝑠 � 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛+𝜗𝜗(1 − 𝑠𝑠) � 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛽𝛽𝑓𝑓(1 − 𝑏𝑏𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛⎠⎟
⎟
⎟
⎞
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With γ = γ0 before the introduction of PrEP, and γ1 after the introduction of PrEP; s = s0 before the introduction of PrEP and s1 after the introduction of PrEP; 
And s1 = s0(1 + (  γ0 −   γ1)). 
1.2 
Dynamic formulation of HIV risk 
The static model was evolved into dynamical system through difference equation structure, taking 
the Bernoulli risk formulation (1.2) as the force of infection on FSW, and an equivalent Bernoulli risk 
formulation of HIV risk as the force of infection on the male partner population. Here, the male 
partner population, for the time period, ℎ, are assumed to have 𝐶𝐶𝑓𝑓 partners, with whom they have 
an average of 𝑛𝑛𝑓𝑓 sex acts each. We assume an average probability of HIV transmission, 𝛽𝛽𝑚𝑚, per 
sexual contact with an HIV infected FSW partner. No male partners are assumed to be taking PrEP. 
Parameter 𝜗𝜗𝑓𝑓 is the proportion of HIV positive FSW that are on ART and 𝜎𝜎𝑚𝑚is the average reduction 
in probability of HIV transmission to men, when the man himself has been circumcised. 
The dynamic HIV compartmental model divides the population, of size N, into susceptible individuals 
S and HIV infected individuals, I. Instead of a static HIV prevalence, 𝑝𝑝, for each population, the 
dynamic model system allows prevalence to change over time as the proportion of HIV infected 
individuals, 𝜆𝜆 = 𝐼𝐼/𝑁𝑁. The model is run from 1980 to 2035, with initial prevalence of HIV at the start 
of the epidemic in 1980 of 𝑝𝑝𝑓𝑓0in FSW and 𝑝𝑝𝑚𝑚0  in male partners. PrEP is introduced for FSW in 2015 
under the Epidemic Equilibrium (i.e. steady state) scenario, and retrospectively in 1995 under the 
Increasing Epidemic scenario where the HIV epidemics in FSW and their male partners are still 
increasing (i.e. transient state). 
The dynamic model system assumes an underlying population mortality rate 𝜇𝜇𝑓𝑓 and 𝜇𝜇𝑚𝑚 in FSW and 
male partners respectively, as well as a rate of AIDS-related deaths of 𝜉𝜉𝑓𝑓 and 𝜉𝜉𝑚𝑚 in FSW and male 
partners respectively. The rate of recruitment into both populations are taken as the population 
growth rates 𝜃𝜃𝑓𝑓 and 𝜃𝜃𝑚𝑚 respectively. 
As little is known about the rate of increase in condom consistency in these populations over time, 
change in condom consistency from the start of the HIV epidemic is approximated by a linear 
increase in consistency between 1980 and the year prior to the introduction of PrEP (2014 for the 
Epidemic Equilibrium analyses, and 1994 for the Increasing Epidemic analyses).  
To account for changes in ART coverage over time, in the dynamic model, ART coverage is taken to 
be zero between 1980 and 2003. Linear scale up assumed from 2003, in line with the wide-scale 
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introduction in South Africa5,6 in 2003, to levels in 2012 for male partners7 and 2014 for FSW8 (these 
being the latest available data for each population to parameterise the model up to the final point of 
fitting in 2014). 
We account for changes in male circumcision levels in the context of the 2007 WHO and UNAIDS 
guidance on scale up voluntary male circumcision levels for HIV prevention9 and the 2010 South 
African government  introduction of their VMMC policy and programme.7 Due to the limited data 
availability on circumcision levels in Hillbrow (or by proxy, Gauteng, the South African Province in 
which it lies), with national survey data only available for 200310 and 20127, we therefore assume 
that circumcision levels are constant at 2003 levels between 1980 and 2003, and that they increase 
linearly to 2012 levels and are constant thereafter (likewise as these are the latest available data to 
parameterise the model up to the final point of model fitting in 2014). 
The equations used for the dynamical system formulation are given by:  
 
Force of infection to FSW from male partners 
Π𝑚𝑚 = 1 − �1 + 𝜆𝜆𝑚𝑚(𝜓𝜓𝑓𝑓 + 𝜔𝜔𝑓𝑓 − 1)�𝐶𝐶𝑚𝑚 
Where 𝜆𝜆𝑚𝑚 = 𝐼𝐼𝑚𝑚𝑁𝑁𝑚𝑚   
2.1 
Force of infection to male partners from FSW 
Π𝑓𝑓 = 1 − �1 + 𝜆𝜆𝑓𝑓(𝜓𝜓𝑚𝑚 + 𝜔𝜔𝑚𝑚 − 1)�𝐶𝐶𝑓𝑓 
 
Where 𝜆𝜆𝑓𝑓 = 𝐼𝐼𝑓𝑓𝑁𝑁𝑓𝑓  and: 
𝜓𝜓𝑚𝑚 = (1 − 𝜏𝜏)
⎝
⎜⎜
⎛
�1 − 𝜗𝜗𝑓𝑓�𝑠𝑠� 1 − 𝛿𝛿𝛽𝛽𝑚𝑚(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛𝑓𝑓+�1 − 𝜗𝜗𝑓𝑓�(1 − 𝑠𝑠)� 1 − 𝛽𝛽𝑚𝑚(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛𝑓𝑓+𝜗𝜗𝑓𝑓𝑠𝑠� 1 − (1 − 𝜚𝜚)𝛿𝛿𝛽𝛽𝑚𝑚(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛𝑓𝑓+𝜗𝜗𝑓𝑓(1 − 𝑠𝑠)� 1 − (1 − 𝜚𝜚)𝛽𝛽𝑚𝑚(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛𝑓𝑓⎠⎟⎟
⎞
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and 𝜔𝜔𝑚𝑚 = 𝜏𝜏
⎝
⎜⎜
⎛
�1 − 𝜗𝜗𝑓𝑓�𝑠𝑠� 1 − (1 − 𝜎𝜎𝑚𝑚)𝛿𝛿𝛽𝛽𝑚𝑚(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛𝑓𝑓+�1 − 𝜗𝜗𝑓𝑓�(1 − 𝑠𝑠)� 1 − (1 − 𝜎𝜎𝑚𝑚)𝛽𝛽𝑚𝑚(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛𝑓𝑓+𝜗𝜗𝑓𝑓𝑠𝑠� 1 − (1 − 𝜎𝜎𝑚𝑚)(1 − 𝜚𝜚)𝛿𝛿𝛽𝛽𝑚𝑚(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛𝑓𝑓+𝜗𝜗𝑓𝑓(1 − 𝑠𝑠)� 1 − (1 − 𝜎𝜎𝑚𝑚)(1 − 𝜚𝜚)𝛽𝛽𝑚𝑚(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛𝑓𝑓⎠⎟⎟
⎞
 
2.2 
 
Population sizes 
𝑁𝑁𝑚𝑚 = 𝑆𝑆𝑚𝑚 + 𝐼𝐼𝑚𝑚 
𝑁𝑁𝑓𝑓 = 𝑆𝑆𝑓𝑓 + 𝐼𝐼𝑓𝑓 
2.3 
Balancing equation 
𝐶𝐶𝑓𝑓 = 𝐶𝐶𝑚𝑚𝑁𝑁𝑓𝑓/𝑁𝑁𝑚𝑚 
2.4 
Difference Equations 
𝑆𝑆𝑓𝑓 𝑡𝑡+1 = 𝜃𝜃𝑓𝑓𝑁𝑁𝑓𝑓 0 + 𝑆𝑆𝑓𝑓 𝑡𝑡 − Π𝑚𝑚𝑆𝑆𝑓𝑓 𝑡𝑡 − 𝜇𝜇𝑓𝑓𝑆𝑆𝑓𝑓 𝑡𝑡  
𝐼𝐼𝑓𝑓 𝑡𝑡+1 = 𝐼𝐼𝑓𝑓 𝑡𝑡 + Π𝑚𝑚𝑆𝑆𝑓𝑓 𝑡𝑡 − (𝜇𝜇𝑓𝑓 + 𝜉𝜉𝑓𝑓)𝐼𝐼𝑓𝑓 𝑡𝑡 
 
𝑆𝑆𝑚𝑚 𝑡𝑡+1 = 𝜃𝜃𝑚𝑚𝑁𝑁𝑚𝑚 0 + 𝑆𝑆𝑚𝑚 𝑡𝑡 − Π𝑓𝑓𝑆𝑆𝑚𝑚 𝑡𝑡 − 𝜇𝜇𝑚𝑚𝑆𝑆𝑚𝑚 𝑡𝑡 
𝐼𝐼𝑚𝑚 𝑡𝑡+1 = 𝐼𝐼𝑚𝑚 𝑡𝑡 + Π𝑓𝑓𝑆𝑆𝑚𝑚 𝑡𝑡 − (𝜇𝜇𝑚𝑚 + 𝜉𝜉𝑚𝑚)𝐼𝐼𝑚𝑚 𝑡𝑡 
2.5 
 
Implementation context: FSW community in Hillbrow, South Africa, and PrEP 
This comparison is undertaken at a time when PrEP has been demonstrated effective for populations 
at substantial risk of HIV.11 However concerns around sub-optimal adherence12,13 and behavioural 
disinhibition14,15 have led to interest in understanding the trade-offs associated with PrEP 
implementation outside of trial settings.16,17 Hillbrow is a pertinent setting for this assessment; a 
context with 72% HIV prevalence among FSW 8 and high prevalence among partner populations.18,19 
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PrEP has been rolled out for FSW in South Africa under the National Sex Worker HIV Plan (2016-
2019),20 however challenges in PrEP retention were observed in TaPS,21 a 2015-2017 PrEP and early 
antiretroviral treatment (ART) demonstration project among the Hillbrow FSW community. Given 
the challenges FSW face in negotiating condom use22 and the financial incentives for condomless sex 
with clients23, this is a timely case study, which we hope will contribute to decision makers’ 
understanding of the impact of reductions in condom use on PrEP effectiveness, should they be a 
program reality.  
 
Additional analyses 
Structural sensitivity analysis 
To assess whether the inclusion of ART, circumcision and STIs in the models affects their conclusions, 
we conducted a model structural sensitivity analysis by rerunning the analyses, having removed all 
parameters relating to: the reduction in HIV transmission on ART and ART coverage; the reduction in 
HIV transmission in peno-vaginal sex when the male partner is circumcised and the proportion of the 
male partner population that is circumcised; and the multiplicative increase in per sex act in the 
probability of HIV transmission in the presence of an STI and the probability at least one person in 
the partnership has an STI. 
 
Fully Endemic scenario 
To assess whether there is a significant difference in the model comparisons when PrEP is 
implemented when the HIV epidemics have fully endemic in the populations, in comparison to when 
they first reach equilibrium, the analyses are repeated with PrEP introduced in 2030, when the 
epidemics are fully established in both FSW and partner populations.
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Model parameterization  
The data and data sources used in the parameterisation and fitting of the models are set out in Table S1 below. Behavioural and epidemiological data are 
taken from Hillbrow, Johannesburg, where available, otherwise extrapolated from consistent high HIV burden contexts in South Africa.  
Parameter Symbol Estimate Low High  References 
Proportion of male partner 
population HIV infected 
𝑝𝑝𝑚𝑚 
 
0.02 0.0 0.05 There are significant challenges in identifying 
prevalence in clients of sex workers. As such, it is 
approximated by prevalence in migrant workers, an 
established client group of FSW in sub-Saharan 
Africa.24 
Year: 1980 
At the start of the epidemic, males are assumed 
(owing to lack of data) to have very low prevalence of 
HIV, between the values stated 
  0.259 0.203 0.325 Year: 2000 
Migrant workers, male, from KwaZulu-Natal, South 
Africa.25 
Low and high estimates are calculated as 95% CI from 
underlying data assuming binomially distributed. 
  0.339 0.275 0.410 Year: 2004 
Non-residents (study proxy for migrant work), men, 
from KwaZulu-Natal, South Africa.26 
Proportion of FSW 
population HIV infected 
𝑝𝑝𝑓𝑓 
 
0.05 0.0 0.1 Year: 1980 
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Parameter Symbol Estimate Low High  References 
 At the start of the epidemic, males are assumed 
(owing to lack of data) to have very low prevalence of 
HIV, between the values stated 
  0.45 0.3891956  
 
0.5123358 Year: 1997 
FSW, Johannesburg, South Africa.27 
Low and high estimates are calculated as 95% CI from 
underlying data assuming binomially distributed. 
  0.718 0.565 0.812 Year: 2014 
FSW Johannesburg, South Africa.8 
Initial condom consistency 
with partners 
𝛾𝛾0 0.05 0.0 0.1 Year: 1980 
At the start of the epidemic, condoms are assumed 
(owing to lack of data) to be used at very low levels, 
between the values stated. 
  0.764 (with 
clients) 
 
0.345 (non-
paying 
partner) 
0.902 (with 
clients) 
 
0.548 (non-
paying 
partner) 
0.609 (with 
clients) 
 
0.173 (non-
paying 
partner) 
Year: 2014 
FSW Johannesburg, South Africa.8 
 
Data used to inform the range of initial condom 
consistencies simulated in the analysis. 
Probability at least one 
person in the partnership 
has an STI 
𝑠𝑠0 0.21 0.15 0.3 Owing to limited data for this population, STI 
prevalence data is taken where available in relation to 
specific HIV-transmission increasing STIs28, and 
otherwise in relation to STI prevalence in general: 
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Parameter Symbol Estimate Low High  References 
Estimate: Prevalence of Neisseria gonorrhoea in 
Hillbrow FSW.29 
Low Estimate: Prevalence of Chlamydia trachomatis & 
Neisseria gonorrhoea in Hillbrow FSW.30  
High Estimate: FSW STI prevalence, Durban.31  
Proportion of HIV+ partner 
population on ART 
𝜗𝜗𝑚𝑚 0.257 0.212 0.308 Proportion of South African males having accessed 
treatment, 2012.7 
Proportion of HIV+ HRW 
women population on ART 
𝜗𝜗𝑓𝑓 0.234 0.506 0.088 Current ART status, FSW, Johannesburg, South Africa, 
2014.8 
Number of generic male 
partners, per 3 month period 
𝐶𝐶𝑚𝑚 106 78 128 Sum of: 
Mean monthly reported number of clients per FSW, 
Hillbrow; multiplied by 3, i.e. 105 (78-126);32 and  
Number of main sexual partners, FSW Hillbrow, i.e. 1 
(0.37-2).33  
Number of males’ female 
partners, per 3 month period 
𝐶𝐶𝑓𝑓 4.5 2.97 6.75 Average number of sex partners for high risk men in 
control arm.34  
Low and high estimates are calculated as 95% CI from 
underlying data assuming binomially distributed. 
Average number of sex acts 
– with generic male 
partners, per 3 month period 
𝑛𝑛𝑚𝑚 1.2  1.05 1.74 Weighted (by number of clients and number of main 
sexual partners stated in calculation of 𝐶𝐶𝑓𝑓) average of: 
- Number of sexual encounters per client, Hillbrow (1-
1.2),30 and   
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Parameter Symbol Estimate Low High  References 
- Mean monthly frequency of sex acts in main 
partnerships, Hillbrow, multiplied by 3: 24 (mid-point) 
(12-36).32 
Average number of males’ 
sex acts – with female 
partner, per 3 month period 
𝑛𝑛𝑓𝑓 6.3 4.5 9.0 Average frequency of sex acts in casual partnerships 
for people with high sexual activity, per month 2.1 
(1.5 – 3.0), multiplied by 3.30 
% male population 
circumcised 
𝜏𝜏 0.252 0.159 0.376 Year: 2003 
Men 15-59 years, Gauteng Province.10 
Low and High Estimates are calculated as 95% CI from 
underlying data assuming binomially distributed. 
  0.482 0.442 0.522 Year: 2012 
Adult males, Gauteng Province.7 
Condom HIV risk reduction 
efficacy per sex act 
𝜀𝜀 0.85 0.9 0.8 Midpoint:35 (with consistent use),36 (with consistent 
use) 
Probability of HIV 
transmission, male to 
female, through peno-
vaginal sex 
𝛽𝛽𝑓𝑓 0.0008 0.0006  0.0011 Per-act HIV-1 transmission probability, male to 
female37  
Probability of HIV 
transmission, female to 
male, through peno-vaginal 
sex 
𝛽𝛽𝑚𝑚 0.0004 0.0001 0.0014 Per-act HIV-1 transmission probability, female to 
male37 
Multiplicative increase in per 
sex act probability of HIV 
𝛿𝛿 3.7 2 6 Combined study effectiveness estimate across STDs, 
and range spanning individual STD combined study 
effect estimates38 
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Parameter Symbol Estimate Low High  References 
transmission in the presence 
of an STI 
Average reduction in 
probability HIV transmission 
on ART 
𝜚𝜚 0.92 0.99 0.9 Estimate:39 accounting for heterogeneity in sexual 
mixing and stage of infection, of all studies reviewed 
in systematic comparison.40 
Low and high: min and max of all studies.40 
Average reduction in 
probability HIV transmission 
to males, when male partner 
has been circumcised 
𝜎𝜎𝑚𝑚 0.6 0.66 0.44 Average,41 low and high risk from CI in42. 
Average reduction in 
probability HIV transmission 
to females, when male 
partner has been 
circumcised 
𝜎𝜎𝑓𝑓 0 0 0.2 Male circumcision; estimates of HIV infection in 
women.41  
Number of unit time steps 
(duration) spent in PrEP 
programme/ cascade 
following uptake 
h 3 months N/A N/A Frequency of HIV testing (minimum of all regular 
testing requirements) WHO Implementation Tool 
(2017).43 
Underlying population 
mortality rate per unit time 
step in females 
𝜇𝜇𝑓𝑓 0.003788 0.003571 0.00625 1/ life expectancy at birth, females, divided by 4 (for 3 
month time unit).44 
Underlying population 
mortality rate per unit time 
step in males 
𝜇𝜇𝑚𝑚  0.003968 0.003571 0.00625 1/ life expectancy at birth, females, divided by 4 (for 3 
month time unit).44 
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Parameter Symbol Estimate Low High  References 
Rate of AIDS deaths per unit 
time step, females  
𝜉𝜉𝑓𝑓 0.018775 0.012108 0.022353 As in,45 from,46 average time from HIV infection to 
death of 10.2 years. Multiplied by 4. Inverted and 
multiplied by (1- proportion of females on ART).  
Rate of AIDS deaths per unit 
time step, males  
𝜉𝜉𝑚𝑚 0.018211  0.016985 0.019436 As in,45 from, 46 average time from HIV infection to 
death of 10.2 years. Multiplied by 4. Inverted and 
multiplied by (1- proportion of males on ART). 
Table S1: Parameters and data sources used in the parameterisation and fitting of the models.  
Low and high estimates are 95% confidence intervals from the named sources, unless otherwise stated.  
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Supplementary Results 
Model fits to data 
The model fits to HIV prevalence corresponding to each level of initial condom consistency are 
shown below in Figure 1 for the Epidemic Equilibrium scenario, and for the Increasing Epidemic 
scenario in Figure 2. 
Epidemic Equilibrium Scenario 
Figure S1: Plots of fits to FSW and male partner population HIV prevalence over time calculated through the dynamic 
model for the Epidemic Equilibrium scenario. 
The plots are given distinctly for each level of initial condom consistency (in 2014) simulated, and in each case display the 
95% and 50% credible intervals and median of all fits. 
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Increasing Epidemic Scenario 
Figure S2: Plots of fits to FSW and male partner population HIV prevalence over time calculated through the dynamic 
model for the Increasing Epidemic scenario.  
The plots are given distinctly for each level of initial condom consistency (in 1994) simulated, and in each case display the 
95% and 50% credible intervals and median of all fits. 
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Model fits for additional analyses 
The model fits to HIV prevalence corresponding to each level of initial condom consistency for the 
structural sensitivity analysis are shown below in Figure 1 for the Epidemic Equilibrium scenario, and 
for the Increasing Epidemic scenario in Figure 2. 
Structural Sensitivity Analysis 
Epidemic Equilibrium Scenario 
Figure S3: Plots of fits to FSW and male partner population HIV prevalence over time calculated through the dynamic 
model for the Epidemic Equilibrium scenario under the structural sensitivity analysis.  
The plots are given distinctly for each level of initial condom consistency (in 2014) simulated, and in each case display the 
95% and 50% credible intervals and median of all fits. 
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Structural Sensitivity Analysis 
Increasing Epidemic Scenario 
Figure S4: Plots of fits to FSW and male partner population HIV prevalence over time calculated through the dynamic 
model for the Increasing Epidemic scenario under the structural sensitivity analysis.  
The plots are given distinctly for each level of initial condom consistency (in 1994) simulated, and in each case display the 
95% and 50% credible intervals and median of all fits. 
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Fully Endemic Scenario 
The model fits to HIV prevalence for the Fully Endemic analysis are the same as those for the 
Epidemic Equilibrium scenario – it is only PrEP that is implemented later in this analysis. 
Boxplots for additional analyses 
The 4x4 boxplots showing 1) the lowest level of condom consistency, and 2) the percentage 
reduction in condom consistency, tolerated following the introduction of PrEP for each of the 
scenarios evaluated are set out as follows: 
- Epidemic Equilibria scenario in Figure S5 and Figure S6 respectively;
- Increasing Epidemic scenario in Figure S7 and Figure S8 respectively;
- Structural sensitivity analysis - Epidemic Equilibrium scenario in Figure S9 and Figure S10
respectively;
- Structural sensitivity analysis – Increasing Epidemic scenario in Figure S11 and Figure S12
respectively; and
- Fully Endemic scenario in Figure S13 and Figure S14 respectively.
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Figure S5: Boxplots comparing the lowest level of condom consistency tolerated on PrEP (for HIV risk not to increase) predicted through the static and dynamic models – PrEP introduced 
at HIV Epidemic Equilibrium.  
The results are shown distinctly for initial condom consistencies (at point of introduction of PrEP) of 10%, 30%, 50% and 70%, and simulated for levels of achieved PrEP use-effectiveness at HIV 
risk reduction of 25%, 45%, 65% and 85%. In the case of the static model, the predicted lowest levels of condom consistency tolerated on PrEP are point estimates. In the case of the dynamic 
model, the predicted lowest levels of condom consistency tolerated on PrEP are given after 3 months, 1 year, 2 years, 5 years, 10 years and 20 years on PrEP. The boxplots depict uncertainty in 
the lowest levels of condom consistency tolerated, with the black line representing the median of all fits, the coloured section the interquartile range and the whiskers the maximum and 
minimum values. 
269 
Figure S6: Boxplots comparing the percentage reduction in condom consistency tolerated on PrEP (for HIV risk not to increase) predicted through the static and dynamic models – PrEP 
introduced at HIV Epidemic Equilibrium.  
The results are shown distinctly for initial condom consistencies (at point of introduction of PrEP) of 10%, 30%, 50% and 70%, and simulated for levels of achieved PrEP use-effectiveness at HIV 
risk reduction of 25%, 45%, 65% and 85%. In the case of the static model, the predicted percentage reductions in condom consistency tolerated on PrEP are point estimates. In the case of the 
dynamic model, the predicted percentage reductions in condom consistency tolerated on PrEP are given after 3 months, 1 year, 2 years, 5 years, 10 years and 20 years on PrEP. The boxplots 
depict uncertainty in the percentage reduction in condom consistency tolerated, with the black line representing the median of all fits, the coloured section the interquartile range and the 
whiskers the maximum and minimum values. 
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Figure S7: Boxplots comparing the lowest level of condom consistency tolerated on PrEP (for HIV risk not to increase) predicted through the static and dynamic models – PrEP introduced 
with Increasing Epidemic.  
The results are shown distinctly for initial condom consistencies (at point of introduction of PrEP) of 10%, 30%, 50% and 70%, and simulated for levels of achieved PrEP use-effectiveness at HIV 
risk reduction of 25%, 45%, 65% and 85%. In the case of the static model, the lowest levels of condom consistency tolerated on PrEP are point estimates. In the case of the dynamic model, the 
lowest levels of condom consistency tolerated on PrEP are given after 3 months, 1 year, 2 years, 5 years, 10 years and 20 years on PrEP. The boxplots depict uncertainty in the lowest levels of 
condom consistency tolerated, with the black line representing the median of all fits, the coloured section the interquartile range and the whiskers the maximum and minimum values. 
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Figure S8: Boxplots comparing the percentage reduction in condom consistency tolerated on PrEP (for HIV risk not to increase) predicted through the static and dynamic models – PrEP 
introduced with Increasing Epidemic.  
The results are shown distinctly for initial condom consistencies (at point of introduction of PrEP) of 10%, 30%, 50% and 70%, and simulated for levels of achieved PrEP use-effectiveness at HIV 
risk reduction of 25%, 45%, 65% and 85%. In the case of the static model, the predicted percentage reductions in condom consistency tolerated on PrEP are point estimates. In the case of the 
dynamic model, the predicted percentage reductions in condom consistency tolerated on PrEP are given after 3 months, 1 year, 2 years, 5 years, 10 years and 20 years on PrEP. The boxplots 
depict uncertainty in the percentage reduction in condom consistency tolerated, with the black line representing the median of all fits, the coloured section the interquartile range and the 
whiskers the maximum and minimum values. 
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Structural sensitivity analysis: Epidemic Equilibrium Scenario 
Figure S9: Boxplots comparing the lowest level of condom consistency tolerated on PrEP (for HIV risk not to increase) predicted through the static and dynamic models – PrEP 
introduced at HIV Epidemic Equilibrium under the structural sensitivity analysis.  
The results are shown distinctly for initial condom consistencies (at point of introduction of PrEP) of 10%, 30%, 50% and 70%, and simulated for levels of achieved PrEP use-effectiveness at HIV 
risk reduction of 25%, 45%, 65% and 85%. In the case of the static model, the lowest levels of condom consistency tolerated on PrEP are point estimates. In the case of the dynamic model, the 
lowest level of condom consistency tolerated on PrEP are given after 3 months, 1 year, 2 years, 5 years, 10 years and 20 years on PrEP. The boxplots depict uncertainty in the lowest level of 
condom consistency tolerated, with the black line representing the median of all fits, the coloured section the interquartile range and the whiskers the maximum and minimum values. 
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Figure S10: Boxplots comparing the percentage reduction in condom consistency tolerated on PrEP (for HIV risk not to increase) predicted through the static and dynamic models – PrEP 
introduced at HIV Epidemic Equilibrium under the structural sensitivity analysis.  
The results are shown distinctly for initial condom consistencies (at point of introduction of PrEP) of 10%, 30%, 50% and 70%, and simulated for levels of achieved PrEP use-effectiveness at HIV 
risk reduction of 25%, 45%, 65% and 85%. In the case of the static model, the predicted percentage reductions in condom consistency tolerated on PrEP are point estimates. In the case of the 
dynamic model, the predicted percentage reductions in condom consistency tolerated on PrEP are given after 3 months, 1 year, 2 years, 5 years, 10 years and 20 years on PrEP. The boxplots 
depict uncertainty in the percentage reduction in condom consistency tolerated, with the black line representing the median of all fits, the coloured section the interquartile range and the 
whiskers the maximum and minimum values. 
274 
Structural sensitivity analysis: Increasing Epidemic Scenario 
Figure S11: Boxplots comparing the lowest level of condom consistency tolerated on PrEP (for HIV risk not to increase) predicted through the static and dynamic models – PrEP 
introduced with Increasing Epidemic under the structural sensitivity analysis.  
The results are shown distinctly for initial condom consistencies (at point of introduction of PrEP) of 10%, 30%, 50% and 70%, and simulated for levels of achieved PrEP use-effectiveness at HIV 
risk reduction of 25%, 45%, 65% and 85%. In the case of the static model, the lowest levels of condom consistency tolerated on PrEP are point estimates. In the case of the dynamic model, the 
lowest levels of condom consistency tolerated on PrEP are given after 3 months, 1 year, 2 years, 5 years, 10 years and 20 years on PrEP. The boxplots depict uncertainty in the lowest level of 
condom consistency tolerated, with the black line representing the median of all fits, the coloured section the interquartile range and the whiskers the maximum and minimum values. 
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Figure S12: Boxplots comparing the percentage reduction in condom consistency tolerated on PrEP (for HIV risk not to increase) predicted through the static and dynamic models – PrEP 
introduced with Increasing Epidemic under the structural sensitivity analysis.  
The results are shown distinctly for initial condom consistencies (at point of introduction of PrEP) of 10%, 30%, 50% and 70%, and simulated for levels of achieved PrEP use-effectiveness at HIV 
risk reduction of 25%, 45%, 65% and 85%. In the case of the static model, the predicted percentage reductions in condom consistency tolerated on PrEP are point estimates. In the case of the 
dynamic model, the predicted percentage reductions in condom consistency tolerated on PrEP are given after 3 months, 1 year, 2 years, 5 years, 10 years and 20 years on PrEP. The boxplots 
depict uncertainty in the percentage reduction in condom consistency tolerated, with the black line representing the median of all fits, the coloured section the interquartile range and the 
whiskers the maximum and minimum values.
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Fully Endemic Scenario 
Figure S13: Boxplots comparing the lowest level of condom consistency tolerated on PrEP (for HIV risk not to increase) predicted through the static and dynamic models – PrEP 
introduced with the Fully Endemic scenario.  
The results are shown distinctly for initial condom consistencies (at point of introduction of PrEP) of 10%, 30%, 50% and 70%, and simulated for levels of achieved PrEP use-effectiveness at HIV 
risk reduction of 25%, 45%, 65% and 85%. In the case of the static model, the lowest levels of condom consistency tolerated on PrEP are point estimates. In the case of the dynamic model, the 
lowest levels of condom consistency tolerated on PrEP are given after 3 months, 1 year, 2 years, 5 years, 10 years and 20 years on PrEP. The boxplots depict uncertainty in the lowest levels of 
condom consistency tolerated, with the black line representing the median of all fits, the coloured section the interquartile range and the whiskers the maximum and minimum values. 
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Figure S14: Boxplots comparing the percentage reduction in condom consistency tolerated on PrEP (for HIV risk not to increase) predicted through the static and dynamic models – PrEP 
introduced with the Fully Endemic scenario.  
The results are shown distinctly for initial condom consistencies (at point of introduction of PrEP) of 10%, 30%, 50% and 70%, and simulated for levels of achieved PrEP use-effectiveness at HIV 
risk reduction of 25%, 45%, 65% and 85%. In the case of the static model, the predicted percentage reductions in condom consistency tolerated on PrEP are point estimates. In the case of the 
dynamic model, the predicted percentage reductions in condom consistency tolerated on PrEP are given after 3 months, 1 year, 2 years, 5 years, 10 years and 20 years on PrEP. The boxplots 
depict uncertainty in the percentage reduction in condom consistency tolerated, with the black line representing the median of all fits, the coloured section the interquartile range and the 
whiskers the maximum and minimum values.
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Tables of Results 
Percentage Reduction in Condom Consistency Tolerated: Tables of percentage change between 
static and dynamic model’s outcomes 
The percentage change between the median and 95% credible interval (CrI) of the static and 
dynamic models’ predictions of the percentage change in condom consistency tolerated over the 
time horizon for both the Epidemic Equilibrium and Increasing Epidemic scenarios are shown in 
Tables S2a and S2b respectively. 
Epidemic Equilibrium Scenario 
Table S2a: Epidemic Equilibrium Scenario: Percentage change between the static and dynamic models’ prediction of the 
percentage change in condom consistency tolerated, when the dynamic model is run over a time horizon of 3 months to 
20 years. 
Increasing Epidemic Scenario 
Table S2b: Increasing Epidemic Scenario: Percentage change between the static and dynamic models’ prediction of the 
percentage change in condom consistency tolerated, when the dynamic model is run over a time horizon of 3 months to 
20 years.  
Tables S2a and S2b respectively show for the scenarios where PrEP is introduced at Epidemic Equilibrium and where PrEP is 
introduced with Increasing Epidemic the percentage change between the static and dynamic models’ prediction of the 
% Change between Static Model and Dynamic Model after
Initial 
Condom 
Consistency
PrEP 
Effectiveness 3 months 1 year 2 years 5 years 10 years 20 years
0.1 0.25 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0.8 % , 0 % )
0.1 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.85 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0.1 % , 0 % )
0.3 0.25 -1.9 %  ( -0.7 % , -1.4 % ) -0.1 %  ( 2.8 % , -0.8 % ) 2 %  ( 9.2 % , -3.3 % ) 4 %  ( 23.5 % , -10.8 % ) 3.6 %  ( 100 % , -19.2 % ) 4 %  ( 67.2 % , -19.2 % )
0.3 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 29.2 % , 0 % )
0.3 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.25 -2.1 %  ( -2 % , -1.5 % ) -2.1 %  ( 1.7 % , -1.5 % ) -2.4 %  ( 10.7 % , -2.7 % ) -2.9 %  ( 32 % , -15.5 % ) -4.4 %  ( 100 % , -28.3 % ) -5.9 %  ( 92 % , -38.9 % )
0.5 0.45 -0.8 %  ( -1.2 % , -0.8 % ) 3.7 %  ( 3.8 % , 5.2 % ) 7.2 %  ( 10.5 % , 8.5 % ) 13.3 %  ( 26.3 % , 13.1 % ) 17.9 %  ( 100 % , 11.8 % ) 21.9 %  ( 62.6 % , 11 % )
0.5 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 32.4 % , 0 % )
0.5 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
0.7 0.25 -2.7 %  ( -1.9 % , -2.3 % ) -4.3 %  ( 1.9 % , -3.7 % ) -8.7 %  ( 7.5 % , -9.3 % ) -13.6 %  ( 27.5 % , -24.7 % ) -19 %  ( 100 % , -40.5 % ) -20.1 %  ( 100 % , -56.7 % )
0.7 0.45 -1.2 %  ( -1.1 % , -1.4 % ) 2.3 %  ( 3.2 % , 2.4 % ) 5.1 %  ( 8.4 % , 5.4 % ) 7.6 %  ( 22.2 % , 5.8 % ) 11.1 %  ( 100 % , 4.8 % ) 14.1 %  ( 66.8 % , 1.2 % )
0.7 0.65 -0.7 %  ( -0.5 % , 0 % ) 5.9 %  ( 5.8 % , 1.2 % ) 12.1 %  ( 11.8 % , 8.1 % ) 20.5 %  ( 24.8 % , 15.9 % ) 26.1 %  ( 100 % , 20.5 % ) 30.6 %  ( 53.5 % , 21 % )
0.7 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0.7 % , 0 % )
% Change between Static Model and Dynamic Model after
Initial 
Condom 
Consistency
PrEP 
Effectiveness 3 months 1 year 2 years 5 years 10 years 20 years
0.1 0.25 0 %  ( 0 % , 0 % ) 0 %  ( 4.3 % , 0 % ) 48.7 %  ( 87.5 % , 5.3 % ) 100 %  ( 100 % , 100 % ) 100 %  ( 100 % , 100 % ) 100 %  ( 100 % , 20.1 % )
0.1 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 4.5 %  ( 69.6 % , 0 % ) 87 %  ( 100 % , 0 % ) 18.4 %  ( 100 % , 0 % )
0.1 0.65 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.85 0.1 %  ( 0.2 % , 0 % ) 0.1 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % )
0.3 0.25 8.8 %  ( 9.3 % , 9 % ) 43.8 %  ( 50.6 % , 40.8 % ) 73.1 %  ( 89.8 % , 62.2 % ) 100 %  ( 100 % , 93.3 % ) 100 %  ( 100 % , 100 % ) 100 %  ( 100 % , 67.7 % )
0.3 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 9.5 % , 0 % ) 22.2 %  ( 41.1 % , 2.5 % ) 66.8 %  ( 89.2 % , 44 % ) 90.1 %  ( 100 % , 61.2 % ) 71.1 %  ( 100 % , 28.5 % )
0.3 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 21.1 % , 0 % ) 22.8 %  ( 63.1 % , 0 % ) 5.7 %  ( 66 % , 0 % )
0.3 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.25 7.1 %  ( 7.1 % , 7.8 % ) 37.2 %  ( 40.7 % , 34.4 % ) 63.1 %  ( 76.8 % , 55 % ) 100 %  ( 100 % , 82.9 % ) 100 %  ( 100 % , 90.5 % ) 100 %  ( 100 % , 50.3 % )
0.5 0.45 4.1 %  ( 3.5 % , 4.4 % ) 27.8 %  ( 27.8 % , 27.6 % ) 45.9 %  ( 48.5 % , 44.2 % ) 72.5 %  ( 83.2 % , 65.2 % ) 86.9 %  ( 100 % , 73.5 % ) 75.4 %  ( 100 % , 54.6 % )
0.5 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 6.7 %  ( 20.4 % , 0 % ) 38.4 %  ( 52.4 % , 21.3 % ) 54.7 %  ( 72.7 % , 35.2 % ) 46.8 %  ( 76.1 % , 15.8 % )
0.5 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 4.7 % , 0 % )
0.7 0.25 5.9 %  ( 4.5 % , 5.6 % ) 32.4 %  ( 31.2 % , 28.7 % ) 54.3 %  ( 61.1 % , 47.2 % ) 92.6 %  ( 100 % , 76.4 % ) 100 %  ( 100 % , 90.3 % ) 91 %  ( 100 % , 47.2 % )
0.7 0.45 2.8 %  ( 2.2 % , 3.1 % ) 23.9 %  ( 22.6 % , 22.7 % ) 40.8 %  ( 39.9 % , 38.6 % ) 66.3 %  ( 73.6 % , 60.3 % ) 80 %  ( 100 % , 70.5 % ) 71.6 %  ( 100 % , 52.4 % )
0.7 0.65 2.1 %  ( 1.6 % , 0 % ) 23.7 %  ( 21.6 % , 16.4 % ) 37.5 %  ( 36.8 % , 31.9 % ) 57.9 %  ( 59.8 % , 53 % ) 68.5 %  ( 75.1 % , 61.9 % ) 63.8 %  ( 81.7 % , 52 % )
0.7 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 5.6 %  ( 21 % , 0 % ) 22.5 %  ( 39.7 % , 2.5 % ) 15.5 %  ( 47.1 % , 0 % )
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percentage change in condom consistency tolerated, when the dynamic model is run over a time horizon of 3 months to 20 
years. The percentage change values stated outside the brackets are the percentage change between the median values 
predicted by the static and dynamic models, and the values in the left and right of the bracket are the percentage change 
between the lower and upper 95% credible intervals predicted by the static and dynamic models respectively.  
Additional analyses – Structural sensitivity analysis 
The percentage change between the median and 95% credible interval (CrI) of the static and 
dynamic models’ predictions of the percentage change in condom consistency tolerated over the 
time horizon for both the Epidemic Equilibrium and Increasing Epidemic scenarios for the structural 
sensitivity analysis are shown in Tables S3a and S3b respectively. 
Structural Sensitivity Analysis 
Epidemic Equilibrium Scenario 
Table S3a: Structural sensitivity analysis: Epidemic Equilibrium Scenario: Percentage change between the static and 
dynamic models’ prediction of the percentage change in condom consistency tolerated, when the dynamic model is run 
over a time horizon of 3 months to 20 years. 
% Change between Static Model and Dynamic Model after
Initial 
Condom 
Consistency
PrEP 
Effectiveness 3 months 1 year 2 years 5 years 10 years 20 years
0.1 0.25 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 42.3 % , 0 % )
0.1 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.85 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0.1 % , 0 % )
0.3 0.25 0.8 %  ( 0.9 % , 0 % ) 10.9 %  ( 11.6 % , 4.1 % ) 20.1 %  ( 23.7 % , 11.2 % ) 34.7 %  ( 45.3 % , 22.5 % ) 44.5 %  ( 100 % , 27.2 % ) 49.9 %  ( 82.6 % , 26 % )
0.3 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 13.4 % , 0 % )
0.3 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.25 0.4 %  ( 0.5 % , 0.6 % ) 8.8 %  ( 10.7 % , 7.6 % ) 16.8 %  ( 22.7 % , 13.9 % ) 30.1 %  ( 49.8 % , 23.5 % ) 39.6 %  ( 100 % , 27.4 % ) 46.2 %  ( 100 % , 28.2 % )
0.5 0.45 0 %  ( 0 % , 0 % ) 0.6 %  ( 10.1 % , 0 % ) 10.5 %  ( 20 % , 0.4 % ) 25.1 %  ( 37.9 % , 14.7 % ) 35.1 %  ( 100 % , 23.5 % ) 41.8 %  ( 70.8 % , 29.1 % )
0.5 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 7.1 % , 0 % )
0.5 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
0.7 0.25 -0.9 %  ( 0 % , 0.4 % ) 5.3 %  ( 8 % , 5 % ) 11.9 %  ( 20.1 % , 8.8 % ) 22 %  ( 47.7 % , 13 % ) 30.4 %  ( 100 % , 12.6 % ) 37.4 %  ( 100 % , 10.3 % )
0.7 0.45 -0.4 %  ( 0 % , 0.6 % ) 7.7 %  ( 8.6 % , 8.6 % ) 15.3 %  ( 17.4 % , 15.6 % ) 28.4 %  ( 36.6 % , 25 % ) 36.8 %  ( 100 % , 30.9 % ) 43.8 %  ( 78.7 % , 34.5 % )
0.7 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 2.3 % , 0 % ) 0.6 %  ( 13 % , 0 % ) 17.4 %  ( 29.8 % , 4.6 % ) 29 %  ( 100 % , 15.2 % ) 36.6 %  ( 57.4 % , 22.1 % )
0.7 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
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Structural Sensitivity Analysis 
Increasing Epidemic Scenario 
Table S3b: Structural sensitivity analysis: Increasing Epidemic Scenario: Percentage change between the static and 
dynamic models’ prediction of the percentage change in condom consistency tolerated, when the dynamic model is run 
over a time horizon of 3 months to 20 years. 
Tables S3a and S3b respectively show, for the scenarios where PrEP is introduced at Epidemic Equilibrium and where PrEP is 
introduced with Increasing Epidemic under the structural sensitivity analysis, the percentage change between the static and 
dynamic models’ prediction of the percentage change in condom consistency tolerated, when the dynamic model is run over 
a time horizon of 3 months to 20 years. The percentage change values stated outside the brackets are the percentage 
change between the median values predicted by the static and dynamic models, and the values in the left and right of the 
bracket are the percentage change between the lower and upper 95% credible intervals predicted by the static and dynamic 
models respectively.  
Additional analyses - Fully Endemic scenario 
The percentage change between the median and 95% credible interval (CrI) of the static and 
dynamic models’ predictions of the percentage change in condom consistency tolerated over the 
time horizon for the additional scenario Fully Endemic (PrEP introduced in 2030) is shown in Table 
S4. 
% Change between Static Model and Dynamic Model after
Initial 
Condom 
Consistency
PrEP 
Effectiveness 3 months 1 year 2 years 5 years 10 years 20 years
0.1 0.25 0 %  ( 0 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 9.2 %  ( 51.6 % , 0 % ) 100 %  ( 100 % , 93.9 % ) 100 %  ( 100 % , 100 % ) 100 %  ( 100 % , 100 % )
0.1 0.45 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0 % , 0 % ) 90.7 %  ( 100 % , 0 % ) 100 %  ( 100 % , 51 % )
0.1 0.65 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 32.2 % , 0 % )
0.1 0.85 0.1 %  ( 0.2 % , 0 % ) 0.1 %  ( 0.2 % , 0 % ) 0.1 %  ( 0.2 % , 0 % ) 0.1 %  ( 0.2 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % )
0.3 0.25 9.1 %  ( 9.9 % , 3.8 % ) 43.3 %  ( 48.7 % , 35.5 % ) 71.6 %  ( 81.8 % , 58.7 % ) 100 %  ( 100 % , 95.2 % ) 100 %  ( 100 % , 100 % ) 100 %  ( 100 % , 100 % )
0.3 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 3.4 % , 0 % ) 50.4 %  ( 68.9 % , 25.6 % ) 91.8 %  ( 100 % , 63.5 % ) 100 %  ( 100 % , 87.9 % )
0.3 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 27.8 % , 0 % ) 47.1 %  ( 90.6 % , 2.2 % )
0.3 0.85 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.25 7.1 %  ( 8 % , 7.1 % ) 37.3 %  ( 42 % , 34.5 % ) 64.2 %  ( 73.8 % , 55.4 % ) 100 %  ( 100 % , 86.3 % ) 100 %  ( 100 % , 100 % ) 100 %  ( 100 % , 100 % )
0.5 0.45 0 %  ( 3.1 % , 0 % ) 21.1 %  ( 30 % , 12.7 % ) 41.7 %  ( 50.7 % , 32.8 % ) 71.8 %  ( 82.6 % , 60.1 % ) 92.7 %  ( 100 % , 76.3 % ) 100 %  ( 100 % , 89 % )
0.5 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 13.6 %  ( 30.7 % , 0 % ) 46.5 %  ( 64.4 % , 25.3 % ) 72.3 %  ( 94.3 % , 46.2 % )
0.5 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 6.1 % , 0 % )
0.7 0.25 5.7 %  ( 6.1 % , 6.2 % ) 30 %  ( 32.8 % , 26.3 % ) 53 %  ( 60.6 % , 44.4 % ) 92.6 %  ( 100 % , 71.8 % ) 100 %  ( 100 % , 91.9 % ) 100 %  ( 100 % , 100 % )
0.7 0.45 3 %  ( 3.3 % , 3.1 % ) 23.8 %  ( 24.9 % , 23.1 % ) 40.8 %  ( 43.1 % , 38 % ) 66.3 %  ( 73.2 % , 58 % ) 85.8 %  ( 98.6 % , 71.8 % ) 100 %  ( 100 % , 83.6 % )
0.7 0.65 0 %  ( 0 % , 0 % ) 4.4 %  ( 18 % , 0 % ) 24 %  ( 35.6 % , 13.2 % ) 50.3 %  ( 60 % , 37.2 % ) 67.6 %  ( 77.4 % , 52.2 % ) 82.7 %  ( 95.9 % , 64.3 % )
0.7 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 16.9 % , 0 % ) 25.5 %  ( 47.4 % , 0 % )
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Fully Endemic Scenario 
Table S4: Percentage change between the static and dynamic models’ prediction of the percentage change in condom 
consistency tolerated, when the dynamic model is run over a time horizon of 3 months to 20 years, under the Fully 
Endemic scenario.  
The percentage change values stated outside the brackets are the percentage change between the median values predicted 
by the static and dynamic models, and the values in the left and right of the bracket are the percentage change between 
the lower and upper 95% credible intervals predicted by the static and dynamic models respectively.  
% Change between Static Model and Dynamic Model after
Initial 
Condom 
Consistency
PrEP 
Effectiveness 3 months 1 year 2 years 5 years 10 years 20 years
0.1 0.25 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.65 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.85 0 %  ( 0.1 % , 0 % ) 0.1 %  ( 0.1 % , 0 % ) 0 %  ( 0.2 % , 0 % ) 0 %  ( 0.1 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0.1 % , 0 % )
0.3 0.25 -0.9 %  ( -1 % , -0.6 % ) 3.5 %  ( 4.2 % , 4.9 % ) 8.2 %  ( 10.3 % , 7.3 % ) 15.8 %  ( 24.6 % , 9.4 % ) 22.1 %  ( 100 % , 8.9 % ) 26.8 %  ( 53.3 % , 7.9 % )
0.3 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 2.1 %  ( 23 % , 0 % )
0.3 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.25 -0.6 %  ( -1 % , -0.7 % ) 4.1 %  ( 4 % , 3 % ) 8.2 %  ( 12 % , 5.7 % ) 15.7 %  ( 35.1 % , 4.7 % ) 20.4 %  ( 100 % , 1.2 % ) 25.4 %  ( 81.6 % , 0.5 % )
0.5 0.45 -0.4 %  ( -0.4 % , -0.5 % ) 7.2 %  ( 6.7 % , 6.8 % ) 13.8 %  ( 13.6 % , 13.4 % ) 24.4 %  ( 27 % , 22.1 % ) 31.6 %  ( 100 % , 25.5 % ) 37.8 %  ( 57.4 % , 28.3 % )
0.5 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 3.6 % , 0 % ) 0.3 %  ( 100 % , 0 % ) 9.7 %  ( 28.8 % , 0 % )
0.5 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
0.7 0.25 -1.1 %  ( -1.3 % , 0 % ) 2.1 %  ( 2.5 % , 2.3 % ) 6.3 %  ( 13.2 % , 2.3 % ) 11.1 %  ( 44.7 % , 0 % ) 15.8 %  ( 100 % , -6.4 % ) 18.9 %  ( 100 % , -10 % )
0.7 0.45 -0.9 %  ( -0.8 % , -0.2 % ) 5.9 %  ( 5.4 % , 6.7 % ) 12.2 %  ( 11.4 % , 12.1 % ) 22.4 %  ( 28.5 % , 19 % ) 29.3 %  ( 100 % , 23.5 % ) 35.8 %  ( 63.7 % , 24.4 % )
0.7 0.65 -0.5 %  ( -0.5 % , 0 % ) 9.2 %  ( 9.4 % , 1.3 % ) 17.9 %  ( 16.9 % , 10.5 % ) 29.9 %  ( 29.5 % , 22.8 % ) 37.9 %  ( 100 % , 29.3 % ) 43.6 %  ( 50.5 % , 34.7 % )
0.7 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 12.6 % , 0 % )
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Lowest Level of Condom Consistency Tolerated: Tables of absolute difference between static and 
dynamic model’s outcomes 
 
The absolute difference between the median and 95% credible interval (CrI) of the static and 
dynamic models’ predictions of the lowest level of condom consistency tolerated over the time 
horizon for both the Epidemic Equilibrium and Increasing Epidemic scenarios are shown in Tables S5a 
and S5b respectively. 
Epidemic Equilibrium Scenario 
 
Table S5a: Epidemic Equilibrium Scenario: Absolute difference between the static and dynamic models’ prediction of the 
lowest level of condom consistency tolerated, when the dynamic model is run over a time horizon of 3 months to 20 
years. 
 
Increasing Epidemic Scenario 
 
Table S5b: Increasing Epidemic Scenario: Absolute difference between the static and dynamic models’ prediction of the 
lowest level of condom consistency tolerated, when the dynamic model is run over a time horizon of 3 months to 20 
years.  
Absolute Difference between Initial Condom Consistency and Lowest Level of Condom Consistency on PrEP
Initial 
Condom 
Consistency
PrEP 
Effectiveness 3 months 1 year 2 years 5 years 10 years 20 years
0.1 0.25 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -0.1 % )
0.1 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.25 0.4 %  ( 0.3 % , 0.1 % ) 0 %  ( 0.2 % , -0.5 % ) -0.5 %  ( 0.8 % , -1.7 % ) -0.9 %  ( 2.7 % , -4.3 % ) -0.8 %  ( 4.8 % , -7.5 % ) -0.9 %  ( 4.8 % , -12.3 % )
0.3 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -3.1 % ) 0 %  ( 0 % , -8.8 % )
0.3 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.25 0.3 %  ( 0.3 % , 0.3 % ) 0.3 %  ( 0.3 % , -0.3 % ) 0.3 %  ( 0.6 % , -1.6 % ) 0.5 %  ( 3.2 % , -4.8 % ) 0.7 %  ( 5.7 % , -8.5 % ) 1 %  ( 7.9 % , -13.8 % )
0.5 0.45 0.3 %  ( 0.3 % , 0.4 % ) -1.5 %  ( -2.6 % , -1.3 % ) -2.8 %  ( -4.2 % , -3.6 % ) -5.2 %  ( -6.3 % , -9 % ) -7 %  ( -5.7 % , -14.1 % ) -8.5 %  ( -5.4 % , -21.5 % )
0.5 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -6.5 % ) 0 %  ( 0 % , -16.2 % )
0.5 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.7 0.25 0.3 %  ( 0.4 % , 0.2 % ) 0.5 %  ( 0.6 % , -0.2 % ) 1.1 %  ( 1.5 % , -0.8 % ) 1.7 %  ( 3.8 % , -3.1 % ) 2.4 %  ( 6.2 % , -6.9 % ) 2.6 %  ( 8.6 % , -12.8 % )
0.7 0.45 0.4 %  ( 0.5 % , 0.3 % ) -0.7 %  ( -0.9 % , -0.8 % ) -1.5 %  ( -1.9 % , -2.2 % ) -2.3 %  ( -2 % , -5.7 % ) -3.4 %  ( -1.7 % , -10.3 % ) -4.3 %  ( -0.4 % , -17.3 % )
0.7 0.65 0.4 %  ( 0 % , 0.2 % ) -3.7 %  ( -0.8 % , -3.1 % ) -7.5 %  ( -5.7 % , -6.3 % ) -12.8 %  ( -11.1 % , -13.3 % ) -16.4 %  ( -14.4 % , -19.2 % ) -19.2 %  ( -14.7 % , -28.5 % )
0.7 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -0.5 % )
Absolute Difference between Initial Condom Consistency and Lowest Level of Condom Consistency on PrEP
Initial 
Condom 
Consistency
PrEP 
Effectiveness 3 months 1 year 2 years 5 years 10 years 20 years
0.1 0.25 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -0.4 % ) -4.9 %  ( -0.5 % , -8.8 % ) -16.6 %  ( -10.5 % , -22.4 % ) -22.4 %  ( -14.4 % , -30.6 % ) -15.2 %  ( -2 % , -28.8 % )
0.1 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) -0.4 %  ( 0 % , -7 % ) -8.7 %  ( 0 % , -17.4 % ) -1.8 %  ( 0 % , -15.3 % )
0.1 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.25 -1.9 %  ( -2.3 % , -1.6 % ) -9.1 %  ( -10.1 % , -8.9 % ) -15.2 %  ( -15.3 % , -15.9 % ) -24.9 %  ( -22.9 % , -27.5 % ) -30.1 %  ( -25.7 % , -35.3 % ) -24.2 %  ( -16.7 % , -35.8 % )
0.3 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -2.9 % ) -6.7 %  ( -0.8 % , -12.3 % ) -20 %  ( -13.2 % , -26.8 % ) -27 %  ( -18.4 % , -36.3 % ) -21.3 %  ( -8.5 % , -37.3 % )
0.3 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -6.3 % ) -6.9 %  ( 0 % , -18.9 % ) -1.7 %  ( 0 % , -19.8 % )
0.3 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.25 -1.2 %  ( -1.6 % , -1 % ) -6.4 %  ( -6.8 % , -6 % ) -10.7 %  ( -10.9 % , -11.3 % ) -18.2 %  ( -16.5 % , -20.4 % ) -22.1 %  ( -18 % , -26.8 % ) -17.2 %  ( -10 % , -26.9 % )
0.5 0.45 -1.5 %  ( -2.1 % , -1.2 % ) -10.9 %  ( -12.9 % , -9.5 % ) -18 %  ( -20.7 % , -16.5 % ) -28.4 %  ( -30.5 % , -28.3 % ) -34.1 %  ( -34.4 % , -36.2 % ) -29.6 %  ( -25.6 % , -37.3 % )
0.5 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) -3.3 %  ( 0 % , -10.2 % ) -19.2 %  ( -10.6 % , -26.2 % ) -27.4 %  ( -17.6 % , -36.4 % ) -23.4 %  ( -7.9 % , -38 % )
0.5 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -2.4 % )
0.7 0.25 -0.8 %  ( -0.8 % , -0.5 % ) -4.3 %  ( -4.3 % , -3.4 % ) -7.2 %  ( -7.2 % , -6.7 % ) -12.2 %  ( -11.5 % , -13.3 % ) -15.3 %  ( -13.6 % , -18.1 % ) -12 %  ( -7.1 % , -19.6 % )
0.7 0.45 -0.9 %  ( -1.1 % , -0.6 % ) -7.3 %  ( -8.1 % , -5.7 % ) -12.4 %  ( -13.8 % , -10.1 % ) -20.2 %  ( -21.6 % , -18.7 % ) -24.4 %  ( -25.2 % , -25.4 % ) -21.8 %  ( -18.8 % , -27.2 % )
0.7 0.65 -1.3 %  ( 0 % , -0.9 % ) -14.8 %  ( -11.5 % , -11.2 % ) -23.5 %  ( -22.3 % , -19.3 % ) -36.3 %  ( -37.1 % , -31.3 % ) -43 %  ( -43.3 % , -39.3 % ) -40.1 %  ( -36.4 % , -42.7 % )
0.7 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) -3.9 %  ( 0 % , -14.7 % ) -15.8 %  ( -1.8 % , -27.8 % ) -10.8 %  ( 0 % , -33 % )
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Tables S5a and S5b respectively show for the scenarios where PrEP is introduced at Epidemic Equilibrium and where PrEP is 
introduced with Increasing Epidemic the absolute difference between the static and dynamic models’ prediction of the 
lowest level of condom consistency tolerated, when the dynamic model is run over a time horizon of 3 months to 20 years. 
The values stated outside the brackets are the absolute difference between the median values predicted by the static and 
dynamic models, and the values in the left and right of the bracket are the absolute difference between the lower and upper 
95% credible intervals predicted by the static and dynamic models respectively.  
 
Additional analyses – Structural sensitivity analysis 
The absolute difference between the median and 95% credible interval (CrI) of the static and 
dynamic models’ predictions of the lowest level of condom consistency tolerated over the time 
horizon for both the Epidemic Equilibrium and Increasing Epidemic scenarios for the structural 
sensitivity analysis are shown in Tables S6a and S6b respectively. 
Structural Sensitivity Analysis 
Epidemic Equilibrium Scenario 
 
Table S6a: Structural sensitivity analysis: Epidemic Equilibrium Scenario: Absolute difference between the static and 
dynamic models’ prediction of the lowest level of condom consistency tolerated, when the dynamic model is run over a 
time horizon of 3 months to 20 years. 
 
 
 
 
 
 
 
Absolute Difference between Initial Condom Consistency and Lowest Level of Condom Consistency on PrEP
Initial 
Condom 
Consistency
PrEP 
Effectiveness 3 months 1 year 2 years 5 years 10 years 20 years
0.1 0.25 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -4.2 % )
0.1 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.25 -0.2 %  ( 0 % , -0.3 % ) -3.2 %  ( -1.2 % , -3.2 % ) -5.9 %  ( -3.4 % , -6.5 % ) -10.2 %  ( -6.8 % , -12.3 % ) -13.1 %  ( -8.2 % , -17.4 % ) -14.7 %  ( -7.8 % , -22.5 % )
0.3 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -4 % )
0.3 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.25 -0.1 %  ( -0.1 % , -0.1 % ) -2 %  ( -1.8 % , -2.2 % ) -3.8 %  ( -3.4 % , -4.7 % ) -6.8 %  ( -5.8 % , -10.2 % ) -9 %  ( -6.8 % , -15.8 % ) -10.5 %  ( -7 % , -22.3 % )
0.5 0.45 0 %  ( 0 % , 0 % ) -0.3 %  ( 0 % , -5 % ) -5.2 %  ( -0.2 % , -10 % ) -12.5 %  ( -7.4 % , -18.9 % ) -17.5 %  ( -11.8 % , -27.7 % ) -20.9 %  ( -14.5 % , -35.4 % )
0.5 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -3.5 % )
0.5 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.7 0.25 0.1 %  ( -0.1 % , 0 % ) -0.9 %  ( -0.9 % , -1.1 % ) -1.9 %  ( -1.7 % , -2.7 % ) -3.5 %  ( -2.4 % , -6.6 % ) -4.8 %  ( -2.4 % , -12.6 % ) -6 %  ( -1.9 % , -19.3 % )
0.7 0.45 0.1 %  ( -0.3 % , 0 % ) -3 %  ( -3.9 % , -2.9 % ) -6 %  ( -7 % , -5.9 % ) -11.1 %  ( -11.2 % , -12.5 % ) -14.4 %  ( -13.9 % , -18.9 % ) -17.1 %  ( -15.5 % , -26.9 % )
0.7 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -1.6 % ) -0.4 %  ( 0 % , -9.1 % ) -12.2 %  ( -3.2 % , -20.9 % ) -20.3 %  ( -10.6 % , -31.4 % ) -25.6 %  ( -15.4 % , -40.2 % )
0.7 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
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Structural Sensitivity Analysis 
Increasing Epidemic Scenario 
 
Table 6b: Structural sensitivity analysis: Increasing Epidemic Scenario: Absolute difference between the static and 
dynamic models’ prediction of the lowest level of condom consistency tolerated, when the dynamic model is run over a 
time horizon of 3 months to 20 years. 
Tables S6a and S6b respectively show, for the scenarios where PrEP is introduced at Epidemic Equilibrium and where PrEP is 
introduced with Increasing Epidemic under the structural sensitivity analysis, the absolute difference between the static and 
dynamic models’ prediction of the lowest level of condom consistency tolerated, when the dynamic model is run over a time 
horizon of 3 months to 20 years. The values stated outside the brackets are the absolute difference between the median 
values predicted by the static and dynamic models, and the values in the left and right of the bracket are the absolute 
difference between the lower and upper 95% credible intervals predicted by the static and dynamic models respectively.  
 
Additional analyses - Fully Endemic scenario 
The absolute difference between the median and 95% credible interval (CrI) of the static and 
dynamic models’ predictions of the lowest level of condom consistency tolerated over the time 
horizon for the additional scenario Fully Endemic (PrEP introduced in 2030) is shown in Table S7. 
Fully Endemic Scenario 
Table S7: Absolute difference between the static and dynamic models’ prediction of the lowest level of condom 
consistency tolerated, when the dynamic model is run over a time horizon of 3 months to 20 years, under the Fully 
Endemic scenario.  
The values stated outside the brackets are the absolute difference between the median values predicted by the static and 
dynamic models, and the values in the left and right of the bracket are the absolute difference between the lower and upper 
95% credible intervals predicted by the static and dynamic models respectively.  
Absolute Difference between Initial Condom Consistency and Lowest Level of Condom Consistency on PrEP
Initial 
Condom 
Consistency
PrEP 
Effectiveness 3 months 1 year 2 years 5 years 10 years 20 years
0.1 0.25 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) -0.9 %  ( 0 % , -5.2 % ) -17 %  ( -9.4 % , -21.5 % ) -28 %  ( -18.2 % , -33.9 % ) -36 %  ( -23.5 % , -44.4 % )
0.1 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) -9.1 %  ( 0 % , -15.8 % ) -20.7 %  ( -5.1 % , -29.5 % )
0.1 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -3.2 % )
0.1 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.25 -2.7 %  ( -1.1 % , -2.7 % ) -12.7 %  ( -10.7 % , -13.2 % ) -21 %  ( -17.6 % , -22.3 % ) -33.4 %  ( -28.6 % , -36 % ) -42.4 %  ( -35.9 % , -47.2 % ) -49.7 %  ( -41 % , -57 % )
0.3 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -1 % ) -15.1 %  ( -7.7 % , -20.7 % ) -27.5 %  ( -19 % , -35 % ) -37.4 %  ( -26.4 % , -48.2 % )
0.3 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -8.4 % ) -14.1 %  ( -0.7 % , -27.2 % )
0.3 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.25 -1.6 %  ( -1.7 % , -1.6 % ) -8.4 %  ( -8.5 % , -8.7 % ) -14.4 %  ( -13.7 % , -15.2 % ) -24.2 %  ( -21.4 % , -26.3 % ) -31.3 %  ( -26.6 % , -34.6 % ) -37.9 %  ( -30.8 % , -42.9 % )
0.5 0.45 0 %  ( 0 % , -1.5 % ) -10.6 %  ( -6.4 % , -15 % ) -20.8 %  ( -16.4 % , -25.4 % ) -35.9 %  ( -30 % , -41.3 % ) -46.4 %  ( -38.2 % , -53 % ) -55.4 %  ( -44.5 % , -63.5 % )
0.5 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) -6.8 %  ( 0 % , -15.3 % ) -23.2 %  ( -12.7 % , -32.2 % ) -36.2 %  ( -23.1 % , -47.2 % )
0.5 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -3 % )
0.7 0.25 -0.9 %  ( -1.1 % , -0.8 % ) -4.9 %  ( -4.8 % , -4.5 % ) -8.6 %  ( -8 % , -8.3 % ) -14.9 %  ( -13 % , -15.3 % ) -20.3 %  ( -16.6 % , -21.8 % ) -25.5 %  ( -20 % , -29.6 % )
0.7 0.45 -1.2 %  ( -1.4 % , -1.2 % ) -9.4 %  ( -10.2 % , -8.5 % ) -16.2 %  ( -16.8 % , -14.7 % ) -26.2 %  ( -25.7 % , -24.9 % ) -33.9 %  ( -31.9 % , -33.5 % ) -41.7 %  ( -37.1 % , -42.3 % )
0.7 0.65 0 %  ( 0 % , 0 % ) -3.1 %  ( 0 % , -12.6 % ) -16.8 %  ( -9.2 % , -24.9 % ) -35.2 %  ( -26 % , -42 % ) -47.3 %  ( -36.5 % , -54.2 % ) -57.9 %  ( -45 % , -67.2 % )
0.7 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -11.8 % ) -17.8 %  ( 0 % , -33.2 % )
Absolute Difference between Initial Condom Consistency and Lowest Level of Condom Consistency on PrEP
Initial 
Condom 
Consistency
PrEP 
Effectiveness 3 months 1 year 2 years 5 years 10 years 20 years
0.1 0.25 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.25 0.2 %  ( 0.2 % , 0.1 % ) -0.7 %  ( -1.2 % , -0.8 % ) -1.7 %  ( -1.8 % , -1.9 % ) -3.2 %  ( -2.3 % , -4.5 % ) -4.5 %  ( -2.2 % , -6.8 % ) -5.5 %  ( -2 % , -9.7 % )
0.3 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -3.4 % ) -0.6 %  ( 0 % , -6.9 % )
0.3 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.25 0.1 %  ( 0.2 % , 0.1 % ) -0.6 %  ( -0.6 % , -0.6 % ) -1.4 %  ( -1.1 % , -1.9 % ) -2.7 %  ( -0.9 % , -5.3 % ) -3.4 %  ( -0.2 % , -8.3 % ) -4.3 %  ( -0.1 % , -12.3 % )
0.5 0.45 0.2 %  ( 0.2 % , 0.2 % ) -2.8 %  ( -3.3 % , -2.3 % ) -5.4 %  ( -6.3 % , -4.7 % ) -9.6 %  ( -10.5 % , -9.3 % ) -12.5 %  ( -12 % , -14.1 % ) -14.9 %  ( -13.4 % , -19.7 % )
0.5 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -1.8 % ) -0.1 %  ( 0 % , -7.9 % ) -4.8 %  ( 0 % , -14.4 % )
0.5 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.7 0.25 0.2 %  ( 0 % , 0.2 % ) -0.3 %  ( -0.3 % , -0.2 % ) -0.9 %  ( -0.3 % , -1.4 % ) -1.5 %  ( 0 % , -5 % ) -2.1 %  ( 0.9 % , -8.3 % ) -2.5 %  ( 1.5 % , -11.8 % )
0.7 0.45 0.2 %  ( 0.1 % , 0.2 % ) -1.8 %  ( -2.4 % , -1.4 % ) -3.8 %  ( -4.4 % , -2.9 % ) -7 %  ( -6.9 % , -7.3 % ) -9.1 %  ( -8.6 % , -11.5 % ) -11.1 %  ( -8.9 % , -16.4 % )
0.7 0.65 0.3 %  ( 0 % , 0.2 % ) -5.9 %  ( -0.9 % , -5 % ) -11.4 %  ( -7.3 % , -9 % ) -19.1 %  ( -16 % , -15.6 % ) -24.2 %  ( -20.5 % , -20.9 % ) -27.9 %  ( -24.3 % , -26.7 % )
0.7 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , -8.8 % )
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Lowest Level of Condom Consistency Tolerated: Tables of percentage change between static and 
dynamic model’s outcomes 
The percentage change between the median and 95% credible interval (CrI) of the static and 
dynamic models’ predictions of the lowest level of condom consistency tolerated in absolute terms 
over the time horizon for both the Epidemic Equilibrium and Increasing Epidemic scenarios are 
shown in Tables S8a and S8b respectively. 
Epidemic Equilibrium Scenario 
 
Table S8a: Epidemic Equilibrium Scenario: Percentage change between the static and dynamic models’ prediction of the 
lowest level of condom consistency tolerated, when the dynamic model is run over a time horizon of 3 months to 20 
years. 
Increasing Epidemic Scenario 
 
Table S8b: Increasing Epidemic Scenario: Percentage change between the static and dynamic models’ prediction of the 
lowest level of condom consistency tolerated, when the dynamic model is run over a time horizon of 3 months to 20 
years.  
Tables S8a and S8b respectively show for the scenarios where PrEP is introduced at Epidemic Equilibrium and where PrEP is 
introduced with Increasing Epidemic the percentage change between the static and dynamic models’ prediction of the 
lowest level of condom consistency tolerated in absolute terms, when the dynamic model is run over a time horizon of 3 
months to 20 years. The percentage change values stated outside the brackets are the percentage change between the 
median values predicted by the static and dynamic models, and the values in the left and right of the bracket are the 
% Change between Static and Dynamic Model after
Initial 
Condom 
Consistency
PrEP 
Effectiveness 3 months 1 year 2 years 5 years 10 years 20 years
0.1 0.25 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.25 4.4 %  ( -0.7 % , 0.9 % ) 0 %  ( 2.8 % , -4.3 % ) -5.6 %  ( 9.2 % , -14.5 % ) -10 %  ( 23.5 % , -36.8 % ) -8.9 %  ( 41.1 % , -64.1 % ) -10 %  ( 67.2 % , -105.1 % )
0.3 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.25 0.9 %  ( -2 % , 0.9 % ) 0.9 %  ( 1.7 % , -0.9 % ) 0.9 %  ( 10.7 % , -4.6 % ) 1.5 %  ( 32 % , -13.7 % ) 2.1 %  ( 100 % , -24.3 % ) 3 %  ( 92 % , -39.4 % )
0.5 0.45 2.8 %  ( -1.2 % , 2.6 % ) -13.8 %  ( 3.8 % , -8.3 % ) -25.7 %  ( 10.5 % , -23.1 % ) -47.7 %  ( 26.3 % , -57.7 % ) -64.2 %  ( 100 % , -90.4 % ) -78 %  ( 62.6 % , -137.8 % )
0.5 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.7 0.25 0.5 %  ( -1.9 % , 0.3 % ) 0.9 %  ( 1.9 % , -0.3 % ) 1.9 %  ( 7.5 % , -1.4 % ) 3 %  ( 27.5 % , -5.3 % ) 4.2 %  ( 100 % , -11.7 % ) 4.6 %  ( 114.4 % , -21.8 % )
0.7 0.45 1 %  ( -1.1 % , 0.7 % ) -1.8 %  ( 3.2 % , -1.8 % ) -3.8 %  ( 8.4 % , -5 % ) -5.8 %  ( 22.2 % , -12.9 % ) -8.5 %  ( 100 % , -23.4 % ) -10.8 %  ( 66.8 % , -39.2 % )
0.7 0.65 5.5 %  ( 0 % , 1.2 % ) -50.7 %  ( 5.8 % , -18.6 % ) -102.7 %  ( 11.8 % , -37.7 % ) -175.3 %  ( 24.8 % , -79.6 % ) -224.7 %  ( 100 % , -115 % ) -263 %  ( 53.5 % , -170.7 % )
0.7 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
% Change between Static and Dynamic Model after
Initial 
Condom 
Consistency
PrEP 
Effectiveness 3 months 1 year 2 years 5 years 10 years 20 years
0.1 0.25 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 87.5 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 100 % , 0 % )
0.1 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.25 -20.7 %  ( 9.3 % , -13 % ) -98.9 %  ( 50.6 % , -72.4 % ) -165.2 %  ( 89.8 % , -129.3 % ) -270.7 %  ( 100 % , -223.6 % ) -327.2 %  ( 100 % , -287 % ) -263 %  ( 100 % , -291.1 % )
0.3 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 41.1 % , 0 % ) 0 %  ( 89.2 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 100 % , 0 % )
0.3 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.25 -3.6 %  ( 7.1 % , -2.8 % ) -19.4 %  ( 40.7 % , -17 % ) -32.4 %  ( 76.8 % , -32.1 % ) -55.2 %  ( 100 % , -58 % ) -67 %  ( 100 % , -76.1 % ) -52.1 %  ( 100 % , -76.4 % )
0.5 0.45 -13.9 %  ( 3.5 % , -7.5 % ) -100.9 %  ( 27.8 % , -59.4 % ) -166.7 %  ( 48.5 % , -103.1 % ) -263 %  ( 83.2 % , -176.9 % ) -315.7 %  ( 100 % , -226.3 % ) -274.1 %  ( 100 % , -233.1 % )
0.5 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 52.4 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 76.1 % , 0 % )
0.5 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.7 0.25 -1.4 %  ( 4.5 % , -0.8 % ) -7.6 %  ( 31.2 % , -5.8 % ) -12.7 %  ( 61.1 % , -11.4 % ) -21.5 %  ( 100 % , -22.5 % ) -26.9 %  ( 100 % , -30.7 % ) -21.1 %  ( 100 % , -33.2 % )
0.7 0.45 -2.3 %  ( 2.2 % , -1.3 % ) -18.5 %  ( 22.6 % , -12.8 % ) -31.4 %  ( 39.9 % , -22.6 % ) -51.1 %  ( 73.6 % , -41.9 % ) -61.8 %  ( 100 % , -57 % ) -55.2 %  ( 100 % , -61 % )
0.7 0.65 -18.1 %  ( 0 % , -5.1 % ) -205.6 %  ( 21.6 % , -63.3 % ) -326.4 %  ( 36.8 % , -109 % ) -504.2 %  ( 59.8 % , -176.8 % ) -597.2 %  ( 100 % , -222 % ) -556.9 %  ( 81.7 % , -241.2 % )
0.7 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 0 % , 0 % )
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percentage change between the lower and upper 95% credible intervals predicted by the static and dynamic models 
respectively.  
 
Additional analyses – Structural sensitivity analysis 
The percentage change between the median and 95% credible interval (CrI) of the static and 
dynamic models’ predictions of the lowest level of condom consistency tolerated in absolute terms 
over the time horizon for both the Epidemic Equilibrium and Increasing Epidemic scenarios for the 
structural sensitivity analysis are shown in Tables S9a andS 9b respectively. 
 
Structural Sensitivity Analysis 
Epidemic Equilibrium Scenario 
 
 
Table S9a: Structural sensitivity analysis: Epidemic Equilibrium Scenario: Percentage change between the 
static and dynamic models’ prediction of the lowest level of condom consistency tolerated, when the 
dynamic model is run over a time horizon of 3 months to 20 years. 
 
 
 
 
 
 
 
% Change between Static and Dynamic Model after
Initial 
Condom 
Consistency
PrEP 
Effectiveness 3 months 1 year 2 years 5 years 10 years 20 years
0.1 0.25 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.25 -33.3 %  ( 0 % , -10.7 % ) -533.3 %  ( 11.6 % , -114.3 % ) -983.3 %  ( 23.7 % , -232.1 % ) -1700 %  ( 45.3 % , -439.3 % ) -2183.3 %  ( 100 % , -621.4 % ) -2450 %  ( 82.6 % , -803.6 % )
0.3 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.25 -0.4 %  ( 0.5 % , -0.3 % ) -7.3 %  ( 10.7 % , -7.5 % ) -13.9 %  ( 22.7 % , -15.9 % ) -24.8 %  ( 49.8 % , -34.6 % ) -32.8 %  ( 100 % , -53.6 % ) -38.3 %  ( 109 % , -75.6 % )
0.5 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 20 % , 0 % ) 0 %  ( 37.9 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 70.8 % , 0 % )
0.5 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.7 0.25 0.2 %  ( 0 % , 0 % ) -1.7 %  ( 8 % , -2 % ) -3.5 %  ( 20.1 % , -4.8 % ) -6.5 %  ( 47.7 % , -11.8 % ) -8.9 %  ( 100 % , -22.5 % ) -11.1 %  ( 139.2 % , -34.4 % )
0.7 0.45 0.3 %  ( 0 % , 0 % ) -9.7 %  ( 8.6 % , -8.1 % ) -19.4 %  ( 17.4 % , -16.5 % ) -35.8 %  ( 36.6 % , -34.9 % ) -46.5 %  ( 100 % , -52.8 % ) -55.2 %  ( 78.7 % , -75.1 % )
0.7 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 29.8 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 57.4 % , 0 % )
0.7 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
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Structural Sensitivity Analysis 
Increasing Epidemic Scenario 
 
Table S9b: Structural sensitivity analysis: Increasing Epidemic Scenario: Percentage change between the static and 
dynamic models’ prediction of the lowest level of condom consistency tolerated, when the dynamic model is run over a 
time horizon of 3 months to 20 years. 
Tables S9a and S9b respectively show, for the scenarios where PrEP is introduced at Epidemic Equilibrium and where PrEP is 
introduced with Increasing Epidemic under the structural sensitivity analysis, the percentage change between the static and 
dynamic models’ prediction of the lowest level of condom consistency tolerated in absolute terms, when the dynamic model 
is run over a time horizon of 3 months to 20 years. The percentage change values stated outside the brackets are the 
percentage change between the median values predicted by the static and dynamic models, and the values in the left and 
right of the bracket are the percentage change between the lower and upper 95% credible intervals predicted by the static 
and dynamic models respectively.  
 
Additional analyses - Fully Endemic scenario 
The percentage change between the median and 95% credible interval (CrI) of the static and 
dynamic models’ predictions of the lowest level of condom consistency tolerated in absolute terms 
over the time horizon for the additional scenario Fully Endemic (PrEP introduced in 2030) is shown in 
Table 10. 
 
 
 
 
 
 
 
% Change between Static and Dyamic Model after
Initial 
Condom 
Consistency
PrEP 
Effectiveness 3 months 1 year 2 years 5 years 10 years 20 years
0.1 0.25 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 100 % , 0 % )
0.1 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % )
0.1 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.25 -385.7 %  ( 9.9 % , -96.4 % ) -1814.3 %  ( 48.7 % , -471.4 % )-3000 %  ( 81.8 % , -796.4 % ) 4771.4 %  ( 100 % , -1285.7 % 6057.1 %  ( 100 % , -1685.7 % -7100 %  ( 100 % , -2035.7 % )
0.3 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 68.9 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 100 % , 0 % )
0.3 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 90.6 % , 0 % )
0.3 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.25 -5.8 %  ( 8 % , -5.4 % ) -30.5 %  ( 42 % , -29.6 % ) -52.4 %  ( 73.8 % , -51.7 % ) -88 %  ( 100 % , -89.5 % ) -113.8 %  ( 100 % , -117.7 % ) -137.8 %  ( 100 % , -145.9 % )
0.5 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 30 % , 0 % ) 0 %  ( 50.7 % , 0 % ) 0 %  ( 82.6 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 100 % , 0 % )
0.5 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 94.3 % , 0 % )
0.5 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.7 0.25 -1.7 %  ( 6.1 % , -1.4 % ) -9.1 %  ( 32.8 % , -8 % ) -16 %  ( 60.6 % , -14.8 % ) -27.6 %  ( 100 % , -27.2 % ) -37.7 %  ( 100 % , -38.8 % ) -47.3 %  ( 100 % , -52.7 % )
0.7 0.45 -3.9 %  ( 3.3 % , -3.3 % ) -30.8 %  ( 24.9 % , -23.6 % ) -53.1 %  ( 43.1 % , -40.8 % ) -85.9 %  ( 73.2 % , -69.2 % ) -111.1 %  ( 100 % , -93.1 % ) -136.7 %  ( 100 % , -117.5 % )
0.7 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 35.6 % , 0 % ) 0 %  ( 60 % , 0 % ) 0 %  ( 100 % , 0 % ) 0 %  ( 95.9 % , 0 % )
0.7 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
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Fully Endemic Scenario 
 
Table S10: Percentage change between the static and dynamic models’ prediction of the lowest level of condom 
consistency tolerated, when the dynamic model is run over a time horizon of 3 months to 20 years, under the Fully 
Endemic scenario.  
The percentage change values stated outside the brackets are the percentage change between the median values predicted 
by the static and dynamic models, and the values in the left and right of the bracket are the percentage change between 
the lower and upper 95% credible intervals predicted by the static and dynamic models respectively.  
 
  
% Change between Static and Dyamic Model after
Initial 
Condom 
Consistency
PrEP 
Effectiveness 3 months 1 year 2 years 5 years 10 years 20 years
0.1 0.25 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.1 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.25 2.1 %  ( -1 % , 0.8 % ) -7.4 %  ( 4.2 % , -6.7 % ) -17.9 %  ( 10.3 % , -16 % ) -33.7 %  ( 24.6 % , -37.8 % ) -47.4 %  ( 100 % , -57.1 % ) -57.9 %  ( 53.3 % , -81.5 % )
0.3 0.45 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.3 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.25 0.3 %  ( -1 % , 0.3 % ) -1.8 %  ( 4 % , -1.7 % ) -4.3 %  ( 12 % , -5.4 % ) -8.2 %  ( 35.1 % , -15.1 % ) -10.3 %  ( 100 % , -23.7 % ) -13.1 %  ( 81.6 % , -35.1 % )
0.5 0.45 1.9 %  ( -0.4 % , 1.3 % ) -26.7 %  ( 6.7 % , -14.6 % ) -51.4 %  ( 13.6 % , -29.9 % ) -91.4 %  ( 27 % , -59.2 % ) -119 %  ( 100 % , -89.8 % ) -141.9 %  ( 57.4 % , -125.5 % )
0.5 0.65 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.5 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
0.7 0.25 0.4 %  ( -1.3 % , 0.3 % ) -0.5 %  ( 2.5 % , -0.3 % ) -1.6 %  ( 13.2 % , -2.4 % ) -2.6 %  ( 44.7 % , -8.5 % ) -3.7 %  ( 100 % , -14.1 % ) -4.4 %  ( 106.3 % , -20 % )
0.7 0.45 0.5 %  ( -0.8 % , 0.5 % ) -4.6 %  ( 5.4 % , -3.2 % ) -9.7 %  ( 11.4 % , -6.6 % ) -17.9 %  ( 28.5 % , -16.5 % ) -23.3 %  ( 100 % , -26 % ) -28.4 %  ( 63.7 % , -37.1 % )
0.7 0.65 4.9 %  ( 0 % , 1.2 % ) -96.7 %  ( 9.4 % , -29.4 % ) -186.9 %  ( 16.9 % , -52.9 % ) -313.1 %  ( 29.5 % , -91.8 % ) -396.7 %  ( 100 % , -122.9 % ) -457.4 %  ( 50.5 % , -157.1 % )
0.7 0.85 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % ) 0 %  ( 0 % , 0 % )
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Additional assessment of results 
Comparison of static and dynamic model outcomes 
Under the scenario that PrEP is introduced at HIV Epidemic Equilibrium, the static and dynamic 
models predict very closely at 3 months (<5% relative difference between medians, and <5% 
relative difference between model 95% credible intervals (CrIs) - see Supplementary Materials 
Tables S2a and S2b), and predict fairly consistently up to a time horizon of 1 year (<10% relative 
difference between the median and 95% CrI predictions). After 5 years, the relative difference 
between the median model predictions is less than 25% (<35% relative difference between their 
95% CrIs); and after 20 years the relative difference between the median model outcomes grows to 
up to 35% (up to 100% relative difference their 95% CrIs). 
The model outcomes are more consistent over time at lower levels of initial condom consistency 
(≤30%), where the relative difference between median predictions is less than 5% (up to 70% 
relative difference between 95% CrIs) over the 20-year time horizon. Where both initial condom 
consistency is low (≤30%) and PrEP use-effectiveness is high (≥65%), there is no change between 
the models’ median predictions (100% relative difference between their 95% CrIs from 10 years). 
The differences between the models are more pronounced over time where initial condom 
consistencies are higher (≥50%) and the levels of PrEP use-effectiveness achieved are lower (≤45%).  
Under the Increasing Epidemic scenario, the comparison between static and dynamic models follow 
a similar trend to those under the Epidemic Equilibrium scenario, however the differences between 
the models are more pronounced over time. After 1 year the relative difference between the model 
medians is up to 45% and up to 55% between the 95% CrIs (in comparison to a relative difference of 
no more than 10% between the medians and 95% CrIs under the Epidemic Equilibrium scenario), and 
by 5 years, the relative difference between the models is up to 100% (in comparison to less than 
25% between model medians and less than 35% between model 95% CrIs under the Epidemic 
Equilibrium scenario). After 20 years the differences between the models starts to decrease in 
response to the natural plateau and slight decline of the underlying HIV epidemics (Supplementary 
Materials Table S2b).  
Under the Epidemic Equilibrium scenario, at the lower and upper bounds of initial condom 
consistencies explored (10% and 70%) and where PrEP use-effectiveness is 85% (i.e. the maximum 
assumed use-effectiveness of condoms35,36), the minimum and maximum whiskers do not protrude 
from the interquartile ranges of the box plots, indicating reasonable consistency of results across the 
model fits. By contrast, under the Increasing Epidemic scenario, the minimum and maximum 
whiskers protrude from the interquartile ranges of the boxplots, other than where PrEP use-
 290 
 
effectiveness is 85% and initial condom consistency is low (≤30%), indicating increased variance in 
the results across model fits in comparison to the Epidemic Equilibrium scenario. 
Additional analyses – structural sensitivity analysis 
Removing the risk parameters relating to ART, circumcision and STIs from the models affects the 
difference between the percentage reduction in condom consistency tolerated predicted by the 
static and dynamic models in certain conditions. Under the Epidemic Equilibrium scenario, the 
notable differences can be seen for initial condom consistencies of 30% upwards and at lower levels 
of PrEP use-effectiveness (≤45%), where the differences between the two models’ estimates of 
percentage reduction in condom consistency tolerated is greater over time (<35% relative difference 
between model medians and <45% between CrIs by 5 years, and <50% relative difference between 
medians and CrIs by 20 years) (Supplementary Materials Figure S6 vs. Figure S10, and Table S2a vs. 
Table S3a). This is likely in response to differences in the underlying epidemic trajectories, which 
level out more quickly where these parameters are not included in the models (as the epidemic 
curves do not see the same slight dip after 2014 when male circumcision and ART are assumed to 
have reached their highest scale-up coverage), but slightly decrease under the base case. 
Accordingly, the slightly higher levels of underlying HIV prevalence in the former scenario result in 
increased HIV risk over time in the dynamic model in the cases where there is less protection (i.e. 
lower levels of PrEP and greater absolute drops in condom consistency). 
Under the Increasing Epidemic scenario, the notable differences are more pronounced at higher 
levels of initial condom consistency (≥50%) and higher levels of PrEP use-effectiveness (≥65%) 
(<25% relative difference between model medians and CrIs by 5 years, and <30% relative difference 
between model medians and <35% between CrIs by 20 years for the Increasing Epidemic scenario) 
(Supplementary Materials Figure S8 and Figure S11, and Table S2b vs. Table S3b). Similarly, this is 
likely in response to differences in the underlying epidemic trajectories, which continue to slightly 
increase over time after levelling out around 2010 where these parameters are not included in the 
models, but level out more evenly under the base case. For the same reasons, unlike under the base 
analysis, where after 20 years the differences between the models starts to decrease in response to 
the natural plateau of the underlying HIV epidemics, the same is not true where the specified risk 
parameters are removed from the equations, in which case the underlying epidemics instead slightly 
increase over time. 
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Additional analyses - Fully Endemic scenario 
Introducing PrEP at 2030 when the underlying HIV epidemics are fully endemic in the populations, as 
opposed to in 2015 when they have just started to stabilise has little effect on the differences 
between the percentage reduction in condom consistency tolerated predicted by the static and 
dynamic models. The main differences are that at low levels of PrEP use-effectiveness (25%), the 
differences between the models are slightly greater under the Fully Settled Epidemic scenario (up to 
25% difference between absolute medians), and whilst the interquartile ranges are narrower under 
the Fully Settled Epidemic scenario, the 95% CrIs are slightly wider under this scenario likely owing to 
greater uncertainty in epidemic pathways further out in time (Supplementary Materials Figure S14, 
and Table S2a vs. Table S4). 
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Supplementary Methods 
 
Model Structure 
 
We use a static Bernoulli formulation of HIV risk1. The sexual partners of high-risk women from 
population 𝑗𝑗 are assumed to come from populations 𝑖𝑖 in which the proportion HIV infected is 𝑝𝑝𝑠𝑠. We 
assume an average probability of HIV transmission, 𝛽𝛽𝑓𝑓, per sexual contact with an HIV infected male 
partner. High risk women are assumed to have 𝐶𝐶𝑠𝑠 number of partners from each population a year, 
with whom they have an average of 𝑛𝑛𝑠𝑠 sex acts a year each. Condoms are assumed to be used with 
partners from each population with consistency 𝛾𝛾𝑠𝑠𝑗𝑗  and have an HIV risk reduction efficacy, 𝜀𝜀, 
including slippage and breakage. Upon introduction, high-risk women from population 𝑗𝑗 are 
assumed to adhere to PrEP at an average level 𝛼𝛼𝑗𝑗, which corresponds to a level of HIV risk reduction, 
𝜃𝜃𝛼𝛼𝑗𝑗 . They are assumed to have 12-month program retention levels 𝑟𝑟𝑗𝑗. Sex acts are assumed to be 
peno-vaginal, the predominant pathway of HIV transmission to heterosexual women in sub-Saharan 
Africa.2  
 
1.0 Individual level - Simple tools to help guide PrEP programme decision making 
1.1 Assessment of HIV risk by risk factor 
For the first analysis of HIV risk, we consider a simple model of HIV risk to a single high-risk woman 
with partners drawn from a single male population. HIV risk to an individual high-risk woman in the 
absence of PrEP is given by 
𝜋𝜋(0) = 1 − �𝑝𝑝 � 1 − 𝛽𝛽𝑓𝑓(1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛 + (1 − 𝑝𝑝)�𝐶𝐶  , 
(S1.1) 
and on PrEP is 
𝜋𝜋(𝜃𝜃𝛼𝛼𝑗𝑗) = 1 − �𝑝𝑝 � 1 − 𝛽𝛽𝑓𝑓 �1 − 𝑟𝑟𝑗𝑗𝜃𝜃𝛼𝛼𝑗𝑗� (1 − 𝜀𝜀𝛾𝛾)�𝑛𝑛 + (1 − 𝑝𝑝)�𝐶𝐶   
(S1.2) 
Using equations (S1.1) and (S1.2), HIV risk reduction on PrEP is given by 
𝜋𝜋(0) − 𝜋𝜋(𝜃𝜃𝛼𝛼𝑗𝑗) 
(S1.3) 
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In order to parameterise the model to the spectrum of HIV risk faced by women in sub-Saharan 
Africa, equation (S1.1) was simulated across the parameter ranges set out in Supporting Information: 
Methods – Table S2, yielding 720,000 distinct parameter sets. 
 
1.2 Simple rule to estimate relative cost-effectiveness 
In estimating the relative cost-effectiveness among women at risk, we considered two high-risk 
women of different risk. One woman is drawn from a traditionally higher-risk population (e.g. female 
sex workers (FSW)) and the other from a relatively lower-risk female population (e.g. adolescent girls 
and young women aged 15-24 years (AGYW)), denoted 𝐻𝐻and 𝐿𝐿 respectively. For simplicity, each 
high-risk woman is assumed to draw their partners from one population group.  
Analysis was conducted over a one-year timeframe, as PrEP is intended for seasons of risk, and few 
PrEP demonstration programs have achieved significant retention in women in this context beyond 
the first 12 months.3,4 Let 𝜋𝜋𝐻𝐻 and 𝜋𝜋𝐿𝐿 denote the respective HIV risk for each woman, with subscripts 
𝐻𝐻and 𝐿𝐿 denoting high and low risk groups Let $𝑋𝑋𝐻𝐻 and $𝑋𝑋𝐿𝐿be the 12-month unit costs of PrEP for 
each woman (the incremental cost of PrEP for a woman retained in a PrEP program over a 12-month 
period). 
Then the cost of averting one HIV infection with PrEP per year is $𝑋𝑋𝐻𝐻
𝜋𝜋𝐻𝐻(0)−𝜋𝜋𝐻𝐻�𝜃𝜃𝛼𝛼𝐻𝐻� and $𝑋𝑋𝐿𝐿𝜋𝜋𝐿𝐿(0)−𝜋𝜋𝐿𝐿�𝜃𝜃𝛼𝛼𝐿𝐿� 
respectively. PrEP will become equally cost-effective in the lower-risk group as it is in the higher-risk 
group where: 
$𝑋𝑋𝐿𝐿
𝜋𝜋𝐿𝐿(0)−𝜋𝜋𝐿𝐿�𝜃𝜃𝛼𝛼𝐿𝐿� = $𝑋𝑋𝐻𝐻𝜋𝜋𝐻𝐻(0)−𝜋𝜋𝐻𝐻�𝜃𝜃𝛼𝛼𝐻𝐻�  
(S1.4) 
Equation (S1.4) can be expressed as 
$𝑋𝑋𝐿𝐿$𝑋𝑋𝐻𝐻 = 𝜋𝜋𝐿𝐿(0)−𝜋𝜋𝐿𝐿�𝜃𝜃𝛼𝛼𝐿𝐿�𝜋𝜋𝐻𝐻(0)−𝜋𝜋𝐻𝐻�𝜃𝜃𝛼𝛼𝐻𝐻�  
(S1.5) 
To derive a simple formulation of equation (S1.5) that is intuitive for policy makers and programmers 
in practical real-world settings, we simplify equations (S1.1) and (S1.2) using binomial theorem. 
Using the example of equation (S1.2), where 𝛽𝛽(1 − 𝑟𝑟𝜃𝜃𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾) ≪ 1 we have: 
𝜋𝜋(𝜃𝜃𝛼𝛼𝑗𝑗) ≈ 1 − �𝑝𝑝 � 1 − 𝑛𝑛𝛽𝛽𝑓𝑓 �1 − 𝑟𝑟𝑗𝑗𝜃𝜃𝛼𝛼𝑗𝑗� (1 − 𝜀𝜀𝛾𝛾)� + (1 − 𝑝𝑝)�𝐶𝐶   
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           ≈ 1 − �1 − 𝑝𝑝𝑛𝑛𝛽𝛽 �1 − 𝑟𝑟𝑗𝑗𝜃𝜃𝛼𝛼𝑗𝑗� (1 − 𝜀𝜀𝛾𝛾)�𝐶𝐶   
for  𝑝𝑝𝑛𝑛𝛽𝛽 �1 − 𝑟𝑟𝑗𝑗𝜃𝜃𝛼𝛼𝑗𝑗� (1 − 𝜀𝜀𝛾𝛾) ≪ 1, 
𝜋𝜋(𝜃𝜃𝛼𝛼𝑗𝑗) ≈ 𝐶𝐶𝑝𝑝𝑛𝑛𝛽𝛽 �1 − 𝑟𝑟𝑗𝑗𝜃𝜃𝛼𝛼𝑗𝑗� (1 − 𝜀𝜀𝛾𝛾).  
(S1.6) 
In other words, the HIV risk reduction to an individual on PrEP can be approximated by the total 
number of sex acts per unit time multiplied by the partner HIV prevalence, the basic risk of HIV 
transmission through peno-vaginal sex (0.0006 - 0.00115), the average proportion of sex acts not 
protected by condoms, and the use-effectiveness of PrEP. The use-effectiveness of PrEP is defined as 
the HIV-risk reduction through use of PrEP at a given level of adherence, for a population with a 
given average program retention level. 
 
Thus the risk reduction in equation (S1.3) is approximately 
𝐶𝐶𝑝𝑝𝑛𝑛𝛽𝛽(1 − 𝜀𝜀𝛾𝛾) − 𝐶𝐶𝑝𝑝𝑛𝑛𝛽𝛽 �1 − 𝑟𝑟𝑗𝑗𝜃𝜃𝛼𝛼𝑗𝑗� (1 − 𝜀𝜀𝛾𝛾), and simplifies to 
𝐶𝐶𝑝𝑝𝑛𝑛𝛽𝛽(1 − 𝜀𝜀𝛾𝛾)𝑟𝑟𝑗𝑗𝜃𝜃𝛼𝛼𝑗𝑗. 
(S1.7) 
Therefore, when 𝛽𝛽 �1 − 𝑟𝑟𝑗𝑗𝜃𝜃𝛼𝛼𝑗𝑗� (1 − 𝜀𝜀𝛾𝛾) ≪ 1 and 𝑝𝑝𝑛𝑛𝛽𝛽 �1 − 𝑟𝑟𝑗𝑗𝜃𝜃𝛼𝛼𝑗𝑗� (1 − 𝜀𝜀𝛾𝛾) ≪ 1,the condition for 
equal cost-effectiveness in equation (S1.5) between two populations with different risk levels 
becomes:  
$𝑋𝑋𝐿𝐿$𝑋𝑋𝐻𝐻 = 𝐶𝐶𝐿𝐿𝑛𝑛𝐿𝐿𝑝𝑝𝐿𝐿(1−𝜀𝜀𝛾𝛾𝐿𝐿)𝑟𝑟𝐿𝐿𝜃𝜃𝛼𝛼𝐿𝐿𝐶𝐶𝐻𝐻𝑛𝑛𝐻𝐻𝑝𝑝𝐻𝐻(1−𝜀𝜀𝛾𝛾𝐻𝐻)𝑟𝑟𝐻𝐻𝜃𝜃𝛼𝛼𝐻𝐻  
(S1.8) 
The relationship on relative cost of PrEP is summarised as follows. 
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1.3 Relative risk reduction on PrEP 
Using equation (S1.5) we calculate the relative risk reduction on PrEP between a higher- and lower-
risk woman. To obtain a spectrum of HIV risk faced by both populations reflective of the sub-Saharan 
African settings, we simulated across the parameter ranges set out in Supporting Information: 
Methods – Table S2, yielding 7,920,000 distinct parameter sets.  
 
2.0 Population level – country case studies 
We modify the risk equations (S1.1) and (S1.2) to consider HIV risk and the scale-up of PrEP at a 
population rather than individual level.  
The total population size of high-risk women of type 𝑗𝑗 is 𝑁𝑁𝑗𝑗, in which the prevalence of HIV is 𝑝𝑝𝑗𝑗 . The 
coverage of PrEP in the population is 𝜔𝜔𝑗𝑗.  
In the process of parameterising the model to specific high-risk women populations, we develop the 
risk equations to also account for population-specific STI levels, levels of viral load suppression due 
to ART in HIV positive partners and male circumcision.  
The parameter 𝑠𝑠𝑠𝑠𝑗𝑗  is the probability that at least one person in the partnership between high risk 
woman from population 𝑗𝑗 and partner from population 𝑖𝑖 has an STI and 𝛿𝛿 is the multiplicative 
increase in per sex act probability of HIV transmission in the presence of an STI.  
Parameter 𝜗𝜗𝑠𝑠 is the proportion of HIV+ partners from population 𝑖𝑖 that are virally suppressed on ART 
and 𝜚𝜚 models the average reduction in the probability of HIV transmission due to viral suppression 
on ART. The parameter 𝜏𝜏𝑠𝑠 is the proportion of male partner population 𝑖𝑖 that are circumcised and 
𝜎𝜎 is the average reduction in probability HIV transmission to women, when the male partner has 
been circumcised.   
Where high-risk women from population 𝑗𝑗 have partners drawn from a single male population, their 
HIV risk for a 12-month period is in the absence of PrEP is given by (leaving the j denotation to 
improve readability): 
Π(0) = 1 − �𝑝𝑝(𝜓𝜓(1−𝜏𝜏),0 + 𝜓𝜓𝜏𝜏,0) + (1 − 𝑝𝑝)�𝐶𝐶   
Where: 
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𝜓𝜓(1−𝜏𝜏),0 = (1 − 𝜏𝜏)�(1 − 𝜗𝜗)𝑠𝑠( 1 − 𝛿𝛿𝛿𝛿)𝑛𝑛 + (1 − 𝜗𝜗)(1 − 𝑠𝑠)( 1 − 𝛿𝛿)𝑛𝑛 + 𝜗𝜗𝑠𝑠( 1 − (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿)𝑛𝑛+ 𝜗𝜗(1 − 𝑠𝑠)( 1 − (1 − 𝜚𝜚)𝛿𝛿)𝑛𝑛� 
𝜓𝜓𝜏𝜏,0 = 𝜏𝜏�(1 − 𝜗𝜗)𝑠𝑠( 1 − (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿)𝑛𝑛 + (1 − 𝜗𝜗)(1 − 𝑠𝑠)( 1 − (1 − 𝜎𝜎)𝛿𝛿)𝑛𝑛+ 𝜗𝜗𝑠𝑠( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿)𝑛𝑛 + 𝜗𝜗(1 − 𝑠𝑠)( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿)𝑛𝑛� 
and 𝛿𝛿 = 𝛽𝛽𝑓𝑓(1 − 𝜀𝜀𝛾𝛾) 
(S2.1) 
For women on PrEP we have 
Π(𝑟𝑟𝜃𝜃𝛼𝛼) = 1 − �𝑝𝑝(𝜓𝜓(1−𝜏𝜏),𝑟𝑟𝜃𝜃𝛼𝛼 + 𝜓𝜓𝜏𝜏,  𝑟𝑟𝜃𝜃𝛼𝛼) + (1 − 𝑝𝑝)�𝐶𝐶   
Where: 
𝜓𝜓(1−𝜏𝜏), 𝑟𝑟𝜃𝜃𝛼𝛼 = (1 − 𝜏𝜏)�(1 − 𝜗𝜗)𝑠𝑠( 1 − 𝛿𝛿𝛿𝛿)𝑛𝑛 + (1 − 𝜗𝜗)(1 − 𝑠𝑠)( 1 − 𝛿𝛿)𝑛𝑛 + 𝜗𝜗𝑠𝑠( 1 − (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿)𝑛𝑛+ 𝜗𝜗(1 − 𝑠𝑠)( 1 − (1 − 𝜚𝜚)𝛿𝛿)𝑛𝑛� 
𝜓𝜓𝜏𝜏, 𝑟𝑟𝜃𝜃𝛼𝛼 = 𝜏𝜏�(1 − 𝜗𝜗)𝑠𝑠( 1 − (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿)𝑛𝑛 + (1 − 𝜗𝜗)(1 − 𝑠𝑠)( 1 − (1 − 𝜎𝜎)𝛿𝛿)𝑛𝑛+ 𝜗𝜗𝑠𝑠( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿)𝑛𝑛 + 𝜗𝜗(1 − 𝑠𝑠)( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿)𝑛𝑛� 
and 𝛿𝛿 = 𝛽𝛽𝑓𝑓(1 − 𝑟𝑟𝜃𝜃𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾) 
(S2.2) 
Similarly, when high-risk women from population 𝑗𝑗 have partners drawn from two male populations 
𝑖𝑖 = 1, 2, their HIV risk for a 12-month period is in the absence of PrEP is given by 
Π(0) = 1 − �𝑝𝑝1(𝜓𝜓(1−𝜏𝜏),01 + 𝜓𝜓𝜏𝜏,01 ) + (1 − 𝑝𝑝1)�𝐶𝐶1�𝑝𝑝2(𝜓𝜓(1−𝜏𝜏),02 + 𝜓𝜓𝜏𝜏,02 ) + (1 − 𝑝𝑝2)�𝐶𝐶2  
Where 
𝜓𝜓(1−𝜏𝜏),01 = (1 − 𝜏𝜏1)�(1 − 𝜗𝜗1)𝑠𝑠1( 1 − 𝛿𝛿𝛿𝛿1)𝑛𝑛1 + (1 − 𝜗𝜗1)(1 − 𝑠𝑠1)( 1 − 𝛿𝛿1)𝑛𝑛1+ 𝜗𝜗1𝑠𝑠1( 1 − (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + 𝜗𝜗1(1 − 𝑠𝑠1)( 1 − (1 − 𝜚𝜚)𝛿𝛿1)𝑛𝑛1� 
𝜓𝜓𝜏𝜏,01 = 𝜏𝜏1�(1 − 𝜗𝜗1)𝑠𝑠1( 1 − (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + (1 − 𝜗𝜗1)(1 − 𝑠𝑠1)( 1 − (1 − 𝜎𝜎)𝛿𝛿1)𝑛𝑛1+ 𝜗𝜗1𝑠𝑠1( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + 𝜗𝜗1(1 − 𝑠𝑠1)( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿1)𝑛𝑛1� 
𝛿𝛿1 = 𝛽𝛽𝑓𝑓(1 − 𝜀𝜀𝛾𝛾1) 
and 
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𝜓𝜓(1−𝜏𝜏),02 = (1 − 𝜏𝜏2)�(1 − 𝜗𝜗2)𝑠𝑠2( 1 − 𝛿𝛿𝛿𝛿2)𝑛𝑛2 + (1 − 𝜗𝜗2)(1 − 𝑠𝑠2)( 1 − 𝛿𝛿2)𝑛𝑛2+ 𝜗𝜗2𝑠𝑠2( 1 − (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + 𝜗𝜗2(1 − 𝑠𝑠2)( 1 − (1 − 𝜚𝜚)𝛿𝛿2)𝑛𝑛2� 
𝜓𝜓𝜏𝜏,02 = 𝜏𝜏2�(1 − 𝜗𝜗2)𝑠𝑠2( 1 − (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + (1 − 𝜗𝜗2)(1 − 𝑠𝑠2)( 1 − (1 − 𝜎𝜎)𝛿𝛿2)𝑛𝑛2+ 𝜗𝜗2𝑠𝑠2( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + 𝜗𝜗2(1 − 𝑠𝑠2)( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿2)𝑛𝑛2� 
𝛿𝛿2 = 𝛽𝛽𝑓𝑓(1 − 𝜀𝜀𝛾𝛾2) 
(S2.3) 
When enrolled on a PrEP program: 
Π(𝑟𝑟𝜃𝜃𝛼𝛼) = 1 − �𝑝𝑝1(𝜓𝜓(1−𝜏𝜏), 𝑟𝑟𝜃𝜃𝛼𝛼1 + 𝜓𝜓𝜏𝜏, 𝑟𝑟𝜃𝜃𝛼𝛼1 ) + (1 − 𝑝𝑝1)�𝐶𝐶1�𝑝𝑝2(𝜓𝜓(1−𝜏𝜏), 𝑟𝑟𝜃𝜃𝛼𝛼2 + 𝜓𝜓𝜏𝜏, 𝑟𝑟𝜃𝜃𝛼𝛼2 ) + (1 − 𝑝𝑝2)�𝐶𝐶2  
Where 
𝜓𝜓(1−𝜏𝜏), 𝑟𝑟𝜃𝜃𝛼𝛼1 = (1 − 𝜏𝜏1)�(1 − 𝜗𝜗1)𝑠𝑠1( 1 − 𝛿𝛿𝛿𝛿1)𝑛𝑛1 + (1 − 𝜗𝜗1)(1 − 𝑠𝑠1)( 1 − 𝛿𝛿1)𝑛𝑛1+ 𝜗𝜗1𝑠𝑠1( 1 − (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + 𝜗𝜗1(1 − 𝑠𝑠1)( 1 − (1 − 𝜚𝜚)𝛿𝛿1)𝑛𝑛1� 
𝜓𝜓𝜏𝜏, 𝑟𝑟𝜃𝜃𝛼𝛼1 = 𝜏𝜏1�(1 − 𝜗𝜗1)𝑠𝑠1( 1 − (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + (1 − 𝜗𝜗1)(1 − 𝑠𝑠1)( 1 − (1 − 𝜎𝜎)𝛿𝛿1)𝑛𝑛1+ 𝜗𝜗1𝑠𝑠1( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + 𝜗𝜗1(1 − 𝑠𝑠1)( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿1)𝑛𝑛1� 
𝛿𝛿1 = 𝛽𝛽𝑓𝑓(1 − 𝑟𝑟𝜃𝜃𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1) 
And 
𝜓𝜓(1−𝜏𝜏), 𝑟𝑟𝜃𝜃𝛼𝛼2 = (1 − 𝜏𝜏2)�(1 − 𝜗𝜗2)𝑠𝑠2( 1 − 𝛿𝛿𝛿𝛿2)𝑛𝑛2 + (1 − 𝜗𝜗2)(1 − 𝑠𝑠2)( 1 − 𝛿𝛿2)𝑛𝑛2+ 𝜗𝜗2𝑠𝑠2( 1 − (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + 𝜗𝜗2(1 − 𝑠𝑠2)( 1 − (1 − 𝜚𝜚)𝛿𝛿2)𝑛𝑛2� 
𝜓𝜓𝜏𝜏, 𝑟𝑟𝜃𝜃𝛼𝛼2 = 𝜏𝜏2�(1 − 𝜗𝜗2)𝑠𝑠2( 1 − (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + (1 − 𝜗𝜗2)(1 − 𝑠𝑠2)( 1 − (1 − 𝜎𝜎)𝛿𝛿2)𝑛𝑛2+ 𝜗𝜗2𝑠𝑠2( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + 𝜗𝜗2(1 − 𝑠𝑠2)( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿2)𝑛𝑛2� 
𝛿𝛿2 = 𝛽𝛽𝑓𝑓(1 − 𝑟𝑟𝜃𝜃𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾2) 
(S2.4) 
All models were programmed in R version 3.3.26. 
 
2.1 Country case studies 
We apply the models to South Africa, Zimbabwe and Kenya, which are have generalised high 
prevalence HIV epidemics.7–10 These countries were chosen as case studies as they span a range of 
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HIV burden levels in the region, they have each have adopted a national PrEP strategy,11,12,13 and 
been at the forefront of PrEP roll-out in sub-Saharan Africa14. 
In each country, we consider four groups of women at high risk of HIV through heterosexual 
transmission2,7,8,9: 𝑗𝑗 = {FSW, adolescent girls and young women aged 15-24 years (AGYW), women 
25-34 years and women 35-49 years}. 
FSW are assumed to have partners drawn from two populations: regular partners and clients. AGYW 
are assumed to have partners drawn from their own age group and also the 25-34 years age group, 
given that 17% and 14% women 15-19 years report relationships with men at least 10 years older in 
Zimbabwe15 and Kenya16 respectively, and 36% South African women 15-19 years report 
relationships with men at least 5 years older.7 Women 25-34 years and women 35-49 years are 
assumed to have partners drawn from their own age groups.  
 
Data ranges to parameterise the models of HIV risk for each high-risk female group were drawn from 
the latest available in the literature and fitted to the latest national estimates of HIV incidence by 
group (see Supporting Information: Methods: Table S2) using Latin Hypercube Sampling (R PSE 
Package17) to yield at least 200 sets of parameter fits for each high-risk woman population modelled. 
 
2.2 Assessment of cost-effectiveness of scaling-up PrEP 
Given the significantly higher individual HIV risk faced by FSW,2 a priority group for PrEP roll-out in 
these settings,11,12,13 we assumed FSW as the benchmark for assessment of cost-effectiveness.  
Let $𝑌𝑌𝑗𝑗 be the unit cost per high risk woman from population 𝑗𝑗 ≠ 𝐹𝐹𝑆𝑆𝐹𝐹 retained in a PrEP program 
for population 𝑗𝑗, with 12-month retention level 𝑟𝑟𝑗𝑗, and $𝑌𝑌𝐹𝐹𝑆𝑆𝐹𝐹 the equivalent unit cost for a FSW PrEP 
program per FSW retained with 12-month retention level 𝑟𝑟𝐹𝐹𝑆𝑆𝐹𝐹. 
Then the program’s cost to avert 1 infection per year due to PrEP in each population is $𝑌𝑌𝑗𝑗
Π𝑗𝑗(0)−Π𝑗𝑗(𝑟𝑟𝑗𝑗𝜃𝜃𝛼𝛼𝑗𝑗) and $𝑌𝑌𝐹𝐹𝐹𝐹𝐹𝐹Π𝐹𝐹𝐹𝐹𝐹𝐹(0)−Π𝐹𝐹𝐹𝐹𝐹𝐹(𝑟𝑟𝐹𝐹𝐹𝐹𝐹𝐹𝜃𝜃𝛼𝛼𝐹𝐹𝐹𝐹𝐹𝐹) respectively. 
A PrEP program for high risk population 𝑗𝑗 ≠ 𝐹𝐹𝑆𝑆𝐹𝐹 will then be equally as cost-effective per infection 
averted due to PrEP, as it is for FSW where  
$𝑌𝑌𝑗𝑗$𝑌𝑌𝐹𝐹𝐹𝐹𝐹𝐹 = Π𝑗𝑗(0)−Π𝑗𝑗(𝑟𝑟𝑗𝑗𝜃𝜃𝛼𝛼𝑗𝑗)Π𝐹𝐹𝐹𝐹𝐹𝐹(0)−Π𝐹𝐹𝐹𝐹𝐹𝐹(𝑟𝑟𝐹𝐹𝐹𝐹𝐹𝐹𝜃𝜃𝛼𝛼𝐹𝐹𝐹𝐹𝐹𝐹)  
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(S2.5) 
To determine the coverage, 𝜔𝜔𝑗𝑗, of PrEP in high-risk woman population 𝑗𝑗 ≠ 𝐹𝐹𝑆𝑆𝐹𝐹 needed to achieve 
the same risk reduction as coverage 𝜔𝜔𝐹𝐹𝑆𝑆𝐹𝐹 in FSW, we have: 
 𝜔𝜔𝑗𝑗𝑁𝑁𝑗𝑗(1 − 𝑝𝑝𝑗𝑗) �Π𝑗𝑗(0) − Π𝑗𝑗(𝑟𝑟𝑗𝑗𝜃𝜃𝛼𝛼𝑗𝑗)� = 𝜔𝜔𝐹𝐹𝑆𝑆𝐹𝐹𝑁𝑁𝐹𝐹𝑆𝑆𝐹𝐹(1 − 𝑝𝑝𝐹𝐹𝑆𝑆𝐹𝐹)�Π𝐹𝐹𝑆𝑆𝐹𝐹(0)− Π𝐹𝐹𝑆𝑆𝐹𝐹(𝑟𝑟𝐹𝐹𝑆𝑆𝐹𝐹𝜃𝜃𝛼𝛼𝐹𝐹𝐹𝐹𝐹𝐹)� , 
(S2.6) 
 when 
𝜔𝜔𝑗𝑗 = 𝜔𝜔𝐹𝐹𝑆𝑆𝐹𝐹 𝑁𝑁𝐹𝐹𝐹𝐹𝐹𝐹(1−𝑝𝑝𝐹𝐹𝐹𝐹𝐹𝐹)�Π𝐹𝐹𝐹𝐹𝐹𝐹(0)−Π𝐹𝐹𝐹𝐹𝐹𝐹(𝑟𝑟𝐹𝐹𝐹𝐹𝐹𝐹𝜃𝜃𝛼𝛼𝐹𝐹𝐹𝐹𝐹𝐹)� 𝑁𝑁𝑗𝑗(1−𝑝𝑝𝑗𝑗)�Π𝑗𝑗(0)−Π𝑗𝑗(𝑟𝑟𝑗𝑗𝜃𝜃𝛼𝛼𝑗𝑗)�  . 
(S2.7) 
These levels of coverage would be at a relative total cost given by 
 $𝑌𝑌𝑗𝑗𝜔𝜔𝑗𝑗𝑁𝑁𝑗𝑗(1−𝑝𝑝𝑗𝑗)$𝑌𝑌𝐹𝐹𝐹𝐹𝐹𝐹𝜔𝜔𝐹𝐹𝐹𝐹𝐹𝐹𝑁𝑁𝐹𝐹𝐹𝐹𝐹𝐹(1−𝑝𝑝𝐹𝐹𝐹𝐹𝐹𝐹) 
(S2.8) 
If PrEP were scaled up at equal coverage in both populations, then the relative number of infections 
averted per year in high-risk woman population 𝑗𝑗 ≠ 𝐹𝐹𝑆𝑆𝐹𝐹with respect to the FSW population would 
be: 
𝑁𝑁𝑗𝑗(1−𝑝𝑝𝑗𝑗)(Π𝑗𝑗(0)−Π𝑗𝑗(𝑟𝑟𝑗𝑗𝜃𝜃𝛼𝛼𝑗𝑗))
𝑁𝑁𝐹𝐹𝐹𝐹𝐹𝐹(1−𝑝𝑝𝐹𝐹𝐹𝐹𝐹𝐹)(Π𝐹𝐹𝐹𝐹𝐹𝐹(0)−Π𝐹𝐹𝐹𝐹𝐹𝐹(𝑟𝑟𝐹𝐹𝐹𝐹𝐹𝐹𝜃𝜃𝛼𝛼𝐹𝐹𝐹𝐹𝐹𝐹))  
(S2.9) 
This is equivalent to the relative total maximum number of infections averted per year if PrEP 
programs were scaled up to all HIV negative women in each population. 
 
For each $100𝑘𝑘 available for PrEP programming for each population, the estimated number of 
infections averted a year in each population would be:  
In high-risk women 𝑗𝑗 ≠ 𝐹𝐹𝑆𝑆𝐹𝐹 
 $100𝑘𝑘$𝑌𝑌𝑗𝑗 (Π𝑗𝑗(0) − Π𝑗𝑗(𝑟𝑟𝑗𝑗𝜃𝜃𝛼𝛼𝑗𝑗)), 
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and in FSW 
 $100𝑘𝑘$𝑌𝑌𝐹𝐹𝐹𝐹𝐹𝐹 (𝛱𝛱𝐹𝐹𝑆𝑆𝐹𝐹(0) − 𝛱𝛱𝐹𝐹𝑆𝑆𝐹𝐹(𝑟𝑟𝐹𝐹𝑆𝑆𝐹𝐹𝜃𝜃𝛼𝛼𝐹𝐹𝐹𝐹𝐹𝐹)) 
(S2.10) 
The proportion of the potential total number of infections that could be averted a year in each 
population with $100𝑘𝑘 is: 
In high-risk women 𝑗𝑗 ≠ 𝐹𝐹𝑆𝑆𝐹𝐹 
 $100𝑘𝑘.(Π𝑗𝑗(0)−Π𝑗𝑗(𝑟𝑟𝑗𝑗𝜃𝜃𝛼𝛼𝑗𝑗)) $𝑌𝑌𝑗𝑗.𝑁𝑁𝑗𝑗(1−𝑝𝑝𝑗𝑗).Π𝑗𝑗(0)  , 
and in FSW 
 
$100𝑘𝑘.(𝛱𝛱𝐹𝐹𝐹𝐹𝐹𝐹(0)−𝛱𝛱𝐹𝐹𝐹𝐹𝐹𝐹(𝑟𝑟𝐹𝐹𝐹𝐹𝐹𝐹𝜃𝜃𝛼𝛼𝐹𝐹𝐹𝐹𝐹𝐹))$𝑌𝑌𝐹𝐹𝐹𝐹𝐹𝐹 .𝑁𝑁𝐹𝐹𝐹𝐹𝐹𝐹(1−𝑝𝑝𝐹𝐹𝐹𝐹𝐹𝐹).𝛱𝛱𝐹𝐹𝐹𝐹𝐹𝐹(0)  
(S2.11) 
 
Estimating costs of PrEP to each high-risk group of women 
We estimated the costs of offering PrEP to each high-risk group of women. FSW were assumed to be 
offered PrEP through programmes with outreach and community mobilisation components. All 
other women were assumed to be offered PrEP through sexual and reproductive health services, 
with services for AGYW having larger counselling components. We reviewed cost data from 
demonstration projects and previous PrEP costing publications in Kenya18,19 and South Africa.3 We 
disaggregated cost estimates into service delivery and drug costs. For our calculations, we replaced 
reported drug costs by a range of USD57-80 per year. The lower bound is the internationally traded 
value of USD3.75 with a 25% top up of freight and distribution costs in country (15% shipping and 
handling charges, and 10% for drug distribution costs).20 The high bound is the highest reported 
price for drugs in the demonstration projects - 30 days TDF/FTC at USD6.75. For Zimbabwe, in 
addition to drug costs, we transferred non-tradable components of South African estimates using 
purchasing power parities21 following standard methods.22 We adjusted all previously published 
costs to USD 2017.23  The amounts and detailed assumptions underpinning the estimated unit costs 
for each high-risk women group by country are set out in Table S1 below. 
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Table of Estimated Unit Costs for High-Risk Women Populations in South Africa, Zimbabwe and Kenya 
Country Population  Unit cost  (min - max) 
Service 
delivery 
excl. drugs 
Drugs only  
(min - max) Comments 
South Africa FSW 190 – 210 130 57 - 80 Unit costs measured during a demonstration project in Johannesburg and 
Pretoria via FSW clinics. Costs reported by Eakle et al3 included direct costs 
(eg, antiretrovirals, laboratory tests and consumables, labour and equipment) 
and indirect costs (eg, management, utilities, and transportation). We 
allocated outreach, demand creation and HCT costs to a unit cost of per 
person-year on PrEP as these were reported separately. 
South Africa AGYW (15-24y) 149 – 169 89 57 - 80 Unit costs estimated from local data and with input from several 
demonstration projects in South Africa. Costs reported by Meyer-Rath et al24 
included direct costs (eg, antiretrovirals, laboratory tests and consumables, 
labour and equipment), indirect costs (eg, management, utilities, and 
transportation), and outreach, demand creation and HCT costs. These 
estimates reflect the authors’ estimation of costs among female adolescents. 
South Africa Women (25-34y) 128 – 148 68 57 - 80 Unit costs estimated from local data and with input from several 
demonstration projects in South Africa. Costs reported by Meyer-Rath et al24 
included direct costs (eg, antiretrovirals, laboratory tests and consumables, 
labour and equipment), indirect costs (eg, management, utilities, and 
transportation), and outreach, demand creation and HCT costs. These 
estimates reflect the authors’ estimation of costs among young women. 
South Africa Women (35-49y) 87 – 107 27 57 - 80 Unit costs estimated from local data and with input from several 
demonstration projects in South Africa. Costs reported by Meyer-Rath et al24 
included direct costs (eg, antiretrovirals, laboratory tests and consumables, 
labour and equipment), indirect costs (eg, management, utilities, and 
transportation), and outreach, demand creation and HCT costs. These 
estimates reflect the authors estimation of costs among pregnant women - 
we assumed for this lowest risk population, the cost will be similar to those 
attending ANC. 
Zimbabwe FSW 293 – 317 237 57 - 80 Drug costs were kept constant and we adjusted service costs in South Africa 
using PPP index.25 
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Zimbabwe AGYW (15-24y) 219 – 243 163 57 - 80 Drug costs were kept constant and we adjusted service costs in South Africa 
using PPP index.25 
Zimbabwe Women (25-34y) 181 - 204 124 57 - 80 Drug costs were kept constant and we adjusted service costs in South Africa 
using PPP index.25 
Zimbabwe Women (35-49y) 106 - 130 50 57 - 80 Drug costs were kept constant and we adjusted service costs in South Africa 
using PPP index.25 
      
Kenya FSW 399 - 423 343 57 - 80 Unit costs measured in preparation for a demonstration project in Nairobi via 
SWOP clinics (for FSW). Costs reported by Cremin et al18 included direct costs 
(eg, antiretrovirals, laboratory tests and consumables, labour and equipment), 
related costs (eg, outreach and demand creation), and indirect costs (eg, 
management, utilities, and transportation).  
Kenya AGYW (15-24y) 358 - 382 302 57 - 80 Unit costs measured as part of a demonstration project aiming to integrate 
PrEP into routine maternal and child health and family planning clinics in 
western Kenya. Costs reported by Roberts et al19 included fixed (start-up 
costs, such as microplanning and training, capital, overheads (e.g. building 
costs, transportation, and airtime) and administrative and supervisory 
personnel) or variable (drugs, clinical personnel direct service costs, 
laboratory testing, and other supplies). These estimates reflect the authors 
measurement of costs among the highest risk subpopulation in the general 
population. 
Kenya Women (25-34y) 294 - 318 238 57 - 80 Unit costs measured as part of a demonstration project aiming to integrate 
PrEP into routine maternal and child health and family planning clinics in 
western Kenya. Costs reported by Roberts et al19 included fixed (start-up 
costs, such as microplanning and training, capital, overheads (e.g. building 
costs, transportation, and airtime) and administrative and supervisory 
personnel) or variable (drugs, clinical personnel direct service costs, 
laboratory testing, and other supplies). These estimates reflect the authors 
measurement of costs among all women. 
Kenya Women (35-49y) 185 - 209 129 57 - 80 Unit costs measured as part of a demonstration project aiming to integrate 
PrEP into routine maternal and child health and family planning clinics in 
western Kenya. Costs reported by Roberts et al19 included fixed (start-up 
costs, such as microplanning and training, capital, overheads (e.g. building 
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costs, transportation, and airtime) and administrative and supervisory 
personnel) or variable (drugs, clinical personnel direct service costs, 
laboratory testing, and other supplies). These estimates reflect the authors 
measurement of costs among all women excluding screening costs. 
Table S1: Table of Estimated Unit Costs for High-Risk Women Populations in South Africa, Zimbabwe and Kenya.  
The estimated unit costs for FSW, AGYW, women 25-34 years and women 35-49 years are shown disaggregated by the portion that is service delivery costs and the portion that is drug costs. 
The costs were calculated in line with the methodology set out in Supporting Information: Methods. The far right hand side column of the table sets out addition comments about specific 
assumptions made in calculating the data.  
*For our calculations, we replaced reported drug costs by a range of USD57-80. The low bound is the internationally traded value of USD3.75 
(https://www.theglobalfund.org/media/5813/ppm_arvreferencepricing_table_en.pdf) plus 25% top up of freight and distribution costs in country (15% shipping and handling charges, and 
10% for drug distribution costs). The high bound is the highest reported price for drugs in the demonstration projects - 30 days TDF/FTC at USD6.75. 
**transferability of costs between countries followed standard guidelines (https://pdfs.semanticscholar.org/36ab/74fd24fb883db703c475364c34ad574a3f35.pdf) 
*** Purchasing Power Parities (PPP) 
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Model calibration  
The data used in the parameterisation and fitting of the models for all 3 country case studies shown in Table S2.  
Parameter Symbol 
Kenya  Zimbabwe South Africa 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Epidemic parameters        
FSW: HIV incidence, per 100 
person years 
𝑖𝑖𝐹𝐹𝑆𝑆𝐹𝐹  3.9 (2.2-5.6) Nairobi, 201126 
Nairobi, 200827 
Estimate is mid-
point. 
For context, 2.6 
Mombasa, 200628 
5.87 (5.55-
6.21) 
2017 estimates29. 
95% confidence 
intervals (CIs) 
estimated assuming 
binomially 
distributed, based 
on population size 
and proportion 
HIV-  
7.2 (4.5-9.8) CAPRISSA 002 200830 
AGYW: HIV incidence, per 100 
person years 
𝑖𝑖𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹 
 
0.28 (0.137 – 
0.490) 
UNAIDS 2018 
Estimates31  
0.53 (0.13, 
0.93) 
2016 estimates32  1.51 (1.31-1.71) National estimates, 
201733 
Women 25-34 years: HIV 
incidence, per 100 person 
years 
𝑖𝑖𝐹𝐹25−34 0.25 (0.120 –
0.431) 
UNAIDS 2018 
Estimates31 
1.11 (0.41, 
1.80) 
2016 estimates32 1.045 (0.87-
1.22) 
2017 estimates34. Low 
and High are min and 
max across all ages 
within range.  
Women 35-49 years: HIV 
incidence, per 100 person 
years 
𝑖𝑖𝐹𝐹35−49 0.16 (0.078–
0.282) 
UNAIDS 2018 
Estimates31 
0.42 (0.00, 
0.92) 
2016 estimates32 0.665 (0.49-
0.84) 
2017 estimates34. Low 
and High are min and 
max across all ages 
within range.  
FSW: Population size, in 
1,000s of women 
𝑁𝑁𝐹𝐹𝑆𝑆𝐹𝐹  134 2013 size 
estimation35 
45 2017 estimates29 138 2013 size estimation36 
AGYW: Population size, in 
1,000s of women 
𝑁𝑁𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹  4,067 2009 census37 1,304 2012 census38 4,901 2018 mid-year 
estimates39 
Women 25-34 years: 
Population size, in 1,000s of 
women 
𝑁𝑁𝐹𝐹25−34 2,935 2009 census37 1,089 2012 census38 5,366 2018 mid-year 
estimates39 
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Parameter Symbol 
Kenya  Zimbabwe South Africa 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Women 34-49 years: 
Population size, in 1,000s of 
women  
𝑁𝑁𝐹𝐹35−49 2,374 2009 census37 817 2012 census38 5,354 2018 mid-year 
estimates39 
Clients of FSW: HIV 
prevalence 
𝑝𝑝𝑐𝑐  0.165 (0.135-0
.194) 
Truck drivers, 
Kenya, 200540 
Maximum county 
male prevalence 
(Siaya, males, 15-49 
years), 20179  
Estimate is mid-
point. 
0.273 (0.248, 
0.295)  
Long distance truck 
drivers, 200541 
0.339 (0.275 – 
0.410) 
Non-residents (study 
proxy for migrant 
work), men, from 
KwaZulu-Natal, South 
Africa, 2004.42 
Men in general population 15-
49 years: HIV prevalence 
𝑠𝑠𝑝𝑝𝑀𝑀15−49 0.045 (0.0448-
0.0451) 
0.045 Males 15-49, 
20179.  
0.044 (0.036-0.052) 
males 15-64 years, 
KAIS, 201243. Use 
KAIS estimates as 
consistent with 
estimates used for 
individual age 
ranges below. No CI 
for 2017 estimate, 
but fits within CI of 
KAIS 
0.107 (0.1066-
0.1074) 
2016 estimates32 
95% CI estimated 
assuming 
binomially 
distributed, based 
on population size38 
0.148 (0.133 – 
0.165) 
National estimates, 
20177 
Men 15-24 years: HIV 
prevalence 
𝑝𝑝𝑀𝑀15−24 0.011 (0.005-0
.018) 
KAIS, 201243 0.030 (0.0297-
0.03030) 
2016 estimates32 
95% CI estimated 
assuming 
binomially 
distributed, based 
on population size38 
0.039 (0.014 – 
0.06) 
AIDSInfo 201731 
Men 25-34 years: HIV 
prevalence 
𝑝𝑝𝑀𝑀25−34 0.054 (0.039-0
.068) 
KAIS, 201243 0.060 (0.0595-
0.0605) 
2016 estimates32 
95% CI estimated 
assuming 
0.124-0.184 Min and max of 5-year 
age categories (full 
national results not yet 
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Parameter Symbol 
Kenya  Zimbabwe South Africa 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
binomially 
distributed, based 
on population size38 
released). National 
estimates, 201733 
Men 35-49 years: HIV 
prevalence 
𝑝𝑝𝑀𝑀35−49 0.064 (0.051-0
.076) 
35 years+, KAIS, 
201243 
0.237 (0.236-0
.238) 
2016 estimates32 
95% CI estimated 
assuming 
binomially 
distributed, based 
on population size38 
0.224-0.248 Min and max of 5-year 
age categories (full 
national results not yet 
released). National 
estimates, 201733 
FSW: HIV prevalence 𝑝𝑝𝐹𝐹𝑆𝑆𝐹𝐹 0.293 (0.290,0
.295) 
 
2013 size 
estimation35 
95% CI estimated 
assuming 
binomially 
distributed, based 
on population size 
0.571 (0.566-
0.576) 
AIDSInfo 201731 
95% CI estimated 
assuming 
binomially 
distributed, based 
on population size38 
0.689 (0.565-
0.812) 
FSW Johannesburg, 
South Africa, 2014.44 
Estimate is 
midpoint.0.10 
AGYW: HIV prevalence 𝑝𝑝𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹  0.03 (0.022-0.
038) 
KAIS, 201243 0.059 (0.0586-
0.0594) 
2016 estimates32 0.102 (0.046–
0.148) 
AIDSInfo 201731 
Women 25-34 years: HIV 
prevalence 
𝑝𝑝𝐹𝐹25−34 0.073 (0.06-0.
087) 
KAIS, 201243 0.182 (0.1813-
0.1827) 
2016 estimates32 0.275-0.347 Min and max of 5-year 
age categories (full 
national results not yet 
released). National 
estimates, 201733 
Women 35-49 years: HIV 
prevalence 
𝑝𝑝𝐹𝐹35−49 0.093 (0.083-0
.113) 
35 years+, KAIS, 
201243 
0.282 (0.281-0
.283) 
2016 estimates32 0.303-0.394 Min and max of 5-year 
age categories (full 
national results not yet 
released). National 
estimates, 201733 
Behavioural parameters        
FSW: number of client 
partners/ year 
𝐶𝐶𝑐𝑐_𝐹𝐹𝑆𝑆𝐹𝐹 320 (276-364) Monthly liaisons 
x12, FSW at 
hotspots along 
360 (234-486) Across studies46,47 
Estimate is 
midpoint. 
424 (312 – 504) Mean monthly 
reported number of 
clients per FSW, 
multiplied by 12.48 
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Parameter Symbol 
Kenya  Zimbabwe South Africa 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Mombasa-Kampala 
highway, 200740 
Median number in 
last 7 days x52 
Nairobi, 201045 
Estimate is 
midpoint. 
FSW: number of regular 
partners from male 
population 15-49 years/ year 
𝐶𝐶𝑀𝑀15−49_𝐹𝐹𝑆𝑆𝐹𝐹  (1-4) Nairobi, 201045 
Point estimate not 
deducible as 
categorical data. 
 
2.0 (0.74-4.0) Imputed from 
South Africa, due to 
lack of data. 
Number of main 
sexual partners per 
6 months, 
multiplied by 2.49 
2.0 (0.74-4.0) Number of main sexual 
partners per 6 months, 
multiplied by 2.49 
FSW: number of sex acts per 
client/ year 
𝑛𝑛𝑐𝑐_𝐹𝐹𝑆𝑆𝐹𝐹 1.59 (1-2.17) FSW at hotspots 
along Mombasa-
Kampala highway, 
200740 
Estimate is 
midpoint. 
1 (1-1.2) Imputed from 
South Africa, due to 
lack of data. 
Number of sexual 
encounters per 
client.50 
1 (1-1.2) Number of sexual 
encounters per 
client.50 
FSW: number of sex acts with 
regular partners/ year 
𝑛𝑛𝑀𝑀15−49_𝐹𝐹𝑆𝑆𝐹𝐹 96 (48-144) Imputed from 
South Africa, due to 
lack of data. 
96 (48-144) Imputed from 
South Africa, due to 
lack of data.  
96 (48-144) Mean monthly 
frequency of sex acts in 
main partnerships, 
multiplied by 12.48 
FSW: average condom 
consistency with clients 
𝛾𝛾𝑐𝑐_𝐹𝐹𝑆𝑆𝐹𝐹 0.773 (0.626-
0.92) 
Paying clients, FSW 
Nairobi, 201045 
UNAIDS, 201731 
Estimate is mid-
point. 
0.708 (0.455-
0.961) 
% reporting full 
adherence to 
condom use51 
2017 estimates29 
Estimate is mid-
point. 
0.764 (0.609-
0.902) 
FSW Johannesburg, 
South Africa, 2014.44 
FSW: average condom 
consistency with regular 
partners 
𝛾𝛾𝑀𝑀15−49_𝐹𝐹𝑆𝑆𝐹𝐹 0.463 (0.386-
0.540) 
Non-paying 
partner, Mombasa, 
200752 
0.3375 (0.333-
0.342) 
Survey, 201153 
Estimate is mid-
point. 
0.345 (0.173-
0.548) 
FSW Johannesburg, 
South Africa, with non-
paying partner, 2014.44 
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Parameter Symbol 
Kenya  Zimbabwe South Africa 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Non-paying 
partner, Nairobi, 
201045 
Estimate is mid-
point. 
FSW: probability at least 1 
person in partnership has an 
STI – with clients 
𝑠𝑠𝑐𝑐_𝐹𝐹𝑆𝑆𝐹𝐹  0.011 (0.004-
0.021) 
Prevalence of 
Neisseria 
gonorrhoea, FSW 
Nairobi, 201045 
0.019 (0.005-
0.034) 
Prevalence of 
Neisseria 
gonorrhoea, 200554 
0.21 (0.15-0.30) Low: Prevalence of 
Chlamydia trachomatis 
& Neisseria 
gonorrhoea in Hillbrow 
FSW.50  
High: FSW STI 
prevalence, Durban.30 
FSW: probability at least 1 
person in partnership has an 
STI – with regular partners 
𝑠𝑠𝑀𝑀15−49_𝐹𝐹𝑆𝑆𝐹𝐹  0.011 (0.004-
0.021) 
Prevalence of 
Neisseria 
gonorrhoea, FSW 
Nairobi, 201045 
0.019 (0.005-
0.034) 
Prevalence of 
Neisseria 
gonorrhoea, 200554 
0.21 (0.15-0.30) Low: Prevalence of 
Chlamydia trachomatis 
& Neisseria 
gonorrhoea in Hillbrow 
FSW.50  
High: FSW STI 
prevalence, Durban.30 
        
AGYW: number of male 
partners 15-24 years/ year 
𝐶𝐶𝑀𝑀15−24_𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹  (0-4) Estimated range, 
Women 15-24, 
201416, accounting 
for the  proportion 
who have never 
had sexual 
intercourse and 
mean lifetime 
partners. 
Point estimate not 
deducible as 
categorical data. A 
wider parameter 
(0-4) Estimated range, 
Women 15-24, 
201515, accounting 
for the  proportion 
who have never 
had sexual 
intercourse and 
mean lifetime 
partners. 
Point estimate not 
deducible as 
categorical data. A 
wider parameter 
(0-4) Estimated range, 
Women 15-24, 201655, 
accounting for the  
proportion who have 
never had sexual 
intercourse and mean 
lifetime partners. 
Point estimate not 
deducible as 
categorical data. A 
wider parameter range 
was considered in the 
fitting process (0-10). 
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Parameter Symbol 
Kenya  Zimbabwe South Africa 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
range was 
considered in the 
fitting process (0-
10). 
range was 
considered in the 
fitting process (0-
10). 
AGYW: number of male 
partners 25-34 years/ year 
𝐶𝐶𝑀𝑀25−34_𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹  (0-4) Estimated range, 
Women 15-24, 
201416, accounting 
for the proportion 
of age-discordant 
relationship. 
Point estimate not 
deducible as 
categorical data. A 
wider parameter 
range was 
considered in the 
fitting process (0-
10). 
(0-4) Estimated range, 
Women 15-24, 
201515, accounting 
for the proportion 
of age-discordant 
relationship. 
Point estimate not 
deducible as 
categorical data. A 
wider parameter 
range was 
considered in the 
fitting process (0-
10). 
(0-4) Estimated range, 
Women 15-24, 201655, 
accounting for the 
proportion of age-
discordant 
relationships. 
Point estimate not 
deducible as 
categorical data. A 
wider parameter range 
was considered in the 
fitting process (0-10). 
AGYW: number of sex acts 
male partners 15-24 years/ 
year 
𝑛𝑛𝑀𝑀15−24_𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹  182 (156-208) Imputed based on 
South Africa, due to 
lack of data 
82 (156-208) Imputed based on 
South Africa, due to 
lack of data 
182 (156-208) 3-4 a week x 52, youth, 
with regular partner, 
200056 Estimate is mid-
point. 
AGYW: number of sex acts 
male partners 24-34 years / 
year 
𝑛𝑛𝑀𝑀25−34_𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹  48 (36-60) Imputed based on 
South Africa, due to 
lack of data 
48 (36-60) Imputed based on 
South Africa, due to 
lack of data 
48 (36-60) 3 sex acts a month, 
youth, non-spousal 
partner, 200056 
5 sex acts a month x12, 
married 18-20 year old, 
average number sex 
acts per short term 
partner formation, 
201657 
Estimate is mid-point 
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Parameter Symbol 
Kenya  Zimbabwe South Africa 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
AGYW: average condom 
consistency with male 
partners 15-24 years 
𝛾𝛾𝑀𝑀15−24_𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹 0.355 (0.11-
0.60) 
Condom use at last 
sexual encounter 
with partner of 
unknown status58 
Condom use at last 
sexual intercourse, 
Women 15-24, 
201416 
Estimate is mid-
point. 
0.406 (0.213- 
0.599) 
% who had 
intercourse in the 
past 12 months 
with a non-marital, 
non-cohabiting 
partner15 
1-[Trial control 
arm, did not use 
condom at last sex, 
females,18-22 year 
olds59] 
Estimate is mid-
point. 
0.588 (0.498 - 
0.677) 
 
 
 
0.498, 0.677. Females, 
males. 15-24 years, 
condom use at last sex, 
2017. 7 
Estimate is mid-point. 
AGYW: average condom 
consistency with male 
partners 25-34 years 
𝛾𝛾𝑀𝑀25−34_𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹 0.292 (0.11-
0.474) 
Condom use at last 
sexual encounter 
with partner of 
unknown status58 
Condom use at last 
transactional sex, 
Women 15-64 
years,  201260 
Estimate is mid-
point. 
0.299 (0.1-
0.498) 
Females aged <25, 
males aged 25+, 
200561  
Never married 
women, % who 
used condom at 
last sexual 
intercourse15 
Estimate is mid-
point. 
0.504 (0.473-
0.534) 
0.473 females 15-24 
years, condom use last 
sex, those with more 
than 1 partner in the 
last year, 2017.7 
Estimate is mid-point. 
AGYW: probability at least 1 
person in partnership has an 
STI – with male partners 15-
24 years 
𝑠𝑠𝑀𝑀15−24_𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹  0.018 (0.002 – 
0.062) 
Gonorrhoea 
prevalence 15-24 
year olds 
(combined study 
with Tanzania), 
201062 
0.018 (0.01 – 
0.029) 
Gonorrhoea 
prevalence 15-24 
year olds, 200162 
0.018 (0.008–
0.041) 
Maximum of 
prevalence of 
gonorrhoea in 15-24 
year old males and 
females 
AGYW: probability at least 1 
person in partnership has an 
STI – with male partners 25-
34 years 
𝑠𝑠𝑀𝑀25−34_𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹  0.009 (0.001 -
0.032) 
Gonorrhoea 
prevalence 25-49 
year olds 
(combined study 
0.025 (0.018 – 
0.036) 
Gonorrhoea 
prevalence 25-49 
year olds, 200162 
0.05 (0.022-
0.04) 
Gonorrhoea 
prevalence 25-49 year 
olds, 201062 (greater 
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Parameter Symbol 
Kenya  Zimbabwe South Africa 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
with Tanzania), 
201062 
than 15-24 years 
estimate above) 
        
Women 25-34 years: number 
of male partners 25-34 years/ 
year 
𝐶𝐶𝑀𝑀25−34_𝐹𝐹25−3  1.96 (0.92-3.0) Lower bound as for 
Zimbabwe 
Estimated upper 
bound, Women 25-
29, 30-39, 
accounting for 
mean lifetime 
partners, 201416 
Estimate is mid-
point. A wider 
parameter range 
was considered in 
the fitting process 
(0-10). 
1.96 (0.92-3.0) Total partnerships 
in last 12 months 
reported by adult 
women, 200563 
Estimated upper 
bound, Women 25-
29, 30-39, 
accounting for 
mean lifetime 
partners, 201515 
Estimate is mid-
point. A wider 
parameter range 
was considered in 
the fitting process 
(0-10). 
2.02 (1.03–3.0) Total partnerships in 
last 12 months 
reported by adult 
women, 200663  
Estimated upper 
bound, Women 25-29 
and 30-39, accounting 
for mean lifetime 
partners, 201655 
Estimate is mid-point. 
A wider parameter 
range was considered 
in the fitting process 
(0-10). 
Women 25-34 years: number 
of sex acts male partners 24-
34 years / year 
𝑛𝑛𝑀𝑀25−34_𝐹𝐹25−3  93 (54-132) Average number of 
sex acts per partner 
per year, before 
intervention, 1998, 
Kenya64 
Upper bound 
imputed from 
South Africa due to 
lack of data 
Estimate is mid-
point. 
96 (60-132) Imputed from 
South Africa due to 
lack of data 
96 (60-132) Mean 5 sex acts a 
month x 12, 18-40 year 
old women, KwaZulu-
Natal, 201065 
2.54 mean sex acts a 
week x52, women, 
200766 
Estimate is mid-point. 
Women 25-34 years: average 
condom consistency with 
male partners 25-34 years 
𝛾𝛾𝑀𝑀25−34_𝐹𝐹25−3  0.183 (0.038-
0.328) 
Women 15-64 
years, Married/ 
0.295 (0.07-
0.520) 
Females ages 25+, 
males aged 25+, 
200561  
0.344 (0.324–
0.366) 
Condom use at last 
sex, 25-49 years, 
201267 
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Parameter Symbol 
Kenya  Zimbabwe South Africa 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Coinhabiting, 
201260 
Women 15-64 
years, 
Casual/Other, 
201260  
Estimate is mid-
point. 
Condom use during 
last sexual 
intercourse, 
women reporting 
2+ partners in last 
12 months, 
max(25-29 year 
olds, 30-39 year 
olds)15 
Estimate is mid-
point. 
Women 25-34 years: 
probability at least 1 person in 
partnership has an STI – with 
male partners 25-34 years 
𝑠𝑠𝑀𝑀25−34_𝐹𝐹25−3  0.009 (0.001 -
0.032) 
Gonorrhoea 
prevalence 25-49 
year olds 
(combined study 
with Tanzania), 
201062 
0.025 (0.018 – 
0.036) 
Gonorrhoea 
prevalence 25-49 
year olds, 200162 
0.05 (0.022-
0.04) 
Gonorrhoea 
prevalence 25-49 year 
olds, 201062 
For model structural 
sensitivity analysis: 
Women 25-34 years: number 
of male partners 35-49 years/ 
year 
𝐶𝐶𝑀𝑀35−49_𝐹𝐹25−3  50% of  
𝐶𝐶𝑀𝑀35−49_𝐹𝐹35−49 As below 50% of  𝐶𝐶𝑀𝑀35−49_𝐹𝐹35−49 As below 50% of  𝐶𝐶𝑀𝑀35−49_𝐹𝐹35−49 As below 
For model structural 
sensitivity analysis: 
Women 25-34 years: number 
of sex acts male partners 35-
49 years / year 
𝑛𝑛𝑀𝑀35−49_𝐹𝐹25−3  𝑛𝑛𝑀𝑀35−49_𝐹𝐹35−49  As below 𝑛𝑛𝑀𝑀35−49_𝐹𝐹35−49 As below 𝑛𝑛𝑀𝑀35−49_𝐹𝐹35−49 As below 
For model structural 
sensitivity analysis: 
Women 25-34 years: average 
condom consistency with 
male partners 35-49 years 
𝛾𝛾𝑀𝑀35−49_𝐹𝐹25−3  𝛾𝛾𝑀𝑀25−34_𝐹𝐹25−34 
(same 
parameter 
value as  
𝛾𝛾𝑀𝑀35−49_𝐹𝐹35−49) 
As above  𝛾𝛾𝑀𝑀25−34_𝐹𝐹25−34 
(minimum of 
this and 
parameter 
value of 
𝛾𝛾𝑀𝑀35−49_𝐹𝐹35−49) 
As above  𝛾𝛾𝑀𝑀25−34_𝐹𝐹25−34 
(same 
parameter 
value as  
𝛾𝛾𝑀𝑀35−49_𝐹𝐹35−49) 
As above  
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Parameter Symbol 
Kenya  Zimbabwe South Africa 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
For model structural 
sensitivity analysis: 
Women 25-34 years: 
probability at least 1 person in 
partnership has an STI – with 
male partners 35-49 years 
𝑠𝑠𝑀𝑀35−49_𝐹𝐹25−3  𝑠𝑠𝑀𝑀25−34_𝐹𝐹25−34
(same 
parameter 
value as  
𝑠𝑠𝑀𝑀35−49_𝐹𝐹35−49
) 
As above  𝑠𝑠𝑀𝑀25−34_𝐹𝐹25−34
(same 
parameter 
value as  
𝑠𝑠𝑀𝑀35−49_𝐹𝐹35−49
) 
As above  𝑠𝑠𝑀𝑀25−34_𝐹𝐹25−34(
same parameter 
value as  
𝑠𝑠𝑀𝑀35−49_𝐹𝐹35−49) 
As above  
        
Women 35-49 years: number 
of male partners 35-49 years/ 
year 
𝐶𝐶𝑀𝑀35−49_𝐹𝐹35−4  1.96 (0.92-3.0) Lower bound as for 
Zimbabwe 
Estimated upper 
bound, Women 30-
39, 40-49, 
accounting for 
mean lifetime 
partners, 201416 
Estimate is mid-
point. A wider 
parameter range 
was considered in 
the fitting process 
(0-10). 
1.96 (0.92-3.0) Total partnerships 
in last 12 months 
reported by adult 
women, 200563 (no 
data to calc 95% CI) 
Estimated upper 
bound for 
maximum women 
30-30, 40-49, 
accounting for 
mean lifetime 
partners,  201515 
Estimate is mid-
point. A wider 
parameter range 
was considered in 
the fitting process 
(0-10). 
2.02 (1.03–3.0) Total partnerships in 
last 12 months 
reported by adult 
women, 200663  
Estimated upper 
bound, Women 30-39, 
40-49, accounting for 
mean lifetime 
partners, 201655 
Estimate is mid-point. 
A wider parameter 
range was considered 
in the fitting process 
(0-10). 
Women 35-49 years: number 
of sex acts male partners 35-
49 years / year 
𝑛𝑛𝑀𝑀35−49_𝐹𝐹35−4  93 (54-132) Average number of 
sex acts per partner 
per year, before 
intervention, 1998, 
Kenya64 
Upper bound 
imputed from 
96 (60-132) Imputed from 
South Africa due to 
lack of data 
96 (60-132) Mean 5 sex acts a 
month x 12, 18-40 year 
old women, KwaZulu-
Natal, 201065 
2.54 mean sex acts a 
week x52, women, 
200766 
Estimate is mid-point. 
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Parameter Symbol 
Kenya  Zimbabwe South Africa 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
South Africa due to 
lack of data 
Estimate is mid-
point. 
Women 35-49 years: average 
condom consistency with 
male partners 35-49 years 
𝛾𝛾𝑀𝑀35−49_𝐹𝐹35−4  0.183 (0.038-
0.328) 
Women 15-64 
years, Married/ 
Coinhabiting, 
201260 
Women 15-64 
years, 
Casual/Other, 
201260  
Estimate is mid-
point. 
0.354 (0.07-
0.638) 
Females ages 25+, 
males aged 25+, 
200561  
Condom use during 
last sexual 
intercourse, 
women reporting 
2+ partners in last 
12 months, 
max(30-39year 
olds, 40-49) year 
olds15 
Estimate is mid-
point. 
0.344 (0.324–
0.366) 
Condom use at last 
sex, 25-49 years, 
201267 
 
Women 35-49 years: 
probability at least 1 person in 
partnership has an STI – with 
male partners 35-49 years 
𝑠𝑠𝑀𝑀35−49_𝐹𝐹35−4  0.009 (0.001 -
0.032) 
Gonorrhoea 
prevalence 25-49 
year olds 
(combined study 
with Tanzania), 
201062 
0.025 (0.018 – 
0.036) 
Gonorrhoea 
prevalence 25-49 
year olds, 200162 
0.05 (0.022-
0.04) 
Gonorrhoea 
prevalence 25-49 year 
olds, 201062 
        
Clients of FSW: proportion of 
HIV+ individuals virally 
supressed 
𝜗𝜗𝑐𝑐  0.358 (0.3222-
0.3938) 
All ages, not 
disaggregated by 
sex (only data 
available), 201768. 
Low and high 
values not reliably 
calculable 
binomially, as 
0.489 (0.4401-
0.5379) 
2016 estimates32. 
Low and high 
values not reliably 
calculable 
binomially, as 
calculated based on 
ART cascade with 
unknown range at 
0.508 (0.451 – 
0.564) 
Prevalence of viral load 
suppression, 15-49 
years, 2017.7 
Estimate is mid-point 
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Parameter Symbol 
Kenya  Zimbabwe South Africa 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
calculated based on 
ART cascade with 
unknown range at 
higher cascade 
levels, so taking low 
and high to be +/-
10% of point 
estimate Same for 
below viral 
suppression data. 
higher cascade 
levels, so taking low 
and high to be +/-
10% of point 
estimate 
Same for below 
viral suppression 
data. 
Men in general population 15-
49 years: proportion of HIV+ 
individuals virally supressed 
𝜗𝜗𝑀𝑀15−49 0.358 (0.3222-
0.3938) 
All ages, not 
disaggregated by 
sex (only data 
available), 201768 
0.489 (0.4401-
0.5379) 
2016 estimates32 0.508 (0.451 – 
0.564) 
Prevalence of viral load 
suppression, 2017.7 
Estimate is mid-point 
Men 15-24 years: proportion 
of HIV+ individuals virally 
supressed 
𝜗𝜗𝑀𝑀15−24 0.358 (0.3222-
0.3938) 
All ages, not 
disaggregated by 
sex (only data 
available), 201768 
0.401 (0.3609-
0.4411) 
 
2016 estimates32 0.491 (0.4419-
0.5401)  
Prevalence of viral load 
suppression, 2017.7 
Low and high values 
not reliably calculable 
binomially, as 
calculated based on 
ART cascade with 
unknown range at 
higher cascade levels, 
so taking low and high 
to be +/-10% of point 
estimate. 
Same for below viral 
suppression data. 
Men 25-34 years: proportion 
of HIV+ individuals virally 
supressed 
𝜗𝜗𝑀𝑀25−34 0.358 (0.3222-
0.3938) 
All ages, not 
disaggregated by 
sex (only data 
available), 201768 
0.365 (0.3285-
0.4015) 
2016 estimates32 0.415 (0.3735-
0.4565) 
Prevalence of viral load 
suppression, 2017.7 
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Parameter Symbol 
Kenya  Zimbabwe South Africa 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Men 35-49 years: proportion 
of HIV+ individuals virally 
supressed 
𝜗𝜗𝑀𝑀35−49 0.358 (0.3222-
0.3938) 
All ages, not 
disaggregated by 
sex (only data 
available), 201768 
0.562 (0.5058-
0.6182) 
2016 estimates32 0.522 (0.4698-
0.5742) 
Prevalence of viral load 
suppression, 35-44 
years, 2017.7 
Clients of FSW: proportion 
circumcised 
𝜏𝜏𝑐𝑐  0.962 (0.9618-
0.9621) 
Males 15-49, 
201416 
95% CI estimated 
assuming 
binomially 
distributed, based 
on population size37 
0.143 (0.1426-
0.1434) 
Males 15-49, 
201515 
95% CI estimated 
assuming 
binomially 
distributed, based 
on population size38 
0.138 (0.1378-0.
1382) 
15-64 years, 2017.7 
95% CI estimated 
assuming binomially 
distributed, based on 
population size39 
Men in general population 15-
49 years: proportion 
circumcised 
𝜏𝜏𝑀𝑀15−49 0.962 (0.9618-
0.9621) 
Males 15-49, 
201416 
95% CI estimated 
assuming 
binomially 
distributed, based 
on population size37 
0.143 (0.1426-
0.1434) 
Males 15-49, 
201515 
0.138 (0.1378-
0.1382) 
15-64 years, 2017.7 
95% CI estimated 
assuming binomially 
distributed, based on 
population size39 
Men 15-24 years: proportion 
circumcised 
𝜏𝜏𝑀𝑀15−49 0.914 (0.9136-
0.9144) 
 
Males 15-24, 
201416 
95% CI estimated 
assuming 
binomially 
distributed, based 
on population size37 
0.188 (0.1873-
0.18878) 
Males 15-24, 
201515 
0.702 (0.7014-0.
7026) 
2017.7 
95% CI estimated 
assuming binomially 
distributed, based on 
population size39 
Men 25-34 years: proportion 
circumcised 
𝜏𝜏𝑀𝑀25−34 0.939 (0.934-
0.946) 
Males 25-29 and 
Males 30-39, 
201416 
Estimate is 
weighted average  
0.107 (0.10-
0.116) 
Males 25-29 and 
Males 30-39, 
201515 
Estimate is 
weighted average 
0.628 (0.6280-0.
6284) 
2017.7 
95% CI estimated 
assuming binomially 
distributed, based on 
population size39 
Men 35-49 years: proportion 
circumcised 
𝜏𝜏𝑀𝑀35−49 0.931 (0.919-
0.94) 
Males 30-39 and 
Males 40-49, 
201416 
0.111 (0.104-
0.116) 
Males 30-39 and 
Males 40-49, 
201515 
0.626 (0.6255-0.
6265) 
35-44 years, 2017.7 
95% CI estimated 
assuming binomially 
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Parameter Symbol 
Kenya  Zimbabwe South Africa 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Estimate is 
weighted average 
distributed, based on 
population size39 
PrEP parameters        
FSW: average 12-month PrEP 
program retention  
𝑟𝑟𝐹𝐹𝑆𝑆𝐹𝐹      22% TAPS3 
FSW: average self-reported 
adherence 
𝛼𝛼𝐹𝐹𝑆𝑆𝐹𝐹      70-85% TAPS3 
FSW: HIV prevention-effective 
PrEP adherence 
𝜃𝜃𝐹𝐹𝑆𝑆𝐹𝐹 Risk reduction of 0.79–0.99 
≥4 out 7 (≥ 57%) reported daily doses of PrEP a week 
Risk reduction of 0.73–1.06 
≥6 out 7 (≥ 86%) reported daily doses of PrEP a 
week 
For self-reported adherence of 70-85%, assume risk 
reduction range spanning range of both risk reduction 
estimates: 0.73-0.99 
Partners Demonstration Project prevention-effective adherence 
analysis - females69 
        
Transmission Probabilities        
Per sex act probability of HIV 
transmission from a 
chronically infected female to 
a male partner 
𝛽𝛽𝑓𝑓 0.00085 
(0.0006 - 
0.0011) 
Per-act HIV-1 
transmission 
probability, male to 
female5  
Estimate is mid-
point 
As stated  
Average reduction in 
probability HIV transmission 
on ART 
𝜚𝜚 0.945 (0.9 – 
0.99) 
Minimum and 
maximum across 
studies70 
Estimate is mid-
point 
HIV risk-reduction efficacy of 
condoms 
𝜀𝜀 0.85 (0.8 - 0.9) With consistent 
use71 and with 
consistent use72 
Estimate is mid-
point 
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Parameter Symbol 
Kenya  Zimbabwe South Africa 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Estimate 
(Low-High) References 
Multiplicative increase in per 
sex act probability of HIV 
transmission in the presence 
of an STI 
𝛿𝛿 4 (2-6) Combined study 
effectiveness 
estimate across 
STDs, and range 
spanning individual 
STD combined 
study effect 
estimates73 
Estimate is mid-
point 
Average reduction in 
probability of HIV 
transmission to women, when 
the male partner has been 
circumcised  
𝜎𝜎𝑓𝑓 0.1 (0–0.2) Male circumcision; 
estimates of HIV 
infection in 
women.74 
Estimate is mid-
point 
Table S2: Parameters and data sources used in the parameterisation and fitting of the models. Point estimates are stated first with lower and upper bounds used in the latin hypercube 
fitting in brackets.  
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Supplementary Results 
Model calibration 
The model fits to HIV incidence for each country and high-risk women population are shown in 
Figures S1-3. 
Figure S1: Model Fits to HIV Incidence Data for South Africa.  
The model outcomes across the parameter ranges simulated through latin hypercube sampling are show in blue. The black 
book-ended lines show the 95% confidence intervals around national HIV incidence estimates (HIV risk per year), and the 
model outcomes that fit within this range are considered to be fits to data. The model outcomes and fitting ranges are 
shown distinctly for the four high-risk women populations: female sex workers (FSW), adolescent girls and young women 
aged 15-24 years (AGYW), women aged 25-34 years and women aged 35-49 years. 
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Figure S2: Model Fits to HIV Incidence Data for Zimbabwe.  
The model outcomes across the parameter ranges simulated through latin hypercube sampling are show in orange. The 
black book-ended lines show the 95% confidence intervals around national HIV incidence estimates (HIV risk per year), and 
the model outcomes that fit within this range are considered to be fits to data. The model outcomes and fitting ranges are 
shown distinctly for the four high-risk women populations: female sex workers (FSW), adolescent girls and young women 
aged 15-24 years (AGYW), women aged 25-34 years and women aged 35-49 years. 
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Figure S3: Model Fits to HIV Incidence Data for Kenya.  
The model outcomes across the parameter ranges simulated through latin hypercube sampling are show in green. The black 
book-ended lines show the 95% confidence intervals around national HIV incidence estimates (HIV risk per year), and the 
model outcomes that fit within this range are considered to be fits to data. The model outcomes and fitting ranges are 
shown distinctly for the four high-risk women populations: female sex workers (FSW), adolescent girls and young women 
aged 15-24 years (AGYW), women aged 25-34 years and women aged 35-49 years. 
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Supplementary Results 
Figure S4 illustrates the relative cost at which PrEP will be equally as cost-effective to scale-up in a 
lower-risk group as it will be in a high-risk group, in the case that HIV prevalence in the higher-risk 
women partner population is 20%. It is demonstrated in four scenarios: underlying HIV prevalence in 
the lower-risk women’s partner population of 5%, 10%, 15% and 20%. This figure corresponds to 
Figure 2 in the main text, which demonstrates that case that HIV prevalence in the higher-risk 
women’s partner population is 40%.  
Figure S4: Relative unit cost at which it is cost-effective to scale-up PrEP from a higher- to lower-risk women group.  The 
heatmaps show the relative unit cost at which it is cost-effective to scale-up PrEP from a higher- to a lower-risk group. The 
relative unit cost at which PrEP is cost-effective is shown by the relative average condom use in the lower-risk group 
compared to the higher-risk group (x-axis), and the relative number of sex acts a month for women in the lower-risk group 
compared to the higher-risk group (y-axis). The unit cost of PrEP in the lower-risk group relative to the higher-risk group at 
which PrEP is equally cost-effective between the two groups is shown by colour, according to the colour key on the right-
hand side of the graph. A colour within the yellow spectrum denotes that the relative unit cost of PrEP in the lower-risk 
group relative to the higher-risk group has to be less than 1 for it to be equally as cost cost-effective. A colour within the 
green spectrum denotes that the relative unit cost of PrEP in the lower-risk group relative to the higher-risk group will be 
greater than 1 for it to be equally as cost cost-effective. The 4 heatmaps correspond respectively (left to right, top to 
bottom) to underlying partner HIV prevalence of 5%, 10%, 15% and 20% in the lower-risk group’s partner population and all 
of them corresponding to 20% HIV prevalence in the higher-risk women’s partner population. The heatmaps are calculated 
using equation (S1.5) from the Supplementary Materials: Methods, assuming that women’s partners are drawn from a 
single population each. The higher-risk group are assumed to have 12-month PrEP program retention levels of 22%3 and 
adherence levels of 70-85% (corresponding to a risk reduction of 73-99%69). The PrEP program retention levels for the 
lower-risk group were simulated between +/- 25% the retention of the higher-risk group.4 For those lower-risk women 
retained in the PrEP program, it was assumed that PrEP adherence was the same as the higher-risk group. 
327 
Comparison of the Maximum Unit Costs of PrEP in Lower-Risk Groups Relative to Unit Costs FSW to be Equally as Cost-Effective, with Estimates of 
Current Relative Unit Costs 
High Risk Women Population 
Country Unit Cost Relative to FSWs AGYW Women 25-34 years Women 35-49 years 
South 
Africa 
Maximum Relative Unit Cost to be Cost-Effective 23.3 % ( 13.3 % , 36.8 % ) 16.2 % ( 9.1 % , 26 % ) 10.5 % ( 5.7 % , 18 % ) 
Estimated Current Relative Unit Cost 79.6 % ( 72.4 % , 86.7 % ) 68.7 % ( 62.7 % , 75.8 % ) 48.3 % ( 42.4 % , 54.7 % ) 
Difference (relative to FSW Unit Cost) -56.2 % ( -69.2 % , -40.4 % ) -52.2 % ( -62.5 % , -41.4 % ) -37.6 % ( -45.8 % , -28.7 % )
Difference (relative to own Unit Cost) -70.8 % ( -83.4 % , -53.2 % ) -76.2 % ( -87.0 % , -62.6 % ) -78.4 % ( -88.1 % , -61.8 % )
Zimbabwe 
Maximum Relative Unit Cost to be Cost-Effective 7.1 % ( 2.7 % , 14.9 % ) 17.7 % ( 7.1 % , 31.2 % ) 11 % ( 5.5 % , 17.2 % ) 
Estimated Current Relative Unit Cost 75.6 % ( 70.8 % , 80.8 % ) 63 % ( 58 % , 67.7 % ) 38.8 % ( 34.1 % , 42.7 % ) 
Difference (relative to FSW Unit Cost) -67.7 % ( -75.1 % , -60.1 % ) -44.6 % ( -58.3 % , -31.1 % ) -28.1 % ( -35.3 % , -18.7 % )
Difference (relative to own Unit Cost) -90.4 % ( -96.5 % , -80.6 % ) -71.8 % ( -88.9 % , -50.8 % ) -72 % ( -86.1 % , -53.6 % )
Kenya 
Maximum Relative Unit Cost to be Cost-Effective 8.1 % ( 3.9 % , 18.5 % ) 9.1 % ( 3.6 % , 17.7 % ) 6.4 % ( 3.1 % , 11.6 % ) 
Estimated Current Relative Unit Cost 90.3 % ( 86.2 % , 94.8 % ) 74.9 % ( 71.1 % , 78.4 % ) 48.1 % ( 45.1 % , 51.6 % ) 
Difference (relative to FSW Unit Cost) -81.5 % ( -89 % , -71 % ) -66 % ( -73.4 % , -57.5 % ) -41.7 % ( -46.4 % , -36.2 % )
Difference (relative to own Unit Cost) -91 % ( -95.7 % , -79.6 % ) -88 % ( -95.3 % , -76.6 % ) -86.7 % ( -93.7 % , -75.4 % )
Table S3: Comparison of the Maximum Unit Costs of PrEP in Lower-Risk Groups Relative to Unit Costs FSW to be Equally as Cost-Effective, with Estimates of Current Relative Unit Costs.  
The table shows the maximum relative unit costs of PrEP in AGYW, women 25-34 years and women 35-49 years relative to the unit costs of PrEP for FSW, for PrEP to be equally as cost-
effective (calculated using equation S1.5 in Supplementary Materials: Methods). It compares this to the estimated current relative unit costs between the populations, calculated using the data 
set out in Table S2. The table shows the difference between these two estimates (relative to the FSW unit cost of PrEP). It also shows what this difference represents relative to the group’s (i.e. 
AGYW, women 25-34 years or women 35-49 years) own unit cost, which is equivalent to the % the unit cost would have to drop for PrEP to be equally as cost-effective as for FSW. The 
comparisons are shown separately for South Africa, Zimbabwe and Kenya. The values shown in the table outside the brackets are the median values, and the values shown in the brackets are 
the 95% credible intervals (CrIs). 
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Table S4 sets out the estimated number of infections that could be averted a year due to PrEP in 
each high-risk women population group, in each country, for every $100,000 available for PrEP 
programming, at the PrEP unit costs stated in Table S2. These data correspond to Figure 4 in the 
main text. 
For each $100k available for PrEP programming a year,  
the number of HIV infections that could be averted due to PrEP 
High Risk Women Population 
Country FSW AGYW Women 25-34 years Women 35-49 years 
South 
Africa 
5.7 ( 3.8 , 8.8 ) 1.7 ( 1.1 , 2.4 ) 1.3 ( 0.9 , 2 ) 1.2 ( 0.8 , 2 ) 
Zimbabwe 3.4 ( 2.9 , 4.1 ) 0.3 ( 0.1 , 0.7 ) 1 ( 0.4 , 1.8 ) 0.9 ( 0.5 , 1.6 ) 
Kenya 1.5 ( 0.9 , 2.4 ) 0.1 ( 0.1 , 0.3 ) 0.2 ( 0.1 , 0.3 ) 0.2 ( 0.1 , 0.3 ) 
Table S4: Median and 95% credible intervals (95% CrIs) of the relative number of infections that could be averted a year 
due to PrEP for each $100k available for PrEP programming. 
 The table shows the median (value outside the brackets) and 95% CrIs (inside the brackets) of the number of HIV infections 
that could be averted a year due to PrEP, for each $100k available for PrEP programming, for FSW, AGYW, women 25-34 
years or women 35-49 years. The relative number of infections that could be averted is calculated using equation S2.10 
from Supplementary Materials and assumes that 12-month PrEP program retention in AGYW, women 25-34 years or 
women 35-49 years is within +/-25% of retention levels for FSW, taken to be 22%, in line with the results of the TAPS 
demonstration project.3 The unit costs of PrEP for each high-risk woman group are as stated in Table S2. AGYW is used as 
shorthand for adolescent girls and young women 15-24 years. 
In South Africa, $100,000 could avert a median 5.7 infections a year or 0.2% (95% CrI: 0.1%, 0.4%) 
of the total infections a year due to PrEP in FSW; median 1.7 infections a year or <0.1% (95% CrI: 
<0.1%, <0.1%) of the total infections a year in AGYW; mediaan 1.3 infections a year or <0.1% (95% 
CrI: <0.1%, <0.1%) of total infections a year in women 25-34 years; and median 1.2 infections a year 
or <0.1% (95% CrI: <0.1%, <0.1%) of total infections a year in women 35-49 years. This highlights, 
that to maximise cost-effectiveness on an individual basis, PrEP would be scaled-up first in FSW, then 
AGYW, then women 35-49 years, then women 25-34 years. 
In Zimbabwe, $100,000 could avert a median 3.4 infections a year or 0.3% (95% CrI: 0.3%, 0.4%) 
of the total infections a year due to PrEP in FSW; median 0.3 infections a year or <0.1% (95% CrI: 
<0.1%, <0.1%) of the total infections a year in AGYW; median 1.0 infections a year or <0.1% (95% CrI: 
<0.1%, <0.1%) of total infections a year in women 25-34 years; and median 0.9 infections a year or 
<0.1% (95% CrI: <0.1%, <0.1%) of total infections a year in women 35-49 years. This highlights, that 
to maximise cost-effectiveness on an individual basis, PrEP would be scaled-up first in FSW, then 
women 25-34 years, then women 35-49 years, then AGYW. 
In Kenya, $100,000 could avert a median 1.5 infections a year or <0.1% (95% CrI: <0.1%, 0.1%) of the 
total infections a year due to PrEP in FSW; median 0.1 infections a year or <0.1% (95% CrI: <0.1%, 
<0.1%) of the total infections a year in AGYW; median 0.2 infections a year or <0.1% (95% CrI: <0.1%, 
<0.1%) of total infections a year in women 25-34 years; and median 0.2 infections a year or <0.1% 
(95% CrI: <0.1%, <0.1%) of total infections a year in women 35-49 years. This highlights, that to 
maximise cost-effectiveness on an individual basis, PrEP would be scaled-up first in FSW, then 
women 25-34 years and women 35-49 years, and then AGYW.  
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Figure S5 shows, the proportion of the total number of HIV infections that could be averted a year 
for each $100k available for PrEP programming.. The corresponding data to the figure are set out in 
Table S5 below. 
Figure S5: Boxplot showing for each $100k available for PrEP programming, the proportion of the total number of HIV 
infections that could be averted a year with these funds.  
The boxplot shows for each $100k available for PrEP programming, the proportion of infections that could be averted a year 
with these funds for each of HIV negative FSW, AGYW, women 25-34 years or women 35-49 years. The proportion of total 
infections that could be averted a year are shown, grouped left to right, for FSW, AGYW, women 25-34 years and women 
35-49 years. Within each age grouping, the results are show by country, left to right, for South Africa (in blue), Zimbabwe 
(in orange) and Kenya (in blue). The proportion of total infections that could be averted a year are calculated using equation 
S2.11 from Supplementary Materials and assumes that 12-month PrEP program retention in AGYW, women 25-34 years or 
women 35-49 years is within +/-25% of retention levels for FSW, taken to be 22%, in line with the results of the TAPS 
demonstration project.3 The abbreviations used in the graph are as follows: AGYW denotes adolescent girls and young 
women 15-24 years, S Africa denotes South Africa and Zim denotes Zimbabwe. 
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For each $100k available for PrEP programming,  
the proportion of HIV infections that could be averted a year 
High Risk Women Population 
Country FSW AGYW Women 25-34 years Women 35-49 years 
South 
Africa 
0.2 % ( 0.1 % , 0.4 % ) 0 % ( 0 % , 0 % ) 0 % ( 0 % , 0 % ) 0 % ( 0 % , 0 % ) 
Zimbabwe 0.3 % ( 0.3 % , 0.4 % ) 0 % ( 0 % , 0 % ) 0 % ( 0 % , 0 % ) 0 % ( 0 % , 0 % ) 
Kenya 0 % ( 0 % , 0.1 % ) 0 % ( 0 % , 0 % ) 0 % ( 0 % , 0 % ) 0 % ( 0 % , 0 % ) 
Table S5: Median and 95% credible intervals (95% CrIs) of the proportion of the total number of HIV infections that could 
be averted a year with each $100k available for PrEP programming.  
Figure S6 sets out the number of HIV negative individuals in each high-risk woman population that 
would need to be enrolled on PrEP to avert the same number of infections as 10% PrEP program 
coverage in HIV negative FSW. The corresponding data to the figure are set out in Table S6. 
Figure S6: Number of HIV negative women needed to be enrolled on PrEP to avert the same number of infections as 
10% PrEP program coverage in HIV negative FSW.  
The violin plot shows number of HIV negative AGYW, women 25-34 years or women 35-49 years in the population that 
would have to be enrolled in a PrEP program in order to achieve the same number of infections averted over 12 months as 
with 10% of the HIV negative FSW population enrolled in a PrEP program. As a comparison, the number of women 
represented by 10% of HIV negative FSW is shown in the far left hand side block of the figure. The number of HIV negative 
women needed to be enrolled on PrEP to avert the same number of infections as 10% PrEP program coverage in HIV 
negative FSW is then grouped left to right, for AGYW, women 25-34 years or women 35-49 years. Within each age 
grouping, the results are show by country, left to right, for South Africa (in blue), Zimbabwe (in orange) and Kenya (in blue). 
In the violin plots, the white dots represent the median values, the thick black vertical lines represent the interquartile 
range, the vertical length of the violin represents the range of values and the width of the violin represents the frequency 
with which those values occur. Where two horizontal grey lines are shown instead of a violin, it indicates that the range of 
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values is limited in variation. The number of HIV negative women needed to be enrolled on PrEP to avert the same number 
of infections averted as 10% PrEP program coverage in HIV negative FSW is calculated using equation S2.7 from 
Supplementary Materials and assumes that 12-month PrEP program retention in AGYW, women 25-34 years or women 35-
49 years is within +/-25% of retention levels for FSW, taken to be 22%, in line with the results of the TAPS demonstration 
project.3 The abbreviations used in the graph are as follows: AGYW denotes adolescent girls and young women 15-24 years, 
S Africa denotes South Africa and Zim denotes Zimbabwe. 
Number of HIV negative women needed to be enrolled on PrEP  
to avert the same number of infections as 10% PrEP program coverage in HIV negative FSW 
High Risk Women Population 
Country FSW (comparator) 
AGYW Women 25-34 years Women 35-49 years 
South 
Africa 
4359 (2774, 
5914 ) 
18531 (9594, 37052 ) 31798 (16411, 65199) 52240 (26287 , 111053) 
Zimbabwe 1933 (1910, 1953) 
27496 (12962, 72904) 14933 (8535, 37453) 36978 (23578, 73838) 
Kenya 9477 (9449, 9513) 
116565 (51258, 
246376) 
151830 (78163, 
380590) 
274531 (149378, 
567706) 
Table S6: Median and 95% credible interval (CrIs) of the number of HIV negative women needed to be enrolled on PrEP to 
avert the same number of infections as 10% PrEP program coverage in HIV negative FSW.  
The table shows the median (value outside the brackets) and 95% CrIs (inside the brackets) of the number of HIV negative 
AGYW, women 25-34 years or women 35-49 years in the population that would have to be enrolled in a PrEP program in 
order to achieve the same number of infections averted over 12 months as with 10% of the HIV negative FSW population 
enrolled in a PrEP program. As a comparison, the median and 95% CrIs of the numbers of women represented by 10% of HIV 
negative FSW is shown in the far left column of the table. The median and 95% CrIs of the numbers of HIV negative women 
needed to be enrolled on PrEP to avert the same number of infections as 10% PrEP program coverage in HIV negative FSW 
is then grouped left to right in the 2nd to 4th columns of the table, for AGYW, women 25-34 years or women 35-49 years 
respectively. Within each age grouping, the results are show by country, for South Africa, Zimbabwe and Kenya in rows 1 to 
3 respectively. The number of HIV negative women needed to be enrolled on PrEP to avert the same number of infections 
averted as 10% PrEP program coverage in HIV negative FSW is calculated using equation S2.7 from Supplementary 
Materials and assumes that 12-month PrEP program retention in AGYW, women 25-34 years or women 35-49 years is 
within +/-25% of retention levels for FSW, taken to be 22%, in line with the results of the TAPS demonstration project.3  
Figure S7 shows PrEP program coverage in HIV negative individuals in each high-risk woman 
population that would need to be enrolled on PrEP to avert the same number of infections as 10% 
PrEP program coverage in HIV negative FSW. The corresponding data are shown in Table S7 below. 
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Figure S7: Boxplot of the PrEP program coverage in HIV negative women needed to avert the same number of HIV 
infections as 10% coverage in HIV negative FSW.  
The boxplot shows the PrEP program coverage in HIV negative AGYW, women 25-34 years or women 35-49 years to avert 
the same number of infections as 10% program coverage in HIV negative FSW. The PrEP program coverage levels are 
shown, grouped left to right, for AGYW, women 25-34 years or women 35-49 years. Within each age grouping, the results 
are show by country, left to right, for South Africa (in blue), Zimbabwe (in orange) and Kenya (in blue). The coverage levels 
are calculated using equation S2.7 from Supplementary Materials and assumes that 12-month PrEP program retention in 
AGYW, women 25-34 years or women 35-49 years is within +/-25% of retention levels for FSW, taken to be 22%, in line with 
the results of the TAPS demonstration project.3 The abbreviations used in the graph are as follows: AGYW denotes 
adolescent girls and young women 15-24 years, S Africa denotes South Africa and Zim denotes Zimbabwe. 
PrEP program coverage in HIV negative women to avert the same number of infections 
as 10% coverage in HIV negative FSW 
High Risk Women Population 
Country AGYW Women 25-34 Women 35-49 years 
South Africa 0.4 % ( 0.2 % , 0.8 % ) 0.7 % ( 0.4 % , 1.4 % ) 1.2 % ( 0.6 % , 2.5 % ) 
Zimbabwe 2.2 % ( 1.1 % , 5.9 % ) 1.2 % ( 0.7 % , 3.1 % ) 3 % ( 1.9 % , 6 % ) 
Kenya 2.9 % ( 1.3 % , 6.3 % ) 3.8 % ( 2 % , 9.7 % ) 6.9 % ( 3.8 % , 14.4 % ) 
Table S7: Median and 95% credible intervals (95% CrIs) of the PrEP program coverage in HIV negative women to avert 
the same number of infections as with 10% PrEP program coverage in HIV negative FSW.  
The table shows the median (value outside the brackets) and 95% CrIs (inside the brackets) of the PrEP program coverage in 
AGYW, women 25-34 years or women 35-49 years to achieve the same number of infections a year as 10% PrEP program 
coverage in HIV negative FSW. The PrEP program coverage is calculated using equation S2.7 from Supplementary Materials 
and assumes that 12-month PrEP program retention in AGYW, women 25-34 years or women 35-49 years is within +/-25% 
of retention levels for FSW, taken to be 22%, in line with the results of the TAPS demonstration project.3 AGYW is used as 
shorthand for adolescent girls and young women 15-24 years. 
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Table S8 shows the relative number of infections that could be averted a year with PrEP at equal 
coverage levels in AGYW, women 25-34 years and women 35-49 years as in FSW. These data 
correspond to Figure 5 in the main text. 
Relative number of infections that could be averted a year on PrEP 
with equal program coverage as in FSW 
High Risk Women Population 
Country AGYW Women 25-34 years Women 35-49 years 
South Africa 24 ( 12 , 45 ) 14 ( 7 , 27 ) 8 ( 4 , 17 ) 
Zimbabwe 4 ( 2 , 9 ) 8 ( 3 , 14 ) 3 ( 2 , 5 ) 
Kenya 3 ( 2 , 8 ) 3 ( 1 , 5 ) 1 ( 1 , 3 ) 
Table S8: Median and 95% credible intervals (95% CrIs) of the relative number of infections that could be averted a year 
on PrEP with equal program coverage as in FSW.  
The table shows the median (value outside the brackets) and 95% CrIs (inside the brackets) of the relative number of 
infections that could be averted a year on PrEP in AGYW, women 25-34 years or women 35-49 years relative to the number 
that could be averted in FSW with equal PrEP program coverage. The relative number of infections that could be averted is 
calculated using equation S2.9 from Supplementary Materials and assumes that 12-month PrEP program retention in 
AGYW, women 25-34 years or women 35-49 years is within +/-25% of retention levels for FSW, taken to be 22%, in line with 
the results of the TAPS demonstration project.3 AGYW is used as shorthand for adolescent girls and young women 15-24 
years. 
Sensitivity analysis 
25% less PrEP-adherence-related HIV risk reduction across all women groups 
Table S9 shows the percentage change in the maximum unit cost at which PrEP will be equally cost-
effective in other high-risk women groups (AGYW, women 25-34 years and women 35-49 years) as in 
FSW, if 25% less PrEP-adherence-related HIV risk reduction were assumed across all women groups. 
These results are a comparison of the results set out in Table S3 (top row for each country) with 
what the results would be if the same analysis were repeated with 25% less PrEP-adherence-related 
HIV risk reduction across all women groups. 
% Change in Maximum Unit Cost at which PrEP is equally as Cost-Effective as for FSW, 
with 25% reduced HIV risk-reduction across all Groups 
High Risk Women Population 
Country AGYW Women 25-34 Women 35-49 years 
South Africa 0.001% (0.000%, 0.003%) -0.002% (-0.002%, 0.000%) 0.000% (-0.002%, 0.000%)
Zimbabwe 0.001% (-0.002%, 0.002%) -0.002% (-0.001%, 0.001%) -0.001% (-0.002%, -0.001%)
Kenya 0.000% (0.000%, 0.001%) 0.001% (0.000%, 0.002%) 0.000% (0.000%, 0.000%) 
Table S9: Percentage change in the maximum unit cost at which PrEP will be equally cost-effective in other high-risk 
women groups (AGYW, women 25-34 years and women 35-49 years) as in FSW, if 25% less PrEP-adherence-related HIV 
risk reduction were assumed across all women groups.  
The table shows the percentage change in the maximum relative unit costs of PrEP in AGYW, women 25-34 years and 
women 35-49 years relative to the unit costs of PrEP for FSW, for PrEP to be equally as cost-effective (calculated using 
equation S1.5 in Supplementary Materials: Methods), if the PrEP-adherence-associated HIV risk reduction were reduced by 
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25% compared to the baseline analysis presented in Table S3 (top row for each country). The comparisons are shown 
separately for South Africa, Zimbabwe and Kenya. AGYW is used as shorthand for adolescent girls and young women 15-24 
years. The values shown in the table outside the brackets are the median values, and the values shown in the brackets are 
the 95% credible intervals (CrIs). All values are shown rounded to the nearest 3 decimal places. 
Table S10 sets out the percentage change in the in the relative number of infections averted a year 
on PrEP with equal coverage as with FSW, if 25% less PrEP-adherence-related HIV risk reduction 
were assumed across all women groups. These results are a comparison of the results set out in 
Table S8 with what the results would be if the same analysis were repeated with 25% less PrEP-
adherence-related HIV risk reduction across all women groups. 
% Change in Relative Number of Infections Averted a Year on PrEP with equal coverage as 
with FSW,  
with 25% reduced PrEP-adherence-related HIV-risk reduction across Groups 
High Risk Women Population 
Country AGYW Women 25-34 years Women 35-49 years 
South 
Africa 0.000 % (-0.001% , 0.000 % ) -0.001 % ( -0.001% , -0.001%) -0.001 % ( -0.001 % , 0.000 % )
Zimbabwe 0.000% (-0.001 % , 0.002 %) -0.002% (-0.001 % , 0.001%) -0.001% (-0.002 % , -0.001 %)
Kenya 0.000% (0.000% , 0.001 %) 0.001% (0.000% , 0.002%) 0.000% (0.000 % , 0.000 %) 
Table S10: Percentage change in the relative number of infections averted a year on PrEP with equal coverage as with 
FSW, with 25% reduced PrEP-adherence-related HIV-risk reduction across groups.  
The table shows the median (value outside the brackets) and 95% CrIs (inside the brackets) of the percentage 
change in the relative number of infections that could be averted a year on PrEP in AGYW, women 25-34 years 
or women 35-49 years relative to the number that could be averted in FSW with equal PrEP program coverage, 
if the PrEP-adherence-associated HIV risk reduction were reduced by 25% compared to the baseline analysis 
presented in Table S8. For the underlying analyses, the relative number of infections that could be averted is 
calculated using equation S2.9 from Supplementary Materials. AGYW is used as shorthand for adolescent girls 
and young women 15-24 years. All values are shown rounded to the nearest 3 decimal places. 
25% less PrEP-adherence-related HIV risk reduction across all non-FSW women groups 
Table S11 sets out the percentage change in the maximum unit cost at which PrEP will be equally 
cost-effective in other high-risk women groups (AGYW, women 25-34 years and women 35-49 years) 
as in FSW, if 25% less PrEP-adherence-related HIV risk reduction were assumed across all non-FSW 
women groups (i.e. AGYW, women 25-34 years and women 35-49 years). These results are a 
comparison of the results set out in Table S3 (top row for each country) with what the results would 
be if the same analysis were repeated with 25% less PrEP-adherence-related HIV risk reduction 
across all non-FSW women groups. 
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% Change in Maximum Unit Cost at which PrEP is equally as Cost-Effective as for FSW,  
with 25% reduced HIV risk-reduction across all non-FSW women groups 
  High Risk Women Population 
Country AGYW Women 25-34 Women 35-49 years 
South Africa 0.253 % (0.252 %, 0.252 %) 0.253 % (0.252 %, 0.252% ) 0.252 % (0.251%, 0.251%) 
Zimbabwe 0.254 % (0.253 %, 0.253 %) 0.253 % (0.253% ,0.254%) 0.252 % (0.252%,0.252%) 
Kenya 0.258 % (0.260 %, 0.256 %) 0.257 % (0.257%,0.258%) 0.256 % (0.255%,0.258%) 
Table S11: Percentage change in the maximum unit cost at which PrEP will be equally cost-effective in other high-risk 
women groups (AGYW, women 25-34 years and women 35-49 years) as in FSW, if 25% less PrEP-adherence-related HIV 
risk reduction were assumed across all non-FSW women groups (i.e. AGYW, women 25-34 years and women 35-49 
years).  
The table shows the percentage change in the maximum relative unit costs of PrEP in AGYW, women 25-34 years and 
women 35-49 years relative to the unit costs of PrEP for FSW, for PrEP to be equally as cost-effective (calculated using 
equation S1.5 in Supplementary Materials: Methods), if the PrEP-adherence-associated HIV risk reduction were reduced by 
25% for all non-FSW women groups compared to the baseline analysis presented in Table S3 (top row for each country). The 
comparisons are shown separately for South Africa, Zimbabwe and Kenya. AGYW is used as shorthand for adolescent girls 
and young women 15-24 years. The values shown in the table outside the brackets are the median values, and the values 
shown in the brackets are the 95% credible intervals (CrIs). All values are shown rounded to the nearest 3 decimal places. 
 
 
Table S12 sets out the percentage change in the in the relative number of infections averted a year 
on PrEP with equal coverage as with FSW, if 25% less PrEP-adherence-related HIV risk reduction 
were assumed across all non-FSW women groups (i.e. AGYW, women 25-34 years and women 35-49 
years). These results are a comparison of the results set out in Table S8 with what the results would 
be if the same analysis were repeated with 25% less PrEP-adherence-related HIV risk reduction 
across all non-FSW women groups. 
 
 
% Change in Relative Number of Infections Averted a Year on PrEP with equal coverage as 
with FSW,  
with 25% reduced PrEP-adherence-related HIV-risk reduction across all non-FSW women 
groups 
  High Risk Women Population 
Country AGYW  Women 25-34 years  Women 35-49 years 
South 
Africa 0.252 % ( 0.250 % , 0.252 % ) 0.251 % ( 0.252 % , 0.252 % ) 0.252 % ( 0.251 % , 0.251 % ) 
Zimbabwe 0.253 % ( 0.254 % , 0.254 % ) 0.253 % ( 0.253 % , 0.254 % ) 0.252 % ( 0.252 % , 0.253 % ) 
Kenya 0.257 % ( 0.260 % , 0.256 % ) 0.26 % ( 0.257 % , 0.258 % ) 0.256 % ( 0.255 % , 0.258 % ) 
 
Table S12: Percentage change in the relative number of infections averted a year on PrEP with equal coverage as with 
FSW, with 25% reduced PrEP-adherence-related HIV-risk reduction across all non-FSW women groups (i.e. AGYW, 
women 25-34 years and women 35-49 years).  
The table shows the median (value outside the brackets) and 95% CrIs (inside the brackets) of the percentage change in the 
relative number of infections that could be averted a year on PrEP in AGYW, women 25-34 years or women 35-49 years 
relative to the number that could be averted in FSW with equal PrEP program coverage, if the PrEP-adherence-associated 
HIV risk reduction were reduced by 25% for all non-FSW women groups compared to the baseline analysis presented in 
Table S8. For the underlying analyses, the relative number of infections that could be averted is calculated using equation 
S2.9 from Supplementary Materials. AGYW is used as shorthand for adolescent girls and young women 15-24 years. All 
values are shown rounded to the nearest 3 decimal places. 
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Structural sensitivity analysis: women 25-34 years have partners from males 35-49 years, in addition 
to 25-34 years 
 
Table S13 sets out the percentage change in the maximum unit cost at which PrEP will be equally 
cost-effective in other high-risk women groups (AGYW, women 25-34 years and women 35-49 years) 
as in FSW, under the structural sensitivity analysis exploring the case that women 25-34 years draw 
partners from males 35-49 years, in addition to 25-34 years. These results are a comparison of the 
results set out in Table S3 (top row for each country) with what the results would be if the same 
analysis were repeated with women 25-34 years drawing partners from males 35-49 years, in 
addition to 25-34 years (assumed to be the only partner population, in Table S3). Whilst the 
structural sensitivity analysis directly affects the model outcomes for women 25-34 years, it also 
indirectly affects the mean and 95% CrI outcomes for FSW, AGYW and women 35-49 year through 
changes to the number of underlying fitted parameter sets across all women groups. 
 
 
 
 
 
% Change in Maximum Unit Cost at which PrEP is equally as Cost-Effective as for FSW,  
with women 25-34 years having partners drawn from 2 populations 
  High Risk Women Population 
Country AGYW Women 25-34 Women 35-49 years 
South 
Africa -0.017 % (-0.063%, 0.017%) -0.091% (-0.157%, -0.089%) 0.016% (-0.009%, 0.060%) 
Zimbabwe 0.003% (0.015%, 0.018%) -0.299% (-0.476%, -0.081%) 0.075% (-0.015%, 0.128%) 
Kenya 0.020% (-0.004%, 0.000%) -0.205% (-0.596%, 0.023%) 0.038% (0.030%, 0.059%) 
Table S13: Percentage change in the maximum unit cost at which PrEP will be equally cost-effective in other high-risk 
women groups (AGYW, women 25-34 years and women 35-49 years) as in FSW, under the structural sensitivity analysis 
exploring the case that women 25-34 years draw partners from males 35-49 years, in addition to 25-34 years.  
The table shows the percentage change in the maximum relative unit costs of PrEP in AGYW, women 25-34 years and 
women 35-49 years relative to the unit costs of PrEP for FSW, for PrEP to be equally as cost-effective (calculated using 
equation S1.5 in Supplementary Materials: Methods), if women 25-34 years are assumed to draw partners from males 35-
49 years, in addition to 25-34 years, compared to the baseline analysis presented in Table S3 (top row for each country). The 
comparisons are shown separately for South Africa, Zimbabwe and Kenya. AGYW is used as shorthand for adolescent girls 
and young women 15-24 years. The values shown in the table outside the brackets are the median values, and the values 
shown in the brackets are the 95% credible intervals (CrIs). All values are shown rounded to the nearest 3 decimal places. 
 
 
Table S14 sets out the percentage change in the in the relative number of infections averted a year 
on PrEP with equal coverage as with FSW, if women 25-34 years are assumed to draw partners from 
males 35-49 years, in addition to 25-34 years. These results are a comparison of the results set out in 
Table S8 with what the results would be if the same analysis were repeated with women 25-34 years 
drawing partners from males 35-49 years, in addition to 25-34 years (assumed to be the only partner 
population, in Table S8). Whilst the structural sensitivity analysis directly affects the model outcomes 
for women 25-34 years, it also indirectly affects the mean and 95% CrI outcomes for FSW, AGYW and 
women 35-49 year through changes to the number of underlying fitted parameter sets across all 
women groups. 
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% Change in Relative Number of Infections Averted a Year on PrEP with equal coverage as 
with FSW,  
with women 25-34 years having partners drawn from 2 populations 
  High Risk Women Population 
Country AGYW  Women 25-34 years  Women 35-49 years 
South 
Africa 0.044 % (-0.091 %, -0.03 %) -0.024 % (-0.176 % , -0.12 %) 0.039 % (-0.054 %, 0.061 %) 
Zimbabwe 0.001 % (0.008 %, 0.015 %) -0.297 % (-0.483 %, -0.087 %) 0.064 % (-0.018 %, 0.125 %) 
Kenya 0.023 % (-0.004 %, -0.002 %) -0.223 % (-0.593 %, 0.023 %) 0.048 % (0.042 % , 0.074 %) 
 
Table S14: Percentage change in the relative number of infections averted a year on PrEP with equal coverage as with 
FSW, under the structural sensitivity analysis exploring the case that women 25-34 years draw partners from males 35-
49 years, in addition to 25-34 years.  
The table shows the median (value outside the brackets) and 95% CrIs (inside the brackets) of the percentage change in the 
relative number of infections that could be averted a year on PrEP in AGYW, women 25-34 years or women 35-49 years 
relative to the number that could be averted in FSW with equal PrEP program coverage, if women 25-34 years are assumed 
to draw partners from males 35-49 years, in addition to 25-34 years, compared to the baseline analysis presented in Table 
S8. For the underlying analyses, the relative number of infections that could be averted is calculated using equation S2.9 
from Supplementary Materials. AGYW is used as shorthand for adolescent girls and young women 15-24 years. All values 
are shown rounded to the nearest 3 decimal places. 
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Pre-exposure prophylaxis (PrEP) for HIV prevention is recommended by the WHO as part of a 
comprehensive HIV prevention package for those at substantial risk of HIV infection[1]. PrEP is 
effective at preventing HIV acquisition, demonstrated by high efficacy in placebo-controlled trials and 
demonstration projects, and increased PrEP coverage is associated with substantial decreases in 
population-level HIV incidence among men who have sex with men (MSM) in high-income settings[2-
4]. Although PrEP is effective in preventing HIV infection, reduced condom use or other increases in 
sexual risk taking risk may increase STI transmission, especially in populations with low PrEP 
adherence, an increase in STIs may play an important role in affecting HIV transmission dynamics. 
Before PrEP was widely available, some urged caution in recommending it because of the potential 
for risk compensation. As cyclists ride faster when made to wear helmets[5], so might PrEP users 
increase condomless sex or sexual partners, increasing the risk of other sexually transmitted 
infections (STIs)[6, 7]. As defined elsewhere[1], risk compensation refers to an increase in risk-
related behaviours, because an intervention reduces perceptions of risk among individuals or a 
population.  
Self-reported condom use and STIs did not change in placebo-controlled PrEP studies[3, 8]. However, 
in some open-label studies where users knew they were taking highly effective PrEP, PrEP use was 
associated with increases in condomless sex and, most importantly, STIs[9]. One observational study 
showed evidence of community-level risk compensation, where MSM not using PrEP also reduced 
condom use as PrEP coverage increased[10]. Importantly, six presentations at the 22nd International 
AIDS Conference in Amsterdam (Table 1) provide further evidence of risk compensation.  
HIV prevention is at a crossroads. The potential effects of increasing STI incidence must be understood 
alongside the HIV benefits of PrEP, especially with suboptimal adherence or antibiotic-resistant STIs. 
We make an urgent call for more evidence on the potential effect of individual and community-level 
risk compensation on HIV and STI transmission among all groups where PrEP is available, alongside 
proportionate and context-specific programming and communication to mitigate risk compensation.  
First, we do not understand how PrEP will affect epidemic dynamics well enough to make informed 
trade-offs between disease burdens from HIV and STIs. Models have not always predicted HIV 
epidemics accurately to-date[11], and more data are needed to fully understand the long-term impact 
of PrEP in a variety of real-world settings, in order to improve incorrect assumptions which reduce 
modeller and policymaker confidence in their projections. Yet modelling is an important component 
of the health technology appraisal process, and will be critical to understand how PrEP’s impact is 
affected by risk compensation and resulting changes in STI dynamics[12]. There are currently few 
behavioural data to parameterise PrEP models, for example risk compensation may cluster among 
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people with different risk factors (e.g. multiple partners or seroconcordance) which are not accurately 
reflected in sexual mixing assumptions. PrEP guidelines also require regular STI testing which could 
increase early diagnosis and treatment, potentially counteracting or even surpassing the effect of any 
increases in risky sexual behaviour. 
Second, the majority of evidence on risk compensation exists among MSM groups in high-income 
countries. Yet PrEP is now a key part of HIV prevention programmes among other high-risk groups, 
for example adolescent girls and young women in sub-Saharan Africa. We have little evidence on risk 
compensation or PrEP adherence among these groups. The burden of STI acquisition is also much 
higher among women of reproductive age, where chlamydia and gonorrhoea can cause a range of 
reproductive morbidity and display increasing antibiotic resistance. Therefore, the generalisability of 
risk compensation evidence and its implications outside high-income MSM groups is very limited.  
Third, more evidence is needed on the effect of community-level risk compensation; in particular 
sexual behaviours among non-PrEP users in the context of PrEP availability, and early treatment for 
people living with HIV (PLHIV). Risk compensation is unlikely to undermine the HIV prevention benefits 
of PrEP among adherent PrEP users. However, small behavioural changes among non-users may 
reduce PrEP’s overall epidemiological benefit. To model this, it is important to quantify the extent to 
which PLHIV are likely to have undetectable viral loads and/or STIs, particularly in low and middle-
income countries where data is scarce.  
Fourth, more research is needed on how users understand PrEP as a complement or substitute for 
alternate prevention strategies. Although guidelines recommend that PrEP users be counselled to 
use condoms, these are inconsistent since eligibility criteria for PrEP include reporting inconsistent 
condom use. Different, effective alternatives may therefore be needed to prevent STIs alongside 
PrEP, as condoms may be hard to promote among people who are primarily concerned with HIV 
prevention.  The extent to which PrEP is used as a substitute to condoms, is likely to vary between 
populations and contexts. It is critical that we understand behavioural and structural approaches 
that support the provision of combination prevention services and tailored prevention packages. 
Finally, where intermittent PrEP is provided, evidence is needed to understand behaviours before, 
during, and between episodes of use. Since intermittent PrEP regimens depend partly on user risk 
perception, it is important to understand how the choice to use PrEP is made, and how time on PrEP 
impacts risk behaviours during and potentially after PrEP use. Importantly, risk perceptions are rarely 
measured but inferred from behaviour change without knowing why behaviours changed – more work 
on measuring risk changing risk perceptions is needed. 
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PrEP has an important role in HIV prevention, and uncertainty in its effect on risk compensation and 
STI incidence should not prevent provision to those at high risk. Nonetheless, in order to support 
effective PrEP programming, researchers and practitioners need reliable and robust behavioural 
evidence from all populations to evaluate its true risks and benefits in order to evaluate its true risks 
and benefits. 
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Authors Title Study 
Population, 
Location 
Evidence type  Findings related to risk compensation 
Rendina et al. 
http://programme.aids2018.org/ 
Abstract/Abstract/8121 
Changes in rectal STI incidence 
and behavioral HIV risk before, 
during, and after PrEP in a 
national sample of gay and 
bisexual men in the United 
States 
MSM, 
multiple 
sites,  
United 
States of 
America  
Behavioural 
indicators, 
STI incidence 
• No change in odds of rectal STI during PrEP use 
or after discontinuation compared to before 
uptake 
• Compared to before PrEP use: 
o 156% increase in condomless anal sex with 
casual partners 
o 410% increase in receptive condomless anal 
sex with serodiscordant male partners while 
on PrEP, but average of <1 act per person 
De Wit et al. 
http://programme.aids2018.org/ 
Abstract/Abstract/10801 
Attitudes regarding HIV, PrEP 
and condom use jointly 
predict risk compensation 
among men who have sex 
with men - findings from the 
VicPrEP implementation 
project, Melbourne 
MSM,  
Melbourne, 
Australia 
Behavioural 
indicators 
• Frequency of condom use for anal sex with 
causal partners decreased significantly over one 
year follow up 
• Median condom protected acts in last three 
months reduced from 3 to 2  
 
Traeger et al. 
http://programme.aids2018.org/ 
Abstract/Abstract/3905 
Changes, patterns and 
predictors of sexually 
transmitted infections in gay 
and bisexual men using PrEP; 
interim analysis from the 
PrEPX demonstration study 
MSM, 
Melbourne, 
Australia 
Behavioural 
indicators, 
STI incidence 
• STI incidence (chlamydia, gonorrhea, syphilis, 
and rectal pharyngeal or urethral infections) 
increased after PrEP use compared to before 
(IRR: 1.42 95%CI: 1.29-1.56) 
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Table 1: Studies presented at AIDS 2018 Amsterdam containing evidence on risk compensation  
 
 
  
Molina et al. 
http://programme.aids2018.org/ 
Abstract/Abstract/13278 
Incidence of HIV-infection in 
the ANRS Prevenir Study in the 
Paris Region with Daily or On 
Demand PrEP with TDF/FTC 
MSM,  
Paris, 
France 
Behavioural 
indicators 
• Indicative (not statistically tested) evidence of 
behavioural risk compensation (condomless sex 
at last intercourse, number of condomless acts in 
previous 4 weeks)  
 
Prestage et al. 
http://programme.aids2018.org/ 
Abstract/Abstract/8042 
A longitudinal analysis of the 
impact of PrEP on sexual 
behaviour and drug use 
among Australian gay and 
bisexual men 
MSM, 
multiple 
sites, 
Australia 
Behavioural 
indicators 
• Among PrEP users significant increase in: 
o Condomless anal sex (78% increase) 
o number of partners in previous six 
months (100% increase) 
o Proportion reporting group sex (96% 
increase) 
Morris et al. 
http://programme.aids2018.org/ 
Abstract/Abstract/11478 
High HIV PrEP adherence is 
associated with syphilis 
incidence 
MSM, 
California, 
United 
States of 
America 
 • The incidence rate of syphilis was over 3 times 
higher among those highly adherent (≥1246 
fmol/punch, consistent with 7 doses per week 
or near perfect dosing) to TFV-DP at week 12 
and week 48, compared to those not highly 
adherent at week 12 and 48  
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